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ABSTRACT 
End binding protein 1 (EB1) is a key element in the complex network of protein-protein inter-
actions at microtubule growing ends which has a fundamental role in microtubule polymeri-
sation. EB1 regulates the microtubule dynamic behaviour, through protein recruitment, and 
has been associated with several disease states, such as cancer and neuronal diseases. Diverse 
EB1 binding partners are recognised through a conserved SxIP motif within an intrinsically 
disordered region enriched with basic, serine and proline residues. Crystal structure of EB1 in 
complex with a peptide containing the SxIP motif demonstrated that the isoleucine-proline 
dipeptide is bound into a well-defined cavity of EB1 that may be suitable for small molecule 
targeting. 
The research described herein reports the use of a multidisciplinary approach for the discovery 
of the first small molecule scaffold to target the EB1 recruiting domain. This approach 
included virtual screening (structure and ligand based design) and multiparameter compound 
selection. Solution NMR structures of the C-terminal domain of EB1 in the free form and in 
complex with the small molecule are also reported. A key finding from these structures is that 
the hydrophobic binding pocket reported to be essential for recruiting SxIP proteins is not pre-
formed but highly dynamic in solution. This brings new insights to the protein recruitment 
mechanism regulated by EB1 and for the identification of new small molecule inhibitors for 
the EB1-SxIP protein interactions. 
The interaction of short length peptides containing the SxIP motif with EB1 was characterised 
through the use of solution NMR and ITC methods. The contributions for the binding of the 
SxIP motif and neighbouring residues to EB1 were quantified in terms of binding energy. A 
structural model shows that the binding pocket of EB1 is largely extended when in complex. 
This research describes not only the first chemical scaffold that targets EB1, it details 
important structural features of the interaction of this protein with SxIP containing peptides. 
This structural information provides fundamental understanding of this interaction that can be 
exploited in the future to discover higher affinity ligands. 
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INTRODUCTION  
1.1 Role of EB1 in +TIP targeting 
 Microtubules 
Cells undergo substantial changes in shape as they grow, divide and move, and the 
cytoskeleton is the principal molecular machinery responsible for these functions.1 The 
cytoskeleton due to its molecular complexity can be divided into three different 
functional subsystems – actin filaments, microtubules (MTs) and intermediate 
filaments.1 These cytoskeletal components interact dynamically to control 
fundamental processes including mitosis, cell division, intracellular transport, cell 
motility and the regulation of cell organization.2 To understand these mechanisms 
represents a challenge and is the focus of intense research. Furthermore, cytoskeletal 
proteins are implicated in many human pathological conditions, including cancer, 
infection, cardiovascular, inflammatory and neurodegenerative diseases.2  
Many of the cytoskeletal activities rely on MTs.2 These cellular polymers are key 
cytoskeleton components of eukaryotic cells playing important roles in many cellular 
processes, including intracellular transport, cell motility, meiosis and mitosis.3,4 Their 
functions include cell shape, cytoplasm organization by positioning organelles, cell 
transport of other cellular entities and cell polarity. In an interphase cell the MT 
cytoskeleton is also critical for cell motility and a key constituent of cilia and flagella. 
During cell division, the MT rearrange into a spindle structure that segregates 
chromosomes.5  
These functions rely on a specific MT ability of fast polymerization dynamics, with 
network-wide turnover rates on the order of minutes - known as “dynamic 
instability”.1,6 This “dynamic instability” comprises periods of persistent microtubule 
growth interrupted by occasional switching to rapid shrinkage – microtubule 
catastrophe – and then by switching back from shrinkage to growth – microtubule 
rescue.3,7  
Structurally, MTs are made from subunits of α and β-tubulin heterodimers which 
assemble, in a head to tail manner, into a polar protofilament.5 The lateral and parallel 
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association of ~13 protofilaments forms a hollow, polar cylinder. These lateral 
contacts are homotypic (α - α and β - β contacts), except at a single site or ‘‘seam’’ 
(with α - β and β - α contacts) (Figure 1.1).8 The polymerisation occurs upon the 
binding of guanosine triphosphate (GTP) to the nucleotide exchangeable site (E-site) 
in β-tubulin. The GTP bound at the N-site (non-exchangeable) in α-tubulin is buried 
at the intradimer interface where it plays a structural role.8 Only dimers bound to GTP 
can polymerise, but upon polymerisation the GTP is readily hydrolysed to guanosine 
diphosphate (GDP) – making these subunits very unstable.9,10 The MT structure is 
stabilised by the GTP subunits at the growing end and a possible loss of GTP-tubulin, 
allows the GDP-tubulin to curve, spreading out and the microtubule shrinks.9,11,12 – 
Figure 1.2.  
 
Figure 1.1 – Schematic representation of the MT structure. β-tubulin is represented in pink and α-tubulin 
in green. 
 
Figure 1.2 - Microtubules grow by addition of GTP-tubulin subunits (red) and microtubule shrinking 
by GDP-tubulin (blue) curving.   
In most cells, MT polymerization is initiated at specific locations (e.g., the centrosome), 
generating microtubule arrays of fixed polarity.13 Polymerization is a polar process 
that reflects the polarity of the tubulin dimer, which in turn dictates the polarity of the 
MT. In other words, purified tubulin polymerizes more quickly from one end, the plus 
end, which is terminated by the β-subunit. The opposite end can slowly grow in vitro, 
though in cells it is usually stabilised or serves as the site of disassembly. It is known 
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as the minus end, and is ended by the α-subunit.14 Both MT ends can interact with sets 
of specific factors that control their dynamic status, intracellular localization and 
attachment to cellular structures.15  
These cellular factors can stabilise or destabilise the MT polymer, controlling its 
dynamic behaviour and can be placed into two categories. The first category 
constituted by motors and microtubule associated proteins (MAPs) bind to MTs and 
alter MT properties in a non-covalent way; the second category includes tubulin post-
translational modification enzymes that chemically modify the tubulin subunits.9,16 For 
the scope of this project the focus will be only on the first category – MAPs. 
Microtubule stability is controlled, to a large extent, by MAPs. For instance, the 
mitotic centromere-associated kinesins (MCAKs) bind to MT ends, destabilising 
them.5 When MCAKs bind to MTs they induce the formation of the curl, weakening 
the association of the terminal GTP-tubulin dimer and promoting the release of GTP 
subunits from the end, which will release the GDP subunits constituent of the 
lattice.5,14 On the other hand, the plus-end-binding proteins (or +TIPs), a structurally 
and functionally diverse group of proteins that are distinguished by their specific 
accumulation at microtubule plus ends, stabilise MTs during their growth phase.14,17 
+TIPs also regulate interactions between MTs and other intracellular structures, for 
instance the anchorage of microtubules the kinetochore of chromosomes, or 
organelles.12,18,19 Loss or inhibition of these proteins compromises microtubule growth 
in many cell types.13  
 Microtubule plus end binding proteins - +TIPs 
As just described, +TIPs are a diverse group of proteins that accumulate specifically 
at the MT plus ends (growing ends). There are two general mechanisms by which 
proteins can target the plus ends of MTs, vectorial transport and direct recruitment. 
They are not mutually exclusive, and both may contribute to the plus-end targeting of 
proteins.20 First, kinesin motor proteins can power the vectorial transport of proteins 
along the MT body to the plus end. Second, a subset of +TIPs bind to unique structural 
features present at the plus end versus the body of the MT, and can recruit additional 
proteins to these sites. The prototypical example of this class of +TIPs are end-binding 
proteins (EBs), which are involved in recruiting binding partners.20  
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In order for +TIPs discriminate between MT lattice and the growing ends there must 
exist a structural difference. The presence of a GTP cap was initially reported as a 
possible structural feature for plus end recognition. However, +TIPs form a comet-like 
accumulation within 0.5–2 µm distance of the centre of the microtubule, a region larger 
than the supposed length of the GTP cap. Alternatively, +TIPs might recognize tubulin 
sheets or individual protofilaments due to their curvature, or might bind certain tubulin 
sites, that are hidden inside the tube or obscured by inter-protofilament contacts in the 
rest of the microtubule.2 
Since the discovery of cytoplasmic linker protein of 170 kDa - CLIP170, the first 
identified +TIP, several structurally unrelated families of +TIPs have been 
identified.2,14 There are more than 20 families of +TIPs, ranging in size from a few 
hundred up to thousands of residues, multi-domain and/or multi-subunit. Despite their 
diversity, they often co-localise and share common activities, being difficult to classify 
in terms of function. Alternatively, conserved modular binding domains, repeat 
sequences and motifs can be used to group these proteins.  
Table 1.1 - Principal +TIPs families and main interactions.12 
Family Examples Interactions 
EB proteins  EB1 
EB2 
EB3 
Other +TIPs 
   
CAP-Gly domain 
proteins 
CLIP-170 
CLIP-115 
p150glued 
KIF13B 
EB1, CLIP-170, CLIP-115, p150glued, MCAK, 
CLASP1 and 2 
EB1, CLIP-170, CLASP1 and 2 
EB1, CLIP-170 
   
SxIP proteins CLASP1/CLASP2 
APC 
MACF 
STIM1 
MCAK 
EB1, CLIP-170, CLIP-115, ACF7 
EB1, MCAK 
EB1, CLASP1 and 2 
EB1 
EB1, CLIP-170, APC 
   
TOG domain CLASPs 
XMAP215/Dis1 
EB1 
The detailed nature, specificity, and modes of regulation of their interactions are 
largely unknown. It has recently been established, however, that the protein-protein 
interaction scaffold of +TIP networks relies on a small number of protein modules and 
linear sequence motifs that are highly conserved throughout eukaryotic organisms. 
Prominent examples are the EB-like domain of end binding proteins, the cytoskeleton-
associated protein glycine-rich (CAP-Gly) domain, and short and acidic carboxy-
terminal sequence motifs – SxIP proteins. Therefore, the simplest way to classify 
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+TIPs into families is by using their domain composition – Table 1.1.2,18,21 
Figure 1.3 describes the main domains and +TIPs that will be described in the next 
sub-sections.  
 
Figure 1.3 – Main +TIPS and their conserved domains. White polygon means any other 
domains/structural features that are relevant for +TIPs interactions networks. 
1.1.2.1 End binding proteins 
Three end-binding family proteins – EB1, EB2 and EB3, have been reported. EB 
family members contain an N-terminal calponin homology (CH) domain that directly 
recognizes a structural feature of growing microtubule ends, and a C-terminal EB 
homology (EBH) domain that mediates binding to other +TIPs.2,22 EB1 was shown to 
promote MT polymerization and interacts directly with many other +TIPs and 
cytoskeletal proteins such as CLIP170, the dynactin large subunit p150Glued, the mitotic 
centromere-associated kinesin (MCAK), the microtubule-actin crosslinking factor 
(MACF) and the adenomatous polyposis coli (APC).23 EB1 and EB3 share a high 
sequence conservation and can form heterodimers.24 Moreover, EB3 binding site is 
very similar to the one observed for EB1 as demonstrated by the structure published 
in 2012 by Bjelić and co-workers – PDB code 3TQ7.24 EB2, opposite to what was 
observed to EB1 and EB3, does not bind to APC, indicating possible structural 
differences. 
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In terms of expression in different cell lines there are also differences. EB1 is 
expressed at constant levels in a variety of cell lines, whereas EB2 and EB3 vary. EB3 
is especially abundant in the central nervous system and in muscles.17,25 It is not 
completely clear what are the roles of EB2 and EB3, but all three end-binding proteins 
are expressed in mammalian cells. Depletion of EB1 had no effect on EB3 localisation, 
but led to the distribution of EB2. Depletion both EB2 and EB3 had no effect on the 
distribution of the remaining EBs. Finally, simultaneous depletion of EB1 and EB3 
caused a redistribution of EB2 similar to the one induced by depletion of EB1 alone.26  
1.1.2.2 CAP-Gly domain proteins 
The cytoskeleton-associated protein glycine rich (CAP-Gly) domain-containing 
proteins have an N-terminal CAP-Gly globular domain containing a unique 
hydrophobic cavity that encompasses the highly conserved GKNDG sequence motif 
and several characteristic glycine residues. The C-terminal region, can recruit various 
cargos, namely for CLIP170 that contains two tandemly repeated metal binding motifs 
(zinc knuckles) and a C-terminal EEY/F. The EEY/F motif is present in the end of the 
C-terminus tail of EB1 and was shown to be a recruiting domain for CAP-Gly 
domains.2,21,27  
Mutations in the CAP-Gly domain of p150Glued subunit of dynactin are associated with 
various neurological disorders. For example, a G59S point mutation has been 
identified in patients with distal spinal bulbar muscular atrophy (dSBMA). In vivo and 
in vitro studies suggest that this mutation causes misfolding of the CAP-Gly motif, and 
reduces the binding affinity of the mutant to microtubules. Five other mutations, G71A, 
G71E, G71R, T72P and Q74P, were identified in patients diagnosed with Perry's 
syndrome, a severe neurological disease whose manifestations are parkinsonism and 
weight loss accompanied by depression, social withdrawal and suicidal attempts. It 
was firstly hypothesized that, as the result of all these mutations, binding to 
microtubules was disrupted, but more recent studies indicate that the binding affinity 
to microtubules is very similar or even higher for these mutants. Instead, the binding 
to EB1 is abrogated.28  
The CAP-Gly domain seems to have two distinct regions that bind to EB1. The first 
comprises the GKNDG motif and several aromatic residues, Phe252, Trp57 and Phe88. 
This site, that has been predicted to interact with MTs, is also shown to be in contact 
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with the EEY motif of EB1. The second interface consists of the β2-β3 loop, 
49ATLFLAT54 showing interactions with the EB1-like motif, i.e. the hydrophobic 
cavity of EB1, with the Ala49 inserted in the pocket.  
Despite the existence of a binding site to MTs in the CLAP-Gly domain, the complete 
deletion of the binding sites in EB1 results in activation of MT polymerisation by EB1 
alone. An explanation is possibly the fact that the EB1 C-terminal acidic tail has a 
unique sequence – 262QEEQEEY268 – very similar to the α-tubulin C-terminus – 
445EEEGEEY451, and if the region that recognises this sequence of EB1 is deleted the 
MT recognition region is also lost.29 
1.1.2.3 SxIP proteins 
Several +TIPs do not appear to use a defined and structured domain for targeting the 
MT ends. Instead, they contain extensive sequence regions that are enriched with basic 
and serine residues. These regions, which are predicted to be flexible, contain a EB1-
binding motif – SxIP, and track the plus ends with EB1 dependency.12,30,31 These are 
known as the SxIP proteins. Included in this vast group one can find the cytoplasmic 
linker associated proteins (CLASPs), APC, MACF, the calcium sensor (STIM1) and 
MCAK.  
Sequence analysis for a large number of these proteins revealed that they are very 
diverse in terms of domain composition but contain low complexity sequence regions, 
rich in basic, serine and proline residues, usually towards the C-terminus.  The SxIP 
motif also termed as microtubule tip localization signal, also shows some variability 
across SxIP proteins21,31,32 and it is likely to occur in many more proteins than the 
+TIPs identified so far.12 The isoleucine (or leucine) and proline residues are involved 
in hydrophobic interactions and are the most important, being also more conserved.22 
The serine at position 1 contributes to hydrogen bonds with conserved residues 
surrounding the EB hydrophobic groove, but recent data indicate that it is not required 
for plus-end tracking.22 Table 3 demonstrates this variability in known, probable and 
potential SxIP motifs found in a wide range of proteins with different cellular functions. 
Less well conserved variations of the SxIP motif can mediate plus-end tracking, and 
many +TIPs contain multiple functional SxIP motifs that act in concert and increase 
the affinity for EB1. CLASP2, for example, contains two adjacent SxIP motifs, which 
increases the affinity of this +TIP for growing microtubule plus ends. CLASP2 is 
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monomeric and one CLASP2 molecule is therefore able to bind to the two EBH 
domains in an EB dimer.12,26  
Table 1.2 – EB1 recruited +TIPs containing confirmed or potential SxIP motifs. Adapted from  Kumar 
& Wittmann, 2012.22 
Protein SxIP motifs Uniprot identifier Proposed functions 
+TIPs with confirmed SxIP motifs 
CLASP1, CLASP2 SKIP SRIP 
Q7Z460 
O75122 
MT capture, dynamics and 
nucleation at the Golgi apparatus 
MACF1 SKIP Q9UPN3 MT capture 
APC SQIP P25054 MT capture; mutated in colon adenocarcinoma 
STIM1 TRIP Q13586 
ER-microtubule interactions; 
activator of store-operated Ca2+ 
entry; mutated in particular 
imunodeficiencies 
MCAK SKIP Q996610 MT depolymerase 
KIF18B SFLP SSLP Q86Y91 MT depolymerase 
SLAIN2 
GGIP 
SAIP 
SGLP 
GGIP 
RSLP 
Q9P270 MT dynamics; recruits XMAP215/ch-TOG to MT plus ends 
Sentin/SSP2 
(Drosophila) TGIP QVUA5 
MT dynamics; recruits 
XMAP215/ch-TOG homolog to MT 
plus ends 
CDK5RAP2 SRLP Q96SN8 
Centrossome maturation; mutated in 
autosomal recessive primary 
microcephaly 
Kebab (Drosophila) TKIP Q9VQ69 Kinetocore component; unknown function 
Ipl1 (S. cerevisae) SKIP SKIP P38991 Yeast Aurora kinase homolog 
+TIPs with probable SxIP motif 
Melanophilin SNLP Q9BV36 Melanosome transport; mutated in Griscelli syndrome 
P140CAP TSIP Q9C0H9 MT interactions in dendritic spines; Src kinase regulator 
MTUS2/TIP 
SRLP 
SNLP 
SRLP 
SLLP 
Q5JR59 MT dynamics; recruits MCAK to MT plus-ends 
FOP SKIP Q95684 Centrossome MT anchoring; mutated in some myeloid cancers 
NAVIGATOR1 
SRIP 
SGIP 
SLIP 
Q8NEY1 
(Q8IVL1, 
Q8IVL0) 
Neurite outgrowth 
DRhoGEF2 SKIP Q44381 RhoGTPase signaling 
Potential SxIP motif-containing EB-binding proteins; unconfirmed plus-end tracking activity 
PSRC1/DDA3 SAIP Q6PGN9 Mitotic regulator of MCAK 
Plexin-B3 SGIP Q9ULL4 Axon guidance 
 Introduction 
 
9 
 
Honnapa and co-workers31, in 2009, assessed the role of the two SxIP motifs by 
replacing the Ile-Pro dipeptide of the two SxIP motifs individually or simultaneously 
by Ser-Ser. The replacement into either of the SxIP motif alone did not reduce binding 
to EB1, but significantly reduced accumulation of CLASP2 mutants at MT plus ends. 
When both Ile-Pro were mutated, CLASP2 had a strong reduction in EB1 binding and 
failed to localize to growing MT ends.31 These findings show that the presence of two 
SxIP motifs increases the affinity of +TIPs for the growing MT ends.   
The mode if interaction of these proteins with EB1 will be more detailed in section 
1.1.5, as it will be one of the main focus of this project. 
1.1.2.4 TOG domain proteins 
In addition to the SxIP motif, CLASPs have a Tumour-overexpressed gene (TOG) like 
domain, and are able to bind to tubulin through these domains. TOG domains are 250 
residue repeats found in several MAPs families allowing direct binding to MTs 
contrarily to what happens to SxIP proteins. 
 Members of the XMAP215/DIS1 family contain several TOG domains in their N-
terminal ends. XMAP215, which contains five TOG domains at its N terminus, 
functions as a processive MT polymerase, binding to tubulin dimers, through a 
conserved flat tubulin flat surface, to facilitate their incorporation into MT plus-
ends.33,34  
TOG-like domains in CLASPs have a convex tubulin-binding surface, suggesting that 
the recognition mechanism of tubulin by CLASPs differs from that of the 
XMAP215/Dis family. Functions of CLASPs are also different from XMAP215/Dis1 
families, including MT rescue and suppressing MT catastrophe events.33,35  
 
1.1.2.5 Main interactions at microtubule plus ends mediated by +TIPS 
As described in the previous sections, EB1 acts as a master regulator at MT plus ends 
protein interactions. However, CAP-Gly proteins despite having two binding motifs 
that bind to EB1 – GKNDG and ATLFLAT - can autonomously target MTs through 
the recognition of the EEY motif in tubulin - Figure 1.4. Both EBs and CLIPs are 
dimers and seem to require at least two tubulin-binding domains (CH or CAP-Gly, 
respectively) to track microtubule ends, suggesting that the affinity of individual sites 
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for microtubules or tubulin is relatively weak. The arrangement of these sites with 
respect to each other does not seem to be important because an artificial combination 
of a CH domain and a CAP-Gly domain is capable of plus-end tracking.2 CLIP170 has 
the EEY/F motif, meaning that, similarly to EB1, it can recruit other CAP-Gly domains. 
Additionally, CLIP170’s zinc knuckles can bind to CLIP170 and p150.  
CLASPs due to their TOG-like domain can directly bind to MTs. They can also bind 
to EB1 using their SxIP motif. In CLASP-depleted cells, EBs localize along the MT 
lattice in addition to plus ends. The MT-binding region of CLASP was sufficient for 
restoring normal EB localization.36 Similarly, XMAP215/DIS1 uses its TOG domain 
to bind directly to MTs. 
Finally, most of SxIP protein can only track the MTs plus ends through EB1 binding. 
These interactions are summarised in Figure 1.4 and Table 1.3.  
Table 1.3 – Summary of known domains and motifs interacting within the +TIP network. Adapted from 
Duellberg et al., 2014.29 
Domain/motif Found in Interacts with 
CH domain N-terminal part of EBs Growing MT plus ends 
EBH domain Part of C-terminal region of EBs 
SxIP motifs,  
CAP-Gly domains of p150 
EEY/F motif C-terminus of EBs, CLIP170 and α-tubulin CLIP170 CAP-Gly domains 
Zinc knuckle CLIP170 CAP-Gly domains  of p150 and CLIP-170 
SxIP motif Several unrelated EB-dependent +TIPs EBH domains 
CAP-Gly domain CLIP170, CLIP115 and p150 EEY/F motifs and EBH domains 
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Figure 1.4 – Schematic representation of possible +TIPs networks at the MT plus ends. Binding of SxIP 
proteins to EBH domain is one of the most well documented interaction, followed by the CAP-Gly 
domain proteins interactions with the EEY motif of EB1. The interaction of the ATFLAT motif from 
CAP-Gly proteins with the EBH domain of EB1 has also been reported. EB1 is shown in green, SxIP 
proteins in red, TOG domain in blue, CAP-Gly proteins in purple. α-tubulin dimer is showed in grey 
and β-tubulin in light blue. 
Due to the importance of EB1 as a recruiting protein to the MT plus ends, a more 
detailed description of the structure features will be subsequently described. 
 Disease states associated with EB1 
EB1 was initially described as a protein that interacts with the C-terminus of APC that 
has a known tumour suppressor function and when mutated may result in colorectal 
cancer.12,37 Observations revealed that these mutations resulted, very often, in the 
truncation of APC leading to the loss of the region that interacts with EB1. It was, 
therefore, postulated that EB1-APC interaction may be important for the tumour 
suppression activity of APC.38 Later, EB1 overexpression has been reported in gastric 
adenocarcinoma, hepatocellular carcinoma, oesophageal squamous cell carcinoma and 
breast cancers.37 Conversely, the knockdown of EB1 expression promoted an increase 
in apoptosis. These functions were associated with the activation of the β-catenin 
pathway – promoting the growth and inhibiting apoptosis.25,37,39 
In addition to the above-mentioned relationship between EB1, APC and 
cancer/apoptosis regulation, EB1 deregulation can influence other biological processes 
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as it recruits a wide number of partners to the MT plus-ends. 40 
Another relevant example is MACF/ACF7, member of the spectraplakin family that 
through their binding to EB1 reinforce links between F-actin and MTs, acting as an 
integrator of MT-actin dynamics.41 Ablation of the ACF7 gene in mice results in 
embryonic lethality and various medical conditions and development defect arise from 
mutations in genes encoding spectraplakins, such as mental retardation, cancer and 
chronic skin blistering.41 
 Structural features of EB1 
EB1 binds to the MT plus ends with higher affinity (about 10-fold higher) when 
compared to the MT lattice, presenting also fast binding/unbinding kinetics.19 These 
characteristics are fundamental for the EB1’s functions at the MT plus ends. This 
protein has been structurally characterised by X-ray crystallography (both N and C-
terminal domains), nuclear magnetic resonance (NMR) spectroscopy (N-terminal 
domain) and small angle X-ray scattering (SAXS), combined with single-particle 
electron microscopy (for the model of the entire EB1 molecule).22,42 SAXS data shows 
the overall structure consists of two large domains, N- and C-terminal, joined via a 
less conserved linker sequence, forming a flexible Y shaped structure (Figure 
1.5).2,42,43 The same low resolution model of the EB1 molecule shows that despite 
being a homodimer, EB1 can be surprisingly asymmetric. The C terminal rod-like 
coiled coil is more closely associated with one of the CH domains and protrudes from 
the microtubule-binding domains at an angle of almost 45o.22 
The N-terminal domain is necessary and sufficient for MT binding. Its structure, 
solved by X-ray crystallography (PDB codes 2R8U (Huang, Lovelace, Smith, & 
Lebioda, unpublished), 1PA7 and 1UEG45 and solution NMR (PDB code 1V5K 
(Tomizawa, Kigawa, Koshiba, Inoue, & Yokoyama, unpublished), revealed a CH fold 
and consists of six helices.23,43 The architecture of the domain is dominated by four 
major α-helices (α1, α3, α4 and α6). The first helix (α1) forms an angle of ~75o with 
the central helices α3 and α4. Three helices α3, α4, and α6 form a parallel three helices 
bundle, giving rise to a hydrophobic core, α4 and α6 are partially exposed to the solvent, 
creating a conserved hydrophobic cleft that provides a potential protein-protein 
interaction surface.  
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Figure 1.5 - Representation of the overall structure of EB1, composed by two larger globular domains 
(N-terminal), joined via a flexible linker to a coiled-coil domain (C-terminal). This figure is a 
reproduction of the one published by Akhmanova & Steinmetz, 2008.2 
EB1 (and its fission yeast homolog Mal3) targets to growing MT ends by recognizing 
a nucleotide-dependent structural state. The binding mode of N-terminal domain of 
Mal3, the fission yeast EB, to MT plus ends was described as the interaction with four 
different tubulin dimers – Figure 1.6.  
 
Figure 1.6 – Suggested binding mode of EB1 CH domain to microtubules. The binding site is formed 
by two adjacent α-tubulin contacts (towards the microtubule plus end) and two adjacent β-tubulin 
contacts (towards the minus end). 
The CH domain binding site is formed by two adjacent α-tubulin contacts (towards the 
microtubule plus end) and two adjacent β-tubulin contacts (towards the minus end 
showing that Mal3 binds to four neighbouring tubulins, at the junction between two 
protofilaments and two longitudinal interfaces.19 Once polymerization occurs, the 
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interaction partners α and β tubulin align themselves in a favourable position and EB1 
may bind to these, stabilising the MTs promoting its MT polymerization.23 Cryo-EM 
structures of MTs co-assembled with EB3 show that the presence of EB promotes a 
compacted MT lattice with a unique lattice twist, which EB itself preferentially binds. 
It was proposed that stabilisation of MTs catalysed by EB is due to the strengthening 
lateral and longitudinal interactions between dimers that promote a more compact MT 
lattice. The compacted lattice could then speed up GTP hydrolysis. The strain 
generated in the tubulin subunit following GTP hydrolysis, will promote the breakage 
of lateral contacts, likely initiated at the weaker seam interface. EBs promote MT 
growth by binding at the intersection of lateral and longitudinal contacts and enforcing 
the proper geometry of contacts to facilitate seam closure.8  
The C-terminal domain of EB1 (EB1c) contains a parallel two-stranded coiled coil 
followed by the unique EB homology domain (EBH) domain containing a four-helix 
bundle and a disordered C-terminal region encompassing the EEY/F sequence motif 
(Figure 1.7).31  
 
Figure 1.7 - Four-helix bundled structure of the C-terminal of EB1 (PDB code 1WU9). Coloured in blue 
are the long helices (α1 and α’1), followed by a hairpin connection (coloured green) leading to a short 
second helix (α2 and α’2, coloured pink). Finally the  C-terminal disordered tail is coloured grey.43  
The two parallel α1-helices of EB1c wrap around each other in a slightly left-handed 
supercoil. The residues occupying the core a and d positions of the four heptad repeats 
(Figure 1.8) between Ala193 and Leu221 pack in a typical “knobs-into-hole” fashion.   
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Figure 1.8 – Sequence for the C-terminal domain of EB1 (EB1c). Coiled coil region shown in blue with 
positions a and d of the heptad repeats underlined. The connection hairpin between the two helices is 
represented in green. The shorter helix is shown in pink followed by the disordered C-terminus in grey. 
Uniprot47 code MAPRE1.  
The EBH domain is responsible for the dimerization of EB1 monomers and represents 
the +TIPs recruitment domain of EB1. This domain has a four-helix bundled structure, 
where the two coiled-coil helices, residues 219-229 (α1), diverge into a fork like 
structure. The following C-terminal helices, residues 237-247 (α2), of each monomer 
form a complementary fork, joining with the α1 helices (Figure 1.7).23 The large 
hydrophobic surface buried in this bundle is expected to significantly contribute to the 
stability of the dimeric structure of EB1c.43 First, the side chains forming the 
hydrophobic core of this bundle (equivalent residue pairs are 221/239, 224/242 and 
227/245) are highly conserved, additionally, mutation of Ile224 to alanine was shown 
to destabilise the four helical bundle and consequently abolish dimerization.27  
Residues 211-229 of the N-terminal region of the coiled coil are highly conserved 
across 13 representative EB1 family members, from yeast to vertebrates. This region 
includes three invariant residues Phe216, Tyr217 and Phe218’, forming the FYF’ motif. 
The configuration of the coiled coil dictates that the spatial FYF’ motif is comprised 
of Phe216 and Tyr217 from one chain and Phe218’ from the other chain of the dimer. 
Additional conserved residues at this junction are two solvent exposed residues of the 
α2 helix: Ile245 and Tyr247. This conserved surface is characterized by a hydrophobic 
character and a negative net charge contributed by the acidic residues Glu211, Glu213, 
Asp215 and Glu225. To evaluate the individual contribution of residues within the 
211-229 conserved region, single alanine mutations were prepared and mutant EB1 
proteins were analysed for MACF21595-1637 (SxIP containing protein) binding. The 
analysis revealed Glu211, Asp215, Phe216, Tyr217, Phe218, Arg222, Glu225 and 
Leu226 as the key binding residues. The FYF’ motif provided a critical contribution 
to the binding interaction since mutation of any of these three residues abolish binding 
- Figure 1.9.27  
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Figure 1.9 - Surface and cartoon representation of EB1. A - conserved residues are explicitly shown as 
sticks for a better visualisation and each monomer coloured differently, cyan and green.48. B – surface 
representation where the residues coloured in red were shown to be important for the binding to 
MACF21595-1637, trough single alanine mutagenesis experiments, as reported by Slep and co-
workers.27                                                                                                                                                                                                
Finally, the flexible C-terminal (Tyr247-Tyr268) tail of EB1 is unstructured and 
flexible, having a highly conserved acidic-aromatic C-terminus – the EEY/F sequence 
motif that is reminiscent of motifs that are found in α-tubulin and CLIP170.2 The 
entirety of the C-terminal disordered region was never characterised since the EBH 
domain of EB1 has only been studied by X-ray crystallography, unsuitable for 
unstructured regions. 
 Interaction between EB1 and SxIP motif proteins 
MT plus-ends protein interactions are very complex and not fully understood as 
previously described. SxIP proteins track the MT plus ends through EB1 recruitment 
and relevant examples of this interaction are MACF, STIM1, APC and CLASPs.5 
Crystal structure of EB1cΔ8-MACFp1 complex (PDB code 3GJO31) provides details 
on the SxIP motif recognition. In this crystal structure EB1c domain (residues 191-
268) and a short peptide (30 amino acid residues), derived from human MACF2, were 
used. There are two EBH homodimers in the asymmetric unit and consequently four 
independent binding sites. MACF2 binding region to EB1 is known as unstructured, 
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and from the 30 amino acids a maximum of 11 can be observed in one of the binding 
sites. Residues outside this SxIP-containing region are less well defined and do not 
participate in specific intermolecular interactions.31 A heptapeptide 5476PSKIPTP5482 
of the ligand is in a very similar conformation for three of them, meaning this sequence 
becomes more structured and less dynamic when bound to EB1 and therefore must be 
of great importance for the interaction. Residues of the SxIP motif make specific 
contacts with the protein. Ser5477 forms an extensive network of hydrogen bonds with 
the highly conserved Arg222, Glu225, Gln229 and Tyr247 residues of EB1 and a water 
molecule. The dipeptide Ile-Pro is buried within a cleft shaped by the residues Phe216-
Arg222, Glu225, Leu246 and Tyr247 of the hydrophobic cavity and Ala248-Pro256 
of the C-terminal tail. Further contacts between Thr5481 and Pro5482 with Phe253, 
Gly252 and Val254 are shown (Figure 1.10).31  
 
Figure 1.10 - Representation of the SxIP binding mode as shown by Honnappa et al.31. SxIP containing 
peptide is shown as light pink sticks, and the SxIP motif is highlights as bright pink sticks. EB1 is overall 
shown as cartoon and surface representation with important residues shown as sticks. The sign ‘ is used 
after the residue name to indicate it belongs to the other monomer. 
Buey et al. in 2012 made a systematic analysis of the important residues for the binding 
based on a 30 residue peptide derived from MACF2 – MACFp1 (the same fragment 
used to obtain the complex published by Honnappa et al., 200949) by mutating each 
one of the 30 positions at a time. They found that the 12 residues spanning the sequence 
region 5476PSKIPTPQRKSP5487 have a major contribution to the binding to EBH 
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domain of EB1. This region obviously includes the SxIP motif (SKIP), although it is 
noteworthy that the replacement of residues in this sequence by negatively charged 
glutamates or aspartates severely impaired the binding. Basic lysine and arginine 
residues are preferred, inclusively for the x position in the SxIP. Notably, this position 
does not tolerate many mutations, being arginine the only substitution that does not 
interfere with the binding. The side chain of this lysine is not pointing directly to the 
EB1 surface; instead, it seems to promote long range electrostatic attractive 
interactions with the negatively charged surface of the flexible C-terminal of EB1, e.g. 
Glu258. From the analysis of the possible replacements in the first position of SxIP, 
serine can only be replaced by threonine that also includes a hydroxyl group in its side 
chain. Regarding isoleucine at position 3, it only bears the replacement by the 
hydrophobic side chain of leucine, with significant reduction of the binding affinity. 
Finally, proline in position 4 cannot be replaced by any amino acid. The ring fills a 
hydrophobic pocket, and any other side chain would have the polar amide group from 
the backbone pointing into this hydrophobic region.49 These observations are 
supported by a sequence alignment of SxIP proteins in Figure 1.11. Sequences 
surrounding functional SxIP motifs are interspersed with positively charged amino 
acids and are particularly enriched in arginine residues. Sequence alignment of 30 
amino acid stretches around the reported microtubule tip localization signal (SxIP) 
shows the prevalence of serine and proline residues around these regions. There is also 
a very low content in negatively charged residues, with higher occurrence of positively 
charged residues (coloured in blue). 
SxIP motifs are required for plus-end tracking, since the mutation of this motif 
abolishes binding to EB1, but by themselves are not sufficient. The hydrophobic 
interaction surface of the SxIP motif, and consequently the binding free energy 
contribution of this interaction, are probably fairly small.22 
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Figure 1.11 - Sequence alignment for known SxIP proteins based on a 30 residue sequence 
encompassing the identified SxIP motif. The sequence is colour coded as: positively charged residues 
(arginine and lysine) coloured in blue, serine and threonine coloured in green, hydrophobic residues 
(isoleucine and leucine) coloured in yellow and proline coloured in orange. Intensity of the colour 
indicates the higher conservation in that position. Figure was made using JalView 2.8.2. 
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The structure of EB1 in complex with the peptide derived from MACF2 also 
demonstrates an additional feature of the interaction. Residues 250-257, which are not 
resolved in the crystal structure of the free EB1c dimer, become structured in complex 
and form a handle-shaped loop wrapped around the bound peptide.31 The EB1 C-
terminus region (Thr249-Tyr268) contains negatively charged residues, in a 19 residue 
span, eight are negatively charged (Figure 1.8). SxIP proteins have high propensity to 
have positively charged residues around the SxIP motif (Figure 1.11) and it is 
reasonable to assume that electrostatic interactions contribute significantly to +TIP 
interactions with EBs.22 In the case of CLASP2, there are indications that conserved 
arginine residues surrounding the SxIP motifs participate in extensive salt-bridge 
networks with negatively charged glutamates near the EB1 C-terminus. Such arginine–
glutamate salt bridges are highly favourable, but they can be efficiently disrupted by 
phosphorylation.22 These electrostatic interactions can be tuned by multisite 
phosphorylation through induction of intermolecular phosphoserine-arginine salt-
bridges as an alternative to the intermolecular interactions with EB1 glutamate 
residues, and this can be a way of controlling these dynamic networks.32 Therefore, 
the recruitment of SxIP motif containing +TIPS through EB1 binding depends on 
hydrophobic interactions of the SxIP motif, that determine specificity and on less 
specific electrostatic interactions that contribute largely to the binding free energy.22  
The SxIP containing regions are within intrinsically disordered regions (IDRs). 
GTSE1, for instance, a protein which secondary structure prediction revealed that it is 
a mostly intrinsically disordered protein (IDP), contains multiple potential ‘‘SKIP’’-
like (SxLP) EB1-interaction motifs surrounded by basic residues.50 At the same time, 
the C-terminal region following the EBH domain of EB1 and involved in the 
interaction with SxIP ligands is highly flexible and disordered. It has been reported 
that complexes involving IDRs are often highly dynamic and short lived.51 IDRs often 
participate in interactions with high specificity but low affinity (µM range), facilitating 
rapid exchange of binding sites between multiple interacting partners. These 
observations are in agreement with what has been reported for the SxIP-EB1 
interactions, where the EB1 binding affinities of many SxIP containing regions are in 
the low/medium micromolar range.49 
For the +TIPs networks mediated by EB1 the existence of IDRs seems to be 
fundamental. The inherent flexibility of IDRs allows for a degree of promiscuity in 
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interactions with cellular partners containing the SxIP motif that will give the 
specificity needed to the interaction, explaining, partly, how EB1 can act as an 
essential adaptor protein at the MT plus ends.  
Due to the important role as a master regulator of protein-protein interactions at the 
MT plus ends the design of small molecule modulators to target EB1 is very attractive. 
This poses a challenge for two reasons, the first related with targeting a protein-protein 
interaction and the second related with the existence of IDRs in both proteins. Both 
subjects, intrinsically disordered regions in intermolecular interactions and protein-
protein interactions, will be subsequently introduced. 
1.2 Protein-protein interactions: a biological challenge for drug target-
ing 
 Protein-protein interactions 
Protein-protein interactions (PPIs) play a central role in many biological processes.52 
With the recent developments in the area of genomics and proteomics, complete 
networks of PPIs within a cell (interactome) were identified, leading to major 
breakthroughs in understanding biological pathways, host-pathogen interactions and 
cancer development.  
It is estimate that 650000 protein-protein interactions exist in human interactome.53,54 
PPIs play a key role in nearly every biological function55, regulating numerous cellular 
processes including signalling pathways, morphogenic pathways and complex 
molecular machines.56 Furthermore, aberrant PPIs contribute to most disease states, 
representing a highly populated class of untouched potential targets for drug 
discovery.54 Thus, it is of great importance to use and develop new technologies to 
target these PPIs by discovering PPI modulators, both as inhibitors or probes to 
understand these complex processes.54,57  
Currently, three main classes of PPI modulators are known, antibodies, peptides and 
small chemical compounds, although nucleic acids and sugar molecules can also be 
used.54 Antibodies have high specificity and are stable in human serum. However, they 
are not cell permeable and do not have oral bioavailability, making it difficult to use 
in therapeutics. Despite that, monoclonal antibodies Avastin and Herceptin are 
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currently in use.52 Peptides usually suffer from poor metabolic stability, low 
bioavailability and can induce immune reactions.58 However, miniature proteins still 
hold a considerable promise given their enhanced conformational and proteolytic 
stability.52 The main advantage is due to its size (~20 residues), these peptides adopt a 
defined conformation improving its stability.57 From a medicinal chemistry and drug 
development perspective, small molecules, which are generally cheaper to 
manufacture than antibodies and peptides and have good oral bioavailability, are still 
the preferred option.58,59 The latter, small drug-like molecules, will be the main focus 
in this work.  
PPIs can occur between two structured protein domains, a structured domain and a 
relatively short peptide, or between two peptide stretches. In many cases, additional 
weak contacts distant to the defined interaction area contribute to binding, thereby 
adding complexity and complicating the prediction of PPI characteristics.60 Structural 
biology has shown that PPI interaction surfaces are generally large (~1500-3000 Å), 
flat61, and generally lack the grooves and pockets present at the surface of proteins that 
bind to small molecules.59 Moreover, most contact surfaces in protein-protein 
interfaces involve amino acid residues that are not contiguous.59 Unlike enzymes or G 
protein-coupled receptors (GPCRs), nature did not offer simple small molecules that 
can start a chemical discovery process and high-throughput screening (HTS) had not 
provided validated hits.62 The chemical space of traditional small-molecule libraries 
deviates from that of PPI inhibitors, thus leading to low hit rates when applied in 
screening for PPI inhibitors. This stimulated the search for alternative strategies 
involving fragment-based screens or natural product inspired libraries that contain 
molecules with relatively high molecular weights and a large number of stereogenic 
centres.60 
The investigation of numerous PPI interfaces revealed that a small subset of residues 
are the major contributors for the free energy of binding. These regions are generally 
called “hot-spots” and often overlap with structurally conserved regions and represent 
a common feature of PPI interfaces.57,60,61 Hot spots tend to cluster at the centre of the 
interface, cover an area comparable to the size of a small molecule, be hydrophobic 
and show conformational adaptivity.62 Using a hot-spot as the starting point for ligand 
identification is generally accepted as a useful strategy  for the discovery of PPI small 
molecule modulators.52  
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Small molecules inhibit PPIs through at least three different mechanisms: orthosteric 
inhibition, allosteric regulation, and interfacial binding/stabilization. The first 
mechanism, orthosteric inhibition, involves direct competition against the interacting 
partners, binding to sites in the target proteins that overlap with the areas used for 
interacting with the partner proteins. The allosteric regulation relies on ligand binding 
induced changes in the target protein. These small-molecule ligands bind to sites 
distinct from the macromolecular interface inducing changes in either the static 
conformation or the dynamic properties of the target protein(s) and hindering the 
native interaction. Finally, an interfacial inhibitor binds to a pocket at the 
macromolecular interface, which sometimes is only transiently formed in a transition 
state, and locks the complex into a conformation that cannot be targeted by the natural 
ligand.63 
Despite all the challenges and difficulties, in the past decade, an increasing number of 
successful cases of PPI inhibitors were reported.  
1.2.1.1 Success cases in modulating protein-protein interactions 
The cytokine interleukine-2 (IL-2) has a key role in the activation of T cells and in the 
rejection of tissues grafts, having a considerable medical interest. A series of small 
molecules that bind to IL-2 were discovered at Sunesis Pharmaceuticals, where 
SP4206 (Figure 1.12) showed to bind with high affinity. A fragment-based approach 
guided by X-ray structures and medicinal chemistry was used in this project since the 
structure of the IL-2-IL-2-Rα complex was not known by that time.59  
Another successful case in protein-protein interactions modulation is the B-cell 
lymphoma 2 (Bcl-2) family members. These are important regulators in apoptosis, and 
can form homo or heterodimers with other family members generating several 
combinations of pro-apoptotic and/or anti-apoptotic complexes. ABT737 (Figure 1.12) 
binds to Bcl-XL, inhibiting its anti-apoptotic activity.59  ABT-26364, a ABT737 
derivative has reached the clinical trials phase.53 This group of compounds was 
discovered using a fragment-based NMR method known as structure–activity 
relationships (SAR) by NMR, and their properties were improved by using NMR-
structure-guided medicinal chemistry.65 
A third success case, the human protein double minute 2 (HDM2) has emerged as an 
excellent drug target for cancer treatment. It binds to the tumour-supressor protein p53 
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and increases its degradation. A benzodiazepinedione and Nutlin-3 (Figure 1.12) 
were found to disrupt the HDM2-p53 complex. Both these scaffolds were discovered 
through HTS and further optimisation of the found hits.59  
These success stories elucidate some features about PPIs that can be useful in other 
drug discovery projects for PPI modulators. For instance, a common myth is that 
protein-protein interfaces are large and flat, often rigid and do not present cavities for 
small molecule binding. However, in all of the supramentioned cases the contact 
surfaces have some adaptability, and cavities that are not seen in structures of either 
the free protein or the protein–protein complex become available for binding.59 A 
single crystal structure may not reveal potential binding modes for small molecules.54 
Eyrish & Helms66 showed through molecular dynamics (MD) simulations that the 
protein surfaces of Bcl-XL, IL-2 and MDM2 form transient binding pockets that were 
not initially observed. 
 
Figure 1.12 – Examples of small molecules that inhibit protein-protein interactions.59  
All the examples described above included an empirical screening process, fragment 
screening or HTS.59 Unfortunately, assays to investigate PPIs are usually difficult to 
apply to HTS. Therefore, structure-based drug design, in silico screening and other 
chemoinformatics strategies need to be developed and applied to facilitate the 
development of PPIs modulators.58 However, given that the type of interactions for 
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PPIs differ from those typical for enzyme and receptor drug targets, exploration of the 
chemical space defined by PPIs requires different approaches not biased by earlier 
drug discovery campaigns.61 Commercial libraries of compounds used for screening 
are generally dominated by past drug discovery research into “druggable” targets, such 
as G-protein-coupled receptors or enzymes.59  
A balance between potency and selectivity required for a PPI modulator and drug-like 
properties for oral administration need to be found in order to successful target the vast 
range of PPIs. In other words, there is the need to find the chemical space of PPIs 
modulators, moving away from the libraries of compounds created primarily focused 
on other classes of targets. 
1.2.1.2 Drug discovery in protein-protein interactions 
To tackle the challenge of finding small molecule inhibitors to target protein-protein 
interactions many approaches were used in the past, biophysical methods (X-ray 
crystallography and NMR), fragment-discovery approaches as SAR by NMR and 
tethering, HTS, and in silico approaches, such as structure- or ligand-based virtual 
screening, protein–protein docking, hot-spot and druggable pocket prediction tools.67  
One of the most successful approaches applied to protein-protein interactions is 
fragment-based drug discovery. Fragment initial hits will have low affinity, but when 
tethered they allow novel areas of chemical space to be explored, creating diversity in 
chemical libraries.59 However, few fragment-based campaigns of PPIs have been 
reported in the literature, let alone advanced into the clinic.68 HTS of compound 
libraries has also been widely used.69 Unfortunately, this strategy requires a large 
physical compound library, a suitable screening method and a validation method. This 
approach has been mostly used in pharmaceutical companies but some academic 
groups have been using it. Nevertheless, it requires not only a suitable system to be 
screened (not all biological systems may be analysed using the same techniques) but 
also a great investment in the latest technologies for compound screening, screening 
libraries, etc. This approach can be also time consuming. Alternative inexpensive and 
fast methods may be the rational drug design/identification through computational 
methods. 
The first step in the rational drug design using computational methods, should be the 
creation and validation of a theoretical model, gathering information from the target 
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and known ligands.70 Identifying in silico virtual hit molecules – virtual screening – is 
usually the next step.  
1.2.1.2.1 Virtual Screening 
The virtual screening of chemical libraries aims to identify new small organic 
molecules that are able to interact with a specific target, modulating its activity.70 
Virtual screening is the in silico analogue of biological screening, with its aim being 
to identify hit molecules from a chemical library using one or more computational 
procedures, to help decide which compounds to screen, synthesise or purchase.71  
There are two main strategies that can be used in virtual screening – ligand-based and 
structure-based design. The ligand-based design approach is based on knowledge of 
known molecules that bind that target (e.g. pharmacophore search). While, when the 
structure of the target is known molecular docking can be performed in a structure-
based design approach72,73 – Table 1.4.  
Table 1.4 – General guidelines when making a decision on the method for computer aided drug design. 
  Ligand(s) 
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û 
Ligand-based design 
• Similarity search 
• Pharmacophore 
• QSAR 
 
Ligand-based design is based on the availability of pharmacologically relevant agents 
and their bioactivities, i.e. known ligands for a certain target. Approaches include 
similarity searching, a host of machine learning methods including quantitative 
structure activity relationships (QSAR) and pharmacophore mapping. If just a single 
molecule is known similarity searching is an option. If some ligands are known it is 
possible to identify a common pharmacophore, followed by a 3D database search. 
When a large number of ligands have been tested for a certain target and there are 
active and inactive structures then machine learning methods and QSAR approaches 
can be used.71 Unfortunately, for EB1 there are no known active ligands, apart from 
the naturally occurring SxIP containing proteins. Therefore, the only ligand-based 
design method that can be applied to this system is the construction of a 
pharmacophore model based on the SxIP feature. A pharmacophore model is “an 
ensemble of steric and electronic features that is necessary to ensure the optimal 
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supramolecular interactions with a specific biological target and to trigger (or block) 
its biological response”.74 From the practical point of view, pharmacophores can be 
used to screen millions of high quality compound structures within a reasonable 
amount of time, particularly when approximations such as rigid pharmacophore fitting 
procedures are used.75 The positioning of key features like hydrogen-bonding and 
hydrophobic groups is summarised in a pharmacophore representation. It can be used 
as a template to select the most promising candidates from a library or as a filter before 
applying a structure-based virtual screening method, so that only 1–10% of the initial 
database has finally to be docked.76  
Structure-based virtual screening methods offer means to directly identify novel 
compounds that complement the target protein surface; these methods are not limited 
by the requirement for template compound(s) implicit to ligand-centric (mimicry) 
approaches.77 Docking is the most used tool for structure-based virtual screening.76 
The docking process involves the prediction of ligand conformation and orientation 
(pose) within a specific binding site.73 Docking algorithms pose small molecules in the 
binding site, being complemented by scoring functions that evaluate the interaction 
between the molecules and the target – scoring.73  
The success of structure-based drug design is well documented; it has contributed to 
the introduction of ~50 compounds into clinical trials and to numerous drug 
approvals.78 In the last years, diverse research groups proposed an integration of 
ligand- and structure-based strategies to increase the success of virtual screening 
processes. On one side pharmacophore information of ligands have been incorporated 
in docking studies, and on the other side docking studies have been carried out finding 
suitable conformations, inside the target binding cavity.79 These successes were 
achieved by using a combination of methods, molecular docking, pharmacophore 
search, application of filters, amongst others.80  
To illustrate the success of computational methods in drug discovery, Aggrastat 
(Figure 1.13), an antiplatelet drug that belongs to glycoprotein IIb/IIIa inhibitors class 
is one of the first commercialized drug whose discovery was influenced by virtual 
screening methods (in this case pharmacophore search).81  
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Figure 1.13 - Aggrastat, an antiplatelet drug of the glycoprotein IIb/IIIa inhibitors class whose discovery 
was influenced by virtual screening methods. 
1.2.1.3 The chemical space of PPI modulators 
The physicochemical properties of the novel chemical entities identified in virtual 
screening have become the subject of intense scrutiny from lead discovery to drug 
candidate. The selection of compounds with acceptable drug-like properties is often 
performed as a post-dock processing.56 In this section the focus will be on molecular 
properties important for drug-like compounds and how the traditional drug like 
properties compare with the PPI modulators, as many reports have found that small 
molecules targeting PPIs often fall outside the chemical space of the current drugs.62,82 
The meaning of ‘‘drug-like’’ is dependent on mode of administration. The original 
Rule of 5 (Ro5)83 deals with orally active compounds and defines four simple 
physicochemical parameter ranges:molecular weight (MW) ≤ 500; logP ≤ 5; H-bond 
donors ≤ 5 and H-bond acceptors ≤ 10; these rules are associated with 90% of orally 
active drugs that have achieved phase II clinical status.84 If a compound fails two or 
more of the Ro5 there is a high probability that the compound will display poor oral 
availability. However, passing the Ro5 is no guarantee that a compound is drug-
like.84,85 
In many cases, at least modifications of Lipinski’s rule-of-five have been allowed to 
account for the larger size and higher hydrophobic content of protein–protein 
interfaces. In fact, by analysing some physicochemical properties of known small 
molecule modulators of PPIs it is evident that some of the identified compounds 
violate one or two Lipinski’s rules, in particular, MW and/or logP and exhibit 
solubility issues.67 
Traditionally, affinity is the first aspect considered for hit selection and optimization. 
However, affinity alone can be misleading as it is often found to be linked with 
molecular size. Thus a focus on affinity leads to a bias towards a selection of bigger 
compounds. In addition, optimization of affinity during subsequent stages of drug 
discovery typically leads to a further increase in molecular weight.86 The idea of ligand 
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efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful 
guide to optimize fragment and lead selection in the discovery process. Moreover, the 
ligand efficiency coefficient used to analyse protein–ligand interactions during the 
course of drug discovery programs has been revisited for PPI modulators and estimated 
to be 0.24 kcal/mol per heavy atom.58,62 This is lower than most kinase inhibitors (0.3–
0.4 kcal/ mol) but on the same order of magnitude of many protease inhibitors (0.25–
0.35 kcal/mol). Consequently, a PPI modulator with a Kd of 10 nM is expected to have 
a molecular weight of approximately 645 g.mol-1 when regular orally available drugs, 
most of the time, are below 500 g.mol-1.58 There are other important issues for drug 
likeness, including lack of reactive functionality (except in prodrugs), cell 
permeability, and, for central nervous system compounds, brain/blood partitioning. An 
acceptable level of solubility is also critical to permit dissolution and absorption; 
virtually all drugs have aqueous solubility above 106 M (log S > – 6).78  
There have been several attempts to find the chemical space of PPI modulators. A 
study presented by Morelli and co-workers in 2011 suggest an adaptation of Lipinski’s 
Ro5 to a “rule of four”.53 After statistical analysis of the 39 inhibitors these authors 
report average values for molecular weight (547 ± 154 g.mol-1, thus MW > 400 g.mol-
1), ALogP (3.99 ± 2.37, thus ALogP > 4), number of rings (4.44 ± 1.02, thus #Rings > 
4) and number of hydrogen bond acceptors (HBA) (6.62 ± 2.60, thus #HBA > 4). 
Figure 1.14 shows a comparison between Ro5 and rule of four. 
Analysis of PPI focused libraries has suggested that, in addition to the features 
formerly presented, PPI modulators often present branched structures and have high 
content in multiple bonds, i.e. have a more tri-dimensional shape around a central 
scaffold.58 The preference towards a tri-dimensional and branched shape may be 
related with the fact that the hot spots on the target protein are commonly composed 
by two to three sub-pockets62 and a branched structure has more chances to fill in these 
sub-pockets. 
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Figure 1.14 – Comparison of Lipinski rule (rule of 5)83 and the values reported for the definition of a 
generic profile for PPI inhibitors (rule of 4) reported by Morelli et al.53 
When looking to protein-protein interfaces one of the interesting features of hot spots 
is their functional and structural adaptivity. Many proteins function by binding to 
multiple partners. An important point is that these proteins tend to use the same hot 
spot, which adapts to present the same residues in different structural contexts.87 
 
 Disorder and dynamics in protein-protein interactions 
For many protein–protein interactions, the apparent complementarity between the two 
surfaces involves a significant degree of protein flexibility and adaptivity.87 As 
presented previously the EBH domain of EB1 does not only bind to IDRs containing 
SxIP motifs, but itself contains an IDR that becomes structured upon complex 
formation (section 1.1.5).  
The binding process in dynamic/disordered regions is of great interest from both 
mechanistic and functional standpoints. Traditionally, there are two models focused 
on flexibility to describe binding processes, induced fit and conformer selection. The 
popular notion of induced fit assumes a passive mutual adaptation, but it does not 
explain specific recognition if the two protein structures are not complementary to start 
with. The opposing idea of conformer selection suggests recognition between the two 
bound conformations that are postulated to occur within the diverse structure 
ensembles of the two free proteins.88 Either the conformational change precedes the 
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binding (conformational selection) or occurs following the binding (induced fit). An 
alternative model that mixes both concepts have been proposed by Grünberg and co-
workers in 2004, were some conformations among the structure ensembles of unbound 
proteins are more prone to recognition than others.89  
Therefore, there might be binding-site conformations that are well-suited to small-
molecule binding yet are not visible in a single crystal structure.87 Solution methods 
for analysis of these complexes with dynamic regions seem to be fundamental to 
understand the underlying mechanisms of binding. 
 Screening techniques in drug discovery applied to protein-protein in-
teractions 
As pointed out before, many of the recent clinically approved drugs have originated 
from HTS campaigns, through the use of microtriter plate-based assays against 
libraries of small molecules.90 When it comes to hit validation, target-based 
biochemical assays have proven their value in PPI drug discovery projects, but cell 
based assays have significantly become more important. Despite that, target validation 
and understanding the underlying mechanisms of action can only be understood 
through target based assays.90 A summary of the assay methods, protein/reagent 
requirement and associated assay cost estimations are shown in Table 1.5. Post-
screening hit validation studies are employed to gain an understanding of the mode of 
action of the molecules. The low-throughput assays described are considered as being 
the most appropriate for this as they provide information such as Kd, kon, koff, 
identification of which protein within the PPI complex they bind to as well as their 
stoichiometry. Cell-based assays are also highly attractive during the hit validation 
phase as a positive outcome (e.g., inhibition of the PPI) assumes that the investigated 
compounds can penetrate the cell membrane and are not cytotoxic.90 
Some of the gold standard assay formats to monitor PPIs have a low-throughput and 
advances are being made to them so as to increase their capacities.90 A recent study 
based on an integrated biophysical approach for fragment screening has shown that the 
use of several different biophysical techniques was essential for the validation of hits 
proceeding from the thermal shift analysis. Whereas thermal shift provided a fast way 
to screen the entire library, NMR allowed the subsequent validation of the resulting 
hits. Thermal shift provided a >50% rate of false positives that were later verified not 
Introduction 
 
32 
 
to bind by NMR; however it significantly enriched the hit rate of the secondary NMR 
screen. Most fragments validated by NMR and isothermal titration calorimetry (ITC) 
were shown by X-ray crystallography to bind, making these techniques ideal for 
compound screening and hit validation.91 
 Table 1.5 - Screening techniques applied in drug discovery assays. This table was originally published 
by Gul & Hadian in 201490 
Technique Throughput Assay type Protein/reagent requirement Assay cost 
Isothermal titration calorimetry Low Biochemical High Low 
Surface plasmon resonance Low Biochemical Low Low/medium 
Microscale thermophoresis Low Biochemical Low Low/medium 
ELISA Low Biochemical Low Low 
Pull-down Low Biochemical Medium/high Low/medium 
NMR and X-ray 
crystallography Low Biochemical High Medium/high 
Amplified luminescent 
proximity homogeneous assay 
screen 
High Biochemical Low High 
Time-resolved Förster 
resonance energy transfer High Biochemical Low High 
Fluorescence polarisation High Biochemical Low Low 
Förster resonance energy 
transfer/biolumniscence High Cell-based Low Low 
Biomolecular fluorescence 
complementation High Cell-based Low Low 
In situ proximity ligation assay Medium/high Cell-based Low Medium/high 
Co-immunoprecipitation Low Cell-based Medium/high Low/medium 
In this project the HTS approach was replaced by a more directed virtual screening 
approach and therefore there is no need of a screening technique that can be applied to 
HTS. The focus of this section will be on the two main techniques used for compound 
screening – solution NMR and ITC.  
1.2.3.1 Nuclear magnetic resonance (NMR) 
The principles of this technique will not be described herein as this is a technique with 
a very wide range of applications and a description of the principles that can be applied 
to compound screening and protein analysis seem to be more appropriate in this 
context. 
NMR can provide a lot of information on a protein-protein or protein-ligand interaction. 
It can be used as a screening tool (with Kd determination possible even for weak 
interactions), structure determination of a complex and dynamic, kinetic and 
thermodynamic aspects of the interaction.92,93 
In recent years, NMR has become a valuable screening tool for the binding of ligands 
 Introduction 
 
33 
 
to protein targets, and has the key advantages of being able to detect and quantify 
interactions with high sensitivity without requiring prior knowledge of protein 
function.94 An advantage of this technique is its versatility, as one can either observe 
the resonances of the ligand or the resonances of the target.92 The observation of the 
ligand resonances is usually applicable to ligands in the low-affinity range (high 
nanomolar to high millimolar range). This is commonly used when either the protein 
is too large to be observed by NMR(> 100 kDa), not available with the desired 15N or 
13C labelling pattern from in vitro production, or it aggregates in solution at high 
concentrations.92 Screening based on the observation of the target protein resonances 
relies on detection of chemical shifts changes of the protein upon titration of the 
ligand.92 In the standard experiment, one needs 15N-labelled protein plus an unlabelled 
ligand, which can be a small molecule or another macromolecule. The ligand is titrated 
into the protein, monitored at each stage of the titration by acquiring a 1H,15N-HSQC 
spectrum. The 1H,15N-HSQC spectrum is the easiest to assign, it is sensitive, and 
signals are usually well resolved, particularly in comparison with the 1H,13C-HSQC. 
The experiment detects just one signal per amino acid corresponding to the backbone 
HN-group (excepting proline), and a small number of side-chain signals (asparagine, 
glutamine and tryptophan, and sometimes, depending on the solution conditions, 
arginine and histidine). The chemical shifts are very sensitive to structural changes and 
can be measured very accurately, meaning that almost any genuine binding interaction 
will produce chemical shift changes in the target.94 If the structure and backbone 
assignment of the protein is known these chemical shift changes will indicate which 
residues are being affected upon binding. Moreover, the shape of the titration curve 
(chemical shift versus concentration of ligand) can often be fitted straightforwardly to 
obtain a value for the dissociation constant of the ligand, Kd. NMR titrations can, 
therefore, directly provide both a Kd value and a binding site from the same set of 
measurements.94 The calculation of Kd values by NMR will be detailed in Chapter 5 
(section 5.1.2). 
In addition to the mapping of the binding site, one of the first steps in any study of 
protein-ligand interactions by NMR is to establish to which region of exchange the 
spectrum corresponds (or, more correctly, the resonances of interest, since different 
resonances can, of course, show different exchange behaviour).93 
For a protein P binding reversibly to a ligand L at a single site,  
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	 , Equation 1.1 
characterised by rate constants for forward and back reactions of kon and koff, the 
dissociation constant Kd is equal to [P][L]/[PL], where [P], [L] and [PL] represent the 
concentrations of free protein, free ligand and complex (Equation1.1)	
, Equation 1.2 
Kd can be thought of as the concentration of the free ligand when half of the binding 
sites are occupied. The forward and back rates are given by [P][L]kon and [PL]koff 
respectively – Equation 1.2. At equilibrium the forward and back rates are equal, 
implying that the dissociation constant Kd is also equal to koff/kon. When exchange is 
fast, i.e. when koff is much greater than the chemical shift difference, then the signals 
in the 1H,15N-HSQC spectrum will move smoothly from their position in the free 
spectrum to those in the bound spectrum, with the frequency of the signal at any 
titration point being the weighted average of free and bound shifts – Figure 1.15, first 
panel. This is usually characteristic of a weak interaction. When the exchange rate is 
slow on the chemical shift timescale, or in other words when koff is significantly slower 
than the difference in Hz between the chemical shifts of free and bound protein, then 
as the ligand is titrated in, the free signal gradually disappears and the bound signal 
appears, the intensities of the two peaks reflecting the concentrations of free and bound 
protein – Figure 1.15, third panel. Slow exchange is usually a good indicator of strong 
binding. If the exchange rate is similar to the shift difference, then signals broaden and 
shift at the same time – intermediate exchange – Figure 1.15, middle panel.  
 
Figure 1.15 – Schematic representation of the effect of exchange regimes on signals in 1H,15N-HSQC 
spectra in a ligand titration into a target 15N labelled protein. First panel is an example of a fast exchange 
regime, middle panel intermediate exchange and third panel shows a system in slow exchange. 
This usually leads to broadening or disappearance of signals, especially in the 
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intermediate points of titration.94,95 
Analysis of the spectral changes described is sufficient for ligand screening. However, 
NMR also offers a possibility of structural analysis of a complex in solution. This 
usually requires stable isotope enrichment of the sample, 15N and 13C, and sometimes 
2H labelling for large proteins (> 30 kDa).95  
Data acquisition and resonance assignment is the first step of structure determination. 
For that, a wide range of 2D and 3D experiments need to be acquired. Three-
dimensional triple resonance experiments that correlate hydrogen (1H), nitrogen (15N) 
and carbon (13C) are fundamental for backbone and sequential assignment. Side-chain 
assignment is usually achieved by using 3D HCCH-total correlation spectroscopy 
(TOCSY) and HCCH-correlational spectroscopy (COSY). Once all backbone and 
side-chain assignments are complete, distance restraints are derived from nuclear 
Overhauser effect spectroscopy (NOESY) data. Intermolecular NOESY contacts 
(between the two elements that form the complex) can be acquired using isotope-
filtered NOESY experiments. These experiments remove coherences of protons 
attached to 15N or 13C, leaving only signals from protons of the unlabelled ligand 
detected in one or more dimensions. In contrast, edited experiments select signals of 
proton attached to 15N or 13C. The isotope-filtered NOE experiments are recorded in 
addition to the conventional 3D 13C- or 15N-edited NOESY experiments, and 
comparison with the latter allows separation of inter- from intramolecular contacts.95 
All the NOE data is converted into distance restraints to perform the structure 
calculation. Here, two problems arise, the NOE assignment and the calculation of 
structures that fulfil the conformational restraints derived from the NOE assignment. 
Molecular dynamics, minimisation and simulated annealing have been successfully 
applied to structure calculation. However, there are no robust methods for NOE 
assignment and this step is still very time consuming and laborious due to the large 
number of assignment possibilities, peak overlap and potential artefacts in the 
spectra.95,96 Programs for NOE automated assignment were developed, for instance 
CANDID/CYANA, AUTOSTRUCTURE or ARIA (Ambiguous Restraints for 
Iterative Assignment)96. The focus will be on ARIA as it was the program used in this 
project for automated NOE assignment. ARIA introduced a very important concept in 
NOE assignment – the use of ambiguous distance constraints. The majority of NOEs 
cannot be assigned unambiguously from chemical shift information alone and the 
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treatment of some distance restraints as ambiguous facilitate the assignment of NOEs 
as the same peak can be assigned to different spin systems. In a later stage (iteration), 
ARIA should be able, at least in theory, to refine the assignments accordingly with the 
lower energy structures obtained from previous iterations.97ARIA assigns NOE cross-
peaks by first deriving all possible assignments for each peak by matching a list of 
chemical shifts. Peak volumes are converted into distance restraints using the isolated 
spin pair approximation, which relates the volume to the inverse sixth power of the 
distance between the two interacting spins (Equation 1.3). 
, Equation 1.3 
where Vij is the volume and dij is the distance.95,96 Distance restraints are then 
calculated based on the cross-peak assignment and Equation 1.3. These restraints are 
subsequently used to calculate structures using Crystallography & NMR System 
(CNS)98 that employs a simulated annealing refinement method. Other restraints, not 
derived from NOE data can be introduced into the calculations to facilitate the process 
and give higher quality models. Examples are hydrogen bonds, J-couplings, residual 
dipolar couplings, disulphide bridges and dihedral angle restraints. Obtaining a correct 
initial fold at the outset of a de novo structure determination can be challenging 
because the powerful structure-based filters used for the elimination of erroneous cross 
peak assignments are not yet operational at that stage. It is of great help for the initial 
phase of the algorithm if the user can supply a limited number of already assigned 
long-range distance constraints, meaning the user still has to provide some assignments 
in order to get the correct protein fold.97 An overview of the whole process for structure 
determination using solution NMR can be found in Figure 1.16. 
 
Figure 1.16 – General overview of the process for structure determination using solution NMR. 
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There is still a long way until structure determination via solution NMR reaches the 
automation existing for more established methods such as X-ray crystallography. 
However, the importance of the information acquired using NMR for characterisation 
of complexes in solution is undeniable. 
1.2.3.2 Isothermal titration calorimetry (ITC) 
The ITC method measures energy (heat) changes that are associated with the binding 
reaction of two components. It is a method that can directly determine the binding 
affinity (Ka) and enthalpy (∆H), and using these values it is possible the calculation of 
free Gibbs energy (∆G) and entropy (T∆S). This is achieved by measuring stepwise 
changes in the heat changes during the course of a titration experiment. The underlying 
stoichiometry of an interaction can also be determined using this method.90,99 
Therefore, ITC has found widespread applicability in the study interaction analysis.99  
The experiment takes place inside a reaction cell containing one of the binding partners. 
Subsequently, the other binding partner (protein or ligand) is injected step-wise into 
the reaction cell (titration) until the required excess of the titrant is reached. The heat 
changes are determined by comparing the reaction cell to the reference cell.90 
Enthalpic and entropic factors can either contribute favourably or unfavourably to ∆G 
(Equation 1.4) resulting in the four possible modes: (i) ∆H>0, ∆S<0; (ii) ∆H<0, ∆S<0; 
(iii) ∆H<0, ∆S>0; and (iv) ∆H>0, ∆S>0. Only modes (ii–iv) yield negative ∆G values, 
leading to binding. While many protein-ligand binding events are driven by enthalpic 
factors, in some cases entropy can contribute favourably towards a negative change in 
free energy and, thus, result in binding.100 
, Equation 1.4 
The change in ∆H is determined by a variety of interatomic forces, including 
electrostatic, van der Waals, and hydrogen-bonding interactions, and the entropic 
contribution ∆S represents the change in the size of the conformational space available 
to the overall system, including the protein, ligand, and solvent molecules. 
Most of the entropically favourable interactions are hydrophobic in nature because of 
large positive solvation entropy changes on reduction of the exposed hydrophobic 
surfaces. Before interacting, the protein and ligand are each solvated separately. Upon 
binding, which in this context usually involves the burial of hydrophobic surfaces, 
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many water molecules from the separate hydration shells surrounding the protein and 
ligand are freed into bulk solvent. This process increases the number of conformational 
states of the water molecules and, thus, of the system as a whole, overcoming the loss 
of entropy due to restraining the molecule and binding site.100 
This method is immobilization-free (solution method and closer to native 
conformations) and has the advantage of not requiring any labelling of any investigated 
protein. ITC can be used to detect interactions between two proteins or between a 
protein and a small molecular weight ligand. However, sample consumption can be 
relatively high when using this technique and therefore it has limited applicability for 
proteins that are difficult to produce in relatively large amounts.90 Another limitation 
of the ITC experiment is having upper/lower limits of binding affinity of ~10 nM and 
~1 mM respectively. These limits are related with the ideal concentrations for the 
macromolecule. High affinity interactions (low Kd) should be studied at low 
concentrations: however, the minimum concentration that will typically cause a 
confidently measurable heat change for a 1:1 interaction is about 10 µM. Low affinity 
interactions (high Kd) should be studied at high concentrations, but the concentration 
that can be used may be limited by availability or solubility of the sample 
molecule.99,101 The development of competition (or ligand displacement) ITC 
experiments has led to binding parameter determination for very strong (or weak) 
binders.  
1.3 Research Aims  
EB1 is a key protein at the MT plus ends protein network, nevertheless, no small 
molecules ligands have been identified or designed to target EB1.  Targeting EB1 
using small molecules could bring immense benefits for a better understanding of its 
role in vivo or even stabilise/destabilise its binding to other molecules – protein-protein 
interaction modulators, ultimately making it “druggable”. 
The main aim of the project is to identify a chemical scaffold based on the SxIP motif 
that can target the EBH domain of EB1. This scaffold can be used for the design of 
molecules that can modulate the interaction of EB1 with SxIP proteins. To achieve this 
goal, intermediate aims were defined. These, include the definition of one or more 
virtual screening approaches to identify hit molecules and binding characterisation of 
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the identified hits using biophysical screening techniques, such as NMR. The 
understanding of how SxIP ligands interact with EB1, identifying which regions 
promote the specificity and which regions contribute to the affinity of the interaction 
will be also covered as this will help to characterise the native interaction and this 
information can be used for subsequent drug design campaigns - Figure 1.17. 
These aims will be covered in five chapters, where chapters 2, 3, 4 and 5 will be 
focused mainly in the two first aims (virtual screening and ligand binding 
characterisation) with Chapter 5 covering the characterisation of the native interaction. 
Chapter 2 will cover the initial attempt to identify EB1 ligands by using a molecular 
modelling approach including pharmacophore search based on the known SxIP motif 
and docking using a crystal structure of EB1. Compounds identified using this method 
will be screened for EB1 binding. 
 
Figure 1.17 – Main aim defined for this project and sub-aims needed to achieve the main goal. 
The next chapter (Chapter 3) includes structural characterisation, using solution NMR, 
of EB1 in the free form and bound to one of the ligands identified in the previous 
chapter. The aim of this chapter is to understand how these compounds interact with 
EB1. Differences between these structures will be described and this information used 
for another attempt to find small molecule inhibitors to target EB1 – Chapter 4, 
extending the contact region beyond the SxIP motif. 
Chapter 5 is a detailed study of short length peptides based on a SxIP protein native 
sequence and their interactions with EB1. The aim of this chapter is to understand the 
Introduction 
 
40 
 
contributions of different regions in the interaction between SxIP proteins and EB1. 
The final section of this chapter is the identification of higher affinity peptide 
sequences that can, in the future, be used to build a new pharmacophore and identify 
EB1 small molecule ligands. 
 
  
Identification of small molecule inhibitors 
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IDENTIFICATION OF 
NOVEL SMALL MOLECULE 
INHIBITORS  
Finding novel small molecule inhibitors that can bind to EB1 is the main aim of this 
chapter. As described in the introduction – Chapter 1, finding small molecule 
modulators for protein-protein interactions is considered one of the current challenges 
in drug discovery. Therefore, a highly comprehensive and targeted approach will be 
used. 
The crystal structure of a complex formed between the C-terminal of EB1 lacking the 
last eight C-terminal residues (EB1cΔ8) and a 30 residue peptide derived from the C-
terminal of human MACF2 (MACFp1)31 is available on the PDB102 with code 3GJO. 
With the complex structure available it is possible to use both ligand and structure-
based design approaches for identification of small molecule modulators. The natural 
ligand, MACFp1, allows to search for compounds that can establish similar 
interactions with the target, EB1cΔ8, whereas the target itself permits further 
refinement of a potential binder through molecular docking. Both pharmacophore-
based and docking based methods have proven to be successful in virtual screening 
projects; however none of the approaches is clearly superior.103 Therefore, the use of 
both approaches can be beneficial. Solution NMR will be the biophysical technique to 
screen the selected compounds. 
2.1 Virtual screening methods applied to identify hit molecules to target 
EB1 
The outcome of the screening process is highly dependent on the type of virtual library 
created.104 As described before the chemical space of PPI inhibitors has not been 
completely defined. There have been efforts to generate PPI focused libraries, for 
example, the 2P2I53,105,106 and TIMBAL107 databases. In order to enhance the chemical 
diversity a PPI focused library was not used, instead ZINC database108,109 was utilised 
to build the compound libraries for the structure-based design. With more than 35 
million purchasable molecules, ZINC, is the largest database of commercially 
available compounds for virtual screening.108 One of the reasons ZINC database was 
chosen is related to the fact that requirements as suitable for organic synthesis and/or 
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purchasability are very important.56,110 The second reason is related to a tool embedded 
with this database – ZINPharmer55. ZINCPharmer provides tools for constructing and 
refining pharmacophore hypotheses directly from molecular structure. Pharmer 
identifies hydrophobic, hydrogen bond donor/acceptor, positive/negative ions and 
aromatic pharmacophore features, searching in ZINC database for conformers that can 
satisfy these features. The concept of hot-spots in PPIs was previously presented. 
Despite there being no non-peptide compounds known to bind to EB1, the four residue 
peptide SxIP has been frequently reported as fundamental for the interaction with the 
EBH domain of EB1. Moreover, as shown before this motif targets a highly conserved 
hydrophobic pocket. By using this knowledge on the native interaction it is possible to 
reduce the number of compounds to be docked and analysed through structure-based 
design methods. 
In terms of molecular docking a clear propensity towards GOLD111–118 (Genetic 
Optimisation for Ligand Docking) has apparently emerged with respect to other 
docking software for PPI drug discovery projects.67 This may be due to two reasons. 
GOLD uses a genetic algorithm (GA) that can be applied to more flexible systems. It 
is known that during the physical binding, both the ligand and the protein adapt their 
conformations to each other (flexibility). As a consequence, docking algorithms 
should handle the flexibility of both ligand and protein. Almost all docking programs 
perform flexible ligand docking while the receptor is kept rigid. One of the exceptions 
is GOLD, which apply some flexibility to the protein during the docking, through 
active site chain rotations and, in a more global level, minimizations.76 This is done by 
using a GA. The GA works by using an evolutionary strategy in exploring the full 
conformational flexibility of the ligand with partial flexibility of the protein. It also 
satisfies the fundamental requirement that the ligand must displace loosely bound 
water on binding.112 The other reason may be the fact GOLD presents four scoring 
functions, allowing the score to a certain binding pose to be attributed based on a wide 
range of different parameters. The four scoring functions will be subsequently 
presented. 
Goldscore has a Van der Waals treatment of clash and dispersion terms and uses a 
crystal structure derived treatment of hydrogen bonding and metal terms 
Chemscore is an empirical scoring function parameterised from 82 complexes of 
known binding affinity. It has a lipophilic-lipophilic contact area term, a geometrically 
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constrained hydrogen bond term and a term to penalise excessive flexibility. 
ASP (Astex Statistical Potential) is a knowledge-based scoring derived from the  
Protein Data Bank (PDB)102  
ChemPLP (Piecewise Linear Potential) is the most recently introduced scoring 
function. This treats neutral and repulsive contacts with a piecewise linear potential 
(PLP). This simple potential has both an attractive and repulsive part for neutral 
contacts and solely a repulsive part for neutral contacts and solely a repulsive part for 
anti-complementary contacts (donor-donor, metal-donor and acceptor-acceptor). The 
Chemscore hydrogen bonding term is used for hydrogen bonds and the Chemscore 
internal energy term is also used. ChemPLP is fast to calculate in comparison to 
Goldscore (benchmarked at 23 seconds for ten times repeat dockings at default settings, 
compared to Goldscore, benchmarked at 90 seconds).119  
Among the available GOLD scoring functions, Chemscore is known to be suited for 
binding sites for which a significant part of the ligand affinity can be ascribed to 
hydrophobic interactions, as is often the case in protein–protein interfaces, while the 
complementary Goldscore is preferred for polar binding sites.67 Different scoring 
functions evaluate the binding using different parameters, having different deficiencies 
and strengths. Sometimes, it is desirable to combine different scoring functions in 
order to obtain better predictions. Thus, a recent trend, consensus scoring, has been 
introduced in molecular docking studies. Consensus scoring gathers information from 
different scoring functions improving the probability of identify “true” ligands.73 
Consensus scoring is recognized to increase hit rates by reducing the number of false 
positives and the errors in the scores/ranks and it should be considered as the most 
reasonable strategy when groping in the dark.67 In addition to a good virtual screening 
protocol, it is often important to prevent investing time and resources in compounds 
that will most likely fail at a later stage of the drug discovery process. One of the 
greatest challenges in the virtual screening remains the simultaneous prediction and 
optimization of both binding affinity and pharmacokinetic properties. In silico methods 
can also be used to predict and analyse molecular properties of the hit molecules, in a 
fast and inexpensive way. The prediction of properties related to drug-likeness, as 
taking onboard ADME (absorption, distribution, metabolism and excretion) 
consideration early in pre-clinical development, may help to avoid costly late-stage 
pre-clinical and clinical failures.78 
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The reasons for this failure have been widely described and may include poor 
pharmacokinetic properties, lack of efficacy or selectivity, toxicity and unexpected 
adverse effects.120 This cannot be totally avoided, although there is knowledge based 
on past experience that can help to flag these undesirable properties. These properties 
can be conflicting with other desirable features such as structure based design 
predictions or chemical diversity. To overcome these conflicting properties one can 
use a multi-objective analysis, where a pool of equivalent optima are obtained for all 
the objectives (properties).120,121 
2.2 Identification of small molecules based on SxIP motif 
It has been widely reported that a diverse a group of +TIPs, the SxIP proteins, contain 
conserved SxIP motifs in intrinsically disordered regions, enriched in basic, serine, 
and proline, residues. The SxIP motif binds, specifically, to the C-terminal domain of 
EB1 – EBH domain.31,49 The crystal structure confirms the most prominent contacts 
involve Ser5477, Ile5479 and Pro5480, positions 1, 3 and 4 of the SxIP motif. Ser5477 
forms an extensive network of hydrogen bonds with highly conserved Arg222, Glu225, 
Gln229 and Tyr247 through a water molecule – Figure 2.1A.31 Lys5478 is within a 
salt bridge distance (~4 Å) to Asp257; however the electron density is poorly defined 
for both side chains, indicating a dynamic region.31 More importantly, Ile5479 and 
Pro5480 are buried within a hydrophobic cavity formed by Lys220’, Leu221 and 
Leu246 and delimited by the aromatic rim at the bottom, Phe216’, Tyr217’ and Phe218, 
followed by Arg222, Glu225, Tyr247, and Ala248 – Figure 2.1B.31,43  
SxIP motif targets the hydrophobic pocket and surrounding areas of EB1c and it does 
seem a good starting point for the design of small molecules that can bind to EB1 and 
therefore block its interaction with other proteins. 
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Figure 2.1- A - Close-up view of the crystal structure of the complex EB1cΔ8-MACFp1. SxIP motif is 
coloured orange EB1 represented as cartoon ribbon (grey). MACFp1 is represented as sticks, with the 
SxIP motif coloured in orange and the remaining residues coloured in yellow. (PDB code 3GJO)15  The 
yellow dashed lines represent hydrogen bonds. B – IP motif (cyan) of MACFp1 and hydrophobic pocket 
of EB1c, formed by Lys220’, Leu221 and Leu246 (coloured in orange) and delimited by Phe216’, 
Tyr217’ and Phe218, followed by Arg222, Glu225, Tyr247, Ala248 (coloured in yellow). C-terminus 
residues (Thr249-Gly260) were removed for a better visualisation. 
2.3 Ligand-based design - Pharmacophore search 
A pharmacophore is the ensemble of steric and electrostatic features of different 
compounds which are necessary to ensure optimal supramolecular interactions with a 
specific biological target.122 In other words, a pharmacophore is an abstract concept 
that describes the common steric and electrostatic complementarities of bio-active 
compounds with the target.123 As referred before, ZINCPharmer was used as a tool for 
pharmacophore definition and database filtering and the SxIP motif was used as the 
starting point to define a pharmacophore model. Besides the type of the interaction 
(hydrogen bond acceptor/donor, hydrophobic, positive/negative ion and aromatic), 
other key information can be incorporated into the pharmacophore model such as the 
three-dimensional location of the interaction, if an interaction is directional (such as 
hydrogen bonding) and also its spatial orientation.123 ZINCPharmer considers that 
hydrogen bond acceptors/donors must be within 4 Å of a hydrogen bond 
donor/acceptor and a hydrophobic feature must be within 6 Å of at least three 
hydrophobic features of the receptor. The direction of the hydrogen bonding is 
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represented, by arrows, while the size of the hydrophobic regions is controlled by the 
radius of the respective sphere - Figure 2.2.55 In this case, since no receptor structure 
was uploaded for the search, radius values and bond directionality were independent 
of the receptor. 
Due to the polar interactions observed for Ser5477 (described in the previous section), 
two hydrogen bond acceptors were defined – Table 2.1. Three hydrophobic centroids 
were defined for Ile5479 and Pro5480 since these residues clearly make hydrophobic 
contacts. Lys5478 was not utilised for the definition of a pharmacophore model since 
it seems to make contacts with a more dynamic region and the aim at this stage is to 
find small molecules that can interact mainly with the hydrophobic cleft formed by the 
two monomers of EB1. In addition, backbone amide for Ile5479 and carbonyls for 
both Ile5479 and Pro5480 were included as hydrogen bond acceptor and donors, 
respectively – Figure 2.2 and Table 2.1. The inclusion of both hydrophobic contacts 
plus hydrogen bond contacts allow for a well-fitted molecule binding to the pocket, 
stabilised by hydrogen bonds.  
 
Figure 2.2 - Representation of the pharmacophore points found for Ser5477, Ile5479 and Pro5480 of 
the MACFp1 peptide. All pharmacophore features are shown in spheres, being the hydrogen bonding 
acceptors showed as orange mesh, hydrogen bonding acceptors in white mesh and hydrophobic as green 
mesh. Orange and grey arrows indicate the direction of the hydrogen bond donor/acceptor, respectively. 
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Table 2.1 - Pharmacophore points found based on Ser5477, Ile5479 and Pro5480 
Pharmacophore 
Class 
Coordinates 
radius residue 
x y z 
H donor -16.20 -30.47 21.17 0.50 Ile5479 
H acceptor -13.21 -33.20 21.86 0.50 Ser5477 
H acceptor -13.64 -30.55 34.37 0.50 Ser5477 
H acceptor -15.25 -28.40 30.36 0.50 Ile5479 
H acceptor -16.20 -25.55 29.38 0.50 Pro5480 
Hydrophobic -16.92 -26.78 32.96 1.00 Ile5479 
Hydrophobic -19.01 -27.81 29.06 1.00 Pro5480 
Hydrophobic -16.39 -28.30 35.09 1.00 Ile5479 
Since a ligand by itself does not provide information about the nature of an interaction, 
the result is not a true pharmacophore. Instead, the pharmacophore derived from a 
single ligand structure should be seen as a 3D similarity search.55  
The search for molecules within the ZINC database containing all these 
pharmacophore points, with a molecular weight smaller than 500 g.mol-1, gave no hits. 
Thus a systematic search was done, removing one, two and three pharmacophore 
points, yielding a total of 71 possible combinations. The result was that 40006 
molecules were found to fit at least five of the defined pharmacophore points. Since 
the number was high, another filter, Root Mean Square Deviation (RMSD) smaller 
than 0.5, was applied retrieving 3933 molecules, which is a much more reasonable 
number to perform molecular docking. Filtering by RMSD restricts the hits to those 
that have the best overall geometric match to the query.55 Since ZINCPharmer offers 
different conformations of the same molecules, repeated molecules were removed, 
retaining 3060 molecules for the docking studies. 
2.4 Molecular Docking studies 
 Molecular Docking method validation and general considerations 
Before performing the molecular docking studies method validation is needed to check 
that docking can predict accurately the binding modes of an interaction. 
Pose selection is a commonly used method for validation of docking methods and 
scoring functions. A compound with a known conformation and orientation, typically 
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from a crystal structure, is re-docked and the results given (poses) are evaluated in 
terms of similarity with the known conformation.124,125 Usually a RMSD lower than 2 
Å between the experimental (crystal structure) and the calculated poses is considered 
a successful validation.76,114 To validate the docking method the peptide fragment of 
MACFp1 – SKIP was used since the main aim of the molecular docking studies in this 
project was to make a virtual screening of small molecules, with a molecular weight 
and size closer to the SKIP motif rather than the 11 residue peptide presented in the 
crystal structure – KPSKIPTPQRK, i.e. ~443 g.mol-1 instead of ~1279 g.mol-1. 
Additionally, the importance of probing the hydration state of a protein binding pocket 
in the un-bound state has been demonstrated and should be a standard element of 
structure-based design.126 For this reason, the pose validation was also performed in 
the presence of a water molecule in the binding site. The crystal structure shows the 
presence of a water molecule that mediates hydrogen bond formation between MACF2 
and EB1.31 When water molecules are known or assumed to play a role in protein-
ligand recognition, the most common strategy is to perform separate docking runs in 
parallel, i.e., one in the absence of water molecules and a second in the presence of 
one or more water molecules.116 
Hydrogen bonds are the most important specific interactions in biological processes. 
Their geometries follow strict rules and therefore this is part of the information that 
can be extracted from crystal structures.126 Due to the importance of these interactions, 
and based on the information retrieved by the crystal structure 3GJO, the following 
hydrogen bond constraints were introduced in GOLD – Arg222, Glu225, Leu246, 
Tyr247, Val254 from chain A and Tyr217 from chain B.31 
Table 2.2 - The average and standard deviation calculated based on 10 docking solutions for the SxIP 
motif 
Rotatable bonds Fixed Not fixed 
 Score RMSD (Ȧ) Score RMSD (Ȧ) 
GoldScore 71.4 (±0.1) 0.25 (±0.02) 70 (±8) 2.3 (±0.9) 
ChemPLP 68.00 (±0.06) 0.48 (±0.02) 77 (±5) 3 (±2) 
ChemScore 34.6 (±0.2) 0.5 (±0.2) 22 (±2) 3 (±2) 
ASP 35.5 (±0.2) 0.45 (±0.08) 36 (±1) 5 (±2) 
 
Table 2.3 - The average and standard deviation calculated based on 10 docking solutions for the SxIP 
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motif, with a H2O molecule and hydrogen bonding constraints 
Rotatable bonds Fixed Not fixed 
 Score RMSD (Ȧ) Score RMSD (Ȧ) 
Goldscore 37.0 (±0.6) 0.40 (±0.03) 47 (±6) 3 (±2) 
ChemPLP 31.1 (±0.1) 0.47 (±0.03) 57 (±7) 3 (±2) 
Chemscore -5.5 (±0.1) 0.30 (±0.05) -9 (±4) 6 (±2) 
ASP -4.02 (±0.08) 0.33 (±0.04) -3 (±8) 7 (±2) 
Goldscore and ChemPLP were found to have a better performance when posing the 
natural ligand – SKIP - for this model. The first molecular docking study, without any 
constraints, gave a smaller RMSD for Goldscore, 0.25 Å when compared with 
ChemPLP, 0.48 Å. The same situation is observed when constraints are applied to the 
docking method, with Goldscore showing a slightly smaller RMSD value, 0.40 against 
0.47 Å obtained for ChemPLP. In this case the difference is much smaller and 
considering the standard deviation values, not significant. Based on both results it was 
decided to choose Goldscore as the scoring function for this study.  
The definition of the binding site was based on a radius of 6 Å around the ligand 
included in the crystal structure Table 2.4. EBH domain of EB1 is a homodimer and 
therefore the binding site is formed by residues belonging to both monomers – chain 
A and chain B.  
Table 2.4 - EB1 active residues used for GOLD for the docking of small molecules inhibitors. These 
residues were defined using a 6 Å radius around the ligand present in the crystal structure. 
Chain A Chain B 
Arg214, Phe218, Leu221, Arg222, Glu225, 
Leu226, Gln229, Leu246, Tyr247, Ala248, 
Thr249, Asp250, Glu251, Gly252, Phe253, 
Val254, Ile255, Pro256, Asp257 
Asp209, Glu213, Phe216, Tyr217, Lys220 
With this binding site definition the area of interaction was not restricted to the region 
were the SxIP motif binds but expands considerably further. This is an important 
feature since it is known that in order to enhance specificity and affinity, additional 
interactions, beyond those present in a single individual “hot spot” are required. 
Nearby residues that do not meet the criteria of a “hot spot" may also play an important, 
if not essential role in the interaction.127  
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 Docking of virtual library obtained from ZINCPharmer 
Effective consideration of key ligand-target interactions, such as hydrogen bonds, and 
other environmental factors during docking, such as target flexibility, metal ions, and 
water molecules, can enhance the docking-based virtual screening performance.128  
Thus, four molecular docking studies were performed, evaluating the 3060 molecules 
and including different variants, like hydrogen bonding constraints and a presence of 
a water molecule. There could be several potential advantages to including water 
molecules in a protein-ligand docking program. First, if the compound interacts with 
the water molecule, including it could improve the predicted binding mode. Several 
studies have been reported in the literature where parallel dockings were done in the 
absence of water molecules and in the presence of some key water molecules. Some 
authors have reported significant improvements in docking performance when water 
molecules were included, whereas others found that including water molecules had 
little effect on the quality of the dockings.116 Regarding the hydrogen bonding 
constraints, GOLD allows the definition of key hydrogen bonds. Molecules that form 
these defined bonds will score higher. In this study the residues chosen from EB1 to 
form key hydrogen bonds with the ligand were: from chain A, Arg222, Glu225, 
Gln229, Val254 and Tyr247 and Tyr217,  from chain B, in agreement with what was 
shown by Honnapa and co-workers.31  
In the first docking study no hydrogen bonding constraints or water molecule were 
included. The second and third docking studies included hydrogen bonding constraints 
and a presence of a water molecule, respectively, while the fourth docking study 
included both features - Table 2.5. 
Table 2.5 - Summary of the considerations, presence of water molecules or definition of key hydrogen 
bonding, made for each docking study. 
 H2O molecule H bond constraints 
1 No No 
2 No Yes 
3 Yes No 
4 Yes Yes 
At this stage, due to the large number of molecules the poses and scores obtained were 
not directly inspected. Instead, an analysis of the whole dataset was performed, using 
an ensemble of techniques described subsequently. 
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2.5 Screening and selection of hit molecules 
 Consensus scoring 
Due to the inherent limitations of the scoring functions, and taking advantage of GOLD 
providing four different scoring functions, the best docked conformer of each 
compound was re-evaluated using other scoring functions – this procedure is known 
as Consensus Scoring.129 Compared to single scoring procedure, Consensus Scoring 
reduces the number of false positives, improving the hit-rates.129 This was one of the 
conclusions from the results of an extensive computational study, of docking 
collections of three-dimensional structures into three different enzymes of 
pharmaceutical interest: p38 MAP kinase, inosine monophosphate dehydrogenase, and 
HIV protease.130  
For this purpose, docking poses obtained using Goldscore were rescored using the 
alternative scoring functions: ASP, Chemscore and ChemPLP. 
 Ligand Efficiency 
Large molecules can form many hypothetical interactions in binding sites and 
therefore have the tendency to generate better scores than smaller compounds.131 
Ligand efficiency is a measurement of the binding energy per atom of a ligand to its 
binding partner, such as a receptor or enzyme. In the case there is no information on 
binding affinities or binding energies, but there is a docking predicted score that can 
be used instead. By normalizing the energy score obtained from the dockings studies 
a docking Ligand Efficiency (dLE) can be calculated:  
 , Equation 2.1 
 Docking descriptors calculation 
The protein-protein interfaces have large contact areas and are typically dominated by 
steric and hydrophobic interactions, although there are also electrostatic interactions 
and hydrogen bonds.56 The latter types of interactions may be considered desirable to 
include as they facilitate the selection of more specific inhibitors which bind through 
these specific interactions.56 Using GoldMine, a tool provided with GOLD that allows 
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the analysis of large quantities of docking information, some docking descriptors, 
including information of the predicted hydrogen bonds between the molecules and the 
protein, were calculated.  
Between the calculated descriptors, there was the number of total hydrogen bonds and 
the number of specific hydrogen bonds. This second descriptor was defined based on 
the hydrogen bonds of the following residues Arg222, Glu225, Gln229, Tyr247, 
Val254 from chain A and Tyr217 from chain B, in agreement with what was shown 
by Honnapa and co-workers31 and with the constraints defined for two of the four 
docking studies. Another descriptor, hydrogen bond efficiency, was calculated based 
on the ratio between the total number of hydrogen bonds and the specific hydrogen 
bonds. 
Using Knime132, and the rule engine node, when the total number of hydrogen bonds 
was the same than the number of specified hydrogen bonds, the hydrogen bond 
efficiency value given was 1. When these features did not match, the rule engine node 
would retrieve 0. 
 Multi-parameter optimization 
Many accomplishments in modern drug discovery are hindered by the lack of 
consideration of multiple molecular properties in the early stages of lead identification 
and optimization. Indeed, one of the common causes for lead compounds to fail in the 
later stages of drug discovery is the lack of consideration of multiple objectives (e.g., 
ADMET properties) at the early stage of optimization of candidate compounds. 
Improving the pharmacological profile of a candidate molecule requires the 
optimization of numerous, often competing objectives (i.e., biological or chemical 
properties), to discover the few improved molecules that represent the best 
compromise of the multiple criteria is determinant for a successful drug.133,121 Pareto-
based methods are capable of optimizing numerous properties simultaneously.121  
Using the Pareto Ranking tool offered by Knime, a multi objective analysis was 
performed in order to select the compounds which had a balance between scoring 
values from the docking and molecular properties. The 3060 docked molecules were, 
therefore, ranked using the following properties: 
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Consensus Scoring and Ligand Efficiency 
Drug-like properties83,134  
ALogP135 <= 5 
LogD <= 4 
180 <= MW <= 500 
Molecular solubility – the higher value the better 
Molecular Polar Surface Area <= 140 
Num of H bond acceptors <= 10 
Num of H bond donors <= 5 
Num of rotatable bonds <= 12 
Hydrogen bond 
Total H bond – the higher value the better 
Specific H bond – the higher value the better 
H bond efficiency – a match between total H bond and specific H bond was ranked 
higher 
After ranking the 3060 docked molecules using the above described Pareto Ranking 
approach, the top ranked 100 molecules were chosen to move forward in the virtual 
screening process. 
 Top ranked 100 molecules – selection of candidate compounds to 
synthesis and biological assays 
To confirm the good binding predictions given by the first docking studies, it was 
decided to perform a molecular docking study for the selected 100 compounds. Since 
the number of molecules is smaller, the best ten solutions instead of one were saved in 
the solution file. If multiple solutions are generated for a ligand it is possible to 
calculate the RMSD of atom positions between each pair of solutions, using GoldMine. 
A smaller RMSD value is indicative that the docking prediction is very similar for the 
ten solutions and consequently gives more strength to the predicted poses and scores. 
In addition, a visual inspection of the poses given by the 10 different solutions was 
performed. The hydrogen bonds formed between the molecules and the residues were 
inspected. These 100 molecules were shown to form hydrogen bonds with the 
following residues: Arg214, Arg222, Glu213, Gly252, Leu221, but more frequently 
with Ala248, Gln229 Glu225, Leu246, Lys220, Phe218, Pro256, Tyr217, Tyr247 and 
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Val254. This is a good indicator since some of these residues are frequently described 
in the literature27,31,43 as components of the EB1 C-terminal binding site. However, a 
critical analysis also shows that these residues are within the defined binding site for 
the molecular docking studies. 
The aqueous solubility of a compound is an important property that influences both 
the bioavailability as well as the magnitude of many ADME properties. However, 
solubilisation is a complicated process influenced by lipophilicity, hydrogen bonding 
formation, crystal packing and counterion.110 With this in mind, for the selection of 
the hit compounds for synthesis, biophysical and biological testing, solubility (logS) 
was a key factor. Within the 100 molecules list, only molecules with a solubility value 
higher than - 4 were selected leading to the selection of only nine molecules. 
Observing the way in which the molecules fit in the binding pocket and possible 
interactions with the target it was decided to select three molecules ZINC12677264, 
ZINC08389070, and ZINC71025726. 
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Table 2.6. ZINC12677264 showed to be the best ranked compound overall, especially 
based on the score/ligand efficiency ranking, rank #1, and hydrogen bonds formed, 
rank #3. The Goldscore fitness score is also the highest of these three candidate 
molecules. ZINC08389070, the third candidate molecule, has a very similar scaffold 
to ZINC12677264, performing better in terms of drug-like properties (rank #2), 
including slightly better solubility value and RMSD (rank #4) and indicating the 
calculated pose is very consistent. ZINC71025726, has the lowest Goldscore fitness 
value of the three compounds, but overall a very balanced position in all the ranks. 
ZINC12677264 and ZINC08389070 are result of the same pharmacophore definition, 
whereas ZINC71025726 results from a different ensemble of pharmacophore features. 
Both searches included three hydrophobic features for Ile5479 and Pro5480 and a 
hydrogen acceptor feature for Ile5479. However, the search that retrieved 
ZINC71025726 included a hydrogen acceptor feature based on the carbonyl of the 
Pro5480 rather than a hydrogen donor feature based on Ile5479 – Table 2.7 and Table 
2.8. 
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Table 2.6 - Summary of rankings and molecular properties for the three candidate molecules resulting from the first virtual screening approach to target EB1. Final rank 
corresponds to the Pareto analysis using rank 1, score and ligand efficiency, rank 2, drug-like properties, rank 3, hydrogen bonds and rank 4, RMSD between the obtained 
solutions. 
Molecule 
name 
Final 
Rank 
Rank 
1 
Rank 
2 
Rank 
3 
Rank 
4 Solubility 
Goldscore 
Fitness Structure Molecular properties 
ZINC12677264 1 5 7 2 10 -3.992 62.3789 
 
 
ZINC71025726 4 8 4 3 6 -3.785 55.3401 
 
 
 
ZINC08389070 9 11 6 5 4 -3.96 55.9363 
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Table 2.7 - Pharmacophore points used for the search that retrieved ZINC71025726. 
Pharmacophore Class residue 	
H acceptor Ile5479 
	
H acceptor Pro5480 
Hydrophobic Ile5479 
Hydrophobic Pro5480 
Hydrophobic Ile5479 
Table 2.8 - Pharmacophore points used for the search that retrieved ZINC08389070 and ZINC12677264. 
Pharmacophore Class residue 	
H donor Ile5479 
	
H acceptor Ile5479 
Hydrophobic Ile5479 
Hydrophobic Pro5480 
Hydrophobic Ile5479 
Despite these differences all molecules are based on pharmacophore features of 
Ile5479 and Pro5480. The conformation of ZINC71025726 is the most similar to the 
natural ligand when compared with other two molecules – Figure 2.3, left hand side 
panel. The RMSD value is, as expected, smaller, 0.275 Å when compared with 
ZINC08389070, 0.475 Å and ZINC12677264, 0.476 Å.  
Regarding the docking poses (right hand side panel of Figure 2.3) one can observe that 
for ZINC71025726 the best scored pose is not much different than the conformation 
obtained from ZINCPharmer. On the other hand, for the other hits the binding poses 
are significantly different from the result obtained from ZINCPharmer. Notable 
features from the highest scored docking poses are, that the aliphatic chain of 
ZINC71025726 seems to emulate the β-branched side chain of isoleucine and the 
proline ring present in this molecule superimposes with Pro5480. 
For ZINC08389070 the isoleucine hydrophobic chain is replaced by the cyclopentyl 
ring, and the Pro5480 replaced by a methyl group. The replacement of the isoleucine 
by a ring can still yield the expected hydrophobic contacts, but constricts the rotation, 
since the methyl groups were replaced by a more rigid group. The methyl replacing 
the proline does not seem to be a disadvantage also since the area where the proline of 
MACFp1 sits is quite small – Figure 2.1B. 
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Figure 2.3 - ZINCPharmer results versus Gold docking poses for the three hit molecules. On the left 
hand side, the results of the search based on the defined pharmacophore model in ZINCPharmer for A 
– ZINC71025726, C – ZINC08389070 and D – ZINC12677264. On the right hand side best scored pose 
for B - ZINC71025726, D – ZINC08389070 and F – ZINC12677264. The crystal structure of 
11MACFp1 is showed in grey, with Ser5477, Ile5479 and Pro 5480 highlighted in orange. 
Finally, ZINC12677264 best scored docking pose does not provide the same 
interesting features as the previous compound, despite the scaffold being very similar. 
However, if analysing the ten best docking poses for this compound four out of ten, 
present a similar conformation to ZINC08389070, and an aromatic π-π stacking 
interaction with Phe218 – Figure 2.4. 
Since, ZINC12677264 was not commercially available at the time, it was decided to 
test ZINC08389070, and ZINC71025726 and find alternatives to ZINC12677264. 
Despite being the best ranked molecule, ZINC12677264, has a very similar scaffold 
to ZINC08389070, and using this approach it is possible to increase the chemical 
diversity of the tested molecules.  
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Figure 2.4 - Alternative pose for ZINC12677264. The cyclopentane ring and the methyl group emulate 
Ile5479 and Pro5480, respectively. The aromatic ring seems to establish aromatic π-π stacking 
interaction with Phe218. 
 Alternative compounds to ZINC12677264 
As stated before, ZINC12677264 was not commercially available and its scaffold is 
very similar to ZINC08389070. Chemical diversity is desirable at an initial stage of 
the drug discovery projects, therefore it was thought to select the best looking and 
consistent pose for ZINC12677264, build a new pharmacophore model and search for 
alternatives in ZINC database. In addition of being the best ranked molecule, 
ZINC12677264, shows a consistent pose where the aromatic ring seems to be in the 
right position to from π-π stacking interactions with Phe218 – Figure 2.4. 
2.5.6.1 ZINCPharmer search 
Using the pose shown in Figure 2.4, one can observe hydrogen bond formation 
between one of the nitrogens in the tetrazole ring and Gln229 and between the NH and 
Glu225, in addition to the aromatic π-π stacking interactions with Phe218. Two 
different pharmacophore models were built based on these interactions – Figure 2.5. 
For the first one, A, only six hits were obtained; therefore, it was decided to remove 
two of the hydrogen bond acceptor groups within the tetrazole ring, leaving only the 
one that clearly seems to establish contact with Gln229 – B. For the latter 166 hits 
were retrieved. It is worth mentioning that the receptor crystal structure with the code 
3GJO, was also uploaded into ZINCPharmer so the interaction pharmacophore will be 
automatically generated based also on the receptor features, e.g. hydrogen bond 
directionality.55 Duplicated molecules were removed, giving a final list with 150 
molecules. 
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Figure 2.5 - representation of the two pharmacophore models built to find alternative molecules to 
ZINC12677264. 
The docking method was optimised in such a way molecules that pose in a similar way 
to ZINC12677264 would be favoured. Therefore, constraints were introduced 
including hydrogen bond constraints and a region constraint. The hydrogen bond 
constraint definition included: Arg222 (η-NH2), Glu225 (δ-CO2), Gln229 (ε- η-NH2), 
Gly252 (backbone CO) and Val254 (backbone NH and CO). The region constraint 
was based on an area of 3 Å around Phe218 and should privilege molecules that 
establish hydrophobic contacts with this region, specifically with aromatic ring. In 
terms of solutions, 100 best solutions were saved into the solutions file, since at this 
stage it was desirable to have a molecule that not only was positioned in a favourable 
way but also the pose was consistent enough to increase the levels of confidence about 
the chosen candidate. Compounds were docked using Goldscore and rescored using 
the remaining scoring options, similarly to what was done for the first set of molecules. 
To select the candidate molecule all molecules with a solubility value lower than – 4 
were removed, leaving only 29 candidate molecules. A multi-parameter analysis was 
then performed based on two ranks, ligand efficiency and RMSD, followed by a visual 
inspection. Unfortunately, none of the first ranked molecules seemed to pose in a way 
that would make possible the existence of aromatic π-π stacking interaction with 
Phe218. In reality, only the sixth ranked molecule (ZINC63526256) seemed to present 
some docking poses consistent with this interaction. Alternatively, most of them 
seemed to interact with Tyr247 instead. The second best ranked molecule, 
ZINC64398049, was chosen based on having a very similar rank position to the first 
hit but having slightly better drug-like properties (i.e. number of hydrogen donors) and 
also due to the most consistent docking pose show the interaction with the hydrophobic 
pocket in addition to an aromatic π-π stacking interaction with Tyr 247 – Figure 2.6. 
Finally, three compounds were selected to screen using solution NMR - 
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ZINC08389070, ZINC71025726 and ZINC64398049. ZINC08389070, 
ZINC71025726 were obtained through a pharmacophore search based on the SxIP 
motif, whereas the last one, ZINC64398049, was obtained through a pharmacophore 
based on the molecule ZINC12677264. This second method has the advantage of 
providing larger chemical diversity, but the specificity given by the pharmacophore 
built on the natural ligand SxIP may be lost. To evaluate the robustness of the virtual 
screening and compound selection methods employed the in vitro screening of these 
molecules will be subsequently described. 
 
Figure 2.6 - ZIN64398049, A – ZINCPharmer result (coloured in green), based on ZINC12677264 
(coloured in orange). B - Best scored pose. The aromatic ring is facing the ring of Tyr247 and is within 
a distance of 3-4 Å, suggesting the possibility of π-π stacking interaction. 
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Table 2.9 - Summary of rankings and molecular properties for the three candidate molecules resulting from a pharmacophore model based on ZINC12677264. Final rank 
corresponds to the Pareto analysis using rank 1, score and ligand efficiency, and rank 2, RMSD between the obtained solutions. 
Molecule Name Final Rank Rank 1 Rank 2 Solubility Structure Molecular Properties 
ZINC44549656 1 1 2 -1.546 
 
 
ZINC64398049 2 1 3 -2.793 
 
 
ZINC63526256 6 3 4 -2.375 
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2.6 NMR based screening for hit candidates based on SxIP motif 
In the initial stage three compounds were screened for binding to EB1cΔ8 using 
1H,15N-HSQC experiments – 1a, corresponds to ZINC08389070, 1b, based on 
ZINC71025726 synthesised in house and 1c, ZINC64398049. Compound 1d, 
ZINC12677264, was later purchased and tested due to the large similarity with 
compound 1a – Table 2.10.  
Table 2.10 - Summary of the candidate hit molecules resulting from virtual screening studies to be tested 
against EB1cΔ8 
 
The 1H and 15N resonances were fully assigned using complementary pairs of triple 
resonance NMR spectra - CBCA(CO)NH13>/HNCACB137 for Cα/Cβ and HNCO138–
140/HN(CA)CO141 for CO connectivities. Backbone resonance assignment will be 
detailed in the next chapter – Chapter 3. 
Ligand-induced chemical shift perturbations (CSPs) in NH resonances on addition of 
the ligand were used as an indication of ligand binding and location of the binding site. 
All compounds were shown to induce CSPs in the backbone of EB1cΔ8, with 1a and 
Code ZINC code Solubility Molecular Weight 
Gold-
Score Structure 
1a ZINC08389070 -3.96 321.4 55.9363 
 
1b ZINC71025726 -3.785 289.4 55.3401 
 
1c ZINC64398049 -2.793 314.3 52.4107 
 
1d ZINC12677264 -3.992 427.5  62.3789 
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1d displaying the largest spectral changes - Figure 2.7, Figure 2.8, Figure 2.9,Figure 
2.10 and Figure 2.11. No broadening was observed for the NH cross-peaks throughout 
the titration, indicating a fast exchange between the free and bound state and, therefore, 
weak interaction.  
 
Figure 2.7 - Overlay of 1H,15N-HSQC spectra recorded at 800 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 1a (5000 µM). The insets show 
regions of interest and the spectra corresponding to the following 1a concentrations, 500, 1000, 1500, 
2000, 2500, 3000, 3500, 4000, 4500 and 5000 µM. 
Compound 1a shows two main regions where chemical shift changes are located -
247YAT249 and 219GKLR222. Overall, the NH resonance for Tyr247 is the most affected 
upon ligand binding, with Δδ = 0.42 ppm - Figure 2.7. 
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Figure 2.8 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 1b (5000 µM). 
For compound 1b, Tyr247 is again the most affected residue, followed by Thr249, 
Arg222 and Lys220 – Figure 2.8. All these CSPs are smaller than the ones observed 
for compound 1a, indicating this is a weaker binder. It is worth to mention that all the 
CSPs are close to the hydrophobic pocket of EB1cΔ8 
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Figure 2.9 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 1c (5000 µM). 
Compound 1c, seems to be the worst ligand and only promotes CSPs for Tyr247 – 
Figure 2.9. Of the three initially tested compounds, 1a, showed to be the most 
promising in terms of magnitude of CSPs and affected residues. Compound 1d 
presents a similar scaffold to 1a, and seems to perform better in terms of scoring in 
docking studies, especially the possible interaction of its aromatic ring with Phe218, 
that would significantly improve the potency of the molecule. 
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Figure 2.10 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 1d (5000 µM). The insets show 
regions of interest and the spectra corresponding to the following 1d concentrations, 500, 1000, 1500, 
2000, 2500, 3000, 3500, 4000, 4500 and 5000 µM. 
1H,15N-HSQC titration confirms partially this hypothesis. Tyr247 is, once again, the 
most affected residue, the CSPs still follows a fast exchange pattern, but the distance 
is larger when compared with 1a (Δδ = 0.66 ppm compared with 0.42 ppm obtained 
for 1a). Interestingly, 247YAT249 and 219GKLR222 are still the main regions where 
chemical shift changes are located. Additionally, Phe218, Phe216 and even Val254 
(Δδ is rather small, 0.06 ppm) are perturbed (Figure 2.10), indicating this compound 
interacts not only with the hydrophobic pocket usually occupied by the IP motif of 
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SxIP proteins but also with the aromatic rim just below it and in a smaller extent with 
the dynamic C-terminus. It is worth mentioning that Val254 seems to be an important 
residue for the interaction of EB1cΔ8 with other molecules, being involved in 
hydrogen bond contacts with MACFp1 as described by Honnapa et al.31 In Figure 2.11 
it is clear that compound 1d promotes the largest chemical shift changes followed by 
compound 1a. 
 
Figure 2.11 - Chemical shift changes plot for the four tested compounds and their distribution per 
EB1cΔ8 residue. 
NMR titration curves show significant deviation from a linear dependence at high 
ligand excess that allows for Kd estimation by fitting the curve into the two-state 
exchange model (Figure 2.12).  In agreement with the CSP amplitudes, the estimated 
binding affinity is higher for 1d (6 ± 1 mM) followed by compound 1a (10 ± 3 mM) - 
Table 2.11. 
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Figure 2.12 - Chemical shift changes plots for Tyr 247, upon titration with 1a (left hand side plot) and 
1d (right hand side panel). 
Table 2.11 – values used to estimate Kd values for interaction between EB1cΔ8-1a and 1d. 
1a  1d 
Residue Kd (mM)        Residue Kd (mM) 
Thr206 6.05  Tyr247 5.29 
Asp209 7.22  Ala248 7.37 
Asp2015 15   6.33 (±1.04) 
Arg241 10    
Tyr247 10    
 9.65 (± 3.09)    
Both best binding compounds 1a and 1d share the same scaffold (Figure 2.13). This 
scaffold has shown to have high specificity (chemical shift mapping and molecular 
docking predictions) to the IP binding site. Moreover, these are the first molecules 
reported to bind to EB1c indicating that the aims of the chapter were achieved. One 
can argue that the binding affinities are not very high (mM); however, it is very close 
to the one showed by the SxIP motif - Figure 2.14. The curvature is more pronounced 
for compound 1d, followed by 1a and finally SKIP peptide, indicating the latter is 
closer to linearity and therefore weaker binding. Full information on the titration of 
this peptide can be found in Chapter 5. Analysis of the docking poses obtained for 
these compounds during the virtual screening and comparison with the IP motif of 
MACFp1 in the crystal structure of the complex indicates that this scaffold may act as 
an IP motif mimetic. The hydrophobic side chain of the isoleucine is replaced by a 
cyclopentyl ring, and the hydrophobic proline ring is replaced by a methyl group - 
Figure 2.13. The tetrazole moiety acts as spacer between both hydrophobic regions 
giving rigidifying the scaffold. 
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Figure 2.13 – Left panel - 3D model for the IP motif and the IP motif mimetic. The IP motif tri-
dimensional representation is based on the crystal structure 3GJO. The IP mimetic compounds 1a (black) 
and 1d (green) are the binding poses predicted by our docking studies using 3GJO structure as the 
EB1cΔ8 model. In both representations the C-terminus tail was removed for clarity. Right panel - 2D 
structure of IP motif and IP mimetic scaffold. 
 
Figure 2.14 – Binding curve for residue Tyr247 for the titrations of the tetramer SKIP (red), compound 
1a (black) and compound 1d (green). Ligand concentration corresponds to the excess of ligand (e.g. 10 
fold excess, 20 fold excess) to the protein concentration (50 µM). The fitted curve performed through 
the equation y=A((B+4x-sqrt((B+4x)^2-(4x) is shown as black dashed line.  
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It is therefore very likely that this scaffold is very specific for this binding site. To 
validate the docking predictions and to gain a structural insight of the binding mode of 
the IP mimetic scaffold the three dimensional NMR structure of EB1cΔ8 bound to 
compound 1a was determined. Additionally, the structure of EB1cΔ8 in the free state 
was also elucidated in order to identify structural changes that may occur upon 
compound binding and to facilitate structure determination of the complex. These 
structures and other aspects considering the binding mode of compound 1a to EB1cΔ8 
will be the subject of the next chapter.
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STRUCTURAL 
CHARACTERISATION OF EB1C 
USING SOLUTION NMR  
It was reported, in the previous chapter, the identification of a IP mimetic scaffold. It 
is now fundamental to understand how this scaffold interacts with EB1 and gain 
structural information on this complex to help to develop higher affinity ligands. For 
that purpose, EB1c will be characterised in the free form and in complex with 
compound 1a. Comparison between the two forms and analysis of the binding mode 
of this scaffold will be also analysed.  
3.1 Design of EB1 fragments 
It has been reported the importance of C-terminal tail on EB1 binding. Therefore, and 
to satisfy the aims of the project it was decided to build two different gene constructs 
to express two versions of the C-terminal of EB1 (EB1c). EB1cΔ8 construct comprises 
residues 191-260 and EB1cΔ16 corresponds to residues 191-252. The choice of these 
two different constructs was based on the necessity of a better understanding of the 
role of flexible tail for the interaction. Full-length EB1c (191-268) was not used in this 
project as the literature indicate the EB1cΔ8 includes all the necessary amino acids for 
the interaction with SxIP proteins.  
3.2 Production of recombinant EB1cΔ8 and EB1cΔ16 
The necessary steps to obtain the two EB1c fragments – EB1cΔ8 (residues 191-260) 
and EB1cΔ16 (residues 191-252), such as cloning, transformation, expression and 
purification are described in more detail in Chapter 7. EB1c fragments were expressed 
in an N-terminal SUMO vector (pOPINS) and high levels of protein expression were 
achieved. The protein was subsequently purified with good yields – Figure 3.1. The 
purification process included Ni affinity chromatography, followed by removal of the 
histidine tag with the use of SUMO protease. This particular step required optimisation 
because the protease was not cleaving the tag with complete efficiency, leaving some 
SUMO-tagged EB1c. This problem was overcome by using a reducing agent, 2-
mercaptoethanol, performing the cleavage at room temperature and using higher 
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concentrations of the protease. Finally, ion exchange purification was performed. The 
SDS-PAGE gels in Figure 3.1 show the steps performed until pure protein was 
obtained. The first corresponds to the purification of EB1cΔ8 and the lanes represent 
the following: 1 – Ni2+ affinity column flow through, 2 - Ni2+ elution with high 
imidazole buffer, 3 – buffer exchange into no imidazole buffer, 4 – after SUMO 
protease cleavage, 5 – Ni2+ reverse purification, 6 – SUMO tag, 7 – pure protein after 
ion exchange chromatography. The second gel corresponds to EB1cΔ16 and the lanes 
follow the subsequent pattern: 1 – before Ni2+ affinity chromatography, 2 – Ni2+ 
affinity column flow through, 3 - Ni2+ elution with high imidazole buffer, 4 – after 
SUMO protease cleavage, 5 – Ni2+ reverse purification, 6 – SUMO tag, 7 – pure protein 
after ion exchange chromatography. The chromatograms obtained for Ni2+ affinity 
chromatography and ion exchange chromatography are shown in Figure 3.2. 
 
Figure 3.1- SDS-PAGE electrophoresis of purified EB1 fragments using 15% Tris-Glycine gels – 
EB1cΔ8 (8 kDa) and EB1cΔ16 (7.2 kDa). Molecular weights of the proteins expressed were predicted 
using ProtParam webserver14>. 
Unlabelled, 15N-labelled, 13C15N-labelled EB1cΔ8, as well as unlabelled and 15N-
labelled EB1cΔ16 samples were characterised using a range of NMR spectroscopic 
experiments. 1H 1-D spectra suggest that both fragments are folded in solution, 
showing an overall dispersion of chemical shifts in the methyl (0-2 ppm) and amide 
(8.5-10 ppm) regions - Figure 3.3 and Figure 3.4. 
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Figure 3.2 - Chromatograms for EB1cΔ8 and EB1cΔ16 purifications. Upper panel – Chromatogram obtained for Ni affinity chromatography for EB1cΔ8 (left hand side) and 
EB1cΔ16 (right hand side). Bottom panel – Chromatogram obtained for ion exchange chromatography for EB1cΔ8 (left hand side) and EB1cΔ16 (right hand side). Both proteins 
were used without further purification after ion exchange chromatography.
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Figure 3.3- 1H 1-D spectra of 15N-EB1cΔ8 at 100 µM acquired at 25oC, with a field strength of 600 
MHz, in 20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3. 
 
Figure 3.4 - 1H 1-D spectra of EB1cΔ16 at 50 µM acquired at 25oC, with a field strength of 600 MHz, 
in 20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3. 
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3.3 Characterisation of EB1c by NMR Spectroscopy 
The C-terminal domain of EB1 has been previously structurally characterised and 
described as a stable dimer with a parallel coiled coil31 Each monomer starts with a 
long smoothly curved helix (residues 191-230), followed by a loop region which 
connects to a shorter second helix (237-248) antiparallel to the longer helix, forming a 
parallel homodimer characterised by the existence of a coiled coil region followed by 
a four helix bundle. The four helix bundle is then followed by a highly disordered and 
flexible C-terminal region.27,31,43 Our construct EB1cΔ8 includes most of the C-
terminal flexible region since this region seems to establish contacts with ligands.31 
 
Figure 3.5 - 1H,15N-HSQC spectrum for EB1cΔ8 acquired at 25oC, with a field strength of 800 MHz, in 
20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3. The spectrum shows the 
protein is folded and the well dispersed peaks allowed a complete backbone assignment. 
Structural characterisation of EB1c using solution NMR 
77 
Both 1H,15N-HSQC spectra (Figure 3.5 and Figure 3.6) present large chemical shift 
dispersion for the NH resonances. The good dispersion is related to protein folding 
meaning that the secondary structure places the residues in defined regions, making 
each residue being in a unique position that will subsequently yield unique NMR 
resonance signals. The main difference is the existence of extra peaks in the EB1cΔ8’s 
spectrum as expected as this construct is larger.  
The 1H,15N-HSQC of EB1cΔ8 was fully assigned by using a sequential assignment 
methodology with complementary pairs of NMR spectra - CBCA(CO)NH/HNCACB 
for Cα/Cβ and HNCO/HN(CA)CO for CO assignment (Figure 3.7). The use of these 
spectra is based on their C correlation with the NH resonances. The 
CBCA(CO)NH/HNCACB relation of i/i-1 was used for the sequential assignment 
building residue connections. Additionally, by estimating the residue type using Cα/Cβ 
chemical shifts to it was possible to estimate possible sequences and integrate them in 
EB1cΔ8 in an iterative way, assigning larger residues stretches with the progress of 
the assignment.  
The HNCO/HN(CA)CO i/i-1 pair, was used to resolve possible ambiguities. In Figure 
3.7 one can observe the overall quality of the CBCA(CO)NH/HNCACB pair is good, 
with good dispersion and resolution of cross-peaks. However, the same region in the 
HNCO/HN(CA)CO pair has a much better quality, showing sharper peaks resolved 
and isolated from neighbouring peaks. It is important to mention that the CO chemical 
shifts can also be used to help predict secondary structure of the protein. The 
assignment procedures are described in Chapter 7. 
With the backbone assignment of EB1cΔ8, all NH resonances present in the 1H-15N-
HSQC were assigned with the exception for the side chains. The NH resonances for 
the other construct were easily assigned by superimposition of this spectrum on the 
previously assigned EB1cΔ8 1H,15N-HSQC. The C-terminal residues for EB1cΔ8 are, 
as expected, more intense – Figure 3.5, left hand side inset, residues Asp257 and 
Glu258 indicating this region is highly dynamic.  
Alternatively, the spectrum for the construct EB1cΔ16 only shows high intensity peaks 
for Asp250 and Glu251. As described before this construct lacks 16 C-terminal 
residues and therefore lacks the C-terminal flexible tail. The main purpose of this 
construct, EB1cΔ16, was to assess the role of the C-terminal flexible region – last eight 
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residues, in the interaction with other molecules. Therefore, the characterisation of this 
construct will not be as thorough (side chain assignment) as the one performed for 
EB1cΔ8 and subsequently presented. 
 
Figure 3.6 - 1H,15N – HSQC spectrum for EB1cΔ16 acquired at 25oC, with a field strength of 600 MHz, 
in 20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3. The spectrum shows 
the protein is folded and the well dispersed peaks allowed a complete backbone assignment. 
Using the HBHA(CO)NH experiment that correlates NH of i to Hα/Hβ of i-1 it is 
possible to assign Hα/Hβ resonances from the NH resonances. The assignment of this 
spectrum was also a confirmation of the NH resonances assignments since Hα/Hβ 
resonances also have characteristic values for each amino acid type and all i/i-1 links 
are confirmed since this experiment works on i/i-1 relation.143–14> 
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Figure 3.7 – Superimposition of the pairs - CBCA(CO)NH/HNCACB and HNCOHN(CA)CO.  
Left panel - the Cα/Cβ peaks of the CBCA(CO)NH spectrum are shown in black, with the Cα/Cβ peaks 
of the HNCACB spectrum are shown in green and red respectively. Right panel – the HN(CA)CO 
spectrum is shown in red, with the C’ peak of the preceding residue being less intense and matching 
the i-1 peak from the HNCO (black) spectrum.  
In general, it is not sufficient to obtain only the backbone assignments, since side 
chains are the major fraction of the protein. Moreover, no protein structure can be 
determined without side chain assignments.  
Hence, 1H,13C-HSQC (Figure 3.8) was assigned, starting with the known resonances 
for α/β resonances, previously obtained from the combination of 
CBCA(CO)NH/HNCACB and HBHA(CO)NH. Using these resonances and the 
through bond correlations given by H(C)CH-TOCSY experiment the remaining atoms 
in the side chain were assigned. Because the resolution of 1H,13C-HSQC is inferior to 
the 1H,15N-HSQC and there are more 1H/13C cross-peaks, the spectrum looks more 
crowded, with more overlapping, therefore, (H)CCH-TOCSY experiment was used to 
discriminate between signals with similar 1H resonances.  
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Figure 3.8 - 1H,13C-HSQC spectrum for EB1cΔ8 acquired at 25oC, with a field strength of 800 MHz, in 
20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3. The spectrum shows 
generally well dispersed peaks. Only methyl region assignments are shown for clarity. Positive contours 
are shown in black and negative contours in red. 
These experiments make use of the TOCSY (Total Correlation Spectroscopy) through-
bond coherence transfer to all coupled spins in a scalar-coupled network (e.g. all 13C 
or 1H atoms of a linear side-chain).  
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The methyl region of 1H,13C-HSQC is very crowded, especially methyl groups of 
valines and leucines. The region around 25-35 ppm in carbon dimension and 1-2.3 
ppm for hydrogen dimension is also very crowded and it was particularly difficult to 
assign. This region contains high density of peaks including β’s for a large number of 
residues – lysine, arginine, glutamic acid, glutamine, methionine, proline; γ’s for 
isoleucine, lysine, arginine, proline and δ’s for lysine. 
The aromatic residues resonances (Figure 3.9) were assigned using the Cα/Cβ and 
Hα/Hβ resonances and a combination of 2D and 3D NOESY spectra for the side chain 
assignment. The main reason for this approach was the poor quality of H(C)CH-
TOCSY spectra for the aromatic region. The signals of the aromatic side chains are 
not well dispersed and required a very careful analysis.  
 
Figure 3.9 - 1H,13C-HSQC spectrum for the aromatic residues of EB1cΔ8 acquired at 25oC, with a field 
strength of 800 MHz, in 20 mM phosphate buffer pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3.  
Once side chain assignments were performed, the NOE spectra ‒ 15N-resolved-13C-
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decoupled-NOESY-HSQC and 13C-resolved-3D-NOESY-HSQC ‒ HSQC dimensions 
were assigned using the root resonances present in both 1H,15N-HSQC and 1H,13C-
HSQC, in a semi-automatic way, i.e. picking the peaks and propagating the 
assignments. 
An extra complication of the EB1c resonance assignment is the fact that is a symmetric 
parallel homodimer, making difficult to distinguish between intraresidue NOEs and 
intermonomer NOEs between the same residue belonging to different monomers. In 
other words, with the assignment of 15N-resolved-13C-decoupled-NOESY-HSQC and 
13C-resolved-3D-NOESY-HSQC one is assigning NOE cross-peaks for only one 
monomer. However, due to the short distance between both monomers it is possible 
that some of these peaks, especially in the methyl region, are intermonomer contacts. 
It was, therefore, of the utmost importance to acquire information about NOE distances 
between the two monomers and therefore position the monomers in respect to each 
other – intermonomer distance restraints. For that purpose, EB1cΔ8 and 15N13C- 
EB1cΔ8 equimolar solutions were mixed and incubated at 37oC for 16 hours. This 
procedure was previously described by De Groot et al14> for an EB1/EB3 heterodimer 
formation. A set of 15N,13C-filtered NMR NOE experiments were acquired permitting 
the calculation of distance restraints between residues located in separate monomers 
(isotopically labelled versus unlabelled). 
With the 15N and 13C resolved 3D-NOESY-HSQC root resonances fully assigned it is 
possible to introduce these chemical shifts and spectra into ARIA96 for an automated 
ambiguous automated assignment. ARIA uses an iterative protocol and the concept of 
ambiguous distance restrains and automatically assigns NOE cross peaks.96 In addition 
to NOE cross peaks and calculated interatomic distances the use of other restraints 
such as dihedral angle or hydrogen bond restraints can be very useful for NMR 
structure calculation. This will be the focus of the next section. 
3.4 Solution NMR structure of EB1cΔ8 
ARIA96 is a widely used automated NOESY assignment procedure that acts as an 
interface for the Crystallography and NMR system - CNS98. A very important concept 
introduced by ARIA is the use of ambiguous distance constraints, where a certain 
chemical shift can be assigned to more than one resonance and later resolved as the 
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calculation proceeds. The use of only unambiguously assigned NOEs hinders the 
automatic NOE assignment since the majority of NOEs are hard to assign 
unambiguously.97 More information on ARIA 2.0 can be found in NOE Assignment 
with ARIA 2.0.14> 
The EB1cΔ8 structure in the unbound state was determined from 2641 restraints from 
which 634 correspond to intermonomer distance restraints, supplemented by 64 
dihedral angle restraints derived from chemical 13C-chemical shift values. Statistics of 
the structure determination are presented in Table 3.1. The process is described in 
Chapter 7. From the 320 structures calculated for the last iteration, 30 were water 
refined. The overlay of the 20 lowest energy structures – Figure 3.10 – shows 
consistency across the 20 structures for the region 191-248 where a helical secondary 
structure can be observed. EB1c is a parallel 2-stranded coiled coil, where the side 
chain of an apolar residue from one chain is inserted into a hole formed by the apolar 
side chains of four residues from the opposing chain – “knob in the hole” like 
structure.14> The coiled coil is then followed by a four helix bundle where contacts 
between four helices can be observed. Finally, a disordered C-terminus region follows, 
where assignments need to be carefully and manually analysed since any wrong or 
highly ambiguous assignment can introduce a bias in this region yielding an incorrect 
structure model.  
The first difficulty encountered when trying to calculate an ensemble of structures 
using dihedral angles and distance restraints was, due to being a large continuous 
helical structure and to the ambiguity given by the large number of leucines and valines 
(11.4% and 8.6% of the total sequence respectively), the calculated monomer would 
invariably fold on itself. This structure yielded high number of violations and high 
energies being, in all aspects, an unfavourable conformation. However, there were not 
enough restraints to fold it without breaking the helix in the region between the leucine 
zipper and the four helical bundle structure (Leu210-Arg214). To overcome this 
problem it was thought that the introduction of hydrogen bond restraints could help to 
stabilise the helical structure of the protein. Therefore, a thorough analysis of the NOEs 
was carried out in order to confirm which regions of the protein have a helical 
conformation. A survey of the sequential and medium range NOEs states that for an 
α-helix secondary structure, NOE cross peaks for Hα of i and HN of i+2 and i+3 should 
be observed, as well as Hα for i and Hβ of i+3.15> 
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Table 3.1 – NMR distance and dihedral statistics and structure statistics determined for the 20 best 
structures of the ensemble of free EB1cΔ8. 
 EB1cΔ8 
Total restraints used 
NOE restraints*  
All 2641 
Protein-ligand NA 
Intermonomer 634 (99) 
Intraresidue 980 
Sequential (|i – j| = 1) 633 
Medium (1 < |i – j| ≤ 4) 850 
Long range (|i – j| > 4) 169 
Dihedral  
ϕ angles 64 
φ angles 64 
Hydrogen bonds 90 
Structure statistics 
Violations 
Distance (> 0.5 Å) 3 
Dihedral angle (> 50)  1 
Energies (cal/mol) 
Overall   -5688 (±169) 
Bond 26 (±2) 
Angle 150 (±7) 
Improper 307 (±50) 
Dihedral 697 (±9) 
Van der Waals -1293 (±12) 
Electrostatic -5576 (±158) 
NOE 352 (±45) 
Geometry – average Values  
Bond 3.45x10
-3
 (±1.14x10
-4
) 
Angle 0.49 (±0.018) 
Improper 1.34 (±0.11) 
Dihedral 40.83 (±0.25) 
Van der Waals 162.96 (±12.05) 
Average pairwise RMSD (Å)**  
Heavy atoms 5.36 (±1.13) 
Heavy atoms – helical region 0.89
 (±0.09) 
Backbone  5.75 (±1.23) 
Backbone – helical region 0.32 (±0.07) 
Ramachandran statistics (%) ***  
Most favoured regions 90.8 (98.8) 
Additional allowed regions 8.8 (1.2) 
Generously allowed regions  0.4 (0) 
Disallowed regions 0.0 (0) 
*Number in brackets corresponds to the restraints assigned manually 
**Helical region corresponds to residues: Glu192-Glu230 and Pro237-Tyr247 
*** Values within brackets correspond to residues Glu192-Glu230 and Pro237-Tyr247 (helical region) 
Therefore, 13C and 15N resolved NOESY-HSQCs were then carefully inspected in 
order to confirm the existence of these NOEs and consequently the α-helical region – 
Appendix (A.1). After proving the structure obeyed this pattern, artificial hydrogen 
bond restraints were introduced for these regions in order to help the protein folding 
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during the calculations. The hydrogen bond restraints in addition to some resolved 
ambiguities during inspection of the 13C and 15N resolved NOESY-HSQCs finally 
yielded the expected helical monomer. 
 
Figure 3.10 – A – Superimposition of the ensemble of 20 lowest energy structures of EB1cΔ8 domain 
in the free form. B – Cartoon representation of the lowest energy structure for EB1cΔ8. 
When compared with heterodimers, homodimers have a larger surface area, fewer 
hydrogen bonds, higher hydrophobicity and typically C2 symmetry.15> The structure 
determination of symmetric homodimers by NMR is impeded by the fact that is 
intrinsically impossible to distinguish between inter and intramonomer NOEs. The 
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only way to resolve this ambiguity is by asymmetric labelling.152  
As expected, applying C2 symmetry restrains was not enough to obtain the homodimer. 
The structure obtained was, invariably two parallel monomers, side by side and not a 
coiled coil. To solve this problem, the inter chain contacts were identified by using 
inter molecular NOEs from a 13C,15N-filtered-NOESY-HSQC experiment performed 
in an isotopically labelled/unlabelled dimer. These NOE restraints were fundamental 
to determination of the correct structure since they give information on the interface 
between both monomers. Additionally, CNS protocols were modified in order to 
optimise these C2 symmetry restraints for a parallel homodimer alternatively to the 
standard definitions based on an antiparallel homodimeric structure - Figure 3.11. 
 
Figure 3.11 – representation of the C2 symmetry restraints used for structure calculation. The 2-fold 
symmetry axis of the dimer is indicated. The distances from i to j’ and from j to i‘ are of equal size. On 
the left hand side the original restraints (antiparallel) and on the right hand side the modified version 
(parallel) used in this project. 
Because of the leucine zipper structure for the lower region of the helical region, more 
difficulties arose. As referred before, the methyl region of 1H,13C-HSQC is highly 
populated and there are some overlapped peaks, especially the ones belonging to 
valines and leucines. This is due to the existence of a contiguous heptad repeat in the 
form abcdefg, where a is valine and d leucine. This repetition of motifs induces similar 
chemical environments for these side chains (residues Leu196-Leu210) – Figure 3.12.  
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Figure 3.12 - Heptad repeat for the coiled coil structure of EB1c, side chains forming the apolar contacts 
are shown as sticks. 
This helical region structurally characterised as a leucine zipper is immediately 
followed by a four helical bundle, from Arg214 to Ala248 with a loop (Asn232-Val238) 
connecting the antiparallel helices for each monomer. The four helix conformation 
creates additional difficulties for correct assignment and structure determination. 
Being A and B the two longer helices of EB1c, A’ and B’ correspond to two identical 
shorter helices running antiparallel to A/B. Consequently, there are two possible 
combinations of inter helices contacts: A – A’ (intramonomer), A – B’ (intermonomer) 
- Figure 3.13.  
 
Figure 3.13 – schematic representation of the four helical bundle of the EBH domain of EB1c and 
possible inter and intramonomer contacts. 
This creates additional difficulties as the contacts between A – A’ and A – B’ are 
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different, different faces of the helices. If the right interaction surfaces are not correctly 
assigned, the position of the four helix bundle will be incorrect. 
This required detailed analysis of these regions and manual assignment of important 
contacts. Distance restraints were then derived from this assignment and used in the 
calculations as absolute NOE restraints, i.e. not filtered out during the iterative 
assignment performed by ARIA, 
Outside the fully structured coiled coil region, 248-260, the protein becomes 
unstructured, being highly dynamic - Figure 3.10A. This trend is supported by the 
RMSD values – Figure 3.14. The RMSD values for both backbone and side chains 
increase sharply from Asp250 onwards. Extra support for this flexibility is given by 
the existence of only intra-residue and sequential (+1/-1) NOE contacts in this region 
(Figure 3.15) and the intensities of the backbone 1H,15N-HSQC (Figure 3.5) cross-
peaks dramatically increased for the corresponding residues.  
 
Figure 3.14 – RMSD calculated per residue for the ensemble of 20 structures that form the solution 
NMR ensemble for EB1cΔ8. In black are shown RMSD values for the backbone and in red for the side 
chains. 
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Figure 3.15 – Strips for the 13C-resolved-NOESY-HSQC for the methyl groups of the following residues 
of the C-terminus of EB1cΔ8 in the free form – Thr249, Val254 and Ile255. The contacts shown refer 
to the aliphatic region ~4.5 ppm to ~0.4 ppm and it is possible to observe the absence of inter-residue 
contacts, except for some sequential residues. 
As described in the previous section, 3.3, and shown in Figure 3.9 the aromatic side 
chain resonances are not very well dispersed, showing some overlap. The main reason 
for this signal clustering is related with the 216FYF218 motif – Figure 3.16, with Phe216’ 
and Phe218 with similar chemical shifts. The assignment of intermononer contacts for 
this region was also of extreme importance since the Phe216’ and Tyr217’ belong to 
one monomer, whereas Phe218 belongs to the other. This area is of particular interest 
Structural characterisation of EB1c using solution NMR 
 
90 
since it forms an aromatic patch at the bottom of the hydrophobic binding site.43  
 
Figure 3.16 – Representation of the aromatic rim of the binding pocket of EB1cΔ8 – the F’Y’F motif. 
 
Figure 3.17 - A – conformations for Arg222 and Tyr247 for all the 20 structures calculated for free 
EB1cΔ8 B - different conformations observed for Arg222 and Tyr247 in solution and how they affect 
the shape and size of the binding pocket. 
It was also observed that two residues part of the hydrophobic pocket, Arg222 and 
Tyr247, present a dynamic behaviour in solution – Figure 3.17. Side chain RMSD 
values for the NMR ensemble for these residues are 1.37 Å for Arg222 and 1.76 Å for 
Tyr247, whereas the average for residues between 193-248 is 0.78 Å. There are NOE 
contacts between the aromatic ring of Tyr247 and Val243, Asp244, Ile245, Leu246, 
and Ala248 in the immediate proximity of Tyr247, compatible with all the detected 
orientations of the side-chain. However, no NOE cross peaks were observed between 
Tyr247 and Gln240 or Glu225, expected for two of the lowest energy structures of the 
protein (Figure 3.18). Similarly, there were no NOEs suggesting a preferential 
conformation of Arg222 side-chain. In the free protein the side-chains of Arg222 and 
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Tyr247 are dynamic, due to the lack of any specific interactions that would stabilise 
their orientation. 
 
Figure 3.18 – Superimposition of the two lowest energy structures of the ensemble obtained for EB1cΔ8 
in the free form. In green it can be seen that Tyr247 is closer to Glu225, whereas in cyan it is closer to 
Gln240. The remaining residues that show distance restraints to Tyr247 are represented in grey sticks. 
Both Arg222 and Tyr247 are part of two of the outer walls of the hydrophobic pocket.31 
Different conformations of these side chains in solution have strong effect on the shape 
and size of the hydrophobic pocket and therefore on small molecule binding. This was 
clearly demonstrated in Figure 3.17B, where when both side chains are in an inner 
position the binding pocket is not formed, as these side chains occlude it. When both 
point outwards, Figure 3.17B, middle panel, the pocket is partially formed but the outer 
wall formed by Tyr247 is not defined. When Tyr247 points inwards and Arg222 
outwards there is a binding pocket defined where the lateral “walls” are defined by the 
side chains of these residues. 
This matter will be further discussed in section 3.6, but for now the solution NMR 
structure for EB1cΔ8 in complex with molecule 1a and differences between free and 
bound form will be analysed. 
3.5 Solution NMR structure of the complex EB1cΔ8-1a 
In the previous section the solution NMR structure of EB1cΔ8 was elucidated and 
described. Notable characteristics such as the side chain mobility of residues in the 
binding site were described. It is important to determine the similarities and differences 
900 
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between EB1cΔ8 in the free form and bound to a small molecule and make conclusions 
of the main structural changes occurring in EB1cΔ8 upon ligand binding. These 
aspects will be subsequently described. 
As described in Chapter 2, the NH resonances for EB1cΔ8 upon 1a titration are 
affected in a fast exchange manner being possible to follow the chemical shift changes 
and propagating the assignments. The same was possible for 1H,13C-HSQC. Most of 
the resonance assignments were possible to assign using this strategy. The resonances 
for the small molecule, 1a, were assigned using 13C, 15N-filtered-NOESY and TOCSY 
experiments. With all the assignments in place it is possible to calculate distance 
restraints and perform structure calculation, similarly to what happened with EB1cΔ8 
in the free form. 
Regarding the structure of the complex EB1cΔ8-1a an additional complication was 
introduced due to the presence of a ligand. Luckily, it was known from the subtle 
chemical shift changes in the 1H,15N-HSQC observed upon ligand addition that there 
were not major structural changes induced by ligand binding, and therefore the 
structure would not be very different from the free form. Hence, it was decided to use 
a simplified approach where the final restraints obtained for EB1cΔ8 were used as the 
initial distance restraints input and the intermolecular restraints between the ligand and 
the protein are introduced to place the ligand relatively to the protein. 
So far, for the free protein there were two combinations of intermolecular restraints – 
chain A to chain B and reciprocally chain B to chain A. Being a symmetric homodimer 
means also that EB1 will have two symmetrical and equivalent binding sites, both 
formed by residues from both monomers - A and B. With a ligand bound to each 
binding site – chains C and D, it is to expect the following combination of 
intermolecular contacts: A-B; A-C; B-C; A-D and B-D being a highly complicated 
system for structure determination using NMR - Figure 3.19. Again, in order to 
simplify the number of possible intermolecular combinations, only one ligand was 
introduced in the calculations to simplify the combination of restraints needed. This is 
a valid strategy as the calculated ligand will be symmetric in terms of binding mode to 
the second ligand. By doing this, the number of possible combinations for 
intermolecular restraints is reduced to: A-C, A-B, A-C and B-C.  
The restraints referring to free EB1c, incompatible with the intermolecular restraints 
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introduced for the complex were automatically removed by ARIA through filtering of 
incompatible restraints with the protein-ligand intermolecular restraints. Using this 
protocol, it was possible to obtain high quality and accurate structures.  
 
Figure 3.19 – Schematic representation of a ligand bound to EB1cΔ8 binding site. The binding site is 
formed by both A and B chains and two ligands can bind simultaneously, C and D. 
In Table 3.2, the parameters used for the calculation of both structures (free and 
complex) are shown. In ARIA, the user can choose between Cartesian and Torsion 
Angle dynamics. Both of these simulating annealing (SA) strategies have been 
optimised for ambiguous NOE-derived restraints. Torsion angle dynamics generally 
produces an increased convergence and leads to better local geometries.15> The 
parameter “temperature” in this context has no physical meaning, but is simply a 
measure of the probability of the macromolecule to cross an energy barrier (i.e., its 
kinetic energy). As mentioned before, to speed up the calculations it was decided to 
use the lower energy structure obtained for free EB1cΔ8 as the starting structure for 
the calculation instead of the extended polypeptide chain based only on the sequence 
of amino acids which is the default option. Therefore, some modifications in the SA 
parameters used for the calculation were necessary. The temperature used for the 
complex structure calculation was lower (2000 K) than the one used for calculation of 
free EB1 (10000 K). Because the structure of free EB1 was used as the initial structure, 
it was not desirable to use high temperatures that would make the simulations highly 
dynamic with possible loss of the introduced structure. Instead, the simulations should 
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have enough freedom only for the protein to adopt the conformation defined by the 
intermolecular restraints. The number of steps is higher for the structure of the complex 
since, in general, the larger the number of cooling steps, the higher the percentage of 
accurate calculated structures, and because the calculated structure was already very 
close to the final form it was important to make sure the selected parameters would 
give an accurate structure and satisfy all the intermolecular NOE restraints between 
the protein and the ligand. 
Table 3.2 – Simulating annealing parameters used for structure determination of free EB1cΔ8 and the 
complex EB1cΔ8/1a. 
 Free Complex 
Type Torsion angle Torsion angle 
Random seed 89764443 89764443 
TAD high temperature 10000.0 2000.0 
TAD time-step factor 9.0 9.0 
Cartesian High temperature 2000.0 2000.0 
Cartesian 1st iteration 0 0 
Time-step 0.00015 0.00075 
Cool1 final temperature 1000.0 1000.0 
Cool2 final temperature 50.0 50.0 
High-temp steps 20000 40000 
Refine steps 8000 16000 
Cool1 steps 10000 40000 
Cool2 steps 8000 32000 
Seventy-five intermolecular NOEs derived from 15N,13C filtered NOESY experiments 
were used for calculating structure of the complex. Statistics of the structure 
determination are presented in Table 3.3. This approach yielded a structure of a 
complex, within a reasonable time and seems a robust and quick way to obtain solution 
structures of weakly bound complexes. The overall structure is shown in Figure 3.20. 
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Table 3.3 - NMR distance and dihedral statistics and structure statistics determined for the 20 best 
structures of the ensemble of the complex EB1cΔ8-1a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Number in brackets corresponds to the restraints assigned manually 
**Helical region corresponds to residues: Glu192-Glu230 and Pro237-Tyr247 
*** Values within brackets correspond to residues Glu192-Glu230 and Pro237-Tyr247 (helical region) 
 EB1c-1a 
Total restraints used 
NOE restraints*  
All 2766 
Protein-ligand 75 
Intermonomer 648 (99) 
Intraresidue 1044 
Sequential (|i – j| = 1) 641 
Medium (1 < |i – j| ≤ 4) 866 
Long range (|i – j| > 4) 169 
Dihedral  
ϕ angles 64 
φ angles 64 
Hydrogen bonds 90 
Structure statistics 
Violations 
Distance (> 0.5 Å) 16 
Dihedral angle (> 50)  0 
Energies (cal/mol) 
Overall   -5716 (±163) 
Bond 38 (±1.5) 
Angle 167 (±5.5) 
Improper 298 (±32) 
Dihedral 713 (±7) 
Van der Waals -1298 (±10) 
Electrostatic -5635 (±17) 
NOE 1280 (±50) 
Geometry – average Values  
Bond	 4.65x10
-3	
(±1.18x10
-4
)	
Angle	 0.67	(±0.013)	
Improper	 1.31	(±0.071)	
Dihedral	 40.94	(±0.25)	
Van	der	Waals	 346.16	(±23.53)	
Average	pairwise	RMSD	(Å)**	  
Heavy	atoms	 4.54	(±9.28x10
-1
)	
Heavy	atoms	–	helical	region	 6.12x10
-1
	(±7.73x10
-2
)	
Backbone  4.92	(±1.12)	
Backbone – helical region 1.57x10
-1
	(±3.61x10
-2
)	
Ramachandran statistics (%)***   
Most	favoured	regions	 90.6	(98.1)	
Additional	allowed	regions	 9.3	(1.9)	
Generously	allowed	regions		 0.1	(0)	
Disallowed	regions	 0.0	(0)	
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Figure 3.20 - A – Superimposition of the ensemble of 20 lowest energy structures of EB1cΔ8 domain 
in complex with 1a. B – cartoon representation of the lowest energy structure for EB1cΔ8 in complex 
with 1a.  1a is shown in sticks, where red represents carbon, blue nitrogen and yellow sulphur. 
Analysis of the structure reveals two important features, the first is compound 1a binds 
to the same region reported to be targeted by the natural SxIP motif and second the 
fact that this structure is very similar to the free form. This last fact is also supported 
by the side chain RMSD values obtained for both ensembles and shown in Figure 3.21. 
The C-terminus remains largely flexible as shown by Figure 3.20A. Similarly, to what 
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was observed for free EB1cΔ8, RMSD values per residue across the 20 structures that 
compose the solution NMR ensemble for this complex show a sharp increase in these 
values is observed from Asp250 onwards – Figure 3.21. Moreover, the only residue 
outside of the structured region that has an intermolecular NOE cross-peak is Thr249, 
which occupies a region very close to the coiled coil. 
 
Figure 3.21 – RMSD values for EB1cΔ8 side chain for free (black) and bound to 1a (red) structures. 
In terms of intermolecular distance restraints between 1a and EB1cΔ8 in the final 
iteration they position the cyclopentyl ring close to Tyr217, Phe218, Leu221, Arg222, 
Leu246 and Tyr247 – all consistent with the hydrophobic binding site targeted by the 
IP motif of the SxIP proteins. The methyl group shows NOE cross-peaks to Tyr217, 
Phe218 and Tyr247, and additional contacts are made with Phe216 and Thr249, the 
latter outside the coiled coil region. Finally, the oxazole moiety does not show any 
intermolecular NOEs. CSP and molecular docking data – Chapter 2 - are, therefore, in 
agreement with the three-dimensional structure of the complex. 
Regarding the binding site dynamics, Arg222 and Tyr247 are now in a more fixed 
conformation when compared with the free form – Figure 3.22 (compare with Figure 
3.17). Side chain RMSD values are now 0.43 Å for Arg222 and 0.80 Å for Tyr247, 
whereas previously were 1.37 Å and 1.76 Å, respectively. Figure 3.21 shows a 
comparison of the RMSD values for amino acid side chains between EB1cΔ8 and 
EB1cΔ8-1a complex and the larger RMSD values for both Arg222 and Tyr247 can be 
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observed.  
 
Figure 3.22 – conformations for Arg222 and Tyr247 for all the 20 structures calculated for free EB1cΔ8 
bound to compound 1a.  
The existence of intermolecular NOEs observed between these residues and the 
cyclopentyl ring of 1a, Figure 3.23, confirms that 1a has a stabilising effect on these 
side-chains. As consequence, the binding pocket remains in the same conformation for 
the ensemble of structures obtained for this complex. 
 
Figure 3.23 - Selected regions of a 13C,15N filtered-2D-NOESY showing intra and intermolecular NOEs 
observed for EB1c-1a complex, acquired at 25oC. The intramolecular NOEs correspond to the aromatic 
protons of the oxazole moiety NOEs to the cyclopentyl ring. The intermolecular NOEs show the NOE 
contacts between the cyclopentyl ring and Phe218, Leu221, Arg222, Leu246 and Tyr247.  
The stabilisation of EB1’s binding pocket upon ligand binding has not been reported 
before. However, analysis of published X-ray crystal structures obtained for free and 
bound form of EB1c indicate that Arg222 and Tyr247 adopt two different 
conformations in the free (PDB codes 1YIG and 1WU927,43) and bound state, (PDB 
code 3GJO31) – Figure 3.24A.  
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These conformations clearly affect the shape of the binding site – Figure 3.24B.  In the 
absence of a ligand the binding pocket is dynamic, changing from the fully open state 
to the fully closed state (Figure 3.17B) with the open state characterised by Tyr247 
side-chain pointing outwards and Arg222 side-chain flattened against the surface of 
the helix leading to the absence of one of the outer walls of the binding pocket. This 
structure is stabilised in the crystallised free EB1c (Figure 3.24B). In the closed form, 
side-chains of Arg222 and Tyr247 point towards each other, completely blocking the 
binding site. This closed form is present in the NMR ensemble for the free protein 
(Figure 3.17B, top panel). Finally, the binding pocket is fully formed in the crystal 
structure of the complex (Figure 3.24B), complex with 1a and some of the structures 
of the free protein NMR ensemble (Figure 3.17B, bottom panel).  
 
Figure 3.24 - A - Two conformations for residues Arg222 and Tyr247 in free (yellow and navy, PDB 
codes 1YIG and 1WU9 respectively) and bound state (magenta, PDB code 3GJO). Leu221 and Leu246 
remain in a stable conformation as they are part of the coiled coil hydrophobic interface and are shown 
as reference points. On the right hand side the same representation with a 270o rotation on the x axis. B 
– Representation of the EB1 pocket shape based on the conformation of residues Arg222 and Tyr247, 
for unbound EB1c (PDB code 1YIG), and bound EB1c (PDB code  3GJO). 
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3.6 Analysis of the implications of the side chain dynamics for Arg222 
and Tyr247 and its influence on small molecule binding 
To further explore the potential effects of the binding pocket dynamics a simple 
experiment was designed where small molecule binding to EB1cΔ8 was re-evaluated 
using a variety of EB1c structures with different binding site conformations. It has 
been widely reported that the cross-docking of a ligand to an ensemble of protein 
structures increases the chances to find near-native solutions.89 Cross-docking consists 
of docking a ligand to an ensemble of different protein conformations.15> This 
approach is essential when targeting dynamic regions.155  
 Cross-docking approach                                                                                                                                                                                        
The four experimentally tested molecules were re-docked using the ensemble of 20 
NMR structures for the free form and three crystal structures – 1YIG27, 1WU943 and 
3GJO31. The first two are a three-dimensional model of EB1c in the absence of ligands 
whereas the latter represents EB1c bound to a SxIP motif containing peptide.  
Average docking score for the NMR ensemble for compound 1d was highest, 64, 
followed by 1a, 53, 1c, 48 and 1b with a score of 46. This ranking is in accordance 
with the in vitro screening, where 1d is the best binding compound, followed by 1a; 
compounds 1c and 1b have much weaker interactions. In contrast, when docked to the 
crystal structure of complex with the peptide (3GJO), compound 1b had a score of 59 
that was higher than for compound 1a (55), in clear disagreement with the 
experimental measurements. This suggests that docking to the NMR ensemble that 
accounts for the dynamics of the binding site, providing a more reliable prediction of 
the binding propensity than the docking to the fully formed binding site of the complex. 
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Figure 3.25 - Predicted docking scores for each compound, 1a, 1b, 1c and 1d, for the ensemble of the 
solution NMR structures of free EB1 (red), crystal structures of free EB1, 1WU9 (yellow) and 1YIG 
(navy), and crystal structure of EB1 in the bound state with SxIP protein, 3GJO (magenta). The score 
obtained for the reference structure where the initial docking calculations were performed – 3GJO, is 
defined by a black horizontal line to facilitate the comparison. 
The modelling indicates that compounds 1a and 1d can interact with a wide range of 
states, where binding site is partially formed, while 1b and 1c only bind to the fully 
formed binding pocket. In agreement with this, while all compounds had low scores 
when docked to the open binding pocket of the crystal structures of the free EB1c, the 
scores of the compounds 1a and 1d were significantly higher than the scores of the 
other two compounds (Figure 3.25). The docking results provide an explanation of 
why compound 1b, that apparently fits the binding pocket well, shows negligible 
interaction with EB1c. This compound can only interact with an extremely small 
population of EB1c where the binding site is fully formed spontaneously, while 
compounds 1a and 1d interact reasonably well with the majority of the configurations 
of the binding pockets, potentially inducing further binding pocket changes after an 
initial docking. Closer agreement with the experimental results suggests that the use 
of solution NMR structures and cross-docking can be a powerful tool in drug design 
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for dynamic regions. 
 Principal component analysis 
Principal component analysis (PCA) is a method to reduce the dimensionality of a data 
set to facilitate a quicker analysis of various variables at the same time, retaining the 
information contained in these variables. This allows for the conversion of possibly 
correlated variables into a set of linearly uncorrelate variables (principal components) 
that can give an insight into the relationships between variables.15> The first principal 
component explains the maximum variance in the data set, the second component 
describes the maximum of the remaining variance, and so on. Therefore, the majority 
of the information in most of data sets will be contained in the first few principal 
components.156 To relate the variations in the binding site geometry to the ligand 
binding properties, a set of geometric parameters that characterise binding site 
variation were calculated and used in PCA to isolate and compare the main 
configurations of the binding pocket. 
Since the main changes in the IP binding pocket are attributed to the Tyr247 and 
Arg222 side-chain dynamics, the distances between ζ groups of these residues, as well 
as between ζ of Arg222 and ζ of Tyr247 to the invariable γ groups of Leu221 and 
Leu246 respectively were measured. Additionally, CASTp15> was used to identify and 
characterise the binding pockets, in terms of size (area and volume), number of 
openings, sum arc length and corner points. 
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Table 3.4 - Parameters used for PCA analysis for the hydrophobic pocket shape and size analysis. NMR ensemble for free EB1cΔ8 is represented by a followed by a number 
where 1 is the lowest energy structure and 20 the highest energy structure. For the complex, EB1cΔ8-1a. the same approach was used but the letter b was used instead. 
 Distances in Å CASTp calculated parameters 
structure Y247-L246 Y247-R222 R222-L221 Number of mouth openings 
Area (Å2) Volume (Å3) sum arc 
length 
corner 
points Solvent 
accessible 
Molecular 
surface 
Solvent 
acessible 
Molecular 
surface 
a1 6.2 9.5 10.8 0 1.01 39.76 0.047 22.54 5.95 10 
a2 5.7 7.7 8.1 0 8.511 83.92 0.834 54.98 23.73 24 
a3 5.7 9 10.8 1 55.546 117.99 28.662 146.9 61.14 35 
a4 5.7 6.6 8.7 1 52.497 120.81 25.188 143.57 62.64 34 
a5 8.2 12.9 8.2 1 17.126 98.98 2.151 77.16 36.74 29 
a6 5.5 6.8 7.8 1 52.621 133.46 23.978 150.3 65.33 44 
a7 5.8 9.3 10.8 2 235.65 364.76 222.704 627.24 196.12 96 
a8 5.3 8.4 10.9 1 48.999 140.17 21.852 148.61 70.47 44 
a9 6.2 10.1 11 1 43.184 105.82 18.735 116.85 46.96 31 
a10 5.7 7.7 9.3 1 64.44 121 41.899 170.09 68.49 38 
a11 8.2 15.5 11 2 62.05 140.35 29.281 164.23 71.83 41 
a12 5.9 9.8 10.7 1 45.449 102.4 25.231 126.74 51.68 33 
a13 6.9 10.1 10.9 1 61.746 141.29 33.273 171.06 72.64 46 
a14 5.5 8.5 10.1 1 34.944 95.88 12.706 99.36 41.04 27 
a15 5.4 8.5 10.1 1 48.167 129.3 18.606 138.81 57.76 42 
a16 8.1 15.9 10.3 1 59.374 123.11 33.243 159.51 69.51 39 
a17 6.1 6.9 8.1 1 48.32 107.57 22.138 128.66 56.61 32 
a18 5.9 6.1 7 1 60.851 128.31 29.974 154.73 59.46 39 
a19 6.4 6.6 8.1 1 47.268 122.42 22.083 136.88 56.2 40 
a20 5.7 8.5 10.6 1 50.097 177.66 20.751 165.42 71.37 45 
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structure Y247-L246 Y247-R222 R222-L221 Number of mouth openings 
Area (Å2) Volume (Å3) sum arc 
length 
corner 
points Solvent 
accessible 
Molecular 
surface 
Solvent 
acessible 
Molecular 
surface 
b1 7.1 8.7 9.9 2 113.463 260.95 63.765 310.72 131.55 81 
b2 6.7 7.9 9.8 2 67.6 152.44 43.335 192.84 75.1 47 
b3 7 9.4 9.9 2 73.991 202.17 40.768 228.6 100.62 66 
b4 6.8 7.6 9.6 2 85.914 235.13 45.588 264.4 116.44 73 
b5 6.6 8 9.7 2 88.005 233.83 44.537 265.02 119.3 70 
b6 6.6 8.4 9.8 2 95.974 240.12 42.286 270.55 122.06 80 
b7 CASTp could not find the right pocket for this structure. It was, therefore, removed from the statistical analysis. 
b8 6.9 8.8 9.8 2 91.69 239.29 50.976 255.84 109.45 68 
b9 6.3 7.8 9.8 2 74.923 209.82 48.153 241.05 108.69 73 
b10 7.2 7.6 9.4 2 84.547 226.73 52.558 260.92 112.61 74 
b11 7.1 8.8 9.8 2 86.247 230.54 50.091 260.88 108.07 74 
b12 7 8.7 9.7 2 88.183 197.39 52.529 249.95 108.17 59 
b13 7 8.2 9.7 2 90.155 262.6 46.776 275.84 114.23 71 
b14 6.6 8.2 9.8 2 84.244 232.91 45.891 252.99 104.37 78 
b15 6.6 8.2 9.8 2 78.433 215.94 43.006 234.72 106.5 63 
b16 6.4 8 9.8 2 102.369 238.6 56.804 289.47 135.06 79 
b17 6.5 8 9.9 2 79.677 213.7 48.089 247.09 107.11 67 
b18 7 9.9 9.9 2 72.998 206.1 40.851 230.86 101.43 66 
b19 7 9.1 9.9 2 104.845 257.13 53.173 106.03 52.39 33 
b20 6.9 8.9 9.9 2 91.618 232.73 58.431 279.48 112.98 71 
1wu9 10.9 11.4 5.5 1 12.183 34.72 4.811 34.67 14.53 12 
1yiga 11.1 11.5 5.5 0 0 0 0 0 0 0 
3gjo 5.7 9.2 9.9 1 161.483 248.75 123.198 409.01 138.15 70 
aCASTp could not find any pocket for the second for the closed conformation for this structure.  
Structural characterization of EB1c using solution NMR 
 
105 
These distances and calculated parameters are described in Table 3.4 and were then 
used to characterise the overall binding site geometry through PCA analysis. 
The first two components of PCA accounted for 86% of the total variation, 
demonstrating that they isolate the main binding site changes and can be reliably used 
for comparison. Notably, the distances of the Tyr247 and Arg222 side-chains have a 
larger contribution for PC2, while the overall binding site parameters calculated via 
CASTp for each pocket have a larger contribution for PC1 - Table 3.5. Thus, the 
location of the structure in the PC1, PC2 plane reflects the relationship between the 
state of the binding pocket and the orientation of the variable side-chains.  
Table 3.5  - PCA analysis results, including standard deviation, variance explained by each principal 
component and total variance explained. The following rows show the PCA loadings of each parameter 
to each principal component. 
Property PC1 PC2 PC3 
Standard Deviation 2.5422 1.4516 0.94879 
Variance Explained 0.64627 0.21071 0.090019 
Total Variance Explained 0.64627 0.85698 0.94700 
Y247-L246 -0.015618 0.61203 0.43986 
Y247-R222 0.032717 0.67285 -0.021162 
R222-L221 0.10616 0.32795 -0.87765 
Number of mouth openings 0.30574 0.22264 0.17339 
Area_SA 0.38862 -0.050398 0.015697 
Area_MS 0.38557 -0.055073 0.020567 
Volume_SA 0.37779 -0.058885 -0.013655 
Volume_MS 0.38932 -0.054128 0.0087726 
sum arc length 0.39108 -0.027500 0.028714 
corner points 0.38342 -0.053330 0.063138 
PCA analysis shows good separation between crystal structures of the free (navy and 
yellow) and peptide-bound (magenta) EB1c on both PC1 and PC2 axis, in agreement 
with the large differences in the binding site configuration. In the crystal structure of 
the free form the binding site is not formed, corresponding to low volumes of the 
pocket (5 Å3 for 1WU9) and low PC1 values. Side-chain of Tyr247 for this structure 
is pointing away from the binding pocket, with large distances and large values of PC2. 
In contrast, the binding pocket is fully formed for the crystal structure of the complex 
with the peptide, corresponding to large pocket volumes (123 Å3) and close distances 
between the side-chains of Tyr247 and Arg222, thus large PC1 and small PC2 values. 
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These structures provide references for the two opposite states of the binding pocket. 
 
Figure 3.26 - PCA analysis of a set of parameters collected to describe the EB1c binding pocket 
conformation. The analysis combines solution NMR structures and crystal structures – solution NMR 
structures for unbound form of EB1c are shown in red, for the complex with 1a are shown in green, 
1WU9 in yellow, 1YIG navy, 3GJO pink. (A total of 86% of the variance can be explained by the two 
principal components, PC1 and PC2 –Table 3.5). 
The structures of the complex with 1a (green) cluster close to the parameters for the 
peptide-bound conformation (3GJO, pink). This demonstrates that the binding pocket 
not only adopts a similar shape and size to the one induced by the natural ligand, but 
Tyr247 and Arg222 are in similar positions. The average volume of the pocket for the 
bound to 1a NMR conformations is 49 Å3 (± 6 Å3), reduced compared to the crystal 
structure of the peptide complex. 
The structures of the NMR ensemble of free EB1c in solution demonstrate the largest 
variation in the binding site characteristics. The majority of structures are located in 
the vicinity of the complex with 1a, however a number of structures are spread across 
the plane. The size of the binding pocket shows a high variability, changing from 0.04 
Å3 for the closed state to 223 Å3 corresponding to the transiently folded C-terminus, 
with the average of 32 Å3 (± 45 Å3). This variability is illustrated by the three 
representatives of the free form of EB1c (Figure 3.27, panels A, B and C), alongside 
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with three representatives of free and bound EB1c, (Figure 3.27, panels D, E and F).  
From the reduced dynamics of Tyr247 and Arg222 side-chains and their optimal 
orientation in the complex with 1a, the interactions at the IP binding site are largely 
utilised by the 1a scaffold, in agreement with the binding properties observed for the 
natural SxIP ligand. The identified IP motif mimetic can be used as a starting point for 
the design of more potent inhibitors to target EB1.  
 
Figure 3.27 - Representation of the binding pockets calculated by CASTp15> webserver – A, B and C, 
structures 1, 10 and 7 from the NMR ensemble for free EB1cΔ8. D, E and F 1WU9, structure 6 from 
NMR ensemble of the bound form and F 3GJO. 
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However, the volume of the binding pocket of the crystal structure with the SxIP 
containing peptide indicates that stabilisation of the Arg222/Tyr247 is not enough to 
maximise the size of the hydrophobic pocket. For the complex with the native SxIP 
containing peptide (structure 3GJO31) the C-terminal flexible region seems to fold on 
the ligand protecting it from the solvent and expanding the hydrophobic pocket. Thus, 
the next generation of the inhibitors should be aimed at extending the binding pocket 
by engaging the dynamic C-terminus and achieve a tighter interaction. That will be the 
focus of the next Chapter. 
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DESIGN AND 
IDENTIFICATION OF INHIBITORS 
BEYOND SXIP MOTIF 
Results obtained from the first generation of inhibitors suggested that it was possible 
to target EB1cΔ8 with small molecules based on IP motif of SxIP proteins. 
Subsequently, in Chapter 3, it was demonstrated that this scaffold stabilises the 
hydrophobic pocket of EB1 that is dynamic in solution. 
However, this did not appear to be sufficient to achieve a strong interaction with EB1c. 
Ideally, one would like to keep part of the scaffold shared between compounds 1a and 
1d, the 2-((1-cyclopentyl-1H-tetrazol-5-yl)thio)propanamide – Figure 4.1A, that is 
thought to replace IP motif, and further extend the molecule in order to gain further 
interactions and achieve tighter binding. Therefore, the aim of this chapter will be the 
design and identification of molecules that target the SxIP binding region and 
simultaneously extend the contact network outside this region. 
4.1 Rational design of a hybrid molecule combining the SxIP mimetic 
scaffold and a tri-peptide 
In order to identify which interactions beyond the SxIP motif are important, the crystal 
structure published by Honnappa et al.31 (PDB code 3GJO) was again examined, 
Figure 4.2. These authors reported that the heptapeptide 5476PSKIPTP5482 is invariably 
bound in very similar conformations, and residues outside this core segment are less 
well defined and do not participate in specific intermolecular interactions. Moreover, 
Thr5481 forms hydrogen bond contacts with Val254 of the mobile C-terminus, so it is 
likely to offer additional interactions. In-house acquired NMR data, NOE cross-peaks 
(Chapter 5), revealed that Thr5481, Pro5482 and Gln5483 are within ~5 Å distance to 
Phe253, Val254, Ile255 and Pro256 of EB1c. Therefore, the tri-peptide 5481TPQ5483 
includes important residues for the interaction with EB1c and can be used for the 
design and identification of molecules that can interact beyond the SxIP region.  
After selection of the docking pose obtained for 1a, and removal of the atoms that do 
not constitute the IP motif mimetic described in Chapter 2, Figure 4.1A, the addition 
of the tri-peptide described above to this anchor motif could potentially improve the 
chances of targeting a region outside of the hydrophobic pocket as shown by the 
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theoretical model in Figure 4.3A. The isoleucine side chain can be emulated by the 
five membered ring, whereas the methyl group occupies a similar position to the 
proline ring. Because both 1a and 1d have an amide bond after the methyl group one 
can make use of it to link it to the tri-peptide in a straightforward manner. Using the 
IP mimetic as an anchor, hopefully tighter binding will be achieved through the extra 
interactions with the dynamic C-terminus through contacts with the tri-peptide, as 
shown in the native interaction between EB1cΔ8-MACFp1. 
 
Figure 4.1 - Structures of A - 2-((1-cyclopentyl-1H-tetrazol-5-yl)thio)propanamide, IP mimetic, and B 
- 2-[(1-Cyclohexyl-1H-tetraazol-5-yl)sulfanyl]propanoic acid . 
 
Figure 4.2 - Representation of the crystal structure of the complex EB1cΔ8-MACFp1, EB1cΔ8 is shown 
as grey cartoon. MACFp1 residues 5475KPSK5477 and 5484RK5485 are shown in grey. MACFp1 residues 
5479IPTPQ5483 are shown in orange (carbon), blue (nitrogen) and red (oxygen). 
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Figure 4.3 – Rational for the design of the hybrid molecule A – IPTPQ, represented in orange (carbon) 
blue nitrogen, and red (oxygen) sticks and IP mimetic scaffold shown in green (carbon), blue (nitrogen), 
red (oxygen) and yellow (sulphur). B – IP shown in orange and hybrid molecule shown in green (carbon), 
blue (nitrogen), red (oxygen) and yellow (sulphur). 
It was, therefore, decided, to synthesise a molecule comprising the 2-((1-cyclopentyl-
1H-tetrazol-5-yl)thio)propanamide scaffold and couple it with a tri-peptide sequence 
corresponding to Thr5481-Pro5482-Gln5483 – Figure 4.3B. To achieve this goal solid 
phase peptide synthesis seems to be an ideal synthesis strategy since it relies on amide 
bond formation and due to a developed protection/deprotection scheme allows for a 
reduced number of side reactions and therefore side products. Additionally, and 
because the compound of interest is attached to a solid support (resin), excess of 
reagents and side products can be washed-off.15> Because this molecule encompasses 
a small molecule scaffold and a peptide moiety, it will be termed as hybrid molecule 
(2a). 
Unfortunately, only a six membered ring version, 2-[(1-Cyclohexyl-1H-tetraazol-5-
yl)sulfanyl]propanoic acid, of this scaffold was commercially available - Figure 4.1B. 
Docking results show the possibility of the six membered ring fit in the pocket, 
although only through biasing the docking prediction by constraint introduction. This 
matter will be further discussed in section 4.1.2. 
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 NMR based screening of the hybrid molecule – 2a 
Titration of compound 2a into EB1cΔ8, final ratio 100:1, promoted NH chemical shift 
changes, indicating chemical shifts of the protein backbone are perturbed upon 
addition of the ligand – Figure 4.4. Chemical shift changes are characteristic of a fast 
exchange regime, similar to what was observed for the first generation molecules. 
 
Figure 4.4 - Overlay of 1H-15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1c (50 µM) – 2a (5000 µM). The insets show regions 
of interest and the spectra corresponding to the following 2a concentrations, 3000 (blue), 3500 (teal), 
4000 (green), 4500 (brown) and 5000 µM (red). 
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Figure 4.5 - Plot of the chemical shift perturbation distances between free EB1cΔ8 and in the presence 
of the respective first generation compound (1a (black) and 1d (green)). Hybrid molecule is shown in 
cyan and 2-[(1-Cyclohexyl-1H-tetraazol-5-yl)sulfanyl]propanoic acid in orange (2a and 2b, 
respectively).  
However, when comparing the chemical shift changes promoted by the hybrid 
molecule, compound 2a, with the IP mimetics identified in Chapter 2, it is clear that 
compound 2a does not target the same region of EB1cΔ8 and the most prominent 
chemical shift changes are within Leu210-Glu213 and Gln229-Ile242 regions – Figure 
4.5. The analysis of the chemical shift perturbations for the scaffold attached to the tri-
peptide, molecule 2b, reveals a similar pattern to the one observed to molecule 2a - 
Figure 4.6. Titration of the tri-peptide, Thr-Pro-Gln into EB1cΔ8 does not induce any 
chemical shift changes into EB1’s backbone resonances.  
This data indicates that the specificity of the IP mimetic scaffold was lost, 247YAT249 
and 219GKLR222 regions not affected by the addition of the ligand, contrarily to what 
happened to the first generation compounds – Chapter 2, section 2.6. Instead the 
chemical shift changes seem to be spread and non-specific - Figure 4.6. A possible 
cause can be the larger size of the ring, cyclohexyl instead of cyclopentyl, as this is the 
main difference between the scaffolds.  
To understand why the specificity for the IP binding site was lost it was decided to 
perform some docking predictions.  
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Figure 4.6 – Chemical shift perturbation mapping on the crystal structure (PDB accession code: 3GJO). 
Panel A corresponds to the chemical shift changes induced by the hybrid molecule (2a) and panel B to 
the changes induced by the scaffold attached to the tri-peptide, molecule (2b). The selected residues 
were selected by applying the following formula: remove all residues with chemical shift changes larger 
than standard deviation (σ) of the chemical shift changes multiplied by three, re-calculate the standard 
deviation (σ) of the chemical shift changes residues and select the residues presenting chemical shift 
changes above that value. Dashed circles represent areas affected by titration of 2a but not 2b. 
 Understanding of the loss of specificity to the IP binding site in the 
hybrid molecule  
Contrarily to what was expected after the design of the hybrid molecule, the cyclohexyl 
ring of the IP mimetic moiety does not occupy the hydrophobic binding pocket. Instead, 
docking pose with higher score prediction inserts the five membered ring of proline 
side chain inside the hydrophobic pocket of EB1cΔ8 – Figure 4.7A. This is not a 
surprise as the natural ligands reported for EB1 have invariably a proline in position 4 
of the SxIP motif and structural data shows this residues side chain should occupy the 
hydrophobic pocket. This analysis suggests the cyclohexyl ring may be too bulky for 
that pocket. To prove this further, it was decided to perform another set of molecular 
docking predictions biasing the insertion of this ring in the pocket.  
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In GOLD, restraints are available for biasing searches towards dockings containing a 
contact between a particular protein-ligand atom pair. There is reported evidence of 
the benefits of using constrains in virtual screening.15> The distance between a 
specified ligand and protein atom can be constrained to lie between minimum and 
maximum distance bounds. During a GOLD run, if a constrained distance is found to 
lie outside its bounds (i.e. between 1.5 and 5 Å), a spring energy term is used to reduce 
the fitness score:  
, Equation 4.1 
where: 
x is the difference between the distance and the closest constraint bound; 
k is a user-defined spring constant – in this case defined as 5. 
A distance constraint was defined where the distance between the six membered ring 
of 2a and the Leu246 side chain of the hydrophobic pocket should between 1.5 and 5 
Å. Solutions inserting the cyclohexyl ring in the hydrophobic pocket should be in 
agreement with this constraint and therefore scored higher than other solutions. As 
expected, the ring adopts the expected position when this constraint is used, indicating 
that despite not being the most natural solution, the cyclopentyl ring is small enough 
to fit in the hydrophobic pocket of EB1c – Figure 4.7B.  
However, the fact that the docking prediction only positioned the cyclohexyl ring in 
the pocket after the use of constraints and the first prediction re-oriented the molecule 
in a way that the proline ring of the tri-peptide was inserted in the pocket instead, gives 
support to the idea that the cyclohexyl ring is not binding in an energetically favourable 
way to the hydrophobic pocket of EB1c. 
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Figure 4.7 – Docking pose for compound 2a. A- docking without any constraints. B – docking 
restraining the cyclohexyl ring distance to Leu246 side chain to a value between 1.5-5 Ȧ. 
4.2 Identification of small molecules based on the hybrid molecule 
Since the in-house synthesised hybrid molecule, compound 2a, did not yield the 
expected results, due to the larger size of the ring, it was thought to use the original 
cyclopentyl hybrid design to build a new pharmacophore model, extending the targeted 
region beyond the IP binding region.  
 Virtual screening 
For this purpose, the hybrid molecule initial model, with a five membered ring was 
uploaded into ZINCPharmer. The uploaded structure was carefully built in order to 
maintain the 2-((1-cyclopentyl-1H-tetrazol-5-yl)thio)propanamide and the tri-peptide 
in the right spatial conformation – Figure 4.1A. When uploading the structure to 
ZINCPharmer, EB1c structure was also uploaded so only the points of contact between 
both molecules were defined as part of the pharmacophore model. Moreover, 
uploading the receptor (EB1c) offers the additional benefit of assigning directionality 
to the hydrogen bond acceptors/donors. Seven pharmacophore points were defined 
based on this approach: hydrophobic interaction for the cyclopentyl ring and methyl 
group, hydrogen bond acceptors for the CO present in the 2-((1-cyclopentyl-1H-
tetrazol-5-yl)thio)propanamide scaffold and the threonine backbone and, finally, three 
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hydrogen bond acceptors, corresponding to the NH from the 2-((1-cyclopentyl-1H-
tetrazol-5-yl)thio)propanamide, the OH of the threonine and the backbone NH of the 
glutamine – Figure 4.8, Table 4.1. 
 
Figure 4.8 – Seven pharmacophore points defined based on the favourable conformation of 2-((1-
cyclopentyl-1H-tetrazol-5-yl)thio)propanamide connected to a tri-peptide, threonine, proline and 
glutamine. Hydrogen bond acceptors indicated by orange arrows, hydrogen bond donors shown as light 
grey arrows and hydrophobic interactions represented as green spheres. The arrows represent the 
directionality of the hydrogen bonds defined by using the protein structure. 
Table 4.1 – Summary of the pharmacophore points defined based on the hybrid molecule model and its 
interaction with EB1cΔ8 
# Pharmacophore Class coordinates radius x y z 
1 Hydrophobic -16.08 -27.78 34.50 1 
2 Hydrophobic -18.42 -27.11 27.82 1 
3 Hydrogen acceptor -14.88 -25.70 25.15 0.5 
4 Hydrogen acceptor 16.07 -25.18 28.89 0.5 
5 Hydrogen donor -12.47 -27.21 26.93 0.5 
6 Hydrogen donor -13.70 -24.47 22.22 0.5 
7 Hydrogen donor -15.27 -26.67 27.35 0.5 
The pharmacophore was queried using all the contact points outlined above, but no 
hits were obtained. Therefore, a systematic search was performed, where all the 
possible combinations were searched for six, five and four pharmacophore points, in 
order to get the maximum number of molecules that can satisfy some of these spatial 
features. A total of 43388 results were yielded from this search, reducing it to 26887 
molecules, after removing duplicated molecules. By applying a filter to include only 
molecules between 400 and 800 g.mol-1, with a maximum number of rotatable bonds 
of 10 and a RMSD below 0.5 Å, the number of molecules was reduced to 2429. The 
molecular weight range choice was based on the fact that to extend the targeted region 
of EB1c there is the need for larger molecules. In addition, a study performed on 
successful cases of inhibitor design for protein-protein interactions propose a “rule of 
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four” as an alternative to the Lipinski’s rule of five.53 These authors propose the 
molecular weight threshold for small molecules that target PPI’s should be higher than 
400 g.mol-1 – Table 4.2. 
Table 4.2 – Comparison between rule of 5, proposed as a set of in silico guidelines applied to drug 
discovery to prioritize compounds with an increased likelihood of high oral absorption and rule of 4, 
conceived to filter databases and accelerate the process of hit identification for protein-protein 
interactions modulators. 
 Rule of 5 83 Rule of 4 53 
Molecular weight (g.mol-1) < 500 > 400 
LogP < 5 > 4 
Number Hbond acceptors < 10 > 4 
Number Hbond donors < 5 - 
Number rings - > 4 
 
The resulting 2429 molecules were then docked using GOLD and the scoring function 
Goldscore. As described in Chapter 2, Goldscore was the scoring function with better 
performance when docking the natural ligand, positioning the ligand in a similar 
conformation to the one shown in the crystallographic structure, 3GJO.  
The importance of water molecules in docking prediction was already described in 
Chapter 2. GOLD provides a clever approach to deal with water molecules in docking 
studies. Water molecules can be allowed to rotate or switch between on and off. 
Adding or “toggling on” a water molecule introduces an entropic penalty to the scoring 
function which needs to be offset by forming hydrogen bonds to the protein and the 
ligand. If the hydrogen bonds formed by the water molecules do not offset the entropic 
penalty introduced by adding the water molecule, then the water molecule will be 
deselected (removed) during the genetic algorithm run.116 It was decided to use this 
functionality offered by GOLD as it has been previously shown that there is a water 
molecule in EB1 binding site.31 No hydrogen bond constraints were included for these 
docking calculations.  
When using Automatic (Ligand-Dependent) Genetic Algorithm Parameter Settings in 
GOLD the Search Efficiency can be used to control the speed of docking and the 
predictive accuracy of the results, higher the efficiency more exhaustive and slower is 
the search. To speed up the process the Virtual Screening option for the GA settings 
in GOLD was chosen. This sets the search efficiency at 30% that can be used for 
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routine work and usually gives comparable predictive accuracy to the slower settings, 
unless the ligand has a large number of rotatable torsions.16>  
The ten best solutions were saved and visually inspected. The criterion used for visual 
inspection was that the pose included interactions outside the hydrophobic pocket, 
extending to a lower region occupied by the tri-peptide Thr-Pro-Gln. Through this 
process the number of molecules to be further studied was reduced to 106 molecules 
– Figure 4.9.  
 
Figure 4.9 – Process for selection of hit compounds that can target EB1c using as initial scaffold the IP 
motif mimetic attached to a tri-peptide. 
 Selection of candidate molecules 
The 106 molecules selected based on their binding pose were re-docked using a search 
efficiency of 200% and the 100 best solutions were saved into the result file for further 
refinement/analysis.  
Up to this stage no filters were used to remove molecules that reveal potential problems 
in terms of ligandibility. The rule of 4 used previously relates only with the capacity 
of being a protein-protein interaction modulator. The use of filters or alerts to remove 
or flag compounds that may not be suitable to become a drug, has been widely used 
by pharmaceutical companies.16> Therefore it was decided to use an online tool that 
could flag potential undesirable compounds before moving forward into candidate 
selection.  
The SmartsFilter (http://pasilla.health.unm.edu/tomcat/biocomp/smartsfilter)16> uses 
a wide set of filters that can be easily applied to a subset of candidate molecules. There 
are seven different filters, from which Blake162, Glaxo163, ALARM NMR164, Oprea165 
and PAINS – Pan-Assay Interference compounds166 were chosen to avoid molecules 
with undesirable characteristics at an early stage of the drug discovery process. 
The Blake filter16>, is based on the work of James Blake, and concerns a model of 
desirable properties for good oral bioavailability.  
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The Glaxo filter16> has three different subfilters, where only two were used to evaluate 
our subset of molecules, namely “unsuitable leads” and “reactive”. Whereas the first 
is clearly described by the name, the latter is based on the existence of reactive species 
that cannot be pooled together in HTS study. At this stage it was not known the number 
of candidate molecules to be screened and the pooling of compounds when performing 
HTS is commonly used to save time and money.  
Because solution-state NMR is the primarily chosen method for compound screening 
in this project, the filter ALARM NMR16> was also applied. This filter can be applied 
to identify potential false positive molecules in NMR based screenings, by reacting 
with protein’s thiol groups. The Oprea filter, developed by Tudor Oprea165, is based 
on a multi-objective analysis of drug-like properties. Finally, the PAINS filter166, 
developed by Jonathan Baell and Georgina Holloway, proposes a method to identify 
frequent hitters, promiscuous compounds, widely found in HTS assays. Compounds 
that did not successfully pass these filters were not removed. Instead, they were 
marked as “pass” or “fail” for each filter and this information used in the final 
assessment of suitable candidates to be screened. 
At this stage, there was sufficient knowledge about these compounds that would permit 
to make a decision of which should be tested. A multi-objective analysis was 
performed, assessing two parameters, the average Goldscore value for the 100 
obtained poses and solubility. In contrast to what was done before (Chapter 2) 
compounds with solubility lower than - 4 were still included for the final analysis. 
Three compounds were chosen based on their Pareto Rank position, availability for 
purchase and molecular diversity - Table 4.3. The method chosen to select these three 
candidate molecules has been summarised in Figure 4.9 and Figure 4.10. 
ZINC40017212 was the fifth best compound in terms of the multi-objective analysis. 
The average Goldscore for 100 poses was high, 66, with a top score of 75. It failed for 
three of the filters, unsuitable leads, ALARM NMR and PAINS, which can be 
attributed in part to its low solubility value, - 4.918. The pharmacophore model of this 
molecule includes the hydrophobic contacts of the cyclopentyl ring and the methyl 
group, in addition to a possible hydrogen bond acceptor (corresponding to the carbonyl 
of 2-((1-cyclopentyl-1H-tetrazol-5-yl)thio)propanamide) and a hydrogen bond donor 
(corresponding to the OH of Thr), respectively pharmacophore points 1, 2, 4 and 5 – 
Table 4.1; Figure 4.11A. 
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Table 4.3 – Selected molecules for testing from the pharmacophore model built from the hybrid molecule. Final rank indicates the overall position of each molecule after a 
Pareto ranking analysis of the 100 solutions for the 106 molecules. Log S refers to the logarithm of aqueous solubility value calculated by Pipeline Pilot16>. Unsuitable leads, 
reactive, ALARM NMR, Blake and Oprea columns state whether a compound passed (green symbol) or failed (red symbol) each filter. Finally, the molecular properties radar 
plot includes six molecular properties and the blue shaded area epresents the chemical space defined for PPI modulators.53 
Molecule 
name 
Final 
Rank 
Log 
S 
Unsuitable 
leads Reactive 
ALARM 
NMR Blake Oprea PAINS Structure Molecular properties 
ZINC40017212 5 -4.9 û ü û ü ü û 
 
 
ZINC31040053 71 -4.9 ü ü û ü ü û 
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Figure 4.10 – Process summarising the final selection of hit compounds to target EB1c based on the scaffold the IP motif mimetic attached to a tri-peptide. 
Molecule 
name 
Final 
Rank 
Log 
S 
Unsuita-
ble 
leads 
Reactive ALARM NMR Blake Oprea PAINS Structure Molecular properties 
ZINC12929029 101 -2.5 ü ü û û û ü 
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In terms of docking pose, ZINC40017212 seems to interact through hydrophobic 
contacts with the hydrophobic pocket of EB1c, Lys220, Arg222, Leu221, Glu225, 
Tyr247, Ala248 and Thr249, but also with a lower region of EB1c, including the 
aromatic patch, Phe216-Tyr-Phe218 and the C-terminal tail, Phe253, Val254 and 
Pro256 – Figure 4.12, A and B. 
ZINC31040053 presents a more modest average Goldscore value of 53 with a top 
score of 59. In terms of filters, fails for both ALARM NMR and PAINS. Again, its 
solubility value is quite low, – 4.911, and that can be a disadvantage for solution NMR 
screening techniques. In terms of pharmacophore model, this molecule coincides with 
pharmacophore points 1, 2, 3 and 5 – Table 4.1; Figure 4.11B. The best scored binding 
pose shows the existence of hydrophobic interactions within the hydrophobic pocket 
and aromatic patch, as well as hydrophobic interactions with C-terminus residues such 
as Val254, Ile255 and Pro256. The hydrophobic pocket seems to be almost invariably 
occupied by the phenyl ring, especially for the top scored solutions - Figure 4.12, 
panels C and D. 
ZINC12929029 shows the lowest Goldscore average value 45 with a top score of 55. 
The pharmacophore points emulated by this molecule are the same as for 
ZINC40017212, 1, 2, 4 and 5 - Table 4.1; Figure 4.11C. The genetic algorithm poses 
the tetrahydroisoquinoline moiety inside the hydrophobic pocket of EB1c. It is not 
clear whether this scaffold is not too bulky for the hydrophobic pocket of EB1c as 
previously reported for the cyclohexyl ring. The fact that this moiety, despite its larger 
size, is more planar and less flexible than the cyclohexyl ring may justify the fit inside 
the pocket. In addition, this molecule seems to bring extra interactions, namely two 
hydrogen bonds. One of the carbonyls act as hydrogen bond acceptor from the 
backbone NH of Val 254 at the same time the NH next to it functions as hydrogen 
bond donor to the carbonyl oxygen of Gly252 – Figure 4.12, panels E and F. 
These three molecules were therefore purchased and subjected to NMR screening, 
through 1H,15N-HSQC spectra analysis upon titration of each compound into EB1cΔ8. 
For clarity the molecules will referred to as 3a (ZINC40017212), 3b (ZINC31040053) 
and 3c (ZINC12929029). 
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Figure 4.11 – Molecules selected for screening based on the pharmacophore model created for the 
hybrid molecule. A – ZINC40017212, B – ZINC31040053 and C – ZINC12929029, represented as 
green sticks, superimposed with the ideal 3D structure designed for the hybrid molecule, showed as 
grey sticks. Areas highlighted in red correspond to the pharmacophore contacts emulated by these 
molecules. 
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Figure 4.12 – Top scored binding pose, left hand side panel, A- ZINC40017212 (3a), C – 
ZINC31040053 (3b) and E – ZINC12929029 (3c). 2D representation of the interactions predicted from 
the docking between B - ZINC40017212 (3a), D – ZINC31040053 (3b) and F – ZINC12929029 (3c). 
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 NMR based screening for hit candidates based on the hybrid mole-
cule 
NMR titrations were, once again, the chosen method to screen the three candidate 
molecules obtained from ligand-based design approach based on the hybrid molecule. 
The results indicate that only 3a and 3b promote chemical shift perturbations in the 
EB1cΔ8 backbone (NH). 
 
Figure 4.13 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 3a (1000 µM). Both samples contained 
4% DMSO-d6, to ensure solubility of 3a and for consistency (in the free protein sample). 
The addition of compound 3a - affects the chemical shifts of amino acids recognised 
as part of the EB1cΔ8 hydrophobic pocket – Leu246, Tyr247 and Thr249, being a 
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good indication that this compound, contrarily of what was observed with the six 
membered ring hybrid molecule, targets the desired region of EB1cΔ8 – Figure 4.13. 
Unfortunately, due to its poor aqueous solubility 3a was only tested up to a 
concentration of 1 mM. The final protein:ligand ratio obtained was  1:20, different 
from the ratios used for the first generation compounds (1:100). Therefore, the 
chemical shift changes observed are not as large as the ones observed for 1a and 1d – 
Chapter 2. 
.  
 
Figure 4.14 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 3b (1000 µM). Both samples contained 
2% DMSO-d6, to ensure solubility of 3b and for consistency (in the free protein sample). 
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Compound 3b promotes similar chemical shift changes in terms of affected amino 
acids and magnitude to the ones observed to 3a. These are mainly confined to the 
hydrophobic binding site of EB1cΔ8 – Figure 4.14. Similarly to the other compound, 
3a, due its poor aqueous solubility the final concentration was 1 mM, whereas the final 
concentration reached for the first generation molecules (Chapter 2) was 5 mM. 
Compounds 3a and 3b, with predicted aqueous solubility values of - 4.918 and -  4.911, 
respectively, interact with EB1cΔ8 but their aqueous solubility is a limitation to obtain 
a Kd value by NMR or even to study further through NOE experiments as it was done 
for compound 1a. 
 
Figure 4.15 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz – in black is presented EB1cΔ8 in 
the free form (50 µM) and in red the complex EB1cΔ8 (50 µM) – 3c (1000 µM). Both samples contained 
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2% DMSO-d6, to ensure solubility of 3c and for consistency (in the free protein sample). 
Finally, for compound 3c, no chemical shift changes were observed (Figure 4.15) at a 
final concentration of 1 mM, and despite this compound having a larger aqueous 
solubility predicted value (calculated logS = - 2.524), it was decided to not proceed 
with the titration since chemical shift changes were not observed at this concentration, 
it would be unlikely that they would be observed at higher concentrations. 
In terms of the distribution of the chemical shift perturbations for 3a and 3b, they 
follow the same pattern as observed for the molecules identified as IP mimetics – first 
generation compounds. Therefore the IP mimetic activity was regained. Analysis of 
the docking poses for these compounds, Figure 4.12, reveals the hydrophobic pocket 
is invariably occupied by a an aromatic ring, benzyl for compound 3a and 2-chloro-
benzyl for compound 3b. Despite its size, same number of carbons as the cyclohexyl 
group, being planar makes benzyl a tolerated chemical moiety for the hydrophobic 
pocket of EB1c, whereas the cyclohexyl, with additional hydrogens and a flexible tri-
dimensional conformation, is not. Moreover, one can observe the appearance of subtle 
chemical shift change for the C-terminus region Glu251-Val254 when comparing with 
the best compound resultant from the first generation inhibitors – Figure 4.17. 
 
Figure 4.16 - Plot of the chemical shift perturbation sum differences between free EB1cΔ8 and in the 
presence of the respective second generation compound (3a and 3b, respectively). 
In summary, the second generation compounds, based on the hybrid molecule scaffold 
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successfully target EB1c, not only the hydrophobic binding site – IP mimetic activity, 
as well the C-terminus, to a smaller extent. Despite their solubility proved to be a major 
limitation, the success of this approach gives extra support to the molecular modelling 
approach used in this project for the identification of small molecules that can bind to 
a protein-protein interface.  
 
 
Figure 4.17 - Plot of the chemical shift perturbation sum differences between free EB1cΔ8 and in the 
presence of the respective first and second generation compounds (1d, 3a and 3b, respectively). The 
chemical shift changes for 3a and 3b were normalised by a factor of five since the final concentration 
of these compounds was five times smaller than the final concentration for compound 1a. 
The hybrid molecule design, due to its novelty, can be considered as another type of 
approach to target protein-protein interactions. The addition of a peptide scaffold to an 
anchor scaffold based on an organic molecule may bring many advantages for the 
design of protein-protein modulators. Through this method, it is possible to target a 
larger area without loss of aqueous solubility due to the peptide moiety. The 
shortcomings of using a peptide scaffold are chemical instability, being prone to 
hydrolysis and oxidation, tendency for aggregation, short half-life and fast elimination, 
poor oral bioavailability and low membrane permeability.16> Multifunctional peptides 
can be used to overcome some of these disadvantages.168 However, that is outside of 
the scope of this project. 
In the next chapter, a detailed study of the interaction of EB1 with SxIP motif 
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containing peptides is described, since it is important to understand the contributions 
of each region for the interaction and this understanding can be used for the 
improvement of the design/identification of small molecules that can interact with EB1. 
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BIOPHYSICAL 
CHARACTERISATION OF 
PHYSIOLOGICAL EB1 INTERACTIONS 
INVOLVING MACF2 
From the previous data, Chapter 2, it is known that the SxIP motif provides specificity 
for EB1c targeting but it is not sufficient to achieve a high affinity interaction. In 
Chapter 4, attempts to extend the interactions beyond the SxIP motif were made with 
limited success.  
The aim of this chapter will be to investigate how does EB1c interact with a native 
ligand – MACF2(Uniprot47 accession number - Q03001), and how does each region 
of the peptide and the protein contribute into the binding affinity. The contribution of 
different ligand regions to the binding to EB1c was evaluated using three peptides 
containing the SxIP motif, SKIP (4MACF), SKIPTP (6MACF) and KPSKIPTPQRK 
(11MACF), respectively. The role of the C-terminal flexible tail of the protein was 
also studied by using two different EB1 C-terminal domain constructs with and 
without this region – EB1cΔ8 (191-260) and EB1cΔ16 (191-252). With this 
information new structural information will be provided and can be used for the design 
of new EB1 targeting scaffolds.  
Finally, higher affinity sequences based on the native sequence were designed through 
the use of mutants. These higher affinity sequences provide interesting insights on the 
binding mechanism to EB1c and provide guidance for future modulator/probe design. 
5.1 NMR screening of MACF2 peptides against EB1cΔ8 
Chemical shift perturbation (CSP) is the only technique that can directly provide an 
estimate of Kd values and location of the binding site from the same set of 
measurements94, hence, it was used to characterise the interaction of MACF2 based 
peptides with EB1cΔ8. Initial screening revealed that interactions between EB1c and 
4MACF and 6MACF are weaker that for the 11MACF. For that reason, the 
concentrations used for the titrations of the shorter ligands were 250, 500, 1000, 2500 
and 5000 µM, respectively 5, 10, 20, 50 and 100-fold excess to the protein. Resonances 
of both complexes with 4MACF and 6MACF are, generally, in fast exchange and the 
spectra presents an overall good dispersion of peaks it was possible to assign all 
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resonances just by following the peak changes from free protein. 
On the other hand, 11MACF seemed to have higher affinity for EB1c and therefore 
the used concentrations are much smaller, 12.5, 25, 75, 82.5, 100, 125, 150, 200 and 
400 µM. 
4MACF, corresponding to the SxIP motif, promotes relatively small, but specific 
chemical shift changes – Figure 5.1. 
 
Figure 5.1 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ8 (50 µM) recorded at 600 MHz – 
in the free form (black) and in the presence of 4MACF (5000 µM, red). The insets show regions of 
interest and the spectra corresponding to the following 4MACF concentrations, 250, 500, 1000, 2500 
and 5000 µM. 
All chemical shift changes for 4MACF titration correspond to a fast exchange regime, 
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where a progressive change in peak position is observed at all ligand concentrations 
used without increase in line-width, indicating weak interaction. The observed 
chemical shift is therefore a weighted average of the chemical shifts for the free protein 
and the complex until the binding partner has been added to excess.94  
The 6MACF addition has much larger effect on the EB1c signals, compared to the 
shorter 4MACF peptide (Figure 5.2).  
 
Figure 5.2 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ8 (50 µM) recorded at 600 MHz – 
in the free form (black) and in the presence of 6MACF (5000 µM). The insets show regions of interest 
and the spectra corresponding to the following 6MACF concentrations, 250, 500, 1000, 2500 and 5000 
µM. 
To the same ligand excess, the chemical shift changes are overall larger and affect a 
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larger number of residues that were not affected before. Tyr247 (Δδ = 0.86 ppm) is 
again the most affected residue with larger chemical shift change, and it is noteworthy 
the peak broadening at a 20-fold excess of the ligand (1000 µM). Glu213 also shows 
line width broadening, but subtler than the one observed for Tyr247. Peak broadening 
suggests this complex is closer to an intermediate exchange regime. Line broadening 
and the larger chemical shift changes are good indicators of stronger binding when 
compared with 4MACF.  
The addition of 11MACF has much larger effect on the EB1cΔ8 spectra than the 
shorter peptides (compare Figure 5.1, Figure 5.2 and Figure 5.3).  
 
Figure 5.3 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ8 (100 µM) recorded at 600 MHz 
in the free form (black) and in the presence of 11MACF (400 µM, red). The insets show regions of 
interest and the spectra corresponding to the following 11MACF concentrations, 12.5, 25, 75, 82.5, 100, 
125, 150, 200 and 400 µM. 
At the 11MACF concentration of 12.5 µM (1:0.125 protein:peptide ratio) a large 
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number of resonances are severely broadened with a minimal change in chemical shifts 
(Figure 5.3, inserts). Despite good peak dispersion, due to the accentuated peak 
broadening it was not possible to simply follow the chemical shift changes. Therefore, 
the NH resonances of the complex were assigned using triple resonance experiments 
similarly to what was performed for free EB1c. Further increase in the peptide 
concentration leads to additional broadening and then disappearance of the cross-peaks 
above 25 µM (1:0.25 protein:peptide ratio). The cross-peaks reappear at 
concentrations above 100 µM (1:1 protein:peptide ratio) at new positions. These 
changes were observed for the chemical shift differences between the free and the 
bound state above 0.45 ppm; resonances of Lys220 (Δδ = 0.61 ppm), Tyr247 (Δδ = 
1.48 ppm), Ala248 (Δδ = 0.45 ppm), Thr249 (Δδ = 0.54 ppm) are shown as clear 
examples of such changes (Figure 5.3, insets). The described spectral changes 
correspond to the intermediate exchange regime.93 The majority of other resonances 
showed progressing shift changes on the peptide addition, often accompanied by a 
limited broadening of cross-peaks; this was observed for the chemical shift differences 
between the free and the bound state below 0.45 ppm. Above 1:1 protein:peptide ratio 
chemical shift changes were very limited, showing that nearly all protein was in the 
bound state; in contrast, significant spectral changes were observed for shorter peptides 
at the ratio as high as 1:100. Overall the resonances are in an intermediate exchange 
regime where extensive line broadening occurs accompanied by a progressive 
chemical shift change. The intermediate exchange and degree of the chemical shift 
changes demonstrate much higher affinity of 11MACF for EB1cΔ8 when compared 
with the shorter peptides. 
In order to slow the exchange rate between free EB1cΔ8 and when bound it was 
decided to perform another titration experiment at lower temperature, 10oC. The 
following protein-ligand ratios were used: 1:0, 1:0.5, 1:0.75, 1:1 and 1:1.5 – Figure 5.4 
and Figure 5.5. For Phe218 it is very clear the coexistence of two intermediate states 
in solution at the 1:0.5 ratio. The third column in Figure 5.5 (top panel) shows the 
existence of three peaks – one corresponds to free EB1, followed by two peaks of 
similar intensity, these correspond to a ligand molecule bound to only one of the 
symmetrical binding sites. Finally, it is still possible to see the existence of a smaller 
intensity peak corresponding to the fully saturated bound form, where the two binding 
sites are occupied by the ligand. Despite exhibiting quite a small chemical shift 
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perturbation upon ligand binding, Gly219, is also an interesting case where it can be 
seen the free protein peak (black, second column), splitting in two peaks with similar 
intensity (blue, third column), representing the two complexes with only one ligand 
bound. With more ligand added (between 1:0.75 and 1:1 ratio), the peak evolves then 
to a sharper conformation corresponding to a fully bound complex. 
 
Figure 5.4 - Overlay of 1H,15N-HSQC spectra recorded at 600 MHz at 10 oC – in black is presented 
EB1cΔ8  in the free form (400 µM) and in red the complex EB1cΔ8  (400 µM) – 11MACF (600 µM).  
Val254, on the other hand, shows a different profile, where one can observe a very 
sharp peak in the free form, indicating this residue is in a highly dynamic region in the 
unbound form. It gradually disappears in this position (decrease of the intensity). The 
opposite phenomenon is observed for the end position, where the peak gradually 
appears increasing in intensity until protein saturation, corresponding clearly to a slow 
exchange regime. In the bound form, this peak is not as sharp as in the free form 
indicating this region become constrained in terms of flexibility. It is noteworthy that 
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Val254 at room temperature presented the two states free and bound. At low 
temperature the same situation is observed with the difference that in the intermediate 
titration points (0.5 and 0.75 µM) is now possible to observe free and bound state at 
the same time. 
It is possible that this difference arises from the fact Val254 being located in the C-
terminal flexible region of EB1cΔ8, whereas Phe218 and Gly219 are closer to the 
binding site. For the residues located close the binding site the different complexes are 
observed because they are directly affected by the binding of the ligand. After the 
ligand binding one assumes the ligand stays in the binding site, and the C-terminus 
wraps around the ligand, reason why only two sets of peaks can be observed for Val254, 
there are no intermediate states. 
 
Figure 5.5 - Zoomed regions of 1H,15N-HSQC spectra recorded at 600 MHz, at 10oC for Phe218 (top 
panel), Gly219 (middle panel) and Val254 (bottom panel). The bottom panel is divided in two sections, 
top section shows the region where the initial Val254 peak appears and the bottom section shows the 
region where the final peak, referring to the bound form appears. First column shows the overlay of all 
spectra, and the consecutive columns show the spectra referring to EB1cΔ8 free at 400 µM, 
EB1cΔ8:11MAC 1:0.5 ratio, 1:0.75 ratio, 1:1 ratio and 1:1.5 ratio, respectively. 
Exchange regime shows that binding affinity increases from 4MACF to 11MACF. The 
use of large concentrations of the shorter length peptides (4MACF and 6MACF 
respectively) may induce non-specific binding. To address this issue, the next section 
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will be dedicated to identification of the affected regions upon ligand binding in 
EB1c’s structure.  
 Chemical shift changes and mapping 
The mapping of the residues affected upon ligand addition, which resonances present 
larger chemical shift changes, gives important information on the region(s) of the 
protein affected upon ligand binding. The chemical shift changes values (Δδ) were 
calculated using Equation 5.1  
, Equation 5.1 
were where, αN= Scaling Factor of 0.15. 
Upon addition of 4MACF, Tyr247 (Δδ = 0.35 ppm) was the most affected residue, 
followed by Thr249 (Δδ = 0.19 ppm). Glu213 (Δδ = 0.062 ppm), Phe218 (Δδ = 0.065 
ppm), Arg222 (Δδ = 0.056 ppm), Glu225 (Δδ = 0.056 ppm) and Ala248 (Δδ = 0.077 
ppm) also shown to be affected by ligand addition to the protein, but to a smaller extent. 
All these amino acid residues are within the region defined as the binding site for the 
SxIP motifs, indicating this small peptide fragment has the specificity for EB1c’s 
hydrophobic binding site despite being such a short sequence. Additional CSPs that 
are not located in the above-mentioned region are observed for Asn235 (Δδ = 0.065 
ppm) and Asp236 (Δδ = 0.078 ppm). Despite these two residues being located further 
away from the binding site but in a dynamic region it is likely that they are not directly 
affected by the ligand but as an allosteric result. These results prove that despite not 
being a very strong interaction, the SxIP sequence reveals a very high specificity for 
the hydrophobic binding site of EBH domain of EB1.  
6MACF induces chemical shift changes in a larger number of residues – Figure 5.7. 
Most of the residues are again located around the binding site for the SxIP motif - 
Arg214 (Δδ = 0.09 ppm), Phe218 (Δδ = 0.11 ppm), Lys220 (Δδ = 0.28 ppm) and 
Ala248 (Δδ = 0.19 ppm). The most affected residue is again Tyr247 (Δδ = 0.86 ppm), 
followed by Thr249 (Δδ = 0.48 ppm) and Val254 (Δδ = 0.40 ppm). Whereas the two 
first are in agreement with what was observed for 4MACF, Val254 is not. Asp250 (Δδ 
= 0.36 ppm) and Gly252 (Δδ = 0.22 ppm) give further evidence that the binding region 
is now more extended than previously. In addition to the extension of the binding 
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region towards the C-terminus of EB1c, the region immediately below the binding site 
– Lys212, Glu213 and Arg214, where the additional peptide residues are expected to 
be located in the complex is affected. This indicates that 6MACF in the complex is 
located in the similar position as the corresponding part of the full length ligand. 
 
Figure 5.6 – A - Histogram representing the chemical shift perturbations observed between free EB1cΔ8 
and bound to 4MACF (SKIP) using the Equation 5.1.  The secondary structure of the EB1 is given 
above the plot. B – Chemical shift changes mapping on the crystal structure (PDB accession code: 
3GJO), the selected residues were selected by applying the following formula: remove all residues with 
chemical shift changes larger than standard deviation (σ) of the chemical shift changes multiplied by 
three, re-calculate the standard deviation (σ) of the chemical shift changes residues and select the 
residues presenting chemical shift changes above that value.	 
Biophysical characterisation of physiological EB1 interactions involving MACF2 
142 
 
 
Figure 5.7 – A - Histogram representing the chemical shift perturbations observed between free EB1cΔ8 
and bound to 6MACF (SKIPTP) using the Equation 5.1. The secondary structure of the EB1 is given 
above the plot. B – Chemical shift changes mapping on the crystal structure (PDB accession code: 
3GJO), the selected residues were selected by applying the following formula: remove all residues with 
chemical shift changes larger than standard deviation (σ) of the chemical shift changes multiplied by 
three, re-calculate the standard deviation (σ) of the chemical shift changes residues and select the 
residues presenting chemical shift changes above that value. 
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Figure 5.8 – A – Histogram representing the chemical shift perturbations observed between free EB1cΔ8 
and bound to 11MACF (KPSKIPTPQRK) using the Equation 5.1. The secondary structure of the EB1 
is given above the plot. B – Chemical shift changes mapping on the crystal structure (PDB accession 
code: 3GJO), the selected residues were selected by applying the following formula: remove all residues 
with chemical shift changes larger than standard deviation (σ) of the chemical shift changes multiplied 
by three, re-calculate the standard deviation (σ) of the chemical shift changes residues and select the 
residues presenting chemical shift changes above that value. 
When analysing the chemical shift changes promoted by 11MACF to EB1cΔ8 the 
more immediate difference is, contrarily to what was observed for the shorter 
sequences, the residue experiencing the largest chemical shift change is not Tyr247 
but Val254 (Δδ of 1.48 and 2.7 ppm respectively), located in the C-terminal tail – 
Figure 5.8. In this region it is also possible to observe significant chemical shift 
changes for Asp250, Glu251, Gly252, Phe253 and Ile255. The remaining chemical 
shift changes are concentrated around the binding site for the SxIP – Phe218, Lys220, 
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Leu221, Glu225, Leu226, Asp244, Leu246, Tyr247, Ala248, Thr249, immediately 
below – Glu213 or immediately above – Cys228, Glu230. 
In a more general overview of the chemical shift changes plots it is clear that two main 
regions affected by the interaction with these ligands – the hydrophobic binding site 
and the C-terminal region, the latter with higher relevance for the stronger ligand – 
11MACF. For the first, it is important to mention that the 4MACF sequence (SKIP) is 
enough to achieve high specificity – no non-specific binding was observed. This is a 
highly relevant fact that shows that even for protein-protein interactions that usually 
present large interfaces it is possible to achieve specificity through such a short four 
residue sequence. Regarding the C-terminal region, the peaks observed for the 
resonances of this region (250–260) for free EB1cΔ8 are sharper and more intense, 
indicating more mobility in this region. However, analysis of the intensities of NH 
cross peaks for the complex formed between EBcΔ8 and each of the peptides shows 
that the intensities get attenuated for this region with the increasing length of the 
peptide – Figure 5.9.  This observation correlates with the fact that the stronger binder, 
11MACF, promoted chemical shift changes in residues in the C-terminal region, 
meaning that engaging of the C-terminus region is important to achieve a tighter 
interaction. 
The results obtained point to an increase in the binding affinity from the shorter 
(4MACF) to the longer peptide (11MACF). The next section will focus on 
determination of binding affinity values. 
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Figure 5.9 – plot of normalised (0-1) NH cross peaks intensities for free EB1cΔ8 (black), final titration 
point for 4MACF (green), 6MACF (blue) and 11MACF (red). 
 Determination of binding affinity by NMR spectroscopy 
The shape of the titration curve (chemical shift vs concentration of ligand) can often 
be fitted straightforwardly to obtain a value for the dissociation constant of the ligand, 
Kd. CSP is the only technique that can directly provide both a Kd value and a binding 
site from the same set of measurements, more details can be found in Chapter 1 
(section 1.2.3.1).94 Using the 1H,15N-HSQC spectra recorded previously, one can trace 
and fit the chemical shift changes using the following equation: 
, Equation 5.2 
where,  
This equation shows that a good estimate of Kd can only be obtained if the 
concentration of protein and ligand is somewhere close to Kd. The optimum value for 
the protein concentration is half of the Kd. Values up to a factor of ten less or more are 
still usable, as long as the range of concentrations of ligand is large enough, but the 
error in the fit rises dramatically away from these conditions. In particular, the ligand 
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should ideally span the range from 0.4 times protein concentration to ten times protein 
concentration (1/5 Kd to 5 times Kd).94 The lowest concentration of protein that can 
usefully be employed for HSQC titrations under optimum conditions of sensitivity is 
currently around 10 µM, implying that Kd values stronger than about 1 µM are too 
strong to be fitted from HSQC spectra. At the other end of the scale, CSP data can be 
used to fit dissociation constants as weak as 10 mM, which is close to the upper limit 
for biologically relevant affinities.94  
The resulting plot must have significant curvature in order to be able to fit effectively, 
if there is not enough curvature it means the binding is very far of reaching saturation.  
For 4MACF, high concentrations of the ligand were used in order to concentration of 
the ligand closer to the Kd value. At the last titration point (5 mM) the ligand 
concentration is about half of the Kd. Although this ligand range of concentrations is 
too low and therefore not ideal for Kd determination by NMR, a Kd value was still 
estimated from the use of Equation 5.2  
As expected, very weak binding is observed and therefore the fitting curve is almost a 
straight line – Figure 5.10. At the ratios below 1:20 the dependence of chemical 
changes on ligand concentration is linear, with a small deviation from the straight line 
at the higher concentrations.  
 
Figure 5.10 – Superposition of the experimental data (blue) and the results of the fitted Equation 5.2 
(red) for Tyr247 (left panel) and Thr249 (right panel) of EB1cΔ8 over the course of the 4MACF. These 
residues show very good agreement between the experimental and fitting function values and hence, 
were used in the Kd value determination process. The black straight line was introduced as a reference 
to facilitate the visualisation of the curvature. 
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Table 5.1 - The Kd values calculated for seven residues of EB1cΔ8 that best fitted the fitting function 
during the NMR titration with 4MACF. 
Residue Kd (mM) 
218F 8.92 ± 3.81 
220K 7.74 ± 2.16 
235N 9.90 ± 3.8 
244D 8.95 ± 3.23 
247Y 12.3 ± 0.91 
248A 8.7 ± 2.86 
249T 16 ± 3.53 
average 10.4 ± 2.90 
 
 
Figure 5.11 - Superposition of the experimental data (blue) and the results of the fitted Equation 1 (red) 
for Tyr247 (left panel), Thr249 (right panel) and Val254 (bottom centre) of EB1cΔ8 over the course of 
the 6MACF concentration titration (blue) and the corresponding fitting function (magenta). Similar 
good agreement between the experimental and fitting function values were observed for all peaks used 
in the Kd value determination. 
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Table 5.2 - The Kd values calculated for 13 residues of EB1cΔ8 that best fitted the fitting function during 
the NMR titration with 6MACF. 
Residue Kd (mM) 
212K 1.69 ±0.14  
213E 2.32 ± 0.46 
218F 1.54 ± 0.11 
221L 1.45 ± 0.08 
222R 1.49 ± 0.16 
224I 1.51 ± 0.14 
247Y 1.96 ± 0.26 
248A 1.67 ± 0.27 
249T 1.66 ± 0.27 
250D 1.96 ± 0.39 
252G 1.58 ± 0.25 
254V 1.81 ± 0.30 
255I 1.90 ± 0.33 
average 1.73 ± 0.24  
As described previously, this condition is far from optimal for accurate Kd 
determination, as the shift dependence does not show enough curvature. However, 
small systematic deviation from the linear dependence is sufficient for the consistent 
fitting of the titrations curves for the peaks with the largest chemical shit differences, 
giving an estimate for the Kd value of ~10 mM (Table 5.1). This value is comparable 
to the maximum concentration of the peptide used in the titration, further supporting 
the validity of the approach.  
Quantitative analysis of spectral changes for 6MACF titrations (see above) indicated 
higher affinity of the interaction with EB1cΔ8 than for 4MACF. In agreement with 
this we detected significant curvature in the titration curves, optimal for the fitting 
(Figure 5.11). The resulting Kd values were close for all the peaks with large chemical 
shift changes that can be reliably followed thought the titration (Table 5.2), giving the 
average value of 1.7 mM for this interaction. This value is significantly lower than the 
maximum peptide concentration used in the titration, making the titration conditions 
close to optimal. 
It was already shown that 11MACF is the strongest binder of the three tested peptides. 
Resonances in an intermediate exchange regime are not ideal for Kd determination 
using chemical shift changes, due to broadening and disappearance of peaks at certain 
ratios and complex concentration dependence of chemical shifts. Therefore, the peaks 
in fast exchange regime with minimal broadening were selected for the Kd estimation. 
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The titration curves for these peaks could be fitted well into the fast exchange model 
(Figure 5.12). However, the variation of the estimated Kd values was large with large 
associated errors (Table 5.3). This variation in the Kd estimates across the peaks 
indicates that the titration conditions are far from optimal. The average Kd value of 1.3 
µM is much smaller than the protein concentration of 100 µM used in the titration, 
leading to the limited curvature; additionally, a number of resonances used in the 
estimation demonstrated different degree of broadening at the intermediate titration 
points, explaining variations in the shape of the titration curves. All the fitting plots 
for these residues show clearly that the system reached saturation immediately above 
1:1 ratio (Figure 5.12) as expected for the estimated Kd value, validating the Kd 
estimation. 
 
Figure 5.12 - The fit curve produced for Phe216 (left upper panel), Phe218 (right upper panel), Leu246 
(left bottom panel) and Thr249 (right bottom panel) of EB1cΔ8 over the course of the 11MACF. These 
residues show very good agreement between the experimental and fitting function values and hence, 
were used in the Kd value determination process. The black straight line was introduced as a reference 
to facilitate the visualisation of the curvature. 
 
Table 5.3 - The Kd values calculated for seven residues of EB1cΔ8 that best fitted the fitting function 
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during the NMR titration with 11MACF. 
Residue Kd (µM) 
216F 0.822 ± 0.77 
218F 3.45 ± 1.26 
230E 0.547 ± 0.92 
244D 0.717 ± 1.70 
246L 1.38 ± 1.38  
248A 1.51 ± 1.86  
249T 0.818 ± 1.23 
average 1.32 ± 1.30 
6MACF titration is the only one that presents ideal conditions for fitting of Equation 
5.2. Despite this it was still possible to estimate Kd values for 4MACF and 11MACF. 
The extension of the SxIP motif by two residues, threonine and proline (SKIPTP), 
improved the binding to EB1cΔ8 by roughly 10 fold – 1.7 mM. Further extension, 
11MACF (KPSKIPTPQRK) has a remarkable effect in the binding affinity, enhancing 
it to about 1000 fold – 1.32 µM. Is this enhancement only result of the interaction of 
the C-terminus as postulated in the beginning of this chapter or are there extra 
contributions with the coiled coil region? To address this question, the next section 
will focus on the testing of the same peptides in the absence of the C-terminus. 
5.2 NMR screening of MACF peptides against EB1cΔ16 
From the previous experiments it was possible to observe that a stronger interaction 
with EB1cΔ8 affected the residues around SxIP binding site but also the residues in 
the C-terminus. To further investigate the role of the C-terminal it was decided to test 
the same set of ligands – 4MACF, 6MACF and 11MACF, in the absence of the eight 
C-terminal residues – EB1cΔ16. The same approach was used before, 1H,15N-HSQC 
titrations, since it involves relatively simple experiments but it gives valuable 
information on the strength and localisation of the interaction. The removal of the C- 
terminus had a minor effect on the NMR spectra, with the 1H,15N-HSQC spectrum 
exhibiting highly dispersed cross-peaks of uniform intensity that correspond to a stable 
coiled coil – section 3.3 – Chapter 3. 
For 4MACF - Figure 5.13, the chemical shift changes are overall smaller than the ones 
observed for the same ligand interaction with EB1cΔ8. However, the trend is similar 
to what was observed for the other construct, with Tyr247 being the most affected 
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residue, followed by Thr249. Glu225, Phe218 and Arg222, similarly to what was 
observed before were also affected upon ligand binding. Overall, the chemical shift 
changes distances were reduced to half of what was observed for EB1cΔ8. 
 
Figure 5.13 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ16 (50 µM) recorded at 600 MHz 
- in the free form (black) and in the presence recorded of 4MACF (5000 µM, red) at 600 MHz The 
insets show regions of interest and the spectra corresponding to the following 4MACF concentrations, 
250, 500, 1000, 2500 and 5000 µM.  
When EB1cΔ16 chemical shift changes are measured upon the addition of 6MACF – 
Figure 5.14, the chemical shift changes distribution is very similar to the one observed 
for EB1cΔ8, with the exception obviously of Val254, not present in this construct. 
Therefore, Tyr247 (Δδ= 0.45 ppm) and Thr249 (Δδ= 0.29 ppm) are, once again the 
most affected residues, followed by Lys220 (Δδ= 0.13 ppm) and Arg222 (Δδ= 0.11 
ppm). Glu213 (Δδ= 0.09 ppm), Phe218 (Δδ= 0.06 ppm), Glu225 (Δδ= 0.09 ppm), and 
Ala248 (Δδ= 0.07 ppm). Similarly to what was observed for the previous ligand the 
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chemical shift changes distances are about half of the ones observed for EB1cΔ8. 
Another striking difference is the fact that a subtle peak broadening was observed for 
resonances such as the ones belonging to Glu213 and Tyr247 when the complex was 
formed with EB1cΔ8, whereas for this complex all resonances are clearly in a fast 
exchange regime. 
 
Figure 5.14 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ16 (50 µM) recorded at 600 MHz 
- in the free form (black) and in the presence recorded of 6MACF (5000 µM, red) at 600 MHz The 
insets show regions of interest and the spectra corresponding to the following 6MACF concentrations, 
250, 500, 1000, 2500 and 5000 µM. 
For 11MACF – Figure 5.15, the removal of the C-terminal tail also moves the 
exchange regime towards fast exchange. This trend is very clear for Ala248 and 
Thr249. The chemical shift changes are now similar in terms of magnitude when 
compared with the complex formed with the previous construct. Ala248 shift change 
is now about five times smaller, Asp250 about two times, Tyr247 about 1.2 times and 
surprisingly the chemical shift change for Thr249 and Arg222 are now larger than the 
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ones observed for the complex with EB1cΔ8.  
 
Figure 5.15 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ16 (100 µM) recorded at 600 
MHz - in the free form (black) and in the presence recorded of 11MACF (400 µM, red). The insets 
show regions of interest and the spectra corresponding to the following 11MACF concentrations, 12.5, 
25, 75, 82.5, 100, 200 and 400 µM.  
The binding is definitely weaker – no significant line broadening and therefore 
intermediate exchange observed, but the chemical shift changes distances are not as 
affected as what was observed for the shorter length peptides. The removal of part of 
the C-terminal flexible tail (residues 253-260) had an obvious effect in the interaction 
between EB1c and MACF2, diminishing the strength of the interaction as it was 
expected.  
 Chemical shift changes and mapping 
In terms of localisation of the binding all three peptides still target the hydrophobic 
binding site specific for the interaction with the SxIP motif, and therefore the absence 
of the C-terminus does not affect the specificity of the SxIP motif for EB1c. On one 
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hand the C-terminal tail seems to contribute for a stronger interaction with ligands, 
nevertheless it is the hydrophobic pocket that gives the specificity for the interaction. 
This was expected since it is widely described in the literature that the specificity for 
the EB1c – SxIP proteins interaction relies on SxIP motif and its interaction with the 
hydrophobic pocket. The extra interactions, away from the binding site, only stabilise 
the interaction.49 Tyr247 and Thr249 are now the residues more affected by the ligand 
interaction. The distribution pattern for the chemical shift changes is similar to the one 
observed before, with the existence of two majorly affected regions – Phe218 – Glu225 
and Tyr247-Thr249. 
The largest chemical shift change observed for the complex with 4MACF is Tyr247 
(Δδ = 0.16 ppm) - Figure 5.16. As described previously the magnitude of the distance 
is now smaller – previous Δδ = 0.35 pm. Similar trend is observed for Phe218, Δδ = 
0.03 vs 0.07 ppm, Arg222, Δδ = 0.03 vs 0.06 ppm, and Glu225, Δδ = 0.04 vs 0.06 ppm. 
When bound to 6MACF, EB1cΔ16 changes in chemical shift follow the same principle 
as for 4MACF - Figure 5.17. Tyr247 shows a Δδ of 0.45 ppm (whereas for EB1cΔ8 
was of 0.86 ppm). Arg214 Δδ changed from 0.16 to 0.08 ppm, Phe216 0.12 to 0.05 
ppm, Lys220 from 0.28 to 0.13 ppm, and finally Ala248 0.19 to 0.07 ppm and Thr249 
from 0.48 to 0.28 ppm. 
The complex with 11MACF does not show the same pattern as the one observed before, 
for the simple reason that some of the affected residues are now not present, e.g. 
Val254. Except for that region the chemical shift changes follow the same pattern, and 
opposite to what was observed for the shorter length peptides not all chemical shift 
distances were reduced. Thr249 has now a larger chemical shift change – Δδ = 0.69 
ppm, whereas previously was 0.55 ppm. Arg222 also has a bigger chemical shift 
change, Δδ = 0.31 ppm and previously 0.19 ppm. All other resonances seem to have 
the chemical shift distances reduced but not to such a noticeable magnitude as the one 
observed for the shorter length peptides. This is a clear effect of the exchange regime 
shifted from intermediate to fast, the binding is weaker but the chemical shift distances 
are not so affected. 
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Figure 5.16 - A - Histogram representing the chemical shift perturbations observed between free 
EB1cΔ16 and bound to 4MACF (SKIP) using the Equation 5.1. The secondary structure of the EB1 is 
given above the plot. B – Chemical shift changes mapping on the crystal structure (PDB accession code: 
3GJO), the selected residues were selected by applying the following formula: remove all residues with 
chemical shift changes larger than standard deviation (σ) of the chemical shift changes multiplied by 
three, re-calculate the standard deviation (σ) of the chemical shift changes residues and select the 
residues presenting chemical shift changes above that value. 
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Figure 5.17 - A - Histogram representing the chemical shift perturbations observed between free 
EB1cΔ16 and bound to 6MACF (SKIPTP) using the Equation 5.1. The secondary structure of the EB1 
is given above the plot. B – Chemical shift changes mapping on the crystal structure (PDB accession 
code: 3GJO), the selected residues were selected by applying the following formula: remove all residues 
with chemical shift changes larger than standard deviation (σ) of the chemical shift changes multiplied 
by three, re-calculate the standard deviation (σ) of the chemical shift changes residues and select the 
residues presenting chemical shift changes above that value. 
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Figure 5.18 – A - Histogram representing the chemical shift perturbations observed between free 
EB1cΔ16 and bound to 11MACF (KPSKIPTPQRK) using the Equation 5.1. The secondary structure of 
the EB1 is given above the plot. B – Chemical shift changes mapping on the crystal structure (PDB 
accession code: 3GJO), the selected residues were selected by applying the following formula: remove 
all residues with chemical shift changes larger than standard deviation (σ) of the chemical shift changes 
multiplied by three, re-calculate the standard deviation (σ) of the chemical shift changes residues and 
select the residues presenting chemical shift changes above that value. 
 Determination of binding affinity by NMR spectroscopy 
Determining the binding affinity for these interactions can be even more challenging 
than before, as these are even weaker than the ones reported for EB1cΔ8. It is 
noteworthy to reinforce the idea these are only approximations and with this approach 
one only wants to facilitate the comparison by attributing numerical values to the 
titrations.  
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Because for the previous Kd determination for the 4MACF-EB1cΔ8 the value was 
already on the upper limit for Kd determination by NMR (10 mM) it was decided to 
not make an attempt for this interaction between the same ligand and the truncated 
version of EB1c (EB1cΔ16) as the interaction is even weaker and the determined value 
would not be meaningful. 
For 6MACF, it is possible to observe that now the fitting curve presents a less 
pronounced curvature – Figure 5.19, very similar to the case observed for the 
interaction 4MACF- EB1cΔ8. The estimated Kd is almost seven times higher than 
before – Table 5.4, indicating that despite this peptide does not seem to make a large 
number of interactions with the C-terminus of EB1c, the removal of this region 
penalises the binding to a large extent. It is possible that the presence of the C-terminus 
shields the ligand from the solvent, leaving hydrophobic residues such as proline or 
isoleucine less solvent exposed. 
As expected, the same trend is observed for 11MACF- EB1cΔ16 – Figure 5.20, Table 
5.5. The estimated Kd is now 12 µM, about ten times higher than the one observed 
previously. Perhaps the lack of the flexible C-terminus is even more noticeable for this 
interaction as 11MACF CSPs indicated that important changes could be observed for 
the C-terminal region upon addition of this ligand. 
 
Figure 5.19 - The fit curve produced for 247Y (left panel), 249T (right panel) of EB1cΔ16 over the 
course of the 6MACF concentration titration (blue) and the corresponding fitting function (magenta). 
These residues show very good agreement between the experimental and fitting function values and 
hence, were used in the Kd value determination process. The black straight line was introduced as a 
reference to facilitate the visualisation of the curvature. 
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Table 5.4 - The Kd measured for five residues of EB1cΔ16 that best fitted the fitting function during the 
NMR titration with 6MACF and hence, were used in the estimation of the binding affinity. 
Residue Kd (mM) 
220K 7.54 ± 2.24 
222R 6.97 ± 2.61 
225E 5.87 ± 1.00 
247Y 8.67 ± 2.37 
249T 6.29 ± 1.17 
average 7.07 ± 1.88 
 
 
 
Figure 5.20 - The fit curve produced for 221L (left panel), 248A (right panel) of EB1cΔ16 over the 
course of the 11MACF concentration titration (blue) and the corresponding fitting function (magenta). 
These residues show very good agreement between the experimental and fitting function values and 
hence, were used in the Kd value determination process. 
Table 5.5 - The Kd measured for four residues of EB1cΔ16 that best fitted the fitting function during 
the NMR titration with 11MACF and hence, were used in the estimation of the binding affinity. 
Residue Kd (µM) 
218F 9.03 ± 3.09 
221L 11.8 ± 4.87 
246L 15 ± 3.74 
248A 13.3 ± 5.83 
average 12.3 ± 4.38 
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5.3 Isothermal titration calorimetry binding assays of 11MACF - 
EB1cΔ8 and 11MACF - EB1cΔ16 
In order to further characterise the complexes formed between 11MACF and EB1cΔ8 
and EB1cΔ16, isothermal titration calorimetry was used. The experimental 
considerations and methods used in this section are described in 7.4.2 – Chapter 7. 
As described in section 1.2.3.2 – Chapter I, ITC directly measures the heat released or 
absorbed during a biomolecular binding event, allowing the simultaneous 
determination of all thermodynamic parameters, including stoichiometry (n), 
equilibrium association constant (Ka), ∆H (enthalpy) and ∆S (entropy) for that 
particular binding interaction. These thermodynamic parameters can be used to 
calculate the Gibbs free energy (∆G) for a particular interaction between two 
macromolecules (Equation 5.3 and 5.4), where a negative value indicates that non-
covalent association is occurring. The binding affinity (Ka), is inverse to the 
dissociation constant (Kd), therefore smaller Kd tighter the binding (Equation 5.5). 
Obtaining all these parameters from one single method makes ITC an extremely useful 
biophysical technique for determination and comparison of biomolecular 
interactions.169,17> 
, Equation 5.3 
, Equation 5.4 
, Equation 5.5 
The interaction with 4MACF and 6MACF was too weak to be measured by ITC. 
However, the same is not true for the interactions of EB1c and the 11mer peptide – 
11MACF. At this stage it would be important to calculate accurately the Kd values for 
both EB1cΔ8 and EB1cΔ16 interactions with 11MACF. In addition, and making use 
of the versatility of this method to calculate parameters such as ∆H and ∆S, it would 
be of interest to know how the presence of the C-terminal flexible tail affects these 
parameters. The individual isotherms for these interactions are shown in Figure 5.21 
and Figure 5.22. A total of three experiments were used to calculate the 
thermodynamic parameters and respective associated errors showed in Table 5.6. 
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Figure 5.21 - The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding exper-
iment between 50 µM EB1cΔ8 (cell) and 750 µM 11MACF (syringe) in 20 mM phosphate, pH 6.5, 50 
mM NaCl, 0.5 µM TCEP, 0.02% NaN3 on an iTC200 Microcalorimeter (MicroCal) at 25oC. Fitting of 
the curve produced by the ITC experiment to a single set of sites curve-fitting model, using Origin7, 
resulted in a binding affinity (Kd) of 2 µM. 
 
Biophysical characterisation of physiological EB1 interactions involving MACF2 
162 
 
 
Figure 5.22 - The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding exper-
iment between 150 µM EB1cΔ16 (cell) and 2250 µM 11MACF (syringe) in 20 mM phosphate, pH 6.5, 
50 mM NaCl, 0.5 µM TCEP, 0.02% NaN3 on an iTC200 Microcalorimeter (MicroCal) at 25oC. Fitting 
of the curve produced by the ITC experiment to a single set of sites curve-fitting model, using Origin7, 
resulted in a binding affinity (Kd) of 26 µM. 
 
Table 5.6 - Thermodynamic parameters obtained for three ITC binding experiments to detect the inter-
actions of 11MACF with EB1cΔ8 and EB1cΔ16. Values shown in this table correspond to the average 
and associated error obtained for the three experiments. 
Interaction Kd (µM) ∆H (kcal mol-1) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
EB1cΔ8 
11MACF 3.80 ± 0.82 -10.57 ± 0.63 3.15 ± 0.64 -7.42 ± 0.12 
EB1cΔ16 
11MACF 41.5 ± 8.84 -7.11 ± 0.44 1.11 ± 0.45 -6.00 ± 0.12 
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Figure 5.23 - The thermodynamic parameters (∆G (blue), ∆H (red) and -T∆S (green)) obtained from 
the binding interaction between the 11MACF and EB1cΔ8 (EB1d8, left hand side) and EB1cΔ16 
(EB1d16, right hand side).  
The interaction between EB1cΔ8 and the 11-residue peptide derived from MACF2, 
11MACF, it is in the low µM range, 3.80 ± 0.82 µM. This value is in agreement to 
what was reported previously for a longer peptide sequence (~26 amino acid residues) 
including this sequence, 3.5 µM. This value was obtained using fluorescence 
polarisation (FP) displacement.17> As expected, and in accordance with what was 
observed by NMR, the Kd for the interaction of the same peptide and EB1cΔ16 
(lacking eight C-terminal residues) is higher, indicating a weaker interaction – 41.5 ± 
8.84 µM, about 10 fold weaker. Once again, this is in agreement with the results 
obtained by NMR, where the estimated Kd changed from 1.32 µM to 12.3 µM. 
A similar effect was demonstrated by Honnappa and co-workers31 where a different 
SxIP containing peptide derived from APC was tested for interaction with EB1c 
lacking the 20 C-terminal residues (191-247). Because these authors removed 
important residues part of the binding pocket such as Ala248 and Thr249, the effect is 
more extreme with no binding observed.  
In terms of thermodynamic parameters contribution, Figure 5.23 represents a graphical 
output of the values present in Table 5.6. ∆G is made up of two different contributions, 
∆H and ∆S, and different combination of these values, in principle, elicit the same 
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binding affinity (i.e. the same ∆G and therefore the same Ka). The binding enthalpy 
(∆H) primarily reflects the strength of the interactions of the ligand with the target 
protein (e.g. van der Waals, hydrogen bonds, etc.) relative to those existing with the 
solvent. The entropy change (∆S), on the other hand, mainly reflects two contributions: 
changes in solvation entropy and changes in conformational entropy. Upon binding, 
desolvation at the binding interface occurs, water is released to bulk solution and a 
gain in solvent entropy is observed. This gain is particularly important for hydrophobic 
groups. At the same time, the ligand and certain groups in the protein lose 
conformational freedom, resulting in a negative change in conformational entropy.17> 
The removal of eight residues from EB1c’s C-terminal tail caused enthalpic 
contributions to be smaller, meaning that it is possible that hydrogen bonds and other 
non-covalent interactions formed between this region and 11MACF may have been 
lost. On the other hand, entropic contributions are more favourable when the majority 
of the C-terminal tail is absent. This may be related with when the C-terminal region 
is present it tends to become more structured upon binding to SxIP containing peptide. 
This observation was already described in this thesis – Figure 5.9. This loss of 
flexibility may cause unfavourable contributions to the system entropy. Despite this, 
the enthalpic loss for this complex outweighs the entropic gains due to the removal of 
the flexible region. 
The X-ray crystal structure published by Honnappa and co-workers in 200931 is the 
only structure published to date where part of the flexible C-terminus is observed, 
meaning this region should in principle be less dynamic when EB1c is bound to a 
peptide derived from a natural ligand. In order to get extra information on how EB1c 
binds to a SxIP containing peptide, it was decided to elucidate the structure in solution 
of the complex formed between EB1cΔ8 and 11MACF. This structure differs from the 
one supra in two main aspects, the first is a structural model in solution, the second is 
the fact the SxIP containing peptide is a shorter sequence, 11 residues instead of 30. 
5.4 Structural elucidation of the complex EB1cΔ8-11MACF using solu-
tion NMR 
In this thesis two solution NMR structures of EB1cΔ8 were already described for the 
free and bound form – Chapter 3. The structure described in this section aims to 
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represent the structural conformations of EB1cΔ8 when bound to a longer and higher 
affinity ligand. The first difference between this complex and the one previously 
elucidated between EB1cΔ8 and molecule 1a is the fact this complex is in intermediate 
exchange and therefore it was not possible to follow the chemical shift changes during 
the course of the titration from the resonances obtained for free EB1cΔ8. Therefore, 
all spectra were assigned in an identical manner to the one described for EB1cΔ8 in 
the free form – Chapter 3. The fact that the complex presents characteristics of an 
intermediate exchange regime, with extensive line broadening for some of the protein 
resonances, it was necessary to add excess of ligand (10:11 ratio) in order to get sharper 
peaks for the ligand without loss (broadening) of the protein resonances – Appendix 
(A.3). 
One hundred and eighty five intermolecular distance restraints were calculated using 
CcpNmr Analysis17> and introduced into the calculations of the complex. One hundred 
and ten distance restraints were iteratively assigned by ARIA174 yielding a total of 298 
distance restraints between the protein and the peptide. Additionally, 209 
intramolecular distance restraints for the peptide were also assigned and introduced –  
Table 5.7. This approach yielded a structure of a complex shown in Figure 5.24. 
Overall EB1cΔ8 maintains the coiled-coil structure composed by a leucine zipper and 
four helical bundle in the upper region. The most remarkable difference between this 
structure and the two previously reported (Chapter 3) is that the C-terminal tail is now 
in a stable and fixed conformation. 
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Table 5.7 - NMR restraints and structure statistics for the structures of EB1cΔ8 in complex with 
11MACF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Number in brackets corresponds to the restraints assigned manually 
**Helical region corresponds to residues: Glu192-Glu230 and Pro237-Tyr247 
*** Values within brackets correspond to residues Glu192-Glu230 and Pro237-Tyr247 (helical region) 
 
 EB1cΔ8-11MACF 
Total restraints used 
NOE restraints*  
All 3863 
Protein-ligand 298 
Intermonomer 924 
Intrapeptide  209 
Intraresidue	 1133 
Sequential (|i – j| = 1) 968 
Medium (1 < |i – j| ≤ 4) 1311 
Long range (|i – j| > 4) 177 
Dihedral  
ϕ angles 65 
φ angles 65 
Hydrogen bonds 90 
Structure statistics 
Violations 
Distance (> 0.5 Å) 42 (±5) 
Dihedral angle (> 50 )  7 (±1) 
Energies (cal/mol) 
Overall   -2179 (±208) 
Bond 119 (±9) 
Angle 479 (±21) 
Improper 242 (±29) 
Dihedral 868 (±14) 
Van der Waals -48 (±28) 
Electrostatic -5903 (±98) 
NOE 1906 (±119) 
Geometry – average Values  
Bond	 7.40x10-3	(±5.7x10-4)	
Angle	 0.91		(±9.96x10-2)	
Improper	 2.50	(±0.30)	
Dihedral	 41.56	(±0.24)	
Van	der	Waals	 428.93	(±83.98)	
Average	pairwise	RMSD	(Å)**	  
Heavy	atoms	 2.41	(±1.25)	
Heavy	atoms	–	helical	region	 1.51	(±0.99)	
Backbone 2.05	(±1.33)	
Backbone – helical region 1.08	(±0.93)	
Ramachandran statistics (%)***  
Most	favoured	regions	 87.0	(99.5)	
Additional	allowed	regions	 10.8	(0.3)	
Generously	allowed	regions	 1.0	(0.2)	
Disallowed	regions	 1.1	(0)	
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Figure 5.24 - A – Superimposition of the ensemble of 20 best structures of EB1cΔ8 domain in complex 
with 11MACF. B – Cartoon representation of the lowest energy structure for EB1cΔ8 in complex with 
11MACF shown in sticks, where green represents carbon, blue nitrogen and red oxygen. 
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The solution NMR structure of EB1cΔ8 in the unbound state elucidated the side chain 
mobility of two residues in the binding site, Arg222 and Tyr247. In the bound form to 
molecule 1a, these residues remained in a stable and fixed conformation. This was 
further proved by the existence of NOE cross peaks between the molecule and both 
residues of the protein. Similarly, for the complex formed between EB1cΔ8 and 
11MACF these residues remain in a stable conformation, with only little side chain 
variability for Arg222. Again, this is supported by the existence of NOE distance 
restraints - Table 5.8.  
Table 5.8 – NOE calculated distance restraints obtained for Arg222 
NOE distance restraints assigned and introduced in the calculations via CcpNmr Analysis 
A Arg222 Hα C Ile5479 Hδ1 4.3 Å 
A Arg222 Hα C Ile5479 Hδ1 4.6 Å 
A Arg222 Hδ1 C Ile5479 Hδ1 4.9 Å 
NOE distance restraints calculated by ARIA 
A Arg222 Hα C Ile5479 Hδ1 2.9 Å 
A Arg222 Hδ1 C Ile5479 Hδ1 4.2 Å 
A Arg222 Hβ1 C Ile5479 Hδ1 4.5 Å 
Table 5.9 - Parameters calculated via CASTp15> webserver for the hydrophobic pocket shape and size 
analysis. 
  Area (Å2) Volume (Å3)   
structure 
Number of 
 mouth 
openings 
Solvent 
accessible 
Molecular 
surface 
Solvent 
accessible 
Molecular 
surface 
sum 
arc 
length 
corner 
points 
1 1 328.791 434.47 320.387 855.13 264.74 110 
2 1 184.29 273.09 173.877 493.53 152.3 74 
3 2 382.843 519.29 445.541 1067.72 319.25 139 
4 2 244.428 351.41 198.826 612.02 200.48 105 
5 1 292.415 402.28 290.323 779.39 258.6 118 
6 1 239.808 353.61 209.158 623.31 211.9 106 
7 1 213.99 359.06 185.383 571.63 184.89 101 
8 2 245.327 390.99 195.283 627.09 220.03 111 
9 1 200.696 311.21 183.17 531.71 169.54 89 
10 1 237.233 366.56 209.798 617.6 185.16 95 
11 1 320.497 494.99 244.091 802.65 285.4 146 
12 1 315.463 426.35 287.722 805.96 255.98 124 
13 1 232.901 351.45 214.77 621.19 205.11 100 
14 1 187.433 265.69 200.472 515.31 147.34 70 
15 1 226.224 360.73 220.101 619.27 191.32 102 
16 1 182.231 266.67 159.245 468.69 146.49 73 
17 1 369.165 532.34 389.309 991.42 290.39 141 
18 1 301.724 397.48 326.503 817.38 245.4 114 
19 1 303.93 424.31 320.598 824.42 250.43 126 
20 1 285.503 384.62 325.76 782.8 216.56 107 
Average 1.2 264.7446 383.33 255.016 701.411 220.07 108 
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Standard deviation 0.4 58.87961 73.83241 76.783 161.532 48.581 20.9 
There are three structures where the arginine side chain occupies a more interior 
position (1, 2 and 4) and these still present large binding pocket volumes (Table 5.9), 
opposing to what was observed in the free form.  
Remarkably, the average binding pocket size for this complex is about five times larger 
than the average obtained for the complex with 1a – 49 Å3 (± 6 Å3) versus 255 Å3 (± 
77 Å3). The main reason this major difference in the binding site is the contribution of 
the C-terminal tail of EB1cΔ8 (residues 248-260). The C-terminus folds around the 
peptide protecting it from the solvent and therefore extending the binding site - Figure 
5.25. 
 
Figure 5.25 – Representation of the binding site of the lowest energy structure (structure 1) obtained for 
the complex EB1cΔ8-11MACF. Protein and ligand are both in cartoon representation, grey and green 
respectively. The binding pocket is represented as a grey mesh and was calculated using CASTp 
webserver (solvent accessible volume of 320 Å3. 
This conformation is observed across the ensemble of 20 calculated structures for this 
complex and further proved by the existence of intermolecular NOEs between the 
ligand and the C-terminus of EB1cΔ8. These contacts include Val254 to the sequence 
5480PTPQR5484, Ile255 to the sequence 5478KIPTP5482, Pro256 to the sequence 
5478KI5479-T5481, and finally Asp257 to Lys5478. Finally, Phe253 establishes most of 
the contacts with Pro5482, with fewer for Ile5479 and Thr5481. A detailed list of the 
distance restraints derived from the NOE data can be found in Appendix A.3. As 
mentioned above the C-terminus of EB1cΔ8 interacts with the peptide – residues 
5478KIPTPQR5484, but the majority of the contacts are within the region 5478KIPTP5482. 
Peptide side chains are therefore more restrained for this region and show good 
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superimposition - Figure 5.26. 
 
Figure 5.26 – Superimposition of the ensemble of structures obtained for the peptide in complex with 
EB1cΔ8 
Regarding the contacts between the peptide and the helical region of EB1cΔ8, small 
number of restraints – eight in total, are observed for Lys5475 and Pro5476 and 
residues Asn223, Glu225 and Leu226. Ser5477 only shows one distance restraint to 
Phe218 and this is quite large distance ~ 6.5 Å. The following residue, Lys5478 is 
solvent exposed making contacts only with the C-terminus of EB1cΔ8. Ile5479 shows 
the largest number of NOE distance restraints; these include the following residues 
from the coiled coil region of EB1cΔ8 – Tyr217, Phe218, Leu221, Arg222, Ile224, 
Glu225, Leu246 and Tyr247. Similarly to Ile5479, Pro5480 shows hydrophobic 
contacts to Tyr217, Phe218 and further down with Thr249. The following threonine 
(5481) is the only residue showing contacts to Phe216, making two additional contacts 
with other two aromatic side chains (Tyr217 and Phe218). Pro5482 is the last residue 
of the peptide making contacts with the coiled region of EB1cΔ8 – Thr249, already in 
the transition region to the C-terminal tail.  
The above contacts from the NMR structures are generally consistent to the ones 
described by Honnappa and co-workers and the structure is very similar to the crystal 
structure 3GJO31. However, the NMR structure gives a better understanding of the 
solution structure of the complex, reassuring that the C-terminus folds upon binding 
and that this region seemed to be fixed in the crystal structure is not derived from 
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crystal packing. It is now very clear that the C-terminal plays a fundamental role in 
ligand-EB1c interactions. It was, therefore, decided to make an attempt in finding a 
higher affinity ligand by introducing mutations that can favour the interaction between 
the ligand and the C-terminus. This process will be subsequently described. 
 
Figure 5.27 – representation of the residues forming the contact interface between EB1cΔ8 and 
11MACF, both shown in cartoon representation with side chain showed for all the residues involved in 
contacts between the two molecules. EB1cΔ8 is shown in grey and 11MACF in green, with oxygen 
shown in red and nitrogen shown in blue for both. 
5.5 Optimisation of the native interaction 
 Molecular modelling 
At this stage it was known the importance of targeting the flexible C-terminus of EB1c, 
therefore it was decided to find ligands that bind tighter to this region through peptide 
mutagenesis. The first step consisted in a literature search to identify possible amino 
acid replacements that would help to achieve a stronger interaction. A paper published 
in 2012 by Buey et al., 201249 shows through a SPOT analysis that 5481TPQ5483 would 
tolerate mutations, especially if amino acid residues with hydrophobic side chains are 
introduced. Thr5481 can be replaced by histidine, isoleucine, leucine, methionine, 
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glutamine, arginine or valine. The following proline (Pro5482) tolerates phenylalanine 
and leucine, whereas the Gln5483 can be replaced by isoleucine, lysine, leucine or 
valine, being leucine the preferable mutation. 
Three versions of mutated peptides were built and analysed through molecular docking 
– KPSKIPLLLRK (11MACF-LLL), KPSKIPVLLRK (11MACF-VLL) and 
KPSKPILLRK (11MACF-ILL). Each pose was initially docked and evaluated using 
Goldscore scoring function (as described in section 8.1.2), and the results were later 
rescored using each scoring function present in GOLD – Chemscore, ChemPLP and 
ASP. Overall 11MACF-LLL obtained higher fitness scores for all scoring functions, 
followed by 11MACF-VLL. 11MACF (wild-type) and 11MACF-ILL seemed to 
compete for the third best overall score. These results are detailed in Table 5.10, Table 
5.11, Table 5.12and Table 5.13. 
Table 5.10 – Fitness scores obtained with Goldscore for the wild-type and mutated versions. 
 11MACF-wt 11MACF-LLL 11MACF-VLL 11MACF-ILL 
1 116.6972 99.0181 109.2072 147.3196 
2 95.596 98.691 103.7247 106.0801 
3 90.5117 97.5353 88.4816 103.5024 
4 86.0151 97.487 77.7022 102.2641 
5 75.067 95.2011 76.4867 95.2081 
6 68.4973 89.3229 44.6624 78.6898 
7 67.8119 84.465 42.4577 34.2308 
8 50.9331 57.7077 41.1628 22.3123 
9 -20.8909 52.4758 14.3184 -70.6193 
10 -34.9973 2.4104 8.3302 -241.4937 
average 59.5241 77.4314 60.6534 37.7494 
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Table 5.11 – Fitness scores obtained with Chemscore for the wild-type and mutated versions. 
 11MACF-wt 11MACF-LLL 11MACF-VLL 11MACF-ILL 
1 -22.7581 -9.5765 -17.2281 -5.7635 
2 -46.008 -19.7418 -26.6175 -17.1386 
3 -22.0417 -19.0367 -7.6088 -26.7014 
4 -45.7151 -11.024 -21.107 -11.639 
5 -41.8411 -13.8251 -44.2843 -12.9866 
6 -41.8287 -17.7299 -29.9582 -29.5592 
7 -43.758 -15.5714 -26.3761 -50.1637 
8 -38.263 -23.1886 -41.2771 -51.7802 
9 -44.3287 -29.5566 -47.0179 -55.7457 
10 -59.8753 -29.5404 -29.8831 -93.4951 
average -40.642 -18.879 -29.136 -35.497 
 
Table 5.12 - Fitness scores obtained with ChemPLP for the wild-type and mutated versions. 
 11MACF-wt 11MACF-LLL 11MACF-VLL 11MACF-ILL 
1 103.8213 -405.4915 94.0879 89.2584 
2 43.1355 90.8319 -1055.4376 95.9891 
3 88.657 91.1274 82.2654 -8942.0868 
4 55.8481 97.2031 75.0087 109.75 
5 -2938.9568 -10005.363 -465.8373 -979.9262 
6 32.0876 15.2989 35.0926 79.6759 
7 73.1813 88.985 65.077 29.6528 
8 -2977.9218 -539.0405 41.4024 26.4023 
9 72.9775 73.5982 -8.4312 21.6552 
10 17.0947 -8454.1646 65.6476 -63.757 
average -543.0076 -1894.702 -107.1125 -953.3386 
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Table 5.13 - Fitness scores obtained with ASP for the wild-type and mutated versions. 
 11MACF-wt 11MACF-LLL 11MACF-VLL 11MACF-ILL 
1 37.9338 19.4951 29.0991 30.3398 
2 6.7662 31.8461 28.7736 35.4951 
3 31.473 31.8952 24.2367 26.3963 
4 -15.557 34.8758 27.5771 23.7509 
5 28.6352 26.0728 18.879 18.5394 
6 17.517 33.6309 2.3211 22.9137 
7 15.0886 11.4932 22.6155 -23.579 
8 -0.3545 11.6971 -3.3258 -9.5648 
9 -12.055 18.9143 11.5336 -30.678 
10 3.7372 17.2829 10.1022 -49.704 
average 11.319 23.72 17.181 4.391 
Regarding the best scored pose for each peptide the most relevant differences that can 
be observed for the mutated region are graphically shown in Figure 5.28. The wild-
type peptide shows two hydrogen bond contacts between Thr5481 (T7) backbone and 
Val254 backbone.   Pro5480 (P6) carbonyl makes an extra hydrogen bond with the 
OH group of Tyr217 and Pro5482 (P8) is involved in hydrophobic interactions with 
Gly252 and Phe253.  
11MACF-LLL does not form the hydrogen bond previously observed between the 
threonine backbone and Val254. Instead Lys5478 (K4) establishes a hydrogen bond 
with Pro256 and the terminal Lys (K11) establishes a similar contact with Ile255. 
Despite loss of two hydrogen bonds with the valine two other contacts were formed 
with the two subsequent residues, Ile255 and Pro256. In terms of hydrophobic 
interactions Val254 is now accessible to make contacts with both side chains of 
Leu5482 (L8) and Lys5485 (K11). Leu 5482 (L8) can also make hydrophobic contacts 
with the hydropobic Phe253 ring and Leu5481 (L7) is accessible to make hydrophobic 
contact with Phe218. The docking prediction reveals that this mutant is likely to give 
extra hydrophobic contributions on EB1 binding, as it could be expected due to its 
hydrophobic nature. 
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Figure 5.28 – Best scored docking poses obtained for A – 11MACF-wt, B – 11MACF- LLL, C - 11MACF-VLL and D – 11MACF-ILL. Peptides carbon atoms are coloured in 
magenta, and EB1’s in light grey. Oxygen is shown in red and nitrogen in blue. Hydrogen bonds are shown as yellow dashed lines and hydrophobic interactions regions are 
identified by a green dashed line. 
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The replacement of Thr5481 by a valine instead of a leucine – 11MACF-VLL, does 
not affect the accessibility of the backbone to establish hydrogen bond contacts with 
Val254. The reason seems to be the size of the side chain. Whereas leucine is a γ 
branched hydrophobic side chain, valine is a β branched hydrophobic side chain 
similarly to threonine. This difference does not affect the spatial rearrangement of the 
peptide side chains in such a way that the backbone of position 7 is not accessible to 
establish hydrogen bond contacts with the backbone of Val254. In the same manner 
the hydrogen bond with the OH of Tyr217 is retained. However, and as expected, extra 
hydrophobic contributions are achieved in comparison with the wild type peptide. The 
side chain of V7 seems to be long enough to establish hydrophobic contacts with the 
side chain of Phe218, as previously observed for the leucine. Similarly to 11MACF-
LLL the side chain of Val254 seems to make hydrophobic contacts with both side 
chains of L8 and K11. 
Finally, 11MACF-ILL shows the same pattern of hydrogen bonds observed for both 
wild type and 11MACF-VLL (Val254 and Tyr217). The most prominent hydrophobic 
contacts between this peptide and the C-terminus of EB1 are between L8 and Phe253 
and K4 and Ile255. 
Overall and based on both fitness scores and predicted binding poses it was decided to 
test two peptides – 11MACF-LLL and 11MACF-VLL. The biophysical assays results 
obtained will be subsequently described in the next section. 
 NMR screening of MACF mutated peptides against EB1cΔ8 
The NMR titrations of 11MACF-LLL and 11MACF-VLL show the chemical shifts 
changes of the NH resonances are in slow exchange regime and therefore the 
complexes formed are tightly bound - Figure 5.29 and Figure 5.30. 
When 12.5 µM of ligand is added to EB1cΔ8, the intensity of the peaks of the protein 
in the free form start to decrease in intensity. Between 50-75 µM of ligand a peak 
correspondent to the bound form appears in a distinct position, and the intensity 
increases with ligand addition reaching saturation between around 1:1 ligand:protein 
ratio (100 µM) - Figure 5.31. 
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Figure 5.29 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ8 (100 µM) recorded at 600 MHz 
- in the free form (black) and in the presence recorded of 11MACF-LLL (400 µM, red). The insets show 
regions of interest and the spectra corresponding to the following 11MACF-LLL concentrations, 12.5, 
25, 75, 82.5, 100, 200 and 400 µM. 
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Figure 5.30 - Overlay of 1H,15N-HSQC spectra of 15N-labelled EB1cΔ8 (100 µM) recorded at 800 MHz 
- in the free form (black) and in the presence recorded of 11MACF-VLL (400 µM, red). The insets show 
regions of interest and the spectra corresponding to the following 11MACF-VLL concentrations, 12.5, 
25, 75, 82.5, 100 and 200 µM. 
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Figure 5.31 – superimposition of the proton projection of Gly219 from 1H,15N-HSQC titration 
experiments performed for EB1cΔ8-11MACF-VLL. On the left hand side one can observe the decrease 
in intensity of the peak correspondent to the free form and sequential increase of intensity of the peak 
for the resonance of the complex (right hand side). 
 
Figure 5.32 – Evolution of the peak changes for Gly233 of EB1cΔ8 upon titration with 11MACF-VLL. 
The top square corresponds to the superimposition of all titration points, and below each titration point 
represented individually. The peaks are coloured in the following manner: free protein – black, followed 
by 12.5 (navy), 25 (blue), 50 (teal), 75 (olive), 82.5 (green), 100 (khaki), 125 (brown), 150 (orange) and 
finally 200 µM of ligand – red. 
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Interestingly, for some residues in the four bundle helix region such as Asn231 and 
Gly233, four resonances are observed in the intermediate titrations points (ligand 
concentration 12.5 – 82.5 µM) - Figure 5.32. Because EB1c is a homodimer and have 
two symmetric binding sites, it is possible that the extra two peaks observed before the 
complex reaches saturations belongs to the conformations of EB1cΔ8 with only one 
of the binding sites occupied by the ligand.  
Similarly to what was observed for 11MACF-wild type, the Val254 NH cross peak for 
both mutants, 11MACF-LLL and VLL, is the most affected upon ligand binding – Δδ 
= 2.9 ppm and Δδ = 3.4 ppm, respectively. Overall the chemical shift changes follow 
a similar pattern to the one obtained for the wild-type, with significant chemical shift 
changes in the C-terminus for Asp250 (Δδ = 1.8 and 1.7 ppm), Gly252 (Δδ = 1.7 and 
1.6 ppm) and Ile255 (Δδ = 0.7 and 1.3 ppm), around the binding site for the SxIP – 
Phe218 (Δδ = 0.4 and 0.5 ppm), Lys220 (Δδ = 0.5 ppm), Leu221 (Δδ = 0.3 ppm), 
Glu225 (Δδ = 0.6 ppm), Leu246 (Δδ = 0.3 ppm), Tyr247 (Δδ = 1.7 ppm), Ala248 (Δδ 
= 0.5 ppm), Thr249 (Δδ = 0.5 and 0.4 ppm), immediately below – Glu213 (Δδ = 0.5 
ppm) or immediately above – Cys228 (Δδ = 0.4 ppm). 
In terms of total distance observed for the chemical shift changes the general trend is 
11MACF-VLL promotes larger chemical shift changes. Good examples of this trend 
are Glu213, Arg214, Asp215, Phe216, Phe218, Arg222, Tyr247 and even more 
noticeable Val254 and other residues from the C-terminus such as Phe253 and Ile255. 
However, this is not true for all resonances, with Tyr217, Lys220 and Thr249 being 
examples were the chemical shift changes are larger for the wild-type peptide. 
The shape of the chemical shift changes also change from a complete linear evolution 
– Phe218, Ala248, to a curved shape – Phe216, Gly219 and Lys220 (Figure 5.33). 
Whereas a linear trend usually means that the binding mode between ligands is the 
same just different strength, the curvature indicates there are differences in binding 
mode between all three ligands. Val254 is an interesting case with the chemical shift 
change being very large for the wild-type and progressing in curved manner for the 
mutated peptides. This may mean this residue is affected in a different manner 
depending on the ligand, which is something to expect since the designed peptides are 
expected to interact with residue in different ways – 11MACF-LLL maximises the 
hydrophobic contacts and 11MACF-VLL should have the hydrophobic contacts 
enhanced similarly to the first mutant, but keep the hydrogen bonds present for the 
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wild-type. 
 
Figure 5.33 – Superimposition of 1H-15N-HSQC for free EB1cΔ8 (black) and final titration points for 
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11MACF-wt (red), 11MACF-LLL (green) and 11MACF-VLL (cyan). The dotted lines represent the 
trajectory of the chemical shift. 
 Isothermal titration calorimetry binding assays of MACF mutated 
peptides 
The NMR titrations indicate that both 11MACF-LLL and 11MACF-VLL bind tighter 
to EB1cΔ8 than the wild type 11MACF, indicating that the introduction of amino acid 
residues with hydrophobic side chains was beneficial to the binding. ITC can provide 
important information that can help to further understand the binding mechanism 
through determination of entropic and enthalpic contributions for the binding.  
 
Figure 5.34 - The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 15 µM EB1cΔ8 (cell) and 225 µM 11MACF-LLL (syringe) in 20 mM phosphate, 
pH 6.5, 50 mM NaCl, 0.5 µM TCEP, 0.02% NaN3 on an iTC200 Microcalorimeter (MicroCal) at 25oC. 
Fitting of the curve produced by the ITC experiment to a single set of sites curve-fitting model, using 
Origin7, resulted in a binding affinity (Kd) of 340 nM. 
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Figure 5.35 - The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 25 µM EB1cΔ8 (cell) and 250 µM 11MACF-VLL (syringe) in 20 mM phosphate, 
pH 6.5, 50 mM NaCl, 0.5 µM TCEP, 0.02% NaN3 on an iTC200 Microcalorimeter (MicroCal) at 25oC. 
Fitting of the curve produced by the ITC experiment to a single set of sites curve-fitting model, using 
Origin7, resulted in a binding affinity (Kd) of 163 nM. 
 
Table 5.14 - Thermodynamic parameters obtained for three ITC binding experiments to detect the 
interactions of 11-residue peptides with EB1cΔ8. Values shown in this table correspond to the average 
and associated error obtained for the three experiments. 
Interaction Kd (µM) ∆H (kcal mol-1) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
EB1cΔ8-11MACF-wt 3.80 ± 0.82 -10.57 ± 0.63 3.15 ± 0.64 -7.42 ± 0.12 
EB1cΔ8-11MACF-LLL 0.030 ± 0.004 -8.26 ± 0.13 -0.65 ± 0.16 -8.91 ± 0.13 
EB1cΔ8-11MACF-VLL 0.015 ± 0.001 -10.50 ± 0.21 1.19 ± 0.21 -9.30 ± 0.03 
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Figure 5.36 - The thermodynamic parameters (∆G (blue), ∆H (red) and -T∆S (green)) obtained from 
the binding interaction between the 11MACF-wt (left hand side), 11MACF-LLL (middle), 11MACF-
VLL (right hand side) and EB1cΔ8.  
The replacement of the TPQ sequence in the wild type peptide by a leucine patch (LLL) 
yielded a binding affinity increase of 10 fold (Kd changed from 3 to 0.3 µM) – Figure 
5.34, Table 5.14 with ΔG value changing from -7.42 to -8.91 kcal mol-1. Due to the 
very significant improvement in the Kd value, one perhaps could expect a greater 
affinity in the overall energy of the reaction (ΔG). However, the enthalpic 
contributions for the binding are now smaller than for the wild type, penalising ΔG. A 
possible explanation can be the unfavourable position of the backbone of position 7 of 
the peptide to establish hydrogen bonds with the backbone of Val254 of the C-terminus 
– Figure 5.28. Entropic contributions underwent a notable improvement and these can 
be associated with the greater affinity of this interaction when compared with the wild 
type ligand – Figure 5.36. Again, molecular docking can justify partially these results. 
Figure 5.28, shows that this the residue in position 7, leucine, can now establish 
hydrophobic interactions with Phe218. In addition, hydrophobic contributions from 
the two subsequent leucine residues with Val254 and Phe253 may justify the higher 
entropic contribution for the formation of this complex (section 5.5.1). 
For the second peptide, 11MACF-VLL, a similar trend is observed, the introduction 
of hydrophobic side chains have a beneficial contribution for the binding. The Kd is 
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now about half that the one observed for 11MACF-LLL, meaning it binds about two 
times tighter – Table 5.14.  ΔG is now -9.30 kcal mol-1 and the lowest for the three 
tested peptides.  The enthalpic contribution improved regarding the complex with 
11MACF-LLL and it is now very close to the wild type. In terms of entropic 
contributions, this complex shows an improvement compared with the wild type (1.19 
kcal mol-1 compared with 3.15 kcal mol-1) but not as good as 11MACF-LLL (-0.65 
kcal mol-1). The size of the side chains of threonine and valine is similar, with the 
advantage of the later can provide extra hydrophobic interactions. It is still possible 
the existence of hydrophobic interaction between the valine in position 7 and Phe218. 
However due to the shorter length of valine side chain, this may not be as strong as the 
one provided by the leucine side chain. Hydrophobic interactions with Val254 are still 
possible, although the interaction with Phe253 seems to have been lost. 
The enthalpy/entropy compensation is a common issue and invariably accompanies 
protein-ligand associations, improving binding enthalpy or entropy changes does not 
guarantee enhanced binding affinity because gains in one thermodynamic parameter 
may be offset by losses in the other.16> With 11MACF-VLL a good balance between 
both entropic and enthalpic terms was achieved.  
Usually establishing strong interactions between polar groups on the ligand and the 
protein is difficult in practice because the energetics of these interactions (hydrogen 
bonds) are strongly distance and angle dependent. Non-directional van der Waals 
contacts are less directional, but dispersion forces are less specific and weaker than 
polar interactions.16>  
The contribution of the solvent to the enthalpic contributions brings extra complication 
to the analysis of thermodynamic contributions in a protein-ligand reaction. Another 
difficulty in optimising bimolecular associations of a protein and ligands using 
thermodynamic information analysis is the loss in rotational and translational entropy 
upon binding may have effects on the entropic term of the binding event. Therefore 
analysis of the influence of thermodynamic parameters and their effects on the binding 
is not a straightforward relationship.16> 
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5.6 Elucidation of the binding contributions to EB1c and the role of the 
C-terminus 
The results described in this chapter demonstrate clearly the importance of the C-
terminus tail in EB1c binding. In this section, the contributions from different regions 
of the protein and ligands for the interaction will be analysed in order to understand 
fully how EB1 recruits SxIP proteins and how that knowledge can be used to design 
higher affinity ligands. 
The short consensus sequence, SKIP, is sufficient and the key consensus sequence to 
specifically interact with EB1c’s hydrophobic cavity. Unfortunately, the binding 
affinity is very weak (10 mM) and consequently not enough to achieve a biological 
response – binding affinities reported for MACF and APC derived peptides (~30 
residues) of 3.5 and 5.8 µM respectively.31,49 Increasing the ligand length by two 
residues, SKIPTP, improves the binding constant to about six fold without losing the 
specific binding. The two additional residues, proline and threonine, seem to engage 
with the lower region of the four helix bundle, just below the SxIP binding site, with 
NOEs to the aromatic patch 216FYF218, and contacts with the C-terminus – 253FVIP256. 
This was expected as the crystal structure reported by Honnappa and co-workers in 
200931 described hydrogen bond formation between Val254’s backbone and Thr5481, 
indicating this residue could have an important role in the interaction. Interaction 
between this peptide (SKIPTP) and EB1cΔ8 seem to have a fair contribution from the 
C-terminus as the ΔG increases from -3.8 kcal.mol-1 to -2.9 kcal.mol-1 (0.9 kcal.mol-1) 
upon removal of the C-terminal tail of EB1c. Regarding the 11 residue peptide, with 
addition of two amino acids in the N-terminus (KP) and three in the C-terminus (QRK), 
the ΔG contribution almost doubles the one observed for the six residue peptide. 
Removal of the binding contributions of the C-terminus have now a larger effect in the 
ΔG, accounted as 1.42 kcal.mol-1, instead of 0.9 kcal.mol-1. In summary, the 
contributions of the peptide residues for the binding to EB1cΔ8 can be observed in 
Figure 5.37, where the SKIP sequence has a contribution of -2.73 kcal.mol-1, the TP 
give an extra contribution of -1.05 kcal.mol-1 (where -0.2 kcal.mol-1 come from 
interactions with the C-terminus of EB1cΔ8). Finally, the full 11 residue native 
sequence adds an extra -3.64 kcal.mol-1 where more than half, 2.22 kcal.mol-1 comes 
from interactions with the C-terminus. 
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Figure 5.37 – schematic representation of the contributions expressed in ΔG for the binding of a native 
sequence peptide derived from MACF2 to EB1cΔ8. Peptide corresponds to the green box and the 
protein is represented in grey, the C-terminal tail contributions are shown on top of the schematic 
representation of the C-terminus, and contributions independent of this region of EB1c are shown 
immediately on the right hand side of the peptide. Finally, in the box on the right hand side there is a 
representation of the total contributions per peptide length.  
Concerning the peptides designed to improve the contributions with the C-terminus of 
EB1c and therefore have higher affinities to EB1c, only one of the mutants, 11MACF-
LLL, was tested in the absence of the C-terminus (EB1cΔ16). The difference in ΔG is 
even larger than the one observed for the native sequence, 2.31 kcal.mol-1 compared 
with the previous 1.42 kcal.mol-1 - . This was expected as this peptide was designed to 
improve the hydrophobic interactions with the C-terminus and removing this region of 
the protein has a more pronounced effect in the binding when compared with other 
ligands. The last mutant to be tested, 11MACF-VLL, is the best ligand tested in the 
course of this project with a Kd of 150 nM and a ΔG of -9.3 kcal.mol-1, indicating that 
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hydrophobic side chains immediately after the SxIP motif seem to be beneficial to the 
binding to EB1c. 
 
Figure 5.38 – summary of Kd and ΔG values obtained using ITC and NMR methods for the tested 
peptides (wild-type and mutated) against EB1c with and without the C-terminus tail, EB1cΔ8, (black) 
and EB1cΔ16 (red), respectively. Top panel shows Kd values per peptide. NMR data is presented as a 
diagonal cross and ITC as a vertical cross. Bottom panel shows ΔG values for each peptide.  
The experiments conducted using different length peptides containing the SxIP motif 
and described in this chapter show that while the SxIP motif is sufficient to target EB1c, 
extra interactions, specifically with the flexible C-terminus are necessary to achieve 
higher affinity. This was further demonstrated by the higher affinity observed in 
peptides designed for enhanced interaction with the C-terminus – 11MACF-LLL and 
11MACF-VLL. With such optimised ligands it is possible to build another 
pharmacophore model and use it to find better small molecule ligands to interact with 
EB1cΔ8. For that, a three-dimensional structure model (X-ray or NMR) would ideally 
provide the information necessary for another iteration in small molecule identification. 
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Unfortunately, structural biology approaches to elucidate the three-dimensional 
structure of proteins are complicated processes and take long time. Therefore, this will 
be left outside the scope of this project and be considered for future work. 
Next Chapter will cover a final discussion/conclusion on what was learned during the 
development of this project and what can be done in the future not only to target the 
EB1-SxIP interaction but also for protein-protein interactions in general. 
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CONCLUSIONS AND 
FUTURE WORK 
 
For many years now the importance of the interactome—the complex network of 
protein-protein interactions—has been recognised as of great value for both biological 
systems and the development of disease states. Despite this, small-molecule drugs that 
act by directly disrupting or promoting the interaction between two proteins are 
relatively rare in comparison to other drug classes, and protein–protein interactions 
(PPIs) are viewed as challenging—in some cases essentially ‘undruggable’—targets.17> 
Nevertheless, the last decade has seen amazing progress in tackling PPI targets with 
synthetic molecules. More than 40 PPIs have now been targeted and several inhibitors 
have reached clinical trials.87  
The main aim of this project was to identify a chemical scaffold based on the SxIP 
motif that can target the EBH domain of EB1. For this purpose an initial virtual 
screening methodology was delineated based on the SxIP scaffold. The method 
developed used a multidisciplinary approach, with an initial pharmacophore model 
used for screening of a large virtual database, followed by molecular docking of the 
selected compounds and a final balanced ranking where docking scores and desirable 
molecular properties were taken into account. The approach proved to be successful 
as two molecules were found to bind specifically to the SxIP binding site. An 
advantage of this method is the fact that is highly targeted when compared with other 
methodologies such as high-throughput screening (HTS), meaning it is possible to 
obtain hit molecules in an inexpensive way, without needing large physical libraries 
of compounds, protein and developing a HTS assay.  
Experimental data on the binding mode of the compounds to the protein by X-ray or 
NMR methods is often important and of great use to understand the mode of binding 
and is crucial for ligand optimisation.17> Having two active hits with the same active 
scaffold prompted the structural elucidation of EB1cΔ8 in the free form and in 
complex with one of these molecules. The data shows that contrary to what was 
initially assumed based on the X-ray structure of EB1cΔ8 bound to 11MACFp131, the 
binding pocket for the IP motif is dynamic in solution and may be completely absent. 
However, the IP mimetic scaffold identified in a previous chapter (Chapter 2) seems 
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to stabilise the two dynamic side chains, Arg222 and Tyr247 that affect the binding 
pocket size and conformation, open vs closed.  
Despite the stabilisation of the binding pocket the compounds identified in Chapter 2 
do not have high affinity for EB1cΔ8 with values of  6-10 mM, having slightly higher 
affinity than the microtubule tip localization signal31 (SxIP), 14 mM. However, the 
same is not true regarding longer peptides containing the SxIP motif (~11-30 residues) 
with binding affinities in the low µM range. It is postulated, based on the structural 
information and the flexibility of the C-terminus tail of EB1cΔ8 that the key to achieve 
a stronger interaction may be to target an extended region beyond the IP binding site. 
Therefore, in Chapter 4, efforts were made in order to design a ligand that can interact 
beyond the IP motif binding site. As an initial approach, a hybrid molecule, composed 
by a small molecule scaffold followed by a peptide moiety was designed. The chemical 
scaffold was based on the previously identified IP mimetic and consequently known 
to be highly specific for EB1’s hydrophobic cavity. The peptide scaffold was based on 
a native ligand’s sequence, MACF2, and was composed by the three residues 
following the SxIP motif – threonine, proline and glutamine. The approach did not 
yield the expected results, and the specificity for EB1’s binding site was lost. A 
possible cause for this problem is the fact that the IP mimetic scaffold utilised was 
different from the one initially identified. It included a six-membered ring instead of a 
five-membered ring and a racemic mixture instead of the previously identified 
enantiomer. The reason to use a different scaffold from the one previously identified 
was due to the use of a commercially available scaffold to facilitate and speed up the 
hybrid molecule synthesis. Despite molecular docking studies demonstrated that the 
six membered ring would still fit in the binding pocket, it is believed that the loss of 
specificity to EB1c’s binding site was caused due to the larger size of the ring. Another 
possibility, is that the use of a proline in the peptide sequence attached to the small 
molecule scaffold could cause the displacement of any other group of the pocket, since 
the proline residue of the SxIP motif is the only absolutely conserved residue, and 
replacement of this residue will result in loss of affinity of the SxIP protein to EB1.17> 
Because the proline residue is flanked by two residues with polar side chains – 
threonine and glutamine, it is very unlikely any of these will go in the hydrophobic 
binding site of EB1c and therefore reducing the affinity and specificity for it. Finally, 
the fact that the tetrazole ring is in an axial position to the cyclopentyl group in the 
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original scaffold, but when using a cyclohexyl ring a bulky substituent will be 
positioned in equatorial position due to steric hindrance. This seems to be the main 
reason why the cyclohexyl group is not suitable to replace the cyclopentyl ring. The 
hybrid molecule approach is an interesting approach where a molecule incorporates a 
molecular scaffold composed by a fragment previously identified coupled with a 
peptide derived from a native ligand. Although the approach failed for the reasons 
outlined above, it would still be of great interest to synthesise another hybrid molecule 
using the exact fragment identified as the IP mimetic.  
Within the same chapter, the process to identify alternatives to the hybrid molecule 
was described. The methodology followed resembles the one used in Chapter 2, 
pharmacophore search, docking and multi-parameter analysis, with the main 
differences being the initial pharmacophore model was built based on the hybrid 
molecule and the use of rule of four53 instead of rule of five83 (please see description 
in Chapter 1, section 1.2.1.3) as guidelines for desirable molecular properties. Two 
additional ligands were identified using this method, but they posed limitations in 
terms of biophysical methods screening as these are larger molecules with poor 
aqueous solubility. Lipophilicity is well known to be the contrast of  aqueous solubility 
and lack of solubility has been a consistent problem for medicinal chemists, when it 
comes to bioavailability.85 Another reason to avoid large and lipophilic compounds 
has been demonstrated by Leeson and Springthorpe and postulates that compounds 
with logP higher than four have increased probability of being promiscuous.17 
Chapter 5 described in detail the interaction of short length peptide based on a native 
sequence of a SxIP protein. Contributions to the binding were calculated and detailed 
in the form of ΔG and Kd values. The SKIP corresponding to the SxIP motif 
contributes for ~37% of the binding. The extension of this short peptide by two 
residues, SKIPTP, yields a higher affinity interaction, part given by some extra 
interactions with the EB1cΔ8 C-terminus. The contribution of these two residues is 
approximately 14%. An eleven residue peptide encompassing the SxIP motif, 
KPSKIPTPQRK, improves largely the binding affinity from mM range to low µM 
range. These extra residues KP------QRK account for the remaining 49% of the 
interaction. Removing of the C-terminus has a large effect in the interaction of this 
peptide with EB1c, 19% of the affinity is lost. Based on the important role of the C-
terminus a series of three peptides was designed based on the native sequence with 
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replacements in three amino acids immediately after the SKIP sequence. The 
mutations involved the replacement of these three amino acids – threonine-proline-
glutamine – by hydrophobic amino acids, including leucine, valine and isoleucine. The 
rational was to increase the hydrophobic interactions and hence the number of contacts 
with the C-terminus improving the binding. After docking studies, two of these 
peptides were selected for testing, respectively KPSKIPLLLRK and KPSKIPVLLRK. 
Both showed an improved binding affinity with Kd values of 300 nM and 150 nM 
respectively. The main difference between these two peptide seems to be that the first 
leucine after the SKIP sequence seems to have a too bulky side chain, forcing the 
peptide to adopt a conformation where the backbone of this residue is not accessible 
to establish hydrogen bond contacts with the backbone of Val254 of the C-terminus, 
as the wild-type threonine does. The replacement of the leucine to a β-branched side 
chain residue such as valine seemed to yield the expected results as the enthalpic 
contributions were improved suggesting the gain of an extra hydrogen bond 
contribution. Additionally, and to prove the higher affinity of these peptides was 
achieved by enhancing the contributions with the C-terminus, the first mutant 
KPSKIPLLLRK was tested against the construct of EB1c lacking the 16 terminal 
residues – C-terminal tail, EB1cΔ16. Whereas for the wild type the difference in the 
binding with and without the C-terminus was from -7.42 kcal.mol-1 to 6 kcal.mol-1, the 
difference is now even larger, from -8.91 kcal.mol-1 to 6.6 kcal.mol-1 (26% instead of 
19%), indicating the C-terminus does indeed contribute for the higher affinity 
interaction observed for this mutant. 
Alternatively to this method, solution NMR was the method of choice for screening of 
all ligands in this project. Additionally, when possible, ITC measurements were also 
performed as they give complementary information that cannot be measured using 
NMR. NMR has become a valuable screening tool for the binding of ligands to protein 
targets, and has the key advantages of being able to detect and quantify interactions 
with high sensitivity without requiring prior knowledge of protein function. 
Furthermore, NMR can provide structural information on both the target and the ligand 
to aid subsequent optimization of weak-binding hits into high-affinity leads.17 
Important lessons were learned during the course of this project. A single high 
resolution structure of a protein may not provide all information needed for structure 
based design, and therefore an ensemble of structures should ideally be used. This is 
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especially true in proteins with dynamic regions. The detailed understanding of the 
native interaction in the beginning of the project would very likely yield higher affinity 
ligands that the ones identified, proving that the acquisition of structural biology data 
is fundamental for any protein-protein interaction targeting project and should not be 
dissociated from the drug discovery efforts, but used in an iterative way. This was a 
mostly iterative project where information obtained from a set of experiments was 
invariably included in the virtual screening methods. The structural information 
obtained from EB1c in its free and two different bound forms was fundamental for the 
understanding how this protein interacts with SxIP proteins. 
In terms of future work that can and should be done, in vivo biological assays of the 
11 residue peptides, wild-type and the two mutants would be certainly the next step. If 
the two mutants, with higher binding affinity measured using biophysical techniques 
can prove their value in vivo, disrupting the binding of SxIP protein to EB1 and 
therefore MT polymerisation, they would give an extremely valuable contribution in 
understanding the complex protein-protein interaction at the MT plus-ends. Structure 
elucidation of one or two of the complexes formed between EB1cΔ8 and the two 
mutants would also contribute for a better understanding of how EB1cΔ8 interacts 
with higher affinity ligands. These two peptides have higher affinities to EB1c than 
any of the natural ligands reported so far. Therefore, upon structural elucidation by 
solution NMR or X-ray crystallography, a high affinity pharmacophore model could 
be built and used for the design and identification of higher affinity small molecule 
modulators for the EB1-SxIP proteins interaction. 
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MATERIALS AND 
METHODS  
7.1 Molecular Modelling 
The crystal structure of a complex formed between the C-terminal of EB1 lacking the 
last eight C-terminal residues (EB1cΔ8) and a 30 residue peptide derived from the C-
terminal of human MACF2 (MACFp1)31, with code 3GJO, was downloaded from the 
RSCB Protein Data Bank (PDB)102. 
 Pharmacophore search 
Load the ligand and protein, if required, into ZincPharmer 
(http://zincpharmer.csb.pitt.edu)55, using Load Features option. Selected options 
included definition of Max RMSD value, molecular weight and number of rotatable 
bonds. The used parameters are defined in results section for each performed search. 
 EB1 Docking Protocol 
The crystal structure of the complex (3GJO) is composed of two homodimers, each 
one with two binding sites and two ligands. For the molecular docking studies just one 
of the homodimers was used. Additionally, crystal structures of free EB1 (PDB codes 
1WU9 and 1YIG) and the ensemble of solution NMR structures obtained during the 
duration of this project were used for the ensemble docking study described in Chapter 
3. 
• Protein-ligand molecular docking at the EB1 binding site performed using 
GOLD 5.0.1102,111–117  
• Wizard utilised to setup and performing docking calculations.  
• Load appropriate file of EB1 protein (pdb format). 
• Hydrogen atoms added to the protein using the protonation rules file provided 
with GOLD  
• When specified HOH19 water molecule was extracted for inclusion in docking 
calculation. All other crystallographic water molecules removed. 
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• Hydrophobic and hydrogen bonds constraints were used or not depending on 
the docking protocol. 
• MACFp1 ligand loaded and used to define the binding site, together with all 
atoms around the ligand within 6 Å.  
• Ligand file(s) loaded containing the compound(s) to be docked (sdf format). 
As standard, for each ligand 10 GA runs are performed.  
• Select the required fitness scoring function i.e. Goldscore. If rescoring is 
required then select an additional scoring method e.g. Chemscore. 
• Option for early termination turned off.  
• Search efficiency set to 200%. When screening a large number of compounds 
(e.g. PPI-NET library) the virtual screening option was used to speed the 
calculations. This option sets search efficiency to 30%. 
• All parameters left as standard, unless otherwise stated.  
• Submit calculation and review results 
 Methods used for screening and selection of target molecules 
7.1.3.1 Calculation of Molecular properties 
Using Pipeline Pilot Professional Client 8.516> a range of molecular properties were 
calculated using the following components ALogP, logD, Solubility, Surface Area and 
Volume, Molecular weight, Num H Acceptor Donors and Molecular Property Counts.  
Both input and output files utilised sdf format. 
 
Figure 7.1 – Protocol created in Pipeline Pilot to calculate diverse molecular properties. 
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7.1.3.2 Ligand Efficiency, calculation and ranking 
Using KNIME 2.6.3 and the Math Formula node with the formula “score”/number of 
atoms, ligand efficiency was calculated for each scoring function. The results were 
ranked in an ascendant order and a new column with a ligand efficiency ranking was 
added to the SD file. 
 
Figure 7.2 – Protocol created using Knime to calculate ligand efficiency for the score results obtained 
for each scoring function present in GOLD. 
7.1.3.3 Calculation of docking descriptors  
For the calculation of docking descriptors GoldMine was used. GoldMine is a tool 
embedded in GOLD for the analysis of large quantities of docking information. For 
that purpose a GoldMine Database was created and the docking results loaded. The 
following docking descriptors were calculated - Simple Descriptors, General contact 
descriptors, H-bond descriptors and Ligand surface area descriptors. Results were 
exported in sdf format. 
7.1.3.4 Multi-objective analysis  
Knime 2.6.3 was used for multi-objective analysis, by using the node Pareto Ranking 
to rank the different parameters required for the analysis. 
 
Figure 7.3 – Example of a multi-objective analysis protocol created using Knime and the use of Pareto 
Ranking node. 
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7.1.3.5 RMSD calculation 
Align molecules using substructure component from Pipeline Pilot was used for 
RMSD calculation between different docking poses. 
7.1.3.6 Application of SmartsFilter 
Upload a sdf format file into 
http://pasilla.health.unm.edu/tomcat/biocomp/smartsfilter and select the following 
options – Blake, Glaxo16>, ALARM NMR164 and PAINS166, include pass/fails in the 
output. Output as sdf format.  
 QSAR experimental procedures 
The following procedure was used to develop a QSAR model using Random Forest 
(RF) or Support Vector Machine (SVM). 
• A dataset of 18 molecules tested was re-docked using GOLD102,111–117 
• Different types of descriptors were calculated for this set of molecules 
o Molecular Fingerprints – FCFP_2, FCFP_4, FCFP_6, ECFP_2, 
ECFP_4, ECFP_6, Estate Keys and MDLPublicKeys were calculated 
using Pipeline Pilot’s16> components.  
o Physicochemical descriptors as ALogP, Solubility, Surface Area and 
Volume, Molecular weight, Num H Acceptor Donors and Molecular 
Property Counts were calculated in Pipeline Pilot as described 
previously in the Calculation of Molecular properties section. 
o Derived from docking: these can be divided in two sub-groups: based 
on the solution files given by GOLD and other descriptors calculated 
using GoldMine as described previously in the Calculation of docking 
descriptors section. These are shown in Appendix (A.4). 
o A set of other descriptors were calculated using Dragon 6 – in total 
3763 2D descriptors from which 330 were used and 4885 3D 
descriptors from which 327 were used.  
• Calculated descriptors on the set of known active/inactive ligands were used as 
the training dataset for a machine learning method by using the Pipeline Pilot 
Materials and methods 
 
201 
 
components Learn R SVM Model and Learn R Forest Model for Support Vector 
Machine and Random Forest models respectively. ROC scores were also 
calculated for cross-validation of the models for each set of descriptors.  
• A sdf format file containing the docking results for the set of compounds to be 
analysed by these models was uploaded into Pipeline Pilot, filtered using 
Model Applicability Filter, and then screened through each model created 
previously. 
7.2 Recombinant EB1 - cloning, expression and purification 
 Materials 
7.2.1.1 Water  
The methods described in this chapter required at least de-ionised, distilled quality 
water; this was provided by the Institute of Integrative Biology, University of 
Liverpool and is termed as RO water in this chapter. For the molecular biology 
methods detailed in this chapter, ultra-pure quality water was required and this was 
obtained by use of a Synergy Water Purification System (Millipore) fitted with a 
SynergyPak® cartridge and a MilliPak-20 Express system; this water is termed as 
MilliQ in the methods discussed subsequently.  
7.2.1.2 General Solvents  
Ethanol: Fisher Scientific  
Methanol: Fisher Scientific 
Isopropanol: Fisher Scientific 
Dimethylformamide: Sigma  
7.2.1.3 General Reagents  
Unless otherwise stated, all reagents used in the methods detailed in this were of 
laboratory grade and supplied by Sigma-Aldrich.  
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7.2.1.4 Cell lines 
Rosetta(DE3)pLacI, BL21 star (DE3) BL21 (DE3) pLysS, Stellar 
7.2.1.5 Antibiotic solutions 
Table 7.1 - antibiotic solution composition and concentrations used in this project. 
Antibiotic Stock solution Solvent Storage temperature Working concentration 
Kanamycin 32 mg/mL RO water -20 oC 32 µg/mL 
Chloramphenicol 34 mg/mL ethanol -20 oC 34 µg/mL 
Ampicillin 50 mg/mL RO water -20 oC 50 µg/mL 
7.2.1.6 Proteases  
The Small ubiquitin-like modifier (SUMO) protease was used to cleave the 
hexahistidine Ni2+ affinity tag in the pOPINS (OPPF-UK) vector. 
7.2.1.7 Media recipes/composition  
The recipes for the different growth media utilised in the methods in this chapter are:  
LB Agar  
• 37 g of LB agar “Miller” (Merck) per 1 L of RO water  
Super Optimal Broth with Catabolite Repression (SOC) medium  
• Tryptone (20 g, Fluka)  
• Yeast extract (5 g, Fluka)  
• NaCl (10 mM, Fisher Scientific)  
• KCl (250 mM, ProLabo) , autoclave and then add the following, after filtered 
sterilised, 
• MgSO4 (10 mM, BDH)  
• Glucose (20 mM, BDH)  
Lysogeny Broth (LB) medium 
• Tryptone 
• Yeast extract  
• NaCl  
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2YT medium 
• 16 g Tryptone 
• 10 g Yeast extract 
• 5 g NaCl 
Minimal medium - Solution A 
• 14.6 g Na2HPO4 
• 5.4 g of KHPO4 
• 1 g of 15NH4Cl2, then autoclave and solution B is added after filtered sterilised 
Minimal medium - Solution B 
• 0.1 M MgSO4 
• 7.5 mM CaCl2 
• 0.75 mM MnCl2 
• 0.25 mM FeSO4 (prepared extemporaneously) 
• 4 g of Glucose/2 g of 13C Glucose 
7.2.1.8 Buffers and other solutions 
TAE buffer (50x) 
• Tris base (2 M, Fisher Scientifc)  
• Glacial acetic acid (5.71% (v/v))  
• EDTA (5 mM) at pH 8.0  
CCMB80 buffer, pH 6.4 
• 10 mM KOAc 
• 80 mM CaCl2 
• 20 mM MgCl2 
• 10% Glycerol 
• Filter sterilise and keep at ~4oC 
Materials and methods 
 
204 
 
Ni2+ Affinity Chromatography binding buffer (Low imidazole buffer) 
• 20 mM Na2HPO4, pH 7.4 
• 0.5 M NaCl  
• 25 mM Imidazole 
Ni2+ Affinity Chromatography elution buffer (High Imidazole buffer)  
• 20 mM Na2HPO4, pH 7.4 
• 0.5 M NaCl  
• 0.5 M Imidazole 
Anion exchange - buffer A 
• 20 mM Tris, pH 8 
• 2 mM DTT 
Anion exchange - buffer B 
• 20 mM Tris, pH 8 
• 2 mM DTT 
• 150 mM NaCl 
SDS-PAGE gel - loading buffer  
• 50 mM Tris/HCl, pH 6.8 
• 10% glycerol (v/v) 
• 2% SDS (w/v) 
• 100 mM DTT 
• 0.1% bromophenol blue 
SDS-PAGE gel - running buffer (10x) 
• Glycine (1.92 M, Fisher Scientific) 
• Tris base (250 mM) 
• SDS (1% w/v) 
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Coomassie G250 Stain Solution  
• Coomassie blue G250 (0.1% (w/v))  
• methanol (45% (v/v))  
• RO water (45% (v/v))  
• acetic acid (10% (v/v))  
De-stain Solution  
• methanol (45% (v/v))  
• RO water (45% (v/v))  
• acetic acid (10% (v/v))  
7.2.1.9 Columns 
HisTrap HP, 5mL (GE Healthcare Life Sciences, 17-2548) 
HiTrap Q Sepharose FF (GE Healthcare Life Sciences, 17-5053) 
 Methods 
The methods presented in this section refer to the methods and techniques used to 
obtain recombinant EB1 to be used in this project. 
7.2.2.1 EB1's EBH Domain Construct Sequences 
The amino acid fragments of EB1 produced for the research described in this thesis 
are detailed in this sub-section and comprise the EBH domain (C-terminal domain), 
differing on the inclusion or not of the C-terminal flexible tail. The first construct, 
named as EB1cΔ8 for practical purposes, includes the sequence between Asp191 and 
Gly260, whereas the second construct, named as EB1cΔ16 comprises the sequence 
Asp191-Gly252 - Table 7.2 and Figure 7.4. 
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Table 7.2 – Parameters calculated using the ProtParam14> tool and the sequences presented in Figure 
7.4. 
 
 
 
 
 
Figure 7.4 – Sequences of the two constructs prepared for EB1c and used in this project. 
7.2.2.2 Molecular Biology 
All PCR fragments were integrated into the OPPF-UK vector suite; all vectors share 
the same enzyme restriction sites and were linearized using KpnI (NEB, #R31425) and 
HindIII (NEB, #R31045) restriction enzymes. EB1cΔ8 fragment cloned into pOPINS 
and pOPINF was provided by Dr Thomas Zacharchenko and EB1cΔ16 construct was 
cloned into pOPINS 
 EB1cΔ8 EB1cΔ16 
Number of amino acids 70 62 
Molecular weight (g.mol-1) 8043.0 7228.1 
Theoretical pI 4.11 4.21 
Extinction coefficient (ε) 2980 2980 
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7.2.2.2.1 Vectors used 
Table 7.3 - Details of the pOPIN vectors used in this project 
Vector Parent  
Vector 
Antibiotic  
resistance 
Forward Primer Extension Reverse Primer Extension 
pOPINF pTriEx2 Ampicillin AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINS pET28a Kanamycin GCGAACAGATCGGTGGT ATGGTCTAGAAAGCTTTA 
7.2.2.2.2 Primer Design 
Primer extensions (Table 7.4) were added in the 3’ direction to facilitate integration in 
the same open reading frame as the fusion tag. Primers were designed to enable 
synchronous primer annealing to the template DNA with minimal CG content to 
prevent secondary structure DNA formation. The primers were required to have 
melting temperatures within 5oC of each other. Additionally, primers were required to 
be non-complementary to prevent primer dimerization.  
Table 7.4 - Primers designed to amplify EB1cΔ16 
Name Sequence (5'3') 
Melting 
temperature 
(oC) 
GC 
content 
(%) 
EB1Δ16-
Fwd 
GCGAACAGATCGGTGGTGATGAAGCAGCTGAATTGATGCAGCA 72 51 
EB1Δ16-
Rev 
ATGGTCTAGAAAGCTTTAGCCTTCATCTGTGGCATAAAGAAT 65 38 
7.2.2.2.3 Polymerase Chain Reaction (PCR) 
A PCR reaction was performed for EB1 [191-252] by preparing a 30 µM solution of 
the primers in nuclease free water and making a “master mix” on ice according with 
the following table. 
Table 7.5 - “Master mix” components and respective volumes used for the PCR reactions performed in 
this project. 
Component Volume (µL) 
10x KOD Hot Start Buffer 5 
DNTP mix (2 mM) 5 
MgSO4 (25 mM) 3 
Primers (30  µM) 2 
DNA template 0.5 
KOD Hot Start (1 U/µL) 1 
Mili Q water 31.5 
Total 50 
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Using a thermal cycler use the following methodologies 
Table 7.6 – temperatures and durations for each step in the PCR reaction. 
Step Temperature Time 
1. Polymerase activation 98oC 2 minutes 
2. Denaturation 
3. Annealing 
4. Extension 
95oC  
47oC 
7 oC 
30 seconds 
30 seconds 
1 minute  
30 cycles for steps 2-4 
5. Final Extension 72oC 10 minutes 
Hold 4oC  
Hot start polymerases are bound by an antibody and inactive, the initiation of the PCR 
reaction required pre-incubation for 98oC for 2 minutes, then 95oC for 2 minutes, 47oC 
- annealing temperature (this varied usually 3oC below the lowest melting temperature 
of the annealing primer) and a final 72oC extension cycle. The cycle was then repeated 
29 times exponentially multiplying the desired DNA fragment. PCR products samples 
were visualised using 2% (w/v) agarose gel.  
The method used was based on the method suggested by NEB 
(https://www.neb.com/protocols/2012/10/04/pcr-using-hot-start-taq-dna-polymerase-
m0495). 
7.2.2.2.4 Plasmid preparation 
The vector pOPINS was transformed into StellarTM Competent Cells in a kanamycin-
selective agar plate. 
A single colony from the transformed plate was then used to inoculate 10 mL of 
kanamycin-selective LB and incubated at 37oC for 14-18 hours, with shaking at 180 
rpm. The 10 mL culture was then used to inoculate 500 mL of kanamycin-selective 
LB and incubated at 37oC for nine hours, with shaking at 180 rpm. 500 µL of 
chloramphenicol (34 mg/mL) were added and the cultures were left to incubate for 
more 16 hours. When low-copy-number plasmids containing the pMB1 or ColE1 
origin of replication are prepared, the yield can be improved by adding 
chloramphenicol to amplify the copy number. The culture was pelleted by 
centrifugation and the pellets frozen at -80oC.  
The plasmid was extracted and purified using the Plasmid Maxi Kit (QIAGEN, cat no 
12162) to yield 100 uL of the plasmid, at the concentrations of 390 ng/µL. 
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To linearize the vector HindIII-HF and KpnI-HF restriction enzymes were used 
according with the standard procedure described for these enzymes. The linearized 
fragment (~5576 kbp) was isolated from a 0.8% Agarose and purified using a gel 
extraction kit (QIAGEN, cat no 28704). 
7.2.2.2.5 Agarose Gel Electrophoresis 
For the preparation of the gels for agarose gel electrophoresis (0.8% – 2% (w/v)) 100 
mL of 1x TAE buffer and 0.8 g – 2 g of powdered agarose (Bioline) were mixed 
gradually and heated with periodic swirling to ensure the agarose dissolved. The 
solution was allowed to cool to < 35oC and the cast for the subsequent gel was created 
by sealing the ends of the agarose gel plate; 10 µL of ethidium bromide (final 
concentration = 0.1µg/mL) was then added to the solution. The mixture was poured 
into the cast, with a sample well comb inserted and allowed to set. Samples to be 
analysed were mixed in 5:1 ratio with 5x loading buffer and the full volume was 
pipetted into individual wells. 1 kb standard DNA marker (New England Biolabs) was 
loaded in a separate well and the gel was run at 60V-90V using a BioRad PowerPac 
3000 for ~40 minutes. The gel was then viewed under trans UV light. 
7.2.2.2.6 In-Fusion Cloning 
For fast and efficient cloning of the PCR products into pOPINS an In-fusion® HD 
Cloning Kit (Clontech, cat no 011614) was used. Since the PCR products were not 
purified a treatment with Cloning Enhancer was performed prior to the In-Fusion 
Cloning reaction. The only difference to the standard protocol was the volume of the 
reaction, where a total of 5 µL was used instead of 10 µL – Table 7.7 
Table 7.7 – components and respective volumes used for the In-fusion reactions 
Component Volume ( µL) 
5X In-Fusion HD Enzyme Premix 1 
Linearized vector 1 
Purified PCR fragment 1 
dH2O 2 
Total 5 
7.2.2.3 Protein expression 
7.2.2.3.1 Competent Cells 
50 µL of commercial glycerol stocks of the BL21 StarTM (DE3) and StellarTM E. coli 
competent cells, were used to inoculate 10 mL of LB medium containing kanamycin 
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(for BL21 StarTM (DE3) cells) no antibiotic (for StellarTM cells) and incubated at 37oC 
for 14-18 hours, with shaking at 180 rpm. 5 mL were used to inoculate 250 mL of LB 
medium that was subsequently incubated at 37oC with shaking at 180 rpm until reach 
an optical density at 600 nm (OD600) of ~0.4. The culture was then centrifuged at 5000 
rpm for 10 minutes at 4oC and the resultant pellet was gently resuspended in 80 mL of 
CCMB80 buffer. This was then incubated at 0oC for 30 minutes before being 
centrifuged at 5000 rpm for 10 minutes at 4oC and resuspended in 10 mL of CCMB80. 
The cells were placed on ice, aliquoted into 50 µL quantities in pre-chilled eppendorfs 
and stored at -80oC for up to three years. 
7.2.2.3.2 Transformation 
~0.4 µL of the desired plasmid was added to 50 µL of competent cells, mixed well and 
incubated at 0oC for 30 minutes. The cells were then incubated at 42oC for 30 seconds 
before being incubated at 0oC for 5 minutes. 450 µL of SOC medium was then added 
and then incubated at 37oC for 1 hour with shaking at 180 rpm. The culture was then 
centrifuged at 400 rpm for 20 seconds and most of the supernatant was removed, 
resuspending the pellet in about 50 µL of the remaining supernatant. The transformed 
cells were then pipetted onto an agar plate (with the necessary antibiotics added, X-
Gal or glucose when needed), and spread evenly using an aseptic technique. The plates 
were then left to incubate at 37oC for ~14-18 hours, without shaking. The agar plates 
can be stored at 4oC for up to two weeks. 
7.2.2.3.3 Expression in 2YT medium 
A single colony from an agar plate was used to inoculate 10 mL of LB medium (with 
the right antibiotics added) and incubate it for 14-18 hours at 37oC with shaking at 180 
rpm. Using the 10 mL of starting culture inoculate 1 L of 2YT medium (with the right 
antibiotics added) and incubate it at 37oC with shaking at 180 rpm until the OD600 
reaches 0.7-0.8. Cool down the cultures for 30 minutes at 18oC and add IPTG (final 
concentration 1 mM), leaving cultures at 18oC for 14-18 hours, with shaking at 180 
rpm. 
The cells were then pelleted by centrifugation, 8000 rpm for 10 minutes at 4oC, 
discarding the supernatant and resuspending in low imidazole buffer and stored at -
80oC until purification. 
7.2.2.3.4 Expression in Minimal Medium 
A single colony from an agar plate was used to inoculate 1 mL of kanamycin-selective 
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LB and incubated at 37oC with shaking at 180 rpm, for 7 hours. 150 µL of the resultant 
cells were added to 20 mL of kanamycin-selective M9 medium and incubated for 14-
18 hours at 37oC, with shaking at 180 rpm. This cell suspension was then added to the 
1 L of kanamycin-selective M9 medium and incubated at 37oC until the OD600 
measured between 0.8 – 1. Cool down the cultures for 30 minutes at 18oC and add 
IPTG (final concentration 0.5 mM), leaving cultures at 18oC for 14-18 hours, with 
shaking at 180 rpm. 
The cells were then pelleted by centrifugation, 8000 rpm for 10 minutes at 4oC, 
discarding the supernatant and resuspending in low imidazole buffer and stored at -
80oC until purification. 
7.2.2.4 Protein Purification 
7.2.2.4.1 Cell Lysis 
The cells were gently thawed at room-temperature (20-25oC), and cocktail VII 
protease inhibitors EDTA free (Calbiochem), bovine deoxyribonuclease (Sigma) and 
2-mercaptoethanol (final concentration 1 mM) were added. Cells were mechanically 
lysed using a Stansted ‘Pressure Cell’ Homogeniser (SFP Ltd), at 1000 PSI. Cells were 
then centrifuged at 18000 rpm for 30 minutes and the supernatant subsequently filtered 
using a 0.22 µM filter.  
7.2.2.4.2 Ni2+ Affinity Chromatography 
A 5 mL HisTrap column (GE Healthcare) was initially washed with MilliQ and then 
equilibrated with low and high imidazole buffers, at 4 mL/min on an ÄKTApurifier10 
FPLC system (GE Healthcare). The filtered cell supernatant was then loaded onto the 
column at a flow rate of 4 mL/min. The bound contents of the column were then eluted 
with a gradient of increasing imidazole concentrations at 4 mL/min and fractionated 
into 5 mL fractions. The fractions were analysed by UV absorbance at 280 nm (A280) 
and those fractions that showed absorption levels above the baseline were analysed 
using SDS polyacrylamide gel electrophoresis (SDS-PAGE). The fractions that 
yielded the desired gel retardation band were combined. 
7.2.2.4.3 SUMO tag cleavage 
The combined fractions yielded from Ni2+ Affinity Chromatography were buffer 
exchanged into low imidazole buffer using a HiPrepTM Desalting column. The column 
was initially washed with MilliQ water and equilibrated using low imidazole buffer. 
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15 mL of sample were loaded onto the column and the protein was recovered with the 
same buffer by observing the UV absorbance at 280 nm, yielding a sample with a 
dilution of 1.2-3 fold. SUMO protease and dithiothreitol (final concentrations of 0.025 
µg/mL and 1 mM, respectively) were added to the eluted sample and left at room 
temperature (20-25oC) for 4 hours. After that time the sample was placed at 4oC for 
14-18 hours. 
7.2.2.4.4 Reverse Purification 
The sample was loaded into a 5 mL HisTrap column (GE Healthcare) at a 4 mL/min 
flow rate and readily collected by observing the UV absorbance at 280 nm. The SUMO 
tag was then eluted by using an increasing concentration of imidazole. 
7.2.2.4.5 Ion exchange chromatography  
The sample was exchanged into 20 mM Tris pH 8, 2 mM dithiothreitol, using a HiPrep 
TM Desalting column and a procedure similar to the one described previously. The 
sample was then loaded into a 5 mL HiTrap Q (GE Healthcare) column at a flow rate 
of 4ml/min. The bound contents of the column were then eluted with a linear gradient 
of 20 mM Tris pH 8, 2 mM dithiothreitol, 1 M NaCl at 4 mL/min and fractionated into 
5 mL fractions. The fractions were analysed by UV absorbance at 280 nm (A280) and 
those fractions that showed absorption levels above the baseline were analysed using 
SDS polyacrylamide gel electrophoresis (SDS-PAGE). The fractions that yielded the 
desired gel retardation band were combined. 
7.2.2.4.6 Concentration of Protein Sample 
Concentration of the combined protein fractions from ion exchange chromatography 
was carried out using Amicon Ultra Centrifugal Filter units with a 3 kDa molecular 
weight cut-off and volume capacity of 15 mL (Millipore). The concentration unit 
membrane was washed by centrifugation (5000 g, swinging bucket rotor) with MilliQ 
and equilibrated with 20 mM Tris pH 8, 2 mM Dithiothreitol. The protein was then 
applied to the unit and centrifuged at 5000 g until the desired final volume of sample 
was achieved. The solution that passed through the membrane (flow through) was 
analysed by UV absorbance at 280 nm to ensure that there was no membrane failure 
and hence, that none of the protein of interest had passed through. After use, the 
concentration units were centrifuged at 5000 g with MilliQ, then 2% (w/v) NaN3 and 
left at 4oC in that solution. 
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7.2.2.4.7 Buffer Exchange of Protein Sample 
The concentrated fractions from the Ion exchange chromatography were then buffer 
exchanged into 20 mM phosphate pH 6.5, 50 mM NaCl, 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP), 0.02% (w/v) NaN3 using a Sephadex G-25 Medium 
Gravity-Flow PD-10 Column (GE Healthcare). The PD-10 column was initially 
washed with 25 mL of MilliQ and then 25 mL of 20 mM phosphate pH 6.5, 50 mM 
NaCl, 0.5 mM TCEP, 0.02% (w/v) NaN3 to equilibrate the column. A maximum of 
2.5 mL of the protein sample was applied to the column - for sample volumes less than 
2.5 mL, add equilibration buffer to adjust the volume up to 2.5 mL after the sample 
has entered the packed bed completely.  The flow through was discarded and the 
sample was eluted by addition of 3.5 mL of 20 mM phosphate pH 6.5, 50 mM NaCl, 
0.5 mM TCEP, 0.02% (w/v) NaN3. The final protein solution was flash frozen with 
liquid nitrogen and stored at -80oC. 
7.2.2.5 Protein concentration determination 
Protein concentration was determined by absorbance at 280 nm using a nano-drop 
3000 and calculated extinction coefficient of respective proteins determined by Prot-
Param14>. 
7.2.2.6 SUMO-Protease production   
Recombinant SUMO protease was produced by using a plasmid provided by Dr Paul 
Elliott in Rosetta pLacI in a ampicilin/chloramphenicol-selective agar plate. One 
single colony was used to inoculate 20 mL of LB medium and incubated at 37oC for 
14-18 hours. 1 L of 2YT medium (ampicilin/chloramphenicol-selective) was 
inoculated using the starting culture and incubated until the OD600 reached 0.6 and then 
induced using IPTG (final concentration of 500 µM) and incubated at 18oC for 14-18 
hours. Cells were pelleted by centrifugation and re-suspended in low imidazole buffer 
containing 10% glycerol, and later lysed as described previoulsy. After nickel affinity 
chromatography protein was exchanged into 50 mM Tris pH 8, 150 mM NaCl, 3 mM 
DTT, 5 mM EDTA, 20% glycerol and flash frozen and stored at -80oC. Activity of the 
protease was tested with and verified using SDS-PAGE. 
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7.3 Organic synthesis methods 
The materials and methods described in this section relate with the synthesis of 
molecules tested in this project – compounds 1b and 2a. 
All reactions were carried out in dry conditions under a nitrogen atmosphere unless 
otherwise stated.  
 Materials 
Elemental analysis was performed by the microanalysis service at the University of 
Liverpool. Mass spectra were collected using Micromass LCT Mass Spectrometer or 
Agilent QTOF 7200 by the mass spectrometry laboratory at the University of 
Liverpool. 1H-NMR spectra were recorded on a Bruker AMX 400 (400 MHz) 
spectrometer, as were 13C-NMR spectra in solutions of CDCl3 and MeOD. The 
chemical shifts are in parts per million (ppm), with tetramethylsilane as the internal 
reference and the coupling constants in hertz (Hz). TLC was performed on silica plates, 
and columns were run on silica gel specifically for flash chromatography. Reagents 
were purchased from SigmaAldrich and Merck. 
 Methods 
7.3.2.1 Compound 1b 
Compound 1b was obtained through a three-step synthesis, as described in Figure 7.5. 
Each reaction will be described in the next subsections. 
 
Figure 7.5 – general scheme for the synthesis of compound 1b. 
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7.3.2.1.1 Synthesis of 3 
Proline benzyl ester (1) (556 mg, 2.3 mmol), 4-methyl valeric acid (327 µL, 2.6 mmol, 
1.1 eq.) and HOBt (398 mg, 2.6 mmol, 1.1 eq.) were dissolved in ~30 mL of anhydrous 
DCM. After ten minutes EDCI (500 mg, 2.6 mmol, 1.1 eq.) were added, followed by 
DIEA ten minutes later (881 µL, 5.06 mmol, 2.20 eq.). The reaction was allowed to 
stir overnight. The DCM was removed and the residue was dissolved in EtOAc. The 
organic layer was washed three times with 1N HCl, three times with saturated NaHCO3 
and three times with brine. The organic layer was dried with Na2SO4, filtered through 
filter paper, and concentrated. The product was purified by column chromatography. 
Fractions were analysed by TLC, concentrated and characterized. 411 mg of product 
were obtained as a colourless oil (59% yield) 1H NMR (400 MHz, CD3OD)δ: 7.35 (br 
d, 5H), 5.14 (d, 2H, J=5.7 Hz), 4.47 (m, 1H), 3.63 (m, 2H) 2.36 (m, 2H), 1.96 (m, 4H), 
1.58 (m, 1H), 1.47 (m, 2H) 0.91 (dd, 6H, J=6.6, 0.98Hz) m/z (LCMS, CI): found 
304.19 (M+H)+, C18H25NO3 , requires 303.18. 
7.3.2.1.2 Synthesis of 4 
The ester 3 was dissolved in MeOH in a Parr bottle. The bottle was flushed with argon 
and 0.050 eq. of 10% Pd/C. The Parr bottle was placed on a Parr hydrogenation 
apparatus and subjected to three charge/purge cycles with H2. The reaction was then 
charged with 5-10 bar hydrogen and shaken. After four and a half hours no starting 
material was observed. The product was dried and 266 mg were obtained as white 
crystals (92% yield). 1H NMR (400 MHz, CD3OD)δ: 4.42 (m, 1H), 3.62 (m, 2H), 2.36 
(m, 2H), 2.24 (m, 2H), 2.02 (m, 2H), 1.61 (m, 2H), 1.52 (m, 2H), 0.93 (d, 6H, J=6.52 
Hz) CHN analysis: C 59.90%, H 8.58% and N 6.62%. C11H19NO3   m/z (LCMS, CI): 
found 214.14 (M+H)+, requires 213.14 
7.3.2.1.3 Synthesis of 6 
Compound 4 (266 mg) and 2-aminopiridine (5) (118 mg, 1.25 mmol, 1 eq.) were 
dissolved in ~7 mL of DCM. The solution was cooled to 0oC, and then DCC (516 mg, 
2.5 mmol, 2 eq.) was added. The solution was stirred at 0oC for two hours and at room 
temperature for another 16 hours. Then the solution was placed in the refrigerator (~ 
4oC) for two hours, and the white solid was filtered. After removal of solvent under 
reduced pressure, the residue was purified by column chromatography. 102 mg of a 
white solid were obtained (29% yield).  
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1H NMR (400 MHz, CDCl3)δ: 9.68 (br s, 1H), 8.29 (d, 1H, 4.0Hz), 8.15 (d, 1H, 8.3 
Hz), 7.66 (td, 1H, J=7.7, J=1.80 Hz), 7.00 (dt, 1H, J=5.3, J=1.80 Hz), 4.79 (dd, 1H, 
J=8.19, J=1.86 Hz), 3.63 (m, 1H), 3.50 (m, 1H), 2.50 (m, 1H), 2.36 (t, 2H, J=7.5Hz) 
2.06 (m, 4H), 1.60 (m, 2H), 0.91 (d, 6H, J=5.92 Hz) 
13C NMR (100 MHz, CDCl3)δ: 175.70, 171.31, 149.27, 139.58, 120.97, 115.45, 62.19, 
49.00, 34.80, 34.07, 29.26, 28.66, 26.47, 23.81, 23.73 
CHN analysis C 66.02%, H 8.01%, N 13.62%, C16H23N3O2 m/z (LCMS, CI): found 
290.18 (M+H)+, requires 289.18 
Total yield - 16% 
7.3.2.2 Compound 2a 
7.3.2.2.1 Synthesis of the tri-peptide 2c 
All glassware/solvents used for this procedure were thoroughly dried. The dry 2-
chlorotrityl resin (resin loading 1.51 mmol/g, 0.755mmol) was swelled in 2.5 mL of 
dry DCM for 15 min. Fmoc-Gln (7) (445 mg, 1.6 eq.) was dissolved in 2 mL of dry 
DCM with ~0. 5mL of DMF (for solubility) and added to the resin. DIPEA (842 µL, 
4 eq. to the amino acid) was added and stirred for two hours. The solvents were then 
filtered and 0.2 mL of MeOH were added to endcap any remaining trityl groups and 
stirred for 15 minutes. The resin was then washed twice with DMF, DCM and MeOH 
(three times). A sample was taken at this stage and checked using the Kaiser test. 
The deprotection of the Fmoc group was made by addition of 2 mL of 20% 
Piperidine/DMF (v/v), followed by a gentle stir for three minutes, removal of the 
solvent and then a second addition of 20% Piperidine/DMF (v/v), stirred for seven 
minutes. The solvent was removed by filtration again and 2 mL of DMF were added 
and left to stir for 30 seconds. This last step was carried out four times. A Kaiser test 
was performed again at this stage. 
The first coupling step was made by addition of Fmoc-Pro (10) (1.55g, 6 eq.) in 6 mL 
DMF with DIC (600 µL, 5 eq.) and HOBt (518 mg, 5eq.) and left overnight, with 
gentle agitation. Another deprotection step was performed, using the same method 
described before. 
Fmoc-Thr (13) (1.57 mg, 6 eq.) were added to 6mL of DMF with DIC (600 µL, 5 eq.) 
and HOBt (518 mg, 5 eq.), and left with agitation for three hours. Another removal of 
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Fmoc group was performed at this stage. 
 
 
Figure 7.6 – general scheme of the method employed for the synthesis of the tri-peptide TPQ, molecule 
2c (15), using solid phase peptide synthesis. 
. 
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7.3.2.2.2 Attachment of 2b 
 
Figure 7.7 – general scheme of the reactions performed to attach the molecule 2b (16) to molecule 2c 
(15), obtaining 2a (17). 
169 mg (0.168 mmol) of the tri-peptide (TPQ-resin) resulted from the previous 
coupling reaction were swelled in DCM for 15 minutes and 50 mg (0.195 mmol, 1.2 
eq.) of molecule 16, DIC (26 mg, 0.195 mmol, 1.2 eq.), HOBt (33 µL, 0.195 mmol, 
1.2 eq.) were added and left to stir overnight.  
Cleavage from the resin was performed by using TFE/acetic acid/DCM (1:1:8). The 
product was purified by preparative HPLC. m/z (LCMS, ESI): found 583.3 (M+H)+, 
requires 582.3 
1H NMR (800 MHz, H2O/2H2O)δ: 7.9 (br d, 1H), 7.6 (s, 1H), 7.2 (br s, 1H 3.5-3.3 (m, 
1H), 2.2-2 (m), 1.9-1.5 (m, 4H), 1.35 (dd, J=0.3 Hz, J=0.2Hz, 10H), 0.9 (dd, J=0.2 Hz, 
J=0.3 Hz, 3H), 0.83 (d, J=0.1 Hz, 3H) 
 
Total Yield – 18% 
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7.4 Protein-ligand interactions 
This section refers to the materials and methods involved in screening and binding 
characterisation of the interaction of different ligands and EB1. The ligands tested 
include peptides and small molecules. The stock solutions prepared for these ligands 
were used for both NMR and ITC. 
Synthetic peptides derived from the C-terminus of the MACF2 (GL Biochem and 
ChinaPeptides, China) were directly resuspended into the identical buffer as the 
protein  - 20 mM phosphate pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% (w/v) NaN3 
- and minimal pH adjustments were made if required. 
100-250 mM stock solutions of the potential EB1 binder were prepared by dissolving 
the appropriate mass of the organic compound in the necessary amount of 
hexadeuterodimethyl sulfoxide (DMSO-d6). 
 NMR Spectroscopy  
7.4.1.1 General  
Samples to be examined by NMR spectroscopy of volumes 600 µL were pipetted into 
Wilmad 5 mm 175 mm 800 MHz Precision Pyrex Glass NMR Tubes (Goss Scientific). 
Samples of limited volume were pipetted into Shigemi Advanced NMR Microtube 
Assembly – Matched with 2H2O, bottom L 8 mm tubes (Sigma-Aldrich).  
The NMR spectra were acquired at 25oC, unless otherwise stated, on either a Bruker 
AVANCE II+ 600 MHz Ultrashield or 800 MHz US2 spectrometer, equipped with 
triple resonance cryoprobes. The Bruker TopSpin programme version 3.1 was used to 
process the resultant NMR spectra and the Collaborative Computational Project for 
NMR Analysis (CcpNmr Analysis)17> software was used for interactive spectral 
analysis and assignment.  
7.4.1.2 Ligand Binding Screening by NMR Spectroscopy 
1D 1H179,18> and 2D 1H-15N HSQC179–181 NMR experiments were performed using 
0.05 mM or 0.1 mM of 15N-labelled EB1 in 20 mM phosphate pH 6.5, 50 mM NaCl, 
0.5 mM TCEP, 0.02% (w/v) NaN3. Two different methods were used, one for the first 
set of tested molecules and another for all the remaining compounds. 
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For the first set of molecules the required volume of each organic compound stock 
solution was added to the protein sample to achieve the desired ratios.  This method 
was also used for the longest peptide sequences tested – 11 residues (11MACF, 
11MACF-LLL and 11MACF-VLL). 
For all the remaining molecules, the method was altered in order to facilitate the 
comparison between experiments by keeping the volume of DMSO-d6 constant. This 
method consisted by preparing two samples with the same concentration of DMSO-
d6, one without ligand and the other with the maximum ligand concentration, and by 
mixing them in the right proportions obtain a range of titration points. The maximum 
DMSO-d6 concentration achieved was 4% (v/v).  For the shorter length peptides – 
4MACF and 6MACF a similar method was used however without any DMSO added. 
Because these are weaker binders when compared with 11MACF, the volume to be 
added to achieve the highest ratio would dilute the sample and therefore affect the 
results. 
The obtained spectra were then assigned by transfer of the previously determined 
unbound backbone assignments of EB1 and analysed to identify which residue(s) had 
been perturbed. The chemical shift perturbation value (∆δ ppm) for each residue was 
then calculated – Equation 8.194,18>, 
, Equation 8.1 
were where, αN= Scaling Factor of 0.15. 
7.4.1.3 Binding Affinity Determination by NMR Spectroscopy 
To determine the binding affinity (Kd) by NMR spectroscopy the same experiments 
used to screen the ligands were used – see previous section. 
The individual residue chemical shifts for each titration point were assigned and fitted 
using Equation 8.2183,18>, 
, Equation 8.2 
where,  
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 Isothermal Titration Calorimetry (ITC) 
All isothermal titration calorimetry experiments were carried out at 25oC on an iTC200 
Microcalorimeter (GE Healthcare) with a 200 µL cell capacity and 40 µL syringe 
volume. For all experiments protein, either EB1cΔ8 or EB1cΔ16 in 20 mM phosphate 
pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% (w/v) NaN3 were in the cell, and the 
ligand was in the syringe. The ITC titration data collected was analysed using the 
Origin®7 software. 
The lyophilised peptides were directly resuspended into the same buffer as the protein 
and minimal pH adjustments were made if required. 
Table 7.8 - Conditions for ITC experiments performed with EB1cΔ8 
ligand 
ligand 
concentration 
(µM) 
protein 
concentration 
(µM) 
injection 
volumes 
(µL) 
number of 
injections 
11MACF 750 50 1.5 25 
11MACF_LLL 225 15 1.5 25 
11MACF_VLL 250 25 1.5 25 
Table 7.9 - Conditions for ITC experiments performed with EB1cΔ16 
ligand 
ligand 
concentration 
(µM) 
protein 
concentration 
(µM) 
injection 
volumes 
(µL) 
number 
of 
injections 
11MACF 2250 150 1.5 25 
11MACF_LLL 2250 150 1.5 25 
 Octet® RED96 
The compounds screened by this method belong to a library of compounds – PPI-Net 
library, and each compound was at a concentration of 10 mM in DMSO. One hundred 
thirty-five compounds were screened at a final concentration of 0.5 mM – Figure 7.8. 
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   - 20 mM PO4, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3 + 0.01% TWEEN +5% DMSO 
   - Plate 20000604 + 20 mM PO4, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3 + 0.01% TWEEN 
   - Plate 20000605 + 20 mM PO4, 50 mM NaCl, 0.5 mM TCEP, 0.02% NaN3 + 0.01% TWEEN 
Figure 7.8 – schematic representation of the plate prepared for Octet® RED96 screening. 
 NMR based structure calculation 
For this section the materials and equipment are the same as described in section 
7.4.1.1. 
7.4.4.1 Resonance assignment for backbone and side-chain 
3D HNCO, HN(CA)CO, HNCA, HNCACB and CBCACONH experiments were used 
for the sequential assignment of the backbone NH, N, CO, Cα and Cβ resonances. Side 
chain assignments were obtained using 3D HBHA(CO)NH, H(C)CH-TOCSY and 
(H)CCH-TOCSY experiments. Aromatic side-chains were assigned using 2D-NOESY 
and 13C-resolved 3D NOESY-HSQC. The resonances of the ligands were assigned 
using 13C,15N-filtered 2D TOCSY and NOESY experiments. 
The HNCACB136,139,18> experiment correlates each NH group in the protein with its 
own 13Cα and 13Cβ chemical shifts and the respective 13Cα/β chemical shifts of the 
preceding residue (i-1 and i); the CBCACONH139,186 correlates a particular NH group 
in the protein with the 13Cα and 13Cβ chemical shifts of the preceding residue (i-1) 
(Figure 7.9). The correlation observed in this complementary set of spectra allowed 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
A A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A2 A3 A4 A5 A6 A7 A8
B
C B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B2 B3 B4 B5 B6 B7 B8
D
E C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C2 C3 C4 C5 C6 C7 C8
F
G D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D2 D3 D4 D5 D6 D7 D8
H
I E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E2 E3 E4 E5 E6 E7 E8
J
K F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F2 F3 F4 F5 F6 F7 F8
L
M G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G2 G3 G4 G5 G6 G7 G8
N
O H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H2 H3 H4 H5 H6 H7 H8
P
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the sequential linking of one NH group to the next (Figure 7.9, top panel).  The 
assignment of the 13C (carbonyl) was accomplished using a similar approach. 
HNCO138,140,187,188 shows the correlation between NH and the carbonyl for the 
preceding residue and HN(CA)CO141,188 correlates the NH with the respective residue 
and the preceding (i-1 and i) - Figure 7.10. By superimposing the two later spectra we 
can link the NH resonances of the residues. The HNCA138,140,189 shows for each NH 
strip the Cα for the respective residue and for the preceding one (i-1 and i) and it is 
useful to complement the assignment, this experiment was only used for backbone 
assignment of the EB1-11MACF complex.   
 
Figure 7.9 - Top panel – Schematic representation of the pair CBCA(CO)NH/HNCACB. 
CBCA(CO)NH spectrum is shown in black, with the Cα/Cβ peaks of the HNCACB spectrum are shown 
in green and red respectively. The bottom panel refers to the resonances that can be observed when 
using this pair of experiments and how are they linked to perform sequential assignment. 
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Figure 7.10 - Top panel – Schematic representation of the pair HN(CA)CO/HNCO used for CO 
assignment performed by sequential assignment; the HN(CA)CO spectrum is shown in red, with the 
CO peak of the preceding residue being less intense and overlapped with the HNCO spectrum showed 
in black. The bottom panel refers to the resonances that can be observed using this pair of experiments 
and how are they linked to perform sequential assignment. 
7.4.4.2 Structure calculation of free EB1cΔ8 
A 1 mM of uniformly isotopically labelled 13C, 15N-EB1 was prepared in 20 mM 
phosphate pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% (w/v) NaN3. A large number 
of experiments were acquired using this sample and are detailed in Table 7.10. Because 
EB1 is a symmetric homodimer the intermonomer contacts of the coiled coil/leucine 
zipper are fundamental for structure elucidation and characterisation. Therefore, a 
sample of 13C, 15N-EB1 and unlabelled EB1 at equimolar concentrations was prepared 
and incubated for 16 hours at 37oC.42 The spectra acquired to characterise the 
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intermonomer contacts are detailed in Table 7.11. 
Table 7.10 – Spectra acquired in a double labelled sample (15N, 13C) for EB1cΔ8 resonance assignment 
NMR experiment No. of Scans 
Mixing 
time 
(ms) 
No. of points 
digitized FID resolution (Hz) Spectrometer 
frequency 
F1 F2 F3 F1 F2 F3 
1D 1H178,17 64 - 8192 - - 2.06 - - 600 MHz 
1D 1H –  
Excitation Sculpting 18 
16 - 32768 - - 0.59 - - 600 MHz 
1H-15N-HSQC 179–18> 4 - 512 1400 - 19.00 9.43 - 600 MHz 
1H-13C-HSQC 
(aliphatic) 19> 
4 - 180 1200 - 105.63 11.00 - 600 MHz 
1H-13C-HSQC-
constant time 
(aliphatic) 19> 
4 - 458 1200 - 41.52 11.00 - 600 MHz 
1H-13C-HSQC 
(aromatic) 
8 - 64 1024 - 94.33 11.74 - 600 MHz 
1H-13C-TROSY 
(aromatic)19> 
8 - 88 1024 - 68.60 11.74 - 600 MHz 
3D-HNCO (nus) 
140,187,18> 
2 - 128 76 1200 23.58 43.21 10.02 600 MHz 
3D-HNCACO 141,18> 2 - 128 76 1200 10.00 27.00 10.02 600 MHz 
3D-CBCACONH 
136,139,18> 
2 - 114 80 1200 57.00 27.00 10.02 600 MHz 
3D-HNCACB (nus) 
137,139,18> 
4 - 1280 80 1200 143.36 41.05 10.02 600 MHz 
3D-HBHACONH 
139,18> 
8 - 200 76 1100 33.01 41.61 13.11 600 MHz 
H(C)CH-TOCSY 193–
19> 
4 - 300 128 1024 23.21 146.19 10.57 600 MHz 
(H)CCH-TOCSY 4 - 128 128 1024 146.19 146.19 10.57 600 MHz 
15N-resolved-13C-
decoupled-NOESY-
HSQC 196,19> 
2 100 512 160 1400 31.26 26.36 11.45 800 MHz 
13C-resolved-NOESY-
HSQC 196,19> 
2 200 512 180 1400 31.26 138.64 11.45 800 MHz 
13C-resolved-NOESY-
HSQC (aromatic) 
8 100 450 52 1200 35.57 154.82 13.36 800 MHz 
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Table 7.11 - Spectra acquired in an unlabelled/labelled sample for intermonomer resonance assignment. 
NMR experiment 
No. 
of 
Scans 
Mixing 
time 
(ms) 
No. of points 
digitized 
FID resolution (Hz) Spectrometer 
frequency 
F1 F2 F3 F1 F2 F3 
15N,13C-filtered-13C-
decoupled-2D-NOESY 
80 200 512 2048 - 31.26 7.83 - 800 MHz 
15N,13C-filtered-2D-NOESY 48 200 400 2048 - 40.01 7.83 - 800 MHz 
2D-NOESY* 72 200 512 2048 - 31.26 7.83 - 800 MHz 
15N,13C-filtered-13C-resolved-
NOESY-HSQC 
8 200 440 68 1400 32.74 165.73 11.45 800 MHz 
15N,13C-filtered-13C-resolved-
NOESY-HSQC* 
8 200 440 64 1400 32.74 176.09 11.45 800 MHz 
15N,13C-filtered-13C-resolved-
NOESY-HSQC (aromatic) 
8 200 400 48 1024 40.02 142.56 12.52 800 MHz 
*spectra acquired in 100% 2H2O (all other experiments acquired with 5-10% 2H2O) 
The majority of restraints for NMR structure calculations are provided by NOESY 
derived distance restraints. However, the NOE assignment is tedious due to the large 
number of assignment possibilities, peak overlap and potential artefacts in the spectra.  
Manual assignment is time consuming and may not provide an accurate structure due 
to human error. In order to hasten the process and reduce the risk of errors, NOE 
assignment was carried out using the program ARIA 2.3.1 (Ambiguous Restraints for 
Iterative Assignment)96. ARIA uses an iterative protocol and the concept of ambiguous 
distance restraints (ADR)19> to automatically assign NOE cross-peaks. It does not 
perform the structure calculations itself but assigns NOE cross-peaks by first deriving 
all possible assignments for each peak by matching a list of chemical shifts with 
frequency ‘windows’ centred around the position of a peak in an iterative structure 
calculation scheme. Structures are calculated using the program CNS (Crystallography 
& NMR System)98,199, ARIA then analyses the conformers obtained in order to update 
the restraints and obtain a set of improved conformer. 
For structure calculation using ARIA two main methods for generation of distance 
restraints can be generally used: restraints can be generated by ARIA itself or restraints 
can be generated in CcpNmr Analysis17> and imported into ARIA. In this project a 
combination of both was used. 
EB1 cross-peaks and peak lists were imported from CcpNmr Analysis into ARIA, and 
restraints generated by ARIA for the 15N-resolved-13C-decoupled-NOESY-HSQC, 
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13C-resolved-NOESY-HSQC, 15N, 13C-filtered-13C-resolved-NOESY-HSQC (inter-
monomer contacts), 13C-resolved-NOESY-HSQC for aromatic resonances. The 
tolerances for direct proton, indirect proton and heteronuclear dimensions were 
defined to 0.02, 0.04 and 0.5, respectively. Spin diffusion correction was also used, by 
inputting the spectrometer frequency, mixing time and correlation time for each 
spectrum –Table 7.12. 
Table 7.12 – Spectra used in ARIA for NOE iterative assignment and distance restraints calculation. 
 
15N-resolved-13C-
decoupled-
NOESY-HSQC 
13C-resolved-
NOESY-
HSQC 
15N,13C-filtered-13C-
resolved-NOESY-
HSQC 
13C-resolved-
NOESY-HSQC 
(aromatics) 
Use manual 
assignments 
Yes Yes Yes Yes 
Enable structural 
rules 
Yes No No No 
To
le
ra
nc
es
 Proton 1 0.02 
Hetero 1 0.5 
Proton 2 0.04 
Hetero 2 0.5 
Molecule 
correlation time 
(ns) 
10 
Spectrometer 
frequency (MHz) 
800 
Mixing time 
(ms) 
100 200 200 100 
Ambiguity level 
(for multimers) 
Intra-molecular 
only 
Unknown Intermolecular only Unknown 
 
All NOESY peaks were picked semi-automatically in CcpNmr Analysis with noise 
and artefact peaks removed manually. Cross-peak intensities were used to evaluate the 
target distances. The ambiguity of these restraints derived from the NOE cross peaks 
was resolved in the ARIA cycles with the violation tolerances set to 3.0-0.1 Å for 
iterations 1-8, respectively.  
As mentioned before, distance restraints generated in CcpNmr Analysis were also 
directly used for the structure calculation, namely dihedral angles, restraints hydrogen 
bond restraints and intermonomer restraints.  
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Table 7.13 – Distance restraints derived by CcpNmr Analysis and imported to ARIA to perform the 
structure calculations. 
Restraint type Number of restraints 
Dihedral 128 
Hydrogen bond 90 
Intermonomer – aliphatic region 83 
Intermonomer – aromatic region 16 
 
Dihedral restraints (φ/ψ) were generated using DANGLE (Dihedral ANgles from 
Global Likelihood Estimates)20> module of CcpNmr Analysis software. DANGLE 
predicts protein backbone φ and ψ angles and secondary structure assignments solely 
from amino acid sequence information, experimental chemical shifts and a database 
of known protein structures and their associated shifts. A total of 128 restraints were 
obtained using DANGLE. 
Hydrogen bond restraints between the N-H group of an amino acid and the C=O group 
of the amino acid four residues earlier (i + 4 → i) were manually inserted in CcpNmr 
Analysis for the regions where the secondary structure is defined as alpha-helical – 
[191-231] and [237-247]. There is a strong reasoning for the use of these “artificial” 
restraints. First of all the NOE data and dihedral angles data were used to predict the 
secondary structure in CcpNmr Analysis and the prediction is not only in accordance 
with previous EB1 published structures24,27,31,44,48,20>, but also with experimental data 
acquired. The 90 restraints included the default “N-H..O=C” and their co-linear 
restraints.  
Distance restraints between atoms in chain A and chain B – intermonomer, were 
generated from assigned peaks from the isotope filtered 13C-NOESY-HSQC and 2D 
NOESY. In total, 99 restraints were used.  
Finally, 320 structures were calculated, 30 best refined in the presence of explicit water 
molecules as described in Table 7.14, 20 lowest structure used for the analysis and 
PDB deposition. For speed, structures are typically calculated “in vacuum” which can 
result artefacts as a result of the simplified treatment of non-bonded forces and missing 
solvent contacts.  ARIA provides the option of refining structures in a shell of water 
molecules for a defined number of structures from the final iteration with a full 
molecular dynamics force field incorporating electrostatics. This refinement helps to 
avoid unrealistic side chain packing and unsatisfied hydrogen bond donors or receptors. 
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To ensure there are no systematic differences that could influence validation results, 
the force fields used for water refinement (file PARALLHDG 5.3) are consistent with 
the force fields used for structure calculation and validation.20> 
Table 7.14 – Parameters used for each iteration of structure calculation, including number of structures 
calculated, use or not of spin diffusion, violation tolerance, and ambiguity cut-off. 
Iteration No. of 
Structures 
Keep n best 
structures 
Use best n 
structures 
Spin 
diffusion 
Violation 
tolerance Å 
Partial 
assignment – 
ambiguity cut-
off 
0 64 10 7 No 3.0 1.0 
1 64 10 7 No 3.0 0.9999 
2 64 10 7 No 3.0 0.999 
3 64 10 7 No 1.0 0.99 
4 64 10 7 No 1.0 0.98 
5 64 10 7 Yes 1.0 0.96 
6 64 10 7 Yes 0.5 0.93 
7 160 10 7 Yes 0.5 0.9 
8 320 20 7 Yes 0.1 0.8 
Water 
refinement 
30 - - - - - 
 
Table 7.15 - Simulating annealing parameters used for structure determination of free EB1cΔ8 
Type Torsion angle 
Random seed 89764443 
TAD high temperature 10000.0 
TAD time-step factor 9.0 
Cartesian High temperature 2000.0 
Cartesian 1st iteration 0 
Time-step 0.00015 
Cool1 final temperature 1000.0 
Cool2 final temperature 50.0 
High-temp steps 20000 
Refine steps 8000 
Cool1 steps 10000 
Cool2 steps 8000 
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7.4.4.3 Structure calculation of EB1cΔ8 – 1a complex 
For this complex it was known, from acquired data – e.g. NH intensities, secondary 
structure prediction, NOEs – that the structure would not be very different from the 
free protein.  
Table 7.16 - Spectra acquired in a double-labelled sample (15N, 13C) for EB1cΔ8-1a complex resonance 
assignment. 
NMR experiment No. 
of 
Scans 
Mixing 
time 
(ms) 
No. of points 
digitized FID resolution (Hz) 
Spectrometer 
frequency 
F1 F2 F3 F1 F2 F3 
1D 1H 64 - 8192 - - 2.54 - - 800 MHz 
1D 1H – Excitation 
Sculpting 
32 - 32768 - - 0.78 - - 800 MHz 
15N,13C-filtered-1D 1H* 256 - 8192 - - 2.73 - - 800 MHz 
1H-15N-HSQC 4 - 360 1600 - 11.72 11.00 - 800 MHz 
3D-CBCACONH 4 - 156 102 1400 147.06 41.35 11.45 800 MHz 
3D-HBHACONH 2 - 200 102 1400 44.01 41.35 11.45 800 MHz 
1H-13C-HSQC (aliphatic) 8 - 200 1400 - 12.58 126.90 - 800 MHz 
1H-13C-HSQC-constant 
time 
(aliphatic) 
4 - 612 1400 - 12.58 41.47 - 800 MHz 
1H-13C-HSQC (aromatic) 16 - 64 1200 - 13.36 125.79 - 800 MHz 
1H- 13C-TROSY 
(aromatic) 
16 - 1200 118 - 13.36 68.23 - 800 MHz 
H(C)CH-TOCSY 2 - 128 48 1024 23.21 146.19 11.74 800 MHz 
HCCH-TOCSY 4 - 128 128 1024 146.19 146.19 11.74 800 MHz 
15N-resolved-13C-
decoupled-TOCSY-HSQC 
2 45 400 102 1024 40.02 37.76 15.65 800 MHz 
15N-resolved-13C-
decoupled-NOESY-
HSQC 
2 150 512 112 1400 31.26 36.21 11.45 800 MHz 
13C-resolved-NOESY-
HSQC 
2 200 512 180 1200 31.26 138.54 13.36 800 MHz 
13C-resolved-NOESY-
HSQC* 
4 100 512 80 1400 28.14 140.87 11.45 800 MHz 
13C-resolved-NOESY-
HSQC (aromatic) 
4 200 450 48 1200 35.57 167.72 13.36 800 MHz 
13C-decoupled-2D-
TOCSY* 
96 45 512 2048 - 31.26 7.83 - 800 MHz 
13C-decoupled-2D-
NOESY* 
128 200 600 2048 - 31.25 7.83 - 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-NOESY 
96 200 400 2048 - 40.00 7.83 - 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-NOESY* 
64 200 512 2018 - 31.25 7.83 - 800 MHz 
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15N,13C-filtered-13C-
resolved-NOESY-HSQC 
8 200 380 64 1400 37.92 176.16 11.45 800 MHz 
*spectra acquired in 100% 2H2O (all other experiments acquired with 5-10% 2H2O) 
 
Therefore we used the final set of restraints – ambiguous and unambiguous - from the 
calculation of the structure of the free protein and introduced intermolecular restraints 
between the small molecule and the protein. Concerning the dihedral angles restraints 
and hydrogen bond restraints the same principle applies. The key for the calculation 
of the structure of this complex is to use as best as we can the intermolecular NOEs 
(protein – small molecule). Topology file for  the small molecule 1a was obtained via 
CcpNmr ACPYPE Portal20>. 
The 15N,13C-filtered-13C-resolved-NOESY-HSQC was carefully assigned and the 
restraints directly used without any filtering. Regarding the intermolecular NOEs from 
15N,13C-filtered-13C-decoupled-2D-NOESY experiment, the assigned restraints were 
also used but it was allowed to ARIA to filter not compatible restraints due to the 
absence of a carbon dimension and the inherent ambiguity. In addition to these 
restraints, restraints derived from assigned peaks of 13C-decoupled-2D-NOESY for the 
aromatic region were also used.  
Table 7.17 – Parameters used for each iteration of structure calculation, including number of structures 
calculated, use or not of spin diffusion, violation tolerance, and ambiguity cut-off. 
Iteration No. of Structures 
Keep n best 
structures 
Use best n 
structures 
Spin 
diffusion 
Violation 
tolerance Å 
Partial 
assignment – 
ambiguity 
cut-off 
0 32 0 7 No 3.0 1.0 
1 32 0 7 No 3.0 0.9999 
2 32 0 7 No 3.0 0.999 
3 32 0 7 No 1.0 0.99 
4 32 0 7 No 1.0 0.98 
5 32 0 7 No 1.0 0.96 
6 32 0 7 No 0.5 0.93 
7 32 0 7 No 0.5 0.9 
8 160 0 20 No 0.1 0.8 
Water 
refinement 
20 - - - - - 
For this calculation an initial structure model was also included. This model came from 
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previous attempt for determine the structure of this complex and had an overall energy 
of -4703 kcal. For that reason it was necessary to modify some dynamic parameters 
related with the simulating annealing protocol, as decreasing the temperature from 
10000 to 2000, and increasing the cooling steps Table 7.18. It has been shown slower 
SA cooling protocols improves the quality of the structures obtained and therefore the 
success of the structure calculation.15> 
Table 7.18 - Simulating annealing parameters used for structure determination of free EB1cΔ8 
Type Torsion angle 
Random seed 89764443 
TAD high temperature 2000.0 
TAD time-step factor 9.0 
Cartesian High temperature 2000.0 
Cartesian 1st iteration 0 
Time-step 0.00075 
Cool1 final temperature 1000.0 
Cool2 final temperature 50.0 
High-temp steps 40000 
Refine steps 16000 
Cool1 steps 40000 
Cool2 steps 32000 
 
7.4.4.4 Structure calculation of EB1cΔ8 - 11MACF complex 
To 277 µL of 1.15 mM uniformly 13C, 15N-EB1cΔ8 in 20 mM phosphate pH 6.5, 50 
mM NaCl, 0.5 mM TCEP, 0.02% (w/v) NaN3, 73 µL of 11MACF stock solution (5.35 
mM) were added, making a final ratio of 1:1. To this sample more 11MACF was then 
added in order to get a 1:2 ratio. A second sample of 1.15 mM uniformly 13C, 15N-
EB1cΔ8 was prepared in 20 mM phosphate pH 6.5, 50 mM NaCl, 0.5 mM TCEP, 0.02% 
(w/v) NaN3 and the following samples were prepared by adding the necessary amount 
of 5.35 mM 11MACF in a sequential manner: 
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Table 7.19 – titration of 11MACF into 13C, 15N-EB1cΔ8 and unlabelled EB1cΔ8 in order to obtain the 
best quality spectra possible for both protein and ligand resonances, i.e. the line broadening is minimised. 
13C, 15N-EB1cΔ8:11MACF ratio EB1cΔ8:11MACF ratio 
10:1 10:9 
10:2 10:10 
10:4 10:11 
10:9  
10:10  
10:11  
For each ratio both 1D 1H and 15N,13C-filtered-1D 1H were acquired in order to find a 
ratio where both protein and peptide peaks were sharp enough to acquire NOE data. 
The 10:11 ratio showed the best compromise in terms of sharp peaks for the peptide 
and sharp peaks for protein (Appendix A.3).  
Table 7.20 - Spectra acquired in a double labelled sample (15N, 13C) for EB1cΔ8-11MACF complex at 
different ratios for resonance assignment. 
NMR experiment Ratio 
No. 
of 
Scans 
Mixing 
time 
No. of digitised 
points FID resolution (Hz) Spectrometer 
frequency 
F1 F2 F3 F1 F2 F3 
1D 1H 1:1 64 - 8192 - - 2.54 - - 800 MHz 
15N,13C-filtered-1D 
1H 
1:1 64 - 8192 - - 1.96 - - 800 MHz 
1H-15N-HSQC 1:1 4 - 360 1600 - 11.72 11.00 - 800 MHz 
1H-13C-HSQC 
(aliphatic) 
1:1 4 - 200 1400  126.90 12.58 - 800 MHz 
1H-13C-HSQC-
constant time 
(aliphatic) 
1:1 4 - 612 1400 - 41.47 12.58 - 800 MHz 
1H-13C-HSQC 
(aromatic) 
1:1 8 - 64 1024 - 94.35 11.74 - 600 MHz 
1H-13C-TROSY 
(aromatic) 
1:1 8 - 88 1024 - 68.60 11.74 - 600 MHz 
3D-HNCO (nus) 1:1 2 - 128 100 1400 31.45 42.17 11.45 800 MHz 
3D-HNCACO 1:1 2 - 96 100 1400 41.93 42.17 11.45 800 MHz 
3D-CBCACONH 
(nus) 
1:1 2 - 156 102 1400 147.06 41.35 11.45 800 MHz 
3D-HNCACB (nus) 1:1 2 - 156 102 1400 147.06 12.58 12.58 800 MHz 
3D-HBHACONH 1:1 2 - 230 102 1400 38.27 41.35 11.45 800 MHz 
H(C)CH-TOCSY 1:1 2 - 300 128 1024 23.21 146.30 10.57 600 MHz 
HCCH-TOCSY 1:1 4 - 128 128 1024 146.30 146.30 10.57 600 MHz 
15N,13C-filtered-13C-
decoupled-2D-
1:1 80 45 512 2048 - 31.25 7.83 - 800 MHz 
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TOCSY 
15N,13C-filtered-13C-
decoupled-2D-
NOESY 
1:1 96 200 512 2048 - 31.25 7.83 - 800 MHz 
1D 1H 1:2 64 - 8192 - - 2.54 - - 800 MHz 
15N,13C-filtered-1D 
1H 
1:2 64 - 8192 - - 1.96 - - 800 MHz 
15N-resolved-HSQC 1:2 2 - 360 1600 - 11.72 11.00 - 800 MHz 
13C-resolved-HSQC 
(aliphatics) 
1:2 4 - 200 1400 - 63.06 12.58 - 800 MHz 
13C-resolved-HSQC-
constant time 
(aliphatics) 
1:2 4 - 612 1400 - 63.06 11.00 - 800 MHz 
3D-CBCACONH 1:2 8 - 156 102 1400 147.06 41.35 11.45 800 MHz 
3D-HNCA 138,140,18> 1:2 8 - 80 98 1400 138.36 43.03 11.45 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-
TOCSY 
1:2 80 45 512 2048 - 31.25 7.83 - 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-
NOESY 
1:2 96 200 512 2048 - 31.26 7.83 - 800 MHz 
15N-resolved-13C-
decoupled-NOESY-
HSQC 
1:2 2 150 512 152 1400 31.25 27.75 11.45 800 MHz 
1D 1H 10:11 64 - 8192 - - 2.54 - - 800 MHz 
1D 1H – Excitation 
Sculpting* 
10:11 128 - 8192 - - 2.73 - - 800 MHz 
15N,13C-filtered-1D 
1H 
10:11 256 - 8192 - - 2.73 - - 800 MHz 
15N,13C-filtered-1D 
1H* 
10:11 256 - 8192 - - 2.73 - - 800 MHz 
1H-15N-HSQC 10:11 2 - 360 1600 - 11.72 11.00 - 800 MHz 
1H-15N-HSQC* 10:11 4 - 360 1600 - 11.72 11.00 - 800 MHz 
1H-13C-HSQC 
(aliphatic) 
10:11 8 - 200 1400 - 126.79 12.58 - 800 MHz 
1H-13C-HSQC-
constant time 
(aliphatic) 
10:11 4 - 612 1400 - 41.43 12.58 - 800 MHz 
1H-13C-HSQC-
constant time 
(aliphatic)* 
10:11 4 - 612 1400 - 41.47 12.58 - 800 MHz 
1H-13C-HSQC 
(aromatic) 
10:11 16 - 64 1200 - 125.80 13.36 - 800 MHz 
1H-13C-TROSY 
(aromatics) 
10:11 16 - 118 1200 - 68.23 13.36 - 800 MHz 
13C-decoupled-2D-
NOESY* 
10:11 16 60 512 1440 - 31.25 11.13 - 800 MHz 
15N,13C-filtered-13C- 10:11 80 45 512 2048 - 31.25 7.83 - 800 MHz 
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decoupled-2D-
TOCSY 
15N,13C-filtered-13C-
decoupled-2D-
TOCSY* 
10:11 64 40 512 1440 - 31.25 11.13 - 800 MHz 
15N,13C-filtered-2D-
NOESY 
10:11 48 200 512 2048 - 31.25 7.83 - 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-
NOESY 
10:11 48 200 512 2048 - 31.25 7.83 - 800 MHz 
15N,13C-filtered-13C-
decoupled-2D-
NOESY* 
10:11 80 200 512 1440 - 31.25 11.13 - 800 MHz 
13C-resolved-
NOESY-HSQC 
10:11 2 200 512 172 1400 31.25 144.99 11.45 800 MHz 
13C-resolved-
NOESY-HSQC* 
10:11 2 200 512 80 1400 28.14 140.87 11.45 800 MHz 
13C-resolved-
NOESY-HSQC 
(aromatics) 
10:11 4 200 450 56 1200 35.56 143.78 13.36 800 MHz 
15N,13C-filtered-13C-
resolved-NOESY-
HSQC 
10:11 8 200 440 68 1400 32.83 165.79 11.45 800 MHz 
15N,13C-filtered-13C-
resolved-NOESY-
HSQC* 
10:11 8 200 440 80 1400 32.75 140.87 11.45 800 MHz 
*spectra acquired in 100% 2H2O (all other experiments acquired with 5-10% 2H2O) 
In order to perform the structure calculation of the complex the parameters used for free EB1cΔ8 were 
used (Table 7.14 and Table 7.15). Three spectra were iteratively assigned by ARIA, 15N-resolved-13C-
decoupled-NOESY-HSQC and two 13C-resolved-NOESY-HSQC experiments with two different 
mixing times, 200 and 100 ms -  
Table 7.21. In terms of restraints introduced into ARIA as CcpNmr Analysis calculated 
restraints from manual assignments or obtained from previous structure calculations 
as .tbl files can be found in Table 7.22. These include dihedral and hydrogen bond 
restraints, similarly to what was described for the previous structures, intermolecular 
restraints between EB1 and 11MACF assigned from filtered experiments and 
intermonomer restraints. The latter include the 99 restraints used in the calculations of 
free EB1cΔ8 resultant from manual assignments but also 249 restraints resultant from 
the final iteration of the same structure, yielding a total of 348 intermonomer restraints. 
 
 
Table 7.21 – Spectra used in ARIA for NOE iterative assignment and distance restraints calculation. 
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15N-resolved-13C-decoupled-
NOESY-HSQC 
13C-resolved-
NOESY-HSQC 
13C-resolved-
NOESY-HSQC 
Use manual 
assignments 
Yes Yes Yes 
Enable structural rules Yes No No 
To
le
ra
nc
es
 Proton 1 0.02 
Hetero 1 0.5 
Proton 2 0.04 
Hetero 2 0.5 
Molecule correlation 
time (ns) 
10 
Spectrometer frequency 
(MHz) 
800 
Mixing time (ms) 100 200 100 
Ambiguity level (for 
multimers) 
Intra-molecular only Unknown Unknown 
Table 7.22 – Distance restraints derived from CcpNmr Analysis or ARIA (calculation of the structure 
of free EB1cΔ8) to perform the structure calculations of the complex. 
Restraint type Number of restraints 
Dihedral 130 
Hydrogen bond 90 
Intermonomer – aliphatic region 83 
Intermonomer – aromatic region 16 
Intermonomer* 249 
Intermolecular  185 
*obtained from ARIA assignment for free EB1cΔ8. 
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APPENDIX 
A.1 Structure determination of free EB1cΔ8 
 
Figure 1 – Secondary structure prediction obtained from the chemical shifts of the EB1cΔ8 obtained using CcpNmr Analysis. 
 xiv 
 
A.2 Structure determination of the complex EB1cΔ8-1a 
 
Figure 2 – structure of molecule 1a and respective atom labels used for NMR resonance assignment. 
Table 1 – intermolecular restraints between EB1cΔ8 and molecule 1a obtained through manual 
assignment and directly input into ARIA. 
Chain Residue Atom Chain Atom Distance (Å) 
B Phe216 Hε C H* 4.8 
A Arg222 Hδ C H3/H5 4.1 
A Arg222 Hγ C H5 4.4 
A Arg222 Hγ C H3/H5 4.5 
A Arg222 Hδ C H4/H6 4.4 
A Arg222 Hδ C H* 4.4 
A Arg222 Hα C H3/H5 4.1 
A Arg222 Hγ C H2/H8 4.4 
A Arg222 Hδ C H3/H5 4.1 
A Arg222 Hα C H4/H6 4.4 
A Arg222 Hδ C H3/H5 4.1 
A Arg222 Hδ C H4/H6 4.4 
A Glu225 Hγ C H3/H5 4.6 
A Leu246 Hδ2 C H4/H6 3.9 
A Leu246 Hδ2 C H3/H5 4 
A Leu246 Hδ1 C H2/H8 4.2 
A Leu246 Hδ1 C H1 4.2 
A Leu246 Hδ1 C H4/H6 3.4 
A Leu246 Hδ1 C H3/H5 3.7 
A Thr249 Hγ C H* 3.1 
A Thr249 Hγ C H9 4.2 
 
 
 
 xv 
 
Table 2 – intermolecular restraints between EB1cΔ8 and molecule 1a obtained through the iterative 
assignment performed by ARIA 
Chain Residue Atom Chain Atom Distance (Å) 
A Arg222 Hδ C H4/H6 4.9 
A Leu246 Hδ1 C H3/H5 3.7 
A Leu246 Hδ1 C H4/H6 3.4 
A Leu246 Hδ2 C H4/H6 3.8 
A Leu246 Hδ2 C H3/H5 3.9 
A Leu246 Hδ1 C H2/H8 4.3 
A Leu246 Hδ2 C H1/H7 4.9 
A Leu246 Hδ2 C H2/H8 4.6 
A Leu246 Hδ1 C H1 4.2 
A Tyr247 Hε C H4/H6 4.1 
A Tyr247 Hε C H2/H8 3.8 
A Tyr247 Hδ C H3/H5 4.6 
A Tyr247 Hδ C H4/H6 4.3 
A Tyr247 Hδ C H1/H7 4.7 
A Tyr247 Hδ C H2/H8 4.3 
A Tyr247 Hε C H3/H5 3.9 
A Tyr247 Hε C H1/H7 4.6 
A Tyr247 Hδ C H* 4.2 
A Tyr247 Hδ C H14/H15 4.9 
A Tyr247 Hε C H 4.5 
A Tyr247 Hε C H* 4.6 
A Tyr247 Hε C H9 4.9 
A Thr249 Hγ2 C H* 3.4 
A Thr249 Hγ2 C H9 4.4 
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A.3 Structure determination of the complex EB1cΔ8-11MACF
 
Figure 3 – 1D 1H acquired for the following protein:peptide ratios – 10:1, 10:2, 10:4, 10:9, 10:10, 10:11. 
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Figure 4 – 15N,13C-filtered-1D 1H acquired for the following protein:peptide ratios – 10:1, 10:2, 10:4, 10:9, 10:10, 10:11. 
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Table 3 – intermolecular restraints between EB1cΔ8 and 11MACF obtained through manual assignment 
and directly input into ARIA. 
Chain Residue Atom Chain Residue Atom Distance (Å) 
B Phe216 Hζ C Thr5481 Hγ2 5.5 
B Phe216 Hε C Thr5481 Hγ2 6.4 
B Tyr217 Hε C Ile5479 Hγ2 4.9 
B Tyr217 Hδ C Ile5479 Hγ2 5.1 
B Tyr217 Hε C Ile5479 Hδ1 5.8 
B Tyr217 Hε C Ile5479 Hβ 6.1 
B Tyr217 Hδ C Ile5479 Hδ1 6.2 
B Tyr217 Hδ C Ile5479 Hβ 6.2 
B Tyr217 Hε C Pro5480 Hβ1 5.5 
B Tyr217 Hδ C Pro5480 Hβ1 5.7 
B Tyr217 Hε C Pro5480 Hγ2 6.2 
B Tyr217 Hδ C Pro5480 Hγ2 6.2 
B Tyr217 Hε C Pro5480 Hβ2 6.5 
B Tyr217 Hε C Thr5481 Hγ2 5.5 
B Tyr217 Hδ C Thr5481 Hγ2 5.7 
A Phe218 Hε C Ser5477 Hβ2 6.5 
A Phe218 Hε C Ile5479 Hγ2 3.8 
A Phe218 Hε C Ile5479 Hγ2 4.1 
A Phe218 Hδ C Ile5479 Hγ2 4.3 
A Phe218 Hε C Ile5479 Hδ1 4.4 
A Phe218 Hε C Ile5479 Hβ 4.5 
A Phe218 Hζ C Ile5479 Hγ2 4.7 
A Phe218 Hζ C Ile5479 Hδ1 4.9 
A Phe218 Hζ C Ile5479 Hβ 5.0 
A Phe218 Hδ C Ile5479 Hγ2 5.0 
A Phe218 Hδ C Ile5479 Hδ1 5.4 
A Phe218 Hδ C Ile5479 Hβ 5.7 
A Phe218 Hε C Ile5479 Hα 6.3 
A Phe218 Hε C Ile5479 Hγ1 6.4 
A Phe218 Hζ C Ile5479 Hγ1 6.5 
A Phe218 Hε C Pro5480 Hγ2 6.3 
A Phe218 Hε C Pro5480 Hβ1 6.5 
A Phe218 Hε C Thr5481 Hγ2 3.9 
A Phe218 Hζ C Thr5481 Hγ2 3.9 
A Phe218 Hε C Thr5481 Hγ2 4.0 
A Phe218 Hζ C Thr5481 Hγ2 4.4 
A Phe218 Hδ C Thr5481 Hγ2 4.5 
A Phe218 Hδ C Thr5481 Hγ2 5.1 
A Phe218 Hε C Thr5481 Hβ 6.3 
A Leu221 Hδ2 C Ile5479 Hδ1 4.1 
A Leu221 Hδ2 C Ile5479 Hγ2 4.2 
A Leu221 Hδ2 C Ile5479 Hγ2 4.4 
A Leu221 Hδ1 C Ile5479 Hγ2 4.5 
A Leu221 Hδ1 C Ile5479 Hδ1 4.5 
A Leu221 Hδ2 C Ile5479 Hδ1 4.6 
A Leu221 Hα C Ile5479 Hδ1 4.8 
A Leu221 Hα C Ile5479 Hδ1 5.0 
A Leu221 Hγ C Ile5479 Hδ1 5.0 
A Leu221 Hα C Ile5479 Hγ2 5.2 
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A Arg222 Hα C Ile5479 Hδ1 4.3 
A Arg222 Hα C Ile5479 Hδ1 4.6 
A Arg222 Hδ1 C Ile5479 Hδ1 4.9 
A Leu246 Hδ1 C Ile5479 Hδ1 3.8 
A Leu246 Hδ1 C Ile5479 Hγ2 4.1 
A Leu246 Hδ2 C Ile5479 Hδ1 4.1 
A Leu246 Hδ2 C Ile5479 Hγ2 4.3 
A Leu246 Hδ1 C Ile5479 Hδ1 4.6 
A Leu246 Hδ1 C Ile5479 Hγ2 4.8 
A Leu246 Hδ1 C Ile5479 Hβ 4.9 
A Leu246 Hδ2 C Ile5479 Hγ1 5.3 
A Leu246 Hδ2 C Ile5479 Hα 5.6 
A Tyr247 Hε C Lys5478 Hβ2 4.0 
A Tyr247 Hε C Lys5478 Hβ1 4.2 
A Tyr247 Hε C Lys5478 Hβ1 4.7 
A Tyr247 Hε C Lys5478 Hε2 5.1 
A Tyr247 Hε C Lys5478 Hα 5.2 
A Tyr247 Hε C Lys5478 Hβ2 5.4 
A Tyr247 Hε C Lys5478 Hδ2 5.5 
A Tyr247 Hε C Lys5478 Hγ2 5.5 
A Tyr247 Hε C Ile5479 Hγ2 3.8 
A Tyr247 Hε C Ile5479 Hα 3.9 
A Tyr247 Hε C Ile5479 Hδ1 4.0 
A Tyr247 Hε C Ile5479 Hβ 4.2 
A Tyr247 Hε C Ile5479 Hγ2 4.4 
A Tyr247 Hε C Ile5479 Hδ1 4.7 
A Tyr247 Hε C Ile5479 Hβ 5.1 
A Tyr247 Hε C Ile5479 Hα 5.2 
A Tyr247 Hδ C Ile5479 Hγ2 5.4 
A Tyr247 Hε C Ile5479 Hγ12 5.5 
A Tyr247 Hδ C Ile5479 Hα 6.0 
A Ala248 Hβ C Pro5480 Hβ1 4.8 
A Thr249 Hγ2 C Lys5478 Hδ1 4.6 
A Thr249 Hγ2 C Pro5480 Hβ1 3.4 
A Thr249 Hγ2 C Pro5480 Hβ2 3.7 
A Thr249 Hγ2 C Pro5480 Hγ2 3.7 
A Thr249 Hγ2 C Pro5480 Hα 4.8 
A Thr249 Hγ2 C Thr5481 Hβ 4.7 
A Phe253 Hε C Ile5479 Hγ2 5.3 
A Phe253 Hε C Ile5479 Hδ1 5.9 
A Phe253 Hδ C Thr5481 Hγ2 5.8 
A Phe253 Hδ C Thr5481 Hα 5.8 
A Phe253 Hε C Thr5481 Hγ2 5.9 
A Phe253 Hε C Thr5481 Hα 6.2 
A Phe253 Hδ C Thr5481 Hβ 6.3 
A Phe253 Hε C Thr5481 Hβ 6.3 
A Phe253 Hε C Pro5482 Hγ2 5.3 
A Phe253 Hδ C Pro5482 Hα 5.6 
A Phe253 Hε C Pro5482 Hβ1 5.7 
A Phe253 Hε C Pro5482 Hα 5.8 
A Phe253 Hδ C Pro5482 Hβ1 5.9 
A Phe253 Hδ C Pro5482 Hγ2 6.0 
A Phe253 Hδ C Pro5482 Hγ1 6.1 
A Phe253 Hδ C Pro5482 Hβ2 6.1 
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A Phe253 Hε C Pro5482 Hγ1 6.1 
A Phe253 Hε C Pro5482 Hβ2 6.1 
A Phe253 Hε C Pro5482 Hδ1 6.2 
A Phe253 Hδ C Pro5482 Hδ1 6.3 
A Phe253 Hε C Pro5482 Hδ2 6.4 
A Phe253 Hδ C Pro5482 Hδ2 6.6 
A Val254 Hγ1 C Thr5481 Hγ2 4.0 
A Val254 Hγ2 C Thr5481 Hγ2 4.5 
A Val254 Hγ1 C Thr5481 Hγ2 4.6 
A Val254 Hγ2 C Thr5481 Hγ2 5.3 
A Val254 Hγ1 C Pro5482 Hα 4.0 
A Val254 Hγ2 C Pro5482 Hα 4.1 
A Val254 Hγ2 C Pro5482 Hβ1 4.7 
A Val254 Hγ1 C Gln5483 Hα 3.1 
A Val254 Hγ2 C Gln5483 Hγ2 3.1 
A Val254 Hγ1 C Gln5483 Hα 3.1 
A Val254 Hγ2 C Gln5483 Hα 3.3 
A Val254 Hγ1 C Gln5483 Hγ2 3.3 
A Val254 Hγ2 C Gln5483 Hβ2 3.3 
A Val254 Hγ2 C Gln5483 Hγ2 3.5 
A Val254 Hγ2 C Gln5483 Hβ1 3.5 
A Val254 Hγ1 C Gln5483 Hγ2 3.5 
A Val254 Hγ2 C Gln5483 Hα 3.6 
A Val254 Hγ1 C Gln5483 Hβ2 3.6 
A Val254 Hγ1 C Gln5483 Hβ1 3.7 
A Val254 Hγ2 C Gln5483 Hβ2 3.7 
A Val254 Hγ2 C Gln5483 Hε21 3.8 
A Val254 Hγ1 C Gln5483 Hβ2 3.8 
A Val254 Hγ2 C Gln5483 Hβ1 3.9 
A Val254 Hγ2 C Gln5483 Hε22 3.9 
A Val254 Hγ1 C Gln5483 Hβ1 4.0 
A Val254 Hγ2 C Gln5483 HN 4.0 
A Val254 Hγ1 C Gln5483 HN 4.1 
A Val254 Hγ1 C Gln5483 Hε2 4.3 
A Val254 Hγ1 C Gln5483 Hε22 4.5 
A Ile255 Hγ2 C Lys5478 Hβ1 3.3 
A Ile255 Hγ2 C Lys5478 Hα 3.4 
A Ile255 Hγ2 C Lys5478 Hε2 3.6 
A Ile255 Hδ1 C Lys5478 Hβ1 3.6 
A Ile255 Hγ2 C Lys5478 Hδ1 3.8 
A Ile255 Hγ2 C Lys5478 Hβ2 3.8 
A Ile255 Hδ1 C Lys5478 Hε2 3.8 
A Ile255 Hδ1 C Lys5478 Hα 3.8 
A Ile255 Hγ2 C Lys5478 Hδ2 3.8 
A Ile255 Hγ2 C Lys5478 Hε1 4.0 
A Ile255 Hδ1 C Lys5478 Hβ1 4.0 
A Ile255 Hδ1 C Lys5478 Hε2 4.1 
A Ile255 Hδ1 C Lys5478 Hα 4.2 
A Ile255 Hδ1 C Lys5478 Hδ1 4.2 
A Ile255 Hδ1 C Lys5478 Hε1 4.2 
A Ile255 Hδ1 C Lys5478 Hβ2 4.4 
A Ile255 Hδ1 C Lys5478 Hδ2 4.4 
A Ile255 Hδ1 C Lys5478 Hε1 4.4 
A Ile255 Hδ1 C Lys5478 Hβ2 4.5 
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A Ile255 Hδ1 C Lys5478 Hδ2 4.6 
A Ile255 Hδ1 C Lys5478 Hγ2 5.0 
A Ile255 Hδ1 C Ile5479 Hα 4.7 
A Ile255 Hδ1 C Pro5480 Hβ1 3.7 
A Ile255 Hδ1 C Pro5480 Hβ2 4.3 
A Ile255 Hγ2 C Pro5480 Hβ1 4.4 
A Ile255 Hδ1 C Pro5480 Hγ2 4.4 
A Ile255 Hγ2 C Pro5480 Hβ2 4.6 
A Ile255 Hγ1 C Pro5480 Hβ1 4.8 
A Ile255 Hδ1 C Pro5480 Hα 4.9 
A Ile255 Hγ1 C Pro5480 Hβ1 5.0 
A Ile255 Hγ2 C Pro5480 Hγ2 5.1 
A Ile255 Hγ2 C Thr5481 Hγ2 4.3 
A Ile255 Hγ2 C Thr5481 HN 4.7 
A Ile255 Hδ1 C Thr5481 Hγ2 4.9 
A Ile255 Hδ1 C Thr5481 HN 5.1 
A Pro256 Hγ2 C Lys5478 Hα 3.6 
A Pro256 Hβ1 C Lys5478 Hα 4.4 
A Pro256 Hγ2 C Lys5478 Hβ1 4.4 
A Pro256 Hβ2 C Lys5478 Hα 4.5 
A Pro256 Hδ2 C Lys5478 Hα 4.6 
A Pro256 Hδ1 C Lys5478 Hα 4.8 
A Pro256 Hγ2 C Lys5478 Hδ2 5.0 
A Pro256 Hβ1 C Lys5478 Hβ1 5.0 
A Pro256 Hγ2 C Ile5479 Hγ2 4.6 
A Pro256 Hγ2 C Thr5481 Hγ2 3.7 
A Pro256 Hβ2 C Thr5481 Hγ2 4.5 
A Pro256 Hδ2 C Thr5481 Hγ2 4.7 
Table 4 – intermolecular restraints between EB1cΔ8 and 11MACF obtained through the iterative 
assignment performed by ARIA 
Chain Residue Atom Chain Residue Atom Distance (Å) 
A Phe218 Hα C Ile5479 Hδ1 4.4 
A Leu221 Hδ2 C Ile5479 Hγ2 3.2 
A Leu221 Hα C Ile5479 Hγ2 3.7 
A Leu221 Hδ2 C Ile5479 Hδ1 3.8 
A Leu221 Hδ1 C Ile5479 Hδ1 3.4 
A Leu221 Hα C Ile5479 Hδ1 3.8 
A Leu221 Hγ C Ile5479 Hδ1 4.4 
A Leu221 Hγ C Ile5479 Hδ1 4.4 
A Arg222 Hα C Ile5479 Hδ1 2.9 
A Arg222 Hδ1 C Ile5479 Hδ1 4.2 
A Arg222 Hβ1 C Ile5479 Hδ1 4.5 
A Asn223 Hα C Lys5475 Hγ2 3.4 
A Ile224 Hδ1 C Ile5479 Hγ2 3.7 
A Ile224 Hγ2 C Ile5479 Hγ2 3.9 
A Ile224 Hδ1 C Ile5479 Hγ2 3.6 
A Ile224 Hδ1 C Ile5479 Hδ1 3.0 
A Glu225 Hβ2 C Ile5479 Hβ 3.6 
A Glu225 Hγ1 C Pro5476 Hβ2 3.8 
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A Glu225 Hα C Ile5479 Hδ1 4.1 
A Glu225 Hγ1 C Ile5479 Hδ1 4.3 
A Glu225 Hγ2 C Ile5479 Hδ1 4.5 
A Leu226 Hδ2 C Lys5475 HE2 4.0 
A Leu226 Hδ1 C Pro5476 Hδ2 4.1 
A Leu226 Hδ1 C Lys5475 HE2 3.8 
A Leu226 Hα C Lys5475 Hγ2 3.0 
A Leu226 Hγ C Lys5475 Hγ2 3.2 
A Leu226 Hδ1 C Lys5475 Hγ2 2.8 
A Leu226 Hβ1 C Lys5475 Hγ2 2.9 
A Leu246 Hδ1 C Ile5479 Hγ1 3.1 
A Leu246 Hδ2 C Ile5479 Hγ2 3.5 
A Leu246 Hβ1 C Ile5479 Hγ1 3.7 
A Leu246 Hδ2 C Ile5479 Hδ1 3.0 
A Leu246 Hα C Ile5479 Hγ2 3.6 
A Leu246 Hδ1 C Ile5479 Hγ2 4.1 
A Leu246 Hδ1 C Ile5479 Hδ1 3.3 
A Thr249 Hα C Pro5480 Hβ2 4.0 
A Thr249 Hγ2 C Pro5480 Hβ2 2.5 
A Thr249 Hγ2 C Pro5480 Hγ2 3.2 
A Thr249 Hγ2 C Pro5480 Hβ1 2.8 
A Thr249 Hβ C Pro5480 Hβ1 3.7 
A Thr249 Hα C Pro5480 Hβ1 3.2 
A Thr249 Hα C Pro5480 Hγ2 3.3 
A Val254 Hγ1 C Pro5482 Hδ2 4.2 
A Val254 Hγ1 C Pro5480 Hβ2 3.4 
A Val254 Hγ2 C Gln5483 Hβ1 3.0 
A Val254 Hγ2 C Arg5484 Hγ1 4.0 
A Val254 Hγ2 C Thr5481 Hγ2 3.2 
A Val254 Hγ2 C Arg5484 HN 2.8 
A Val254 Hγ1 C Gln5483 Hβ1 3.2 
A Val254 Hγ1 C Arg5484 Hγ1 3.9 
A Val254 Hγ1 C Thr5481 Hγ2 3.7 
A Val254 Hγ1 C Thr5481 HN 2.8 
A Val254 Hγ1 C Gln5483 HE2 3.9 
A Val254 Hβ C Thr5481 HN 3.2 
A Val254 Hβ C Pro5482 Hγ2 3.8 
A Val254 Hγ2 C Gln5483 Hβ1 4.1 
A Val254 Hγ1 C Gln5483 Hα 2.4 
A Val254 Hγ1 C Thr5481 Hγ2 3.7 
A Val254 Hγ1 C Thr5481 Hβ 3.8 
A Val254 Hγ2 C Gln5483 Hα 2.9 
A Val254 Hγ2 C Gln5483 Hγ2 2.8 
A Val254 Hγ2 C Gln5483 Hβ2 2.7 
A Val254 Hγ2 C Gln5483 HE2 3.2 
A Val254 Hγ2 C Gln5483 HE2 3.3 
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A Val254 Hγ1 C Gln5483 Hγ2 3.0 
A Val254 Hγ1 C Gln5483 Hβ2 3.0 
A Val254 Hγ1 C Gln5483 HN 3.3 
A Val254 Hγ1 C Gln5483 HE2 3.8 
A Val254 Hγ2 C Pro5482 Hα 3.6 
A Val254 Hγ1 C Pro5482 Hα 3.4 
A Val254 Hγ2 C Thr5481 Hβ 3.8 
A Ile255 Hγ2 C Pro5480 Hβ2 4.5 
A Ile255 Hβ C Pro5480 Hβ1 5.5 
A Ile255 Hα C Thr5481 HN 3.2 
A Ile255 Hγ1 C Pro5480 Hβ1 3.7 
A Ile255 Hδ1 C Pro5480 Hβ1 3.0 
A Ile255 Hδ1 C Lys5478 Hα 3.3 
A Ile255 Hγ2 C Lys5478 Hγ2 3.5 
A Ile255 Hδ1 C Lys5478 Hδ1 3.8 
A Ile255 Hδ1 C Ile5479 Hγ2 3.8 
A Ile255 Hγ2 C Lys5478 HE2 3.1 
A Ile255 Hγ2 C Lys5478 Hβ1 2.8 
A Ile255 Hδ1 C Lys5478 HE2 3.3 
A Ile255 Hγ2 C Lys5478 Hδ1 2.6 
A Ile255 Hγ2 C Lys5478 Hα 2.4 
A Ile255 Hγ2 C Pro5480 Hγ2 4.2 
A Ile255 Hγ2 C Pro5480 Hβ2 3.8 
A Ile255 Hγ2 C Lys5478 Hβ2 3.2 
A Ile255 Hγ1 C Pro5480 Hβ1 3.5 
A Ile255 Hδ1 C Pro5480 Hα 3.9 
A Ile255 Hδ1 C Pro5480 Hγ2 3.7 
A Ile255 Hδ1 C Pro5480 Hβ2 3.5 
A Ile255 Hγ2 C Lys5478 Hδ2 3.8 
A Pro256 Hδ2 C Thr5481 Hγ2 3.9 
A Pro256 Hδ2 C Lys5478 Hα 3.0 
A Pro256 Hγ2 C Lys5478 Hδ1 3.5 
A Pro256 Hγ2 C Ile5479 Hγ2 3.5 
A Pro256 Hγ2 C Lys5478 Hγ2 3.5 
A Pro256 Hβ1 C Lys5478 Hγ2 3.8 
A Pro256 Hδ2 C Thr5481 HN 3.7 
A Pro256 Hδ1 C Thr5481 Hγ2 4.1 
A Pro256 Hα C Thr5481 Hγ2 3.8 
A Pro256 Hγ2 C Lys5478 Hβ2 3.6 
A Pro256 Hγ2 C Lys5478 Hβ1 3.4 
A Pro256 Hγ2 C Thr5481 Hγ2 3.5 
A Pro256 Hγ2 C Thr5481 HN 3.7 
A Pro256 Hβ2 C Thr5481 Hγ2 3.6 
A Pro256 Hγ2 C Lys5478 Hα 2.3 
A Asp257 Hβ2 C Lys5478 Hα 2.9 
A Asp257 Hβ1 C Lys5478 Hα 3.0 
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A.4 Screening of a PPI focused library 
 
It has been shown that successful inhibitors of protein− protein interactions tend to 
have certain properties that distinguish them from more traditional drugs designed for 
more conventional target classes, such as enzymes, G protein-coupled receptors, ion 
channels, nuclear hormone receptors, etc.20> It has been shown that these compounds 
tend to be larger and more three-dimensional.205 A more detailed description of the 
properties identified for this class of molecules has been detailed in Chapter 1, section 
1.2.1.3. 
Over the past few years there have been efforts in building chemical libraries enriched 
in small molecules with these desirable properties. A compound library containing 
1534 compounds reported to have chemical properties within the chemical space of 
PPI modulators was made available during the course of this project – PPI-Net 
compound library. The library was obtained through the “Protein-Protein Interactions 
Network” (PPI-Net) and funded by EPSRC grants (EP/I037210/1 and EP/I037172/1) 
and GlaxoSmithKline (GSK).  
The strategy applied to screen this library and described herein is different from what 
was performed in the previous chapters but it is a valid complementary approach for 
identification of PPI modulators. 
A.4.1  Virtual screening of the PPI-Net library 
The entirety of the PPI-Net library (1534 molecules) was subjected to an initial in 
silico screen using a structure-based virtual screening approach – docking. For that 
purpose GOLD111–118 was used. An important use of protein–ligand docking programs 
is virtual screening of large libraries where each compound in turn is docked into a 
target binding site and scored for their predicted strength of binding. Ideally, the 
docking needs to be quick but the results reliable. Speeding up a docking protocol is 
often done at the cost of sampling fewer binding modes, which can lead to reduced 
success rates.114 The default genetic algorithm (GA) parameters in GOLD result in 
thorough but relatively slow searches per processing core, acceptable for individual 
ligand docking but not of much use for large libraries, unless many cores are used in 
parallel.20> In virtual high throughput screening (HTS) it is more important to predict 
relative ligand binding affinities than accurate binding poses. Therefore, the choice of 
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scoring function is clearly important. It has been reported that Goldscore outperforms 
Chemscore in predicting affinities, especially at fast search settings. In addition, the 
search efficiency (from GA settings) can be used to further control the speed of 
docking and the predictive accuracy (i.e. the predictivity) of the results. With the 
search efficiency set at 100% GOLD will attempt to apply optimal settings for each 
ligand. For a ligand with five rotatable bonds this will be around 30000 GA operations. 
If the search efficiency is set to 50%, then GOLD will perform around 15000 
operations thereby speeding up the docking by a factor of two, but the search space 
would be less well explored. The virtual screening option offered by GOLD sets the 
search efficiency at 30%. This setting is suitable for routine work and usually gives 
comparable predictive accuracy to the slower settings, unless the ligand has a large 
number of rotatable torsions.160 Therefore, the 1534 compounds were screened using 
this option.  
After structure-based screening it is necessary to perform a virtual hit compound 
selection. There are several ways of achieving this, and some of these were described 
in the previous chapters, e.g. ligand efficiency, Pareto ranking, etc. In order to 
complement these approaches and as there was already some information about which 
molecules formed favourable interactions with the target protein – we used 
quantitative structure-activity relationship (QSAR) analysis was complemented with 
compound plate selection. These approaches will be subsequently described. 
A.4.2  Quantitative structure-activity relationship (QSAR) analysis 
Drug discovery is an iterative process with a cycle of design, synthesis and testing. 
Analysis of the results from one iteration provides information and knowledge that 
will be introduced in the next cycle, enhancing it and yielding more results.71 At this 
stage of the project there were a small number of molecules tested, some with “positive” 
data (i.e. interaction with EB1) and some with “negative” data. As described in the 
introductory chapter – section 1.2.1.2.1 – when a number of active and inactive 
compounds are known it is possible to perform a QSAR analysis. QSAR analysis refers 
to the use of machine learning methods to correlate structural or physiochemical 
properties (molecular descriptors) of a molecule with a measured property, such as 
biological or chemical reactivity.71 Classical QSAR methods rely on structural features 
or lipophilicity, polarizability, electronic and steric properties (Hansch analysis). With 
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the advance of structural biology methods such as X-ray protein crystallography, 
additional information from the three dimensional structures could be integrated into 
the QSAR models – 3D QSAR. The comparative molecular field analysis – CoMFA 
method was the first real 3D QSAR method. A CoMFA analysis identifies regions in 
three-dimensional space that are favourable or unfavourable for a ligand-target 
interaction.20> A group of chemically related compounds with the same mechanism of 
action are selected. In contrast with classical QSAR methods these should share a 
common pharmacophore and not the same molecular scaffold.207  
Norfloxacin is one of the first examples of success of application of QSAR methods. 
This scaffold was found through 2D-QSAR studies made on the antibacterial activities 
of monosubstituted 1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids - Figure . 
Donepezil hydrochloride is another successful application of QSAR methods, where 
X-ray crystallography and molecular modelling studies where used in combination 
with QSAR analysis - Figure .20> 
 
Figure 1 – Examples of molecules currently used as drug that were found through the successful 
application of QSAR methods. 
The first step in the QSAR analysis is to compile all the tested compounds against 
EB1cΔ8, and classify them as active/inactive – Table 1. Compounds that promoted 
significant NMR chemical shift changes in the NH resonance of EB1cΔ8 are 
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considered as active and therefore have a green mark. Inactive compounds that did not 
promote chemical shift changes in NH resonances of EB1cΔ8 are marked as red 
crosses. The first generation compounds correspond to the virtual screening and in 
vitro testing described in Chapter 2. Compound ZINC12677264 (1d) is not included 
since at the time of this analysis the compound had not been tested. Second generation 
compounds correspond to the work described in Chapter 4. Finally, in-house 
compounds, correspond to a small compound collection existent prior to the start of 
this project that was screened using the same method used for the previous compounds 
– chemical shift perturbations upon ligand titration. 
Table 1 – Molecules previously tested against EB1cΔ8.  
Code Structure Binding to EB1cΔ8  
ZINC08389070 
 
ü First generation 
ZINC71025726 
 
û First generation 
ZINC64398049 
 
û First generation 
ZINC40017212 
 
ü Second generation 
ZINC31040053 
 
ü Second generation 
ZINC12929029 
 
û Second generation 
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ZINC50136319 
 
û In-house compounds 
ZINC51305175 
 
û In-house compounds 
ZINC56787233 
 
û In-house compounds 
ZINC64898686 
 
û In-house compounds 
ZINC66121638 
 
û In-house compounds 
ZINC02638973 
 
û In-house compounds 
ZINC67146994 
 
û In-house compounds 
ZINC67208611 
 
û In-house compounds 
ZINC67846598 
 
û In-house compounds 
ZINC67962567 
 
û In-house compounds 
ZINC68228234 
 
û In-house compounds 
ZINC68451427 
 
û In-house compounds 
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For the QSAR ligand-based design it is necessary to calculate a set of molecular 
descriptors which capture numerically the structure and properties of each compound. 
These descriptors vary in complexity, from molecular weight to quantum mechanical 
derived values, and their complexity is usually associated with a better discriminatory 
capability.71  
A.4.3  QSAR descriptors 
The descriptors selected cover not only properties intrinsically related with the 
molecular structure (ligand based) but also with the predicted binding mode for each 
compound – docking based descriptors. These are schematically represented in Figure 
2 and detailed in Chapter 7 – section 7.1.4. 
The 2D descriptors are based on the two-dimensional and three-dimensional structure 
of the molecules, whereas 3D descriptors are based on the conformation of the 
molecule in its predicted binding mode. Fingerprints and physicochemical properties 
were both calculated using Pipeline Pilot16>. Molecular fingerprints define the 
structure of a molecule using a series of binary digits (bits) that represent the presence 
or absence of particular substructures in the molecule.209 Dragon descriptors were 
calculated using Dragon 6210, a software that can calculate up to 4885 molecular 
descriptors. Given the large number of molecular descriptors available, selection 
procedures can be used to identify those descriptors which best represent the data. 
Some molecular descriptors calculated using Dragon 6 correspond to molecular 
properties and therefore overlap with physicochemical properties (e.g. molecular 
weight). Finally, the three-dimensional descriptors, based on binding prediction and 
derived from the docking results can be divided in two groups: based on GOLD 
solutions and descriptors calculated through GoldMine based on docking predictions. 
In the first group one can encounter descriptors such as predicted binding score, scores 
from hydrogen bond formation between the ligand and the protein, i.e., the output 
present in a Gold solution file. The second group includes the descriptors calculated in 
GoldMine based on the docking output. Examples are number of hydrogen bond 
contacts, hydrophobic buried area, number of all contacts between the ligand and the 
protein (general contact count), etc. Both sets of 3D descriptors are detailed in Table 
2 and 3. 
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Figure 2 – Types of molecular descriptors calculated on a set of 18 molecules previously tested against 
EB1cΔ8. Top scheme shows the descriptors calculated only based on the chemical structure of the 
molecules. Bottom scheme represents the two sets of descriptors calculated based on the docking results 
– these include parameters relative to the molecular structure of the ligands but also regarding the pose 
obtained from docking calculations. 
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Table 2 – Molecular descriptors obtained directly from GOLD docking solutions. 
A
SP
 
Gold.ASP.ASP 
Gold.ASP.DEClash 
Gold.ASP.DEInternal 
Gold.ASP.Fitness 
Gold.ASP.Internal.Correction 
Gold.ASP.Map 
Gold.ASP.SBar 
C
he
m
sc
or
e 
Gold.Chemscore.DEClash 
Gold.Chemscore.DEClash.Weighted 
Gold.Chemscore.DEInternal 
Gold.Chemscore.DEInternal.Weighted 
Gold.Chemscore.Fitness 
Gold.Chemscore.Hbond 
Gold.Chemscore.Hbond.Weighted 
Gold.Chemscore.Internal.Correction 
Gold.Chemscore.Internal.Correction.Weighted 
Gold.Chemscore.Internal.Hbond 
Gold.Chemscore.Internal.Hbond.Weighted 
Gold.Chemscore.Lipo 
Gold.Chemscore.Lipo.Weighted 
Gold.Chemscore.Metal 
Gold.Chemscore.Metal.Weighted 
Gold.Chemscore.SBar 
Gold.Chemscore.Zero.Coef 
G
ol
ds
co
re
 
Gold.Goldscore.External.Hbond 
Gold.Goldscore.External.Hbond.Weighted 
Gold.Goldscore.External.Vdw 
Gold.Goldscore.External.Vdw.Weighted 
Gold.Goldscore.Fitness 
Gold.Goldscore.Internal.Correction 
Gold.Goldscore.Internal.Correction.Weighted 
Gold.Goldscore.Internal.Hbond 
Gold.Goldscore.Internal.Hbond.Weighted 
Gold.Goldscore.Internal.Torsion 
Gold.Goldscore.Internal.Torsion.Weighted 
Gold.Goldscore.Internal.Vdw.Weighted 
C
he
m
PL
P 
Gold.PLP.Chemscore.CHOScore 
Gold.PLP.Chemscore.Hbond 
Gold.PLP.Chemscore.Internal.Correction 
Gold.PLP.Chemscore.Metal 
Gold.PLP.Fitness 
Gold.PLP.PLP 
Gold.PLP.SBar 
Gold.PLP.ligand.clash 
Gold.PLP.ligand.torsion 
Gold.PLP.part.buried 
Gold.PLP.part.hbond 
Gold.PLP.part.metal 
Gold.PLP.part.nonpolar  
Gold.PLP.part.repulsive 
Table 3 – Molecular descriptors calculated using GoldMine for solutions obtained for each scoring 
function, ASP, Chemscore, Goldscore and ChemPLP. 
Contact 
descriptors 
General contact count 
Hydrogen bond contact count 
Hydrophobic buried area 
Hydrophobic contacts contact count 
Simple descriptors 
Exposed hydrophobic count 
Ligand acceptor count 
Ligand clash count 
Ligand donor count 
Ligand hbond count 
Molecular weight 
Occluded ligand acceptor count 
Occluded ligand donor count 
Occluded ligand polar count 
Occluded protein acceptor count 
Occluded protein donor count 
Occluded protein polar count 
Occluded rotatable bond count 
Surface Area Ligand Buried Surface Area 
Docked 
Undocked 
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Given the large amount of information it is likely that some of this information may 
be redundant, therefore, descriptor selection is an integral part of QSAR development. 
It should help to reduce the vast number of descriptors, increasing the chance of 
finding a significant QSAR model, i.e. only a small number descriptors are actually 
correlated with biological activity.71,20> The first type of descriptors to remove will be 
the constant values, as nothing is gained from their inclusion. Correlated descriptors 
should be also removed. Lastly, they should be evenly distributed and without outliers. 
This may require scaling some descriptors.71 For example, from the descriptors 
calculated for Goldscore from the solution output file 12 descriptors were removed, 
such as “protein active residues”, common to all the docking runs and therefore 
contained no discriminatory information, keeping a final number of 12 used 
descriptors. 
A.4.4  Method validation 
With the first step of QSAR analysis, encoding molecular properties into numeric 
values, accomplished the next step was to build a predictive model. Random Forest 
(RF) and Support Vector Machine (SVM) were used as machine learning methods to 
build the predictive models. RF is based on an ensemble, or forest, of decision trees. 
The trees are built using a training sample of a reduced size selected at random with 
replacement from original data. Using the new training sample, a tree is grown with 
randomly selected descriptors. The remaining training data is used to estimate error 
and variable importance. RF is easy to use, as the user needs to fix only two parameters: 
the number of trees in the forest and the number of descriptors in each tree. A large 
number of trees should be grown, and the number of descriptors to be taken is the 
square root of the total number of descriptors.211,21> SVM maps the data into a high-
dimensional space, using a kernel function that is typically nonlinear. An optimal 
separation between two classes is achieved by maximising the margin between the 
closest points, known as support vectors.211,212 Both seem to perform well in terms of 
classification models, performing similarly when compared. These methods have been 
widely used in chemoinformatics, and are easily accessible via platforms such as R213, 
making them a good starting point for machine learning methods. 
One of the dangers in QSAR analysis is building a model that lacks both explanatory 
and predictive ability, being essentially meaningless. Because of this risk, it is 
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important to validate the built models and, if necessary, make adjustments to methods 
or parameters to improve their quality.21> Therefore, the resulting datasets were 
validated using cross validated receiver operator curve area under the curve (ROC 
AUC) score. A cross-validation method excludes a fraction of the training data from 
the model building process and makes predictions for the left-out data using the model 
built from the remaining data. ROC curve is a visual illustration of the success and 
error observed in a classification model. A perfect model will score 1.0 meaning that 
there is a 100% true positive rate and a 0% false positive rate. When a score is 0.5 the 
test becomes useless as it makes a random prediction, 50% true positive versus 50% 
false positive, meaning that a “useful” ROC score needs to be between 0.5 and 1.215 
Based on the ROC scores, from the descriptors mentioned in Table 4, only the ones 
calculated based on the binding pose (GOLD) were used for analysis as they proved 
to be able to perform a better discrimination in both machine learning models (ROC >> 
0.5). Therefore, three models were calculated for each scoring function – one based on 
the parameters calculated for each docking solution (i.e. solutions), the second was 
based on descriptors calculated using GoldMine (i.e. calculated descriptors) but not 
the direct output from the docking. A third model that combines both sets of 
descriptors was also calculated (solutions and calculated descriptors). 
Most of the so-called classification models are really ranking models. That is, their 
basic prediction is not a specific class assignment but instead a score (or set of scores) 
that indicates the relative likelihood that a sample is in one class as opposed to 
another.21> To turn a ranker into a true classifier requires specification of a cut-off 
value for the score. For score values below the cut-off, one classification is attributed 
(e.g. inactive); for scores above the cut-off they are classified alternatively (e.g. active). 
The cut-off value chosen for a given model depends on our relative preference for true 
positives versus false positives, or specificity versus sensitivity. In this case, molecules 
with a score predicted to be higher than 0.5 were classified as active. 
 
 
 
 
 
 xxxiv 
 
Table 4 – ROC scores obtained for cross validation of the models built based on each set of descriptors 
as an evaluation of the applicability of each set of descriptors and model.  
Descriptors 
Random Forest 
ROC score 
Support Vector Machine 
ROC score 
Molecular Fingerprints 
FCFP_2 0.60 0.60 
FCFP_4 0.64 0.51 
FCFP_6 062 0.56 
ECFP_2 0.60 0.82 
ECFP_4 0.78 0.56 
ECFP_6 0.58 0.51 
Estate keys 0.93 0.51 
MDL public keys 0.56 0.62 
Physicochemical descriptors 
Pipeline Pilot 0.76 0.60 
GOLD 
Chemscore – solutions 0.99	 0.99	
Chemscore – GoldMine descriptors 0.99 0.99 
Chemscore - solutions & GoldMine descriptors 0.99 0.99 
Goldscore – solutions 0.99 0.99 
Goldscore – GoldMine descriptors 0.99 0.99 
Goldscore - solutions & GoldMine descriptors 0.99 0.99 
ASP – solutions 0.99 0.97 
ASP – GoldMine descriptors 0.99 0.99 
ASP – solutions & GoldMine descriptors 0.99 0.99 
ChemPLP – solutions 0.99 0.97 
ChemPLP – GoldMine descriptors 0.99 0.99 
ChemPLP - solutions & GoldMine descriptors 0.99 0.99 
Dragon descriptors 
2D 0.67 0.56 
3D 0.64 0.56 
 
Finally, and because not all molecules may be suitable to be evaluated using these 
models the model applicability filter node of Pipeline Pilot was used to remove 
molecules that are outside the models’ applicability domain.21> Because the model 
was built on a training set, molecules outside the chemical space defined by the 
training set are not suitable to be screened using these models. A total of 208 (out of 
1534) molecules passed the model applicability filter, from which only 49 had 
 xxxv 
 
solubility values (logS) higher than -4. As reported in previous chapters (Chapters 2 
and 4) -4 is an acceptable cut off value for aqueous solubility so the molecules can be 
screened using biophysical methods such as solution NMR and ITC. These were 
ranked using a Pareto ranking approach based on the probability of a molecule being 
active calculated by each model and aqueous solubility. Next section will describe this 
analysis. 
A.4.5  Pareto rank 
As described above three models based on descriptors obtained from docking solutions, 
GOLD solutions, GoldMine descriptors and both, were built for each scoring function 
and for each machine learning method – SVM and RF. Each model defined the 
molecules in terms of the probability of being active (true) or inactive (false) and 
attributed a score to each molecule. The molecules were then ranked using a 
multiobjective analysis – Pareto ranking. 
A Pareto ranking node was created for each model based on descriptors obtained from 
the docking using each scoring function – Goldscore, Chemscore, ChemPLP and ASP.  
Molecules with a higher probability to be active were ranked higher, followed by 
aqueous solubility ranking (higher the value of log S the better) – Figure 3. 
 
Figure 3 – Scheme describing the Pareto ranking approach used to rank the compounds from the PPI-
Net library using the scores obtained from the QSAR models. 
This approach was adopted for both SVM based and RF based models. As mentioned 
before a total of 49 molecules passed the model applicability filter and had a solubility 
values higher than -4, and therefore only these molecules were ranked in this manner. 
Analysis of the ranks obtained for both RF and SVM models reveals that for the ten 
best ranked molecules, eight are common to both ranks – Table 5. The presence of 
aromatic rings is high, 17 in total from which four are heteroaromatic.  
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Table 5 – Ten best ranked compounds for both RF and SVM models. 
ID	 RF	rank	
SVM	
rank	 Structure	 ID	
RF	
rank	
SVM	
rank	 Structure	
777	 1	 1	
	
1219	 7	 8	
	
1428	 2	 2	
	
871	 -	 8	
	
367	 3	 3	
	
454	 8	 -	
	
675	 4	 6	
	
603	 9	 -	
	
1372	 5	 5	
	
661	 -	 9	
	
75	 6	 10	
	
668	 10	 4	
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Three of the compounds have macrocycles, between seven and eight membered rings. 
In terms of solubility values these vary between -3.08 and -3.96, still within an ideal 
range for biophysical methods (NMR and ITC) testing.  
At this time there was the opportunity of testing a large number of compounds using a 
HTS method - Octet® RED96 System. Consequently, an alternative virtual screening 
method was used in order maximise the number of compounds with the highest 
probability of success tested in a short period of time. This method will be 
subsequently described. 
A.4.6  Selection of compounds for high throughput screening method - 
Octet® RED96 System 
Virtual screening has been largely mentioned in this thesis as a way of ranking a library 
of compounds from best to worst and it also can be used to facilitate the biological 
screening of the compounds, and one of the ways described herein has been related 
with the choice of molecules with adequate aqueous solubility values.  
When screening a large library of compounds one must be aware of the time 
consuming step of sample preparation for biological screen. In principle, sample 
preparation of a whole 96 well plate is quicker than selecting samples from 96 wells 
from different plates. Therefore, it was decided to develop a virtual screening method 
that will indicate the 96-well plate(s) out of 20 which contains the highest number of 
virtual hits. 
To start, all compounds were docked, using GOLD, and two methods used were 
normal docking and biased docking. These are more detailed in the methodology 
chapter - Chapter 7. At this stage some important binding features of EB1 were already 
known and the bias of docking studies can improve the hit rate by introducing some 
restraints that will rank higher compounds establishing desired contacts, occupying 
desired positions.15> Specifically, the two restraints included at this stage were a region 
constraint and a hydrogen bond constraint. The first will rank higher molecules that 
pose in a way that hydrophobic atoms are within a region defined as 3.5 Å region 
around Leu221 and Leu246, since these two residues are part of the hydrophobic cavity 
thoroughly characterised in Chapter 3. The second will favour scaffolds that make a 
hydrogen bond contact with the backbone of Val254 (Figure 4), also mentioned in this 
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thesis as a fundamental contact with the C-terminus of EB1c. This aspect is mostly 
addressed in Chapter 5. The reasoning for the use of these two constraints is to give 
higher scores to compounds that, when bound to EB1, make hydrophobic contacts with 
Leu221/Leu246 and/or hydrogen bond contacts with Val254, and are therefore, similar, 
to the native interactions. 
 
Figure 4 – Constraints used for the biased docking method. The yellow sphere represents a 3.5 Å radius 
around the coordinates -19.61, -26.09, 37.19. The sphere was designed in order to accommodate most 
of leucine side chains for Leu221 and Leu2446. The two green spheres represent hydrogen bond 
constraints with atoms number 515 and 518, corresponding to NH and CO of Val254 respectively.  
Therefore, two different docking studies were performed, both using Goldscore as 
scoring function. Because the first docking study was performed without any docking 
constraint will be termed as “normal”, whereas the second with the two described 
constraints will be termed as “biased”. Subsequently, the poses obtained for each 
docking study using the GA and scored using Goldscore, were rescored using the three 
alternative scoring functions: ASP, Chemscore and ChemPLP – Figure 5. 
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Figure 5 – Diagram summarising the method used to obtain fitness scores for the 1534 compounds of 
the PPI-Net library. 
Ten GA runs were performed and stored for each compound. Despite a prediction of 
a good fitness score by the scoring function being important, the consistent calculation 
of relatively high scored poses across several GA runs is also important. Consequently, 
for each compound, and each scoring function two values were attributed: the best 
fitness and the average obtained across the ten GA runs. 
Finally, and because the compound library is relatively diverse, with compounds from 
two different suppliers, with molecular weights ranging from 232.21 to 530.51 g.mol-
1, it was decided to apply a normalisation factor so scores obtained would be more 
homogeneous and less affected by the size/structure of the molecule. Therefore, ligand 
efficiency (LE) was calculated. This approach was utilised before and is described in 
Chapter 2 (score/number of heavy atoms). 
At this moment the 1534 molecules were organised in four different ranks: 
1. LE Rank – normal docking: rank calculated based on the ligand efficiency 
values obtained for the best score 
2. Average LE Rank – normal docking: rank calculated based on the ligand 
efficiency values obtained for the average score 
3. LE Rank – biased docking: rank calculated based on the ligand efficiency 
values obtained for the best score 
4. Average LE Rank – biased docking: rank calculated based on the ligand 
efficiency values obtained for the average score 
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It is not clear which rank will give more meaningful discrimination between active and 
inactive compounds. Ideally, all of them should be incorporated into the analysis. A 
method used frequently in this project to rank compounds through a balanced selection 
of different parameters, Pareto ranking, was again used. In addition to rank higher the 
best molecules in each previously described rank, aqueous solubility was again 
introduced as part of the balanced selection. 
At this stage compounds were ranked based on docking predicted scores and aqueous 
solubility. The next step will be selecting the 96-well plate with probability of having 
more active hits. For this selection two considerations were taken into account. The 
first is obviously related with the Pareto ranking, the plate with more compounds in 
the top ranked positions should, in principle, be considered for testing. A box plot was 
created based on the values obtained from Pareto ranking per plate barcode. The results 
are in Figure 6 and show plates 2000604-607 occupy not only in a lower position in 
the plot, indicating small values for the Pareto ranking and therefore higher hierarchy 
in the rank, but also the boxes are smaller indicating a smaller dispersion of values.   
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Figure 6 – Box plot based on the Pareto ranking obtained for the 1534 compounds of PPI-Net library. 
The ends of the whiskers represent the 95th and 5th percentiles, the ends of the boxes represent the 75th 
and 25th percentiles, the horizontal line represents the median and the white circle represents the mean 
value. Outliers are shown as red squares. 
The second is related with chemical diversity, as when performing an initial screening 
a diverse set of molecules with different properties is desirable as it improves the 
chances of not only finding hits but also gives better possibilities for hit optimisation. 
To evaluate chemical diversity DataWarrior21> was used. DataWarrior is a multi-
purpose data analysis tool where data can be filtered on structural motives, views are 
chemistry aware, molecule properties can be predicted from chemical structures, and 
specialized chemoinformatics methods explore the relationship between chemical 
structure and measured properties. Compounds belonging to plates (20000)604-607 
(for clarity the prefix 20000 from each barcode will be omitted from now on) were 
grouped according with their structure similarity, based on SkelSpheres descriptor, 
described as the most accurate descriptor for calculating similarities of chemical 
graphs in DataWarrior. The map obtained is in Figure 7, where plate 604 seems to be 
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clustered four big clusters of chemical structure similarity, meaning the compounds 
within this plate are not very diverse using the SkelSpheres descriptor. Solubility 
analysis was also incorporated to help plate selection – see legend in Figure 7. Plate 
604 solubility is mostly between green (logS around -4 and -5) and yellow (logS 
around -6). Plate 605 is well dispersed with fewer connections between compounds 
belonging to the same plate. Solubility values are now better, varying between cyan 
(logS ~ -3) and yellow (logS ~ -6). Compounds in the plate 606 show good diversity 
as well. Solubility wise, it looks this plate contain highly soluble compounds. Finally, 
plate 607 also shows good dispersion. However, few small clusters of structurally 
related compounds can be observed. Overall, these compounds seem to have good 
solubility values.  
A first analysis would possibly dictate that plates 605, 606 and 607 would probably 
the most suitable for in vitro screening, because they have better solubility values. 
However, in Figure 6 considerations about aqueous solubility were already included 
in the analysis. It was therefore decided to make a balance between predicted affinity 
and solubility. Plate 605 is clearly the plate with higher ranked compounds based on 
binding affinity prediction and solubility. In terms of the plate with compounds 
predicted to bind tighter to EB1c, plate 604 is clearly the front-runner. Finally, it was 
decided to select these two plates 604 and 605 for Octet® RED96 System screening. 
It is worth mentioning that four compounds included in these plates are found in the 
final compound selection obtained from QSAR approach, namely 1030, 1057 and 
1071 from plate 604 and 1081 from plate 605. 
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Figure 7 – Dispersion map based for the four 96-well plates to be analysed. Each square represents a different compound, coloured by plate. Connection lines are for neighbour 
compounds, i.e. compounds with similar structures. Background colour is related with the molecular solubility (logS). As an example, the two compounds on the right hand 
side corresponds to the two compounds from plate 606 selected in the map. These compounds have a SkelSpheres similarity value of 0.83. The figure was produced using 
DataWarrior21>. 
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A.4.7  Octet® RED96 System screening 
From the PPI-Net library 135 compounds, corresponding to plates 604 and 605 were 
tested using the Octet® RED96 System. This method is based on attachment of the 
target protein to a surface support (biosensor) through biotinylation reaction and then 
dipping the chip (biosensor) in ligand solution. The measurements provide kinetic 
parameter parameters such as Ka and Kd. 
This technique normally relies on biosensors that can be re-used.21> Upon binding of 
a ligand to a protein one should observe two distinct processes: the association and the 
dissociation. Figure 8 shows an ideal situation where the association phase can be 
observed up to 90 seconds followed by dissociation. Aspects related with this method 
will not be further detailed as this was an exploratory project which aim was to try to 
find a HTS method that could be applied for protein-protein interactions, as an 
alternative to biophysical techniques used (NMR and ITC).  
From the previous section results, it was decided to test all the compounds present in 
plates 604 and 605, yielding a total of 135 compounds. A 384-well plate was used to 
screen the selected compounds, where each well containing compound was 
accompanied with a blank well (without ligand) with dissociation buffer. Ligand 
concentration in each well was 500 µM. 
Nineteen compounds were selected as possible ligands for EB1cΔ8, 11 from plate 604 
and eight from plate 605 – Table 6. The average molecular weight for the selected 
compounds is 435 ± 16 g.mol-1. In terms of aqueous solubility these are more diverse, 
with logS values from -4.4 to -7.0, indicating that some of these compounds may not 
be suitable for testing using NMR or ITC due to their poor aqueous solubility. These 
compounds show a profile consistent with the association/dissociation pattern 
expected for a favourable interaction with the protein – Figure 9. None of these 
compounds correspond to the four compounds common to the QSAR final dataset and 
the tested compounds.  
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Figure 8 – Example of association/dissociation data normally obtained from Octet® RED96 System. 
The image was obtained from the supplier’s website http://www.fortebio.com/octet-RED96.html. 
Table 6 – Compounds selected as active after Octet® RED96 System screening. 
Octet Well Plate barcode 
PPI-Net 
plate well 
Vendor ID PPI-Net ID 
A9 20000604 A10 BDH34136166 1064 
C6 20000604 B7 BDH32350590 1041 
C7 20000604 B8 BDG34020588 1049 
C9 20000604 B10 LAS34137204 1065 
E1 20000604 C2 LAS34122636 1002 
E2 20000604 C3 LAS34124173 1010 
I8 20000604 E9 BDG34020575 1060 
K7 20000604 F8 BDG34020582 1053 
K8 20000604 F9 BDH34136185 1061 
O7 20000604 H8 BDH32352181 1055 
O8 20000604 H9 BDG34137236 1063 
A12 20000605 A3 BDG340205579 1088 
C13 20000605 B4 BDG34127776 1105 
C14 20000605 B5 BDG34018779 1097 
E13 20000605 C4 BDG340020587 1098 
E17 20000605 C8 BDG34125650 1130 
I15 20000605 E6 BDG34136119 1116 
K17 20000605 F8 LAS34135965 1133 
O14 20000605 H5 BDG34129080 1111 
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The remaining compounds showed either no response or the curve obtained was not 
consistent with association/dissociation pattern. Some showed only association and no 
dissociation and for some the association/dissociation curve gave opposite responses 
to the ones expected. A possible explanation may be non-specific binding to the 
surface. 
Unfortunately, many of the association/dissociation plots were inconclusive since 
some biosensors, when reused, were contaminated by ligands that failed to dissociate 
at the wash stage, thus affecting the subsequently analysed ligands using the same 
biosensor. This problem shows two limitations of this technique for HTS. The first is 
related with the speed and automation of the technique. In order to be a good HTS 
method it should be fast and automated.21> Replacing the contaminated sensors would 
require stopping the analysis which would need both time and supervision. Secondly, 
the reusability of the biosensors was one of the manufacturer’s selling point and from 
a HTS point of view one wants not only a reliable technique that can screen many 
compounds in a short period of time but also inexpensive enough to be a HTS 
technique. Buying a biosensor for each compound is expensive not only in terms of 
consumables but in terms of protein used.  
Another difficulty found when testing Octet® RED96 System is the low limit for 
compound concentration. This may be a complication when doing a first HTS in order 
to find active compounds. One does not expect, at least at a very initial stage to have 
highly active compounds. Alternatively, and because this technique allows for the 
calculation of parameters such as Ka, Kd, this technique seems to be suitable for hit 
validation, and in that case as a complementary method to a HTS screening. However, 
when testing the active molecules found to bind to EB1cΔ8 by solution NMR the 
results showed these compounds did not interact with EB1. A possible reason for that 
is the fact that high concentrations of these molecules are needed to have an interaction 
since these are weak binders. Ideally, one would like select some of these compounds, 
both active and inactive, do the opposite test, screening them using solution NMR. 
Additionally, testing molecules 1030, 1057, 1071 and 1081, by NMR could be another 
interesting, since these are common to both virtual screening approaches used to screen 
this library.  
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Figure 9 – Data obtained from Octet® RED96 System screening for compounds 1064 (top panel) and 
1053 (bottom panel) as examples of positive hits for EB1c binding. 
 
 
 
 
 
 
 
 
 
